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Thesis Summary 
Background: Oral anticoagulation (OAC) reduces stroke risk in patients with atrial 
fibrillation (AF) however it is often underutilized and sometimes refused by patients. 
This programme of work included a meta-synthesis and two inter-linking studies 
aiming to explore patients’ and physicians’ experiences of AF and OAC.   
Methods: A meta-synthesis of qualitative evidence was conducted which informed the 
empirical work. Semi-structured individual interviews were utilised. Study 1: Three AF 
patient sub-groups were interviewed; accepted (n=4), refused (n=4), or discontinued 
(n=3) warfarin. Study 2: Four physician sub-groups (n=4 each group) prescribing OAC 
to AF patients were interviewed: consultant cardiologists, consultant general 
physicians, general practitioners and cardiology registrars. Data was analysed using 
interpretative phenomenological analysis. 
Results: Study 1: Three over-arching themes comprised patients’ experiences: (1) the 
initial consultation, (2) life after the consultation, and (3) patients’ reflections. Patients 
commented on the relief and reassurance experienced during the consultation but they 
perceived the decision making process mostly led by the physician. Lack of education 
and take-home materials distributed during the initial consultation was highlighted. 
Patients who had experienced stroke themselves or were caregivers, were more 
receptive to education aimed towards stroke risk reduction rather than bleeding risk. 
Warfarin monitoring was challenging for patients, however some patients perceived it 
as beneficial as it served to enhance patient-physician relationship.  
Study 2: Two over-arching themes emerged from physicians’ experiences: (1) 
communicating information and (2) challenges with OAC prescription for AF. 
Physicians’ approach to the consultation style shifted through a continuum of 
compliance-adherence-concordance during the consultation. They aimed for 
concordance, however challenges such as time and the perceived patient trust in them 
as the expert, led to physicians adopting a paternalistic approach. Physicians also 
pointed out challenges associated with guideline adherence and the need to adopt a 
multi-disciplinary approach, where other health professionals could provide on-going 
education. 
Conclusion: This programme of work has illustrated the benefit of taking an in depth 
phenomenological approach to understanding the lived experience of the physician- 
patient consultation. Together with the meta-synthesis, this work has strengthened the 
evidence base and demonstrated that there is a need to target patients' and 
physicians' ability to communicate with each other in a comprehensible way.  
 
Keywords: Patients’ and physicians’ experiences, interpretative 
phenomenological analysis, meta-synthesis, atrial fibrillation, oral-
anticoagulation therapy 
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rhythm, if possible. 
Anticoagulant  A medicine that thins the blood and helps prevent blood 
from clotting, sometimes referred to as a "blood thinner". 
Anticoagulation  The process of thinning the blood to help prevent it from 
clotting. 
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blood away from the heart to the rest of the body. 
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atrium)  
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Atrial fibrillation   The most common type of arrhythmia. When you have 
AF, the atria of the heart quiver rapidly and unevenly - 
changing the rhythm of the heart. The heart beats in an 
irregular manner. 
Bradycardia  Slowness of the heartbeat, usually defined as a rate 
under 60 beats per minute. 
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too high for humans to hear). Sometimes used to 
diagnose illnesses. 
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how the heart beats. 
Embolus A thrombus that travels from the blood vessel or heart to 
another location in the body. 
Fibrin A white insoluble fibrous protein which forms part of the 
blood clot. 
Heart attack  Also known as a myocardial infarction. Damage or 
death of a portion of the heart muscle (myocardium) 
caused by a blocked blood supply to that area. 
Heart disease  Any condition that doesn't allow the heart to function 
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High blood pressure  High arterial blood pressure, also known as 
hypertension, is generally defined as being above 140 
mm Hg systolic and 90 mm Hg diastolic. Normal blood 
pressure is considered to be less than 120 mm Hg 
systolic and 80 mm Hg diastolic (120/80). 
International 
Normalised ratio 
A system established by the World Health Organization 
(WHO) and the International Committee on Thrombosis 
and Haemostasis for reporting the results of blood 
coagulation (clotting) tests. Abbreviated INR. Under the 
INR system, all results are standardized. 
Intra-atrial blood 
stasis  
Stoppage of the normal flow of a blood in the atria (the 
top chambers of the heart). 
Lone AF  Atrial fibrillation that occurs in an otherwise structurally 
normal heart, in a patient without other medical 
conditions. 
Normal sinus rhythm  The ‘normal’, regular rhythm the heart. 
Pacemaker  An electrical device (a small metal case containing a 
tiny battery and computer chip) that creates an electrical 
impulse to stimulate the heart muscle to beat in a more 
normal rate. 
Palpitations A term often used to describe an irregular heartbeat, or 
the sensation of skipped or extra heartbeats. 
Percutaneous 
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Non-surgical invasive procedure used to treat narrowing 
of the coronary arteries of the heart 
Paroxysmal AF  The heart beats in and out of normal sinus rhythm, 
going from atrial fibrillation to normal sinus rhythm on its 
own. Episodes last no longer than 1 week. 
Persistent AF  Episodes of atrial fibrillation lasting longer than 1 week 
which do not go away on their own. Medical treatment is 
necessary to restore normal sinus rhythm. 
Permanent AF  A person's normal heartbeat is atrial fibrillation and 
cannot be returned to normal rhythm. 
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Plaque A build-up of substances from a fluid, such as 
cholesterol, in the blood vessels. 
Platelet A type of blood cell that helps prevent bleeding by 
causing blood clots to form. 
Prophylaxis Prevention 
Rate  The speed of the heartbeat. 
Rhythm  The pattern of the heart-beat. 
Stroke  An interruption of blood supply to the brain. A stroke 
happens when blood flow to a part of the brain is 
interrupted because a blood vessel in the brain is 
blocked or bursts open. If blood flow is stopped for 
longer than a few seconds, that part of the brain cannot 
get blood and oxygen. Brain cells can die, causing 
permanent damage. 
Systolic dysfunction A loss in the efficiency of the function of the cardiac 
muscle, leading to and increased blood volume and 
decreased contractility of the heart muscle.  
Tachycardia Increased speed of the beating of the heart, usually with 
a heart rate above 100 beats per minute. 
Thrombosis The formation and development of a thrombus or blood 
clot in the blood vessel. 
Thromboprophylaxis The prevention of a clot (thrombus) forming. 
Time in therapeutic 
range 
For patients taking warfarin the term therapeutic range 
signifies the range at which the blood thinning is 
maximised to reduce the risk of stroke and minimise 
bleeding risks. For patients with atrial fibrillation taking 
warfarin the therapeutic range should be 2.0-3.0. 
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Often called a "mini-stroke", they are considered to be 
warning strokes as a blood clot temporarily blocks an 
artery. TIAs usually last no more than five minutes, and 
may only last for seconds. Those who have had a TIA 
are much more likely to have a stroke. One-third of 
those who have had a TIA will have a stroke, often 
within a year.  
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Chapter 1: Introduction 
1.1 Introduction 
Atrial Fibrillation (AF), is the most common heart rhythm condition and is 
associated with increased morbidity and mortality (Camm, Kirchhof, Lip, 
Schotten, Savelieva, Ernst et al., 2010; Fuster, Ryden, Cannom, Crijns, Curtis, 
Ellenbogen et al., 2006; Rudolf, Lip, Bakhshi, Camm, Davis, Deacon et al., 
2006).  AF is an independent risk factor for stroke, with AF patients having a 
risk five times higher than normal to get a stroke (Wolf, Abbott & Kannel, 1991). 
Hence, stroke risk reduction with oral anticoagulation therapy (OAC) is a crucial 
component of AF management (Camm et al, 2010; Lane & Lip, 2008a). 
However, although warfarin is the recommended OAC treatment for AF 
patients at moderate to high-risk of stroke (Camm et al, 2010; Camm, Lip, De 
Caterina, Savelieva, Atar, Hohnloser et al., 2012) it is still underutilized (Ogilvie, 
Newton, Welner, Cowell, & Lip. 2010). There is a paucity of literature that 
qualitatively explores the experiences that influence physicians’ decisions to 
prescribe or withhold warfarin in eligible AF patients and the experiences that 
influence AF patients’ to accept, refuse or discontinue warfarin. Thus the 
objective of this thesis was to understand the physicians’ and patients’ 
experiences of AF and OAC therapy and how these experiences influenced 
their choices with regards OAC therapy prescription and acceptance, refusal or 
discontinuation.   
 
Therefore, this chapter will aim to provide an overview of the bio-psychosocial 
perspective of AF and OAC with warfarin. AF and OAC will be introduced. In 
addition discussion of, the epidemiology and prognosis of AF, the use OAC 
therapy for stroke prevention in AF and current clinical guideline 
recommendations for OAC will be outlined. Also discussed in this chapter are 
the barriers to OAC therapy. These include patient barriers, such as patient 
beliefs and illness perceptions, and the psychological influence on the 
perceptions of symptoms. Physician barriers, including the difference between 
physicians’ and patients’ perception of stroke risk reduction, fear of litigation 
and knowledge of guidelines are also explored. In addition, health-care system 
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barriers, which include consultation time constraints and system influences on 
OAC monitoring are also discussed. These discussions will provide a 
background for the rationale of the study outlined in the final section of this 
chapter. 
 
1.2 What is Atrial Fibrillation (AF)? 
1.2.1 Definition 
AF is defined as a supraventricular tachyarrhythmia which is characterised by a 
predominantly uncoordinated atrial activation with consequent deterioration of 
atrial mechanical function (Camm et al., 2010, 2012; Fuster, et al., 2006;  
Rudolf et al., 2006). Put more simply, AF is a condition of the heart that causes 
an irregular pulse. The electrical impulses that usually coordinate the heartbeat 
become disorganised and the heart starts beating irregularly and too fast 
(Camm et al, 2010; National Institute for Health and Clinical Excellence [NICE], 
2006). Patients may experience AF symptoms that include palpitations, chest 
pain, dizziness, shortness of breath and fainting, however, in the majority of 
cases AF is asymptomatic (Camm et al., 2010; Fuster et al., 2006; NICE, 2006; 
Rudolf et al., 2006). 
 
1.2.2 Classification of Atrial Fibrillation 
Atrial fibrillation is categorised into four clinical sub-types, based on the 
temporal pattern of the arrhythmia (Camm et al, 2010):  paroxysmal, persistent, 
long-standing and permanent AF.  Paroxysmal AF occurs when episodes of the 
arrythmia terminate spontaneously, usually within 48 hours but may continue 
for up to seven days.  Persistent AF is when the episode of arrhythmia 
continues requiring electrical or pharmacological cardioversion for termination 
and lasts for more than seven days. AF patients are categorised as ‘long-
standing persistent’ when the AF has lasted for more than one year but a 
decision is adopted to try to return the patient to sinus rhythm utilising a rhythm 
control strategy (anti-arrhythmic drugs and/or cardioversion/AF ablation). Atrial 
fibrillation is classified as permanent when the arrhythmia has been present for 
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one year or more and this is accepted by the patient (and physician) as the 
patient’s ‘normal’ heart rhythm.  
1.2.3 Epidemiology  
1.2.3.1 Incidence and Prevalence 
Data from the Framingham Heart Study (Lloyd-Jones, Wang, Leip, Larson, 
Levy, Vasan, et al, 2004) suggests that the lifetime risk for the development of 
AF for men and women aged 40 years and older is approximately 1 in 4. This 
lifetime risk is similar to that reported in the Rotterdam study (Heeringa, van der 
Kuip, Hofman, Kors, Van Herpen, Stricker, et al, 2006), which found that the 
risk associated with developing AF in people over 55 years of age was 24% for 
men and 22% for women. The age- and sex-adjusted incidence of AF per 1000 
person-years among the 4618 US patients of Olmsted County, Minnesota, who 
had ECG (Electrocardiogram) confirmed first AF in the period 1980 to 
2000, was 3.04 (95% CI 2.78 – 3.31) in 1980 and 3.68 (95% CI 3.42 – 3.95) in 
2000, with a relative increase of 12.6% (2.1% - 23.1%) in total (Miyasaka, 
Barnes, Gersh Cha, Bailey, Abhayaratna et al., 2006). They estimated that by 
the year 2050, the projected number of persons with AF in the United States 
alone could reach 15.9 million, if the age-adjusted incidence continues to 
increase at the same rate (Miyasaka, et al., 2006). 
 
The prevalence of AF continues to rise with advancing age and appears to be 
similar to the UK, in Europe and the United States, at around 2-3% (Heeringa, 
et al., 2006; Lloyd-Jones, et al., 2004; Nieuwlaat, Capucci, Camm, Olsson, 
Andresen, Davies, et al., 2005; Rietbrock, Heeley, Plumb & van Staa, 2008; 
Stewart, Murphy, Walker, McGuire & McMurray, 2004; Wilhelmsen, Rosengren, 
& Lappas, 2001). In the United States, the number of people who are 
diagnosed with AF is above 2.2 million (Fowler & Ruh, 2006; Go, et al., 2001; 
Miyasaka et al., 2006; You, Singer, Howard, Lane, Eckman, Fang et al., 2012). 
In the UK, the Renfrew-Paisley study (Stewart, Hart, Hole, & McMurray, 2001), 
analysing ECG data of 15,406 patients (45.8% male) aged 45-64 years, the 
population prevalence of AF was 6.5 cases per 1000 patients. Locally, in the 
West Birmingham AF project (Lip, et al., 1997), the prevalence of AF was 2.4% 
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in two general practices and a further extension of this project showed that the 
prevalence of AF among Indo-Asians aged over 50 years in primary care was 
0.6% (Lip, et al., 1998). The Newcastle survey screened 4,843 people aged 65 
years or more in general practices and found a prevalence of AF of 4.7% 
(Sudlow, Thomson, Thwaites, Rodgers, & Kenny, 1998). Among UK hospital 
admissions, AF is present in 3-6% of the acute medical admissions (Lip, Tean, 
& Dunn, 1994; Zarafis, Beevers & Lip, 1997). 
 
1.2.3.2 Risk factors for the development of atrial fibrillation 
There are many well-established risk factors associated with the development 
of AF, namely age, male sex, hypertension, diabetes mellitus and metabolic 
syndrome. As indicated in the previous section, increasing age is associated 
with a greater prevalence and incidence of AF (Heeringa et al, 2006; Kirchhof, 
Lip, Van Gelder, Bax, Hylek, Kaab et al., 2012; Lloyd-Jones et al, 2004; 
Miyasaka, et al., 2006; Rietbrock et al, 2008; Stewart et al., 2001; Wilhelmsen, 
Rosengren, & Lappas, 2001). Male sex has also long been associated with 
incident AF (Benjamin, Levy, Vaziri, D’Agostino, Belanger & Wolf, 1994; Gami, 
Hodge, Herges, Olson, Nykodym, Kara et al., 2007; Gammage, Parle, Holder, 
Roberts, Hobbs, Wilson et al., 2007; Kirchhof et al., 2012; Marcus, Alonso, 
Peralta, Lettre, Vittinghoff, Lubitz et al., 2010; Schnabel, Sullivan, Levy, 
Pencina, Massaro, D’Agostino et al., 2009; Smith, Newton-Cheh, Almgren, 
Struck, Morgenthaler, Bergmann et al., 2010). Interestingly, this is in contrast 
with the observation that female gender is a risk factor for stroke in patients 
with established AF (Lane & Lip, 2009; Stroke Risk in Atrial Fibrillation Working 
Group, 2007). In the Framingham study (Benjamin, et al., 1994) the 
development of AF was associated with increasing age (odds ratio (OR) 2.1 for 
men and 2.2 for women, p <0.0001), diabetes (OR 1.4 for men and 1.6 for 
women), hypertension (OR 1.5 for men and 1.4 for women), and valve disease 
(OR 1.8 for men and 3.4 for women). 
 
Similarly, lifestyle and dietary factors are also associated with development of 
AF. Such factors include excessive alcohol consumption over a short period of 
time, excessive caffeine consumption and emotional or physical stress and 
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obesity (Camm, et al., 2010; Fuster, et al., 2006; Kirchhof et al., 2012; NICE, 
2006). Interestingly, recent studies have also documented a relationship 
between long-term vigorous endurance sport practice or rigorous occupational 
physical activity in athletes and AF (Heidbuchel, Anne, Willems, Adriaenssens, 
Van de & Ector, 2006; Kirchhof et al., 2012; Molina, Mont, Marrugat, Berruezo, 
Brugada, Bruguera, et al., 2008; Mont, 2010; Mont, Tamborero, Elosua, Molina, 
Coll-Vincent, Sitges, et al., 2008; Taggar & Lip, 2008) 
 
1.2.4 Prognosis  
1.2.4.1 Morbidity and mortality  
Several factors associated with AF, including intra-atrial blood stasis, structural 
heart disease or blood vessel abnormalities and abnormal platelets and 
haemostasis, lead to a prothrombothic state. This in turn leads to a 
predisposition to thrombus (clot) formation, known as thrombogenesis (Lip, 
1995). Further, this prothrombotic state can lead to stroke and 
thromboembolism in AF patients, with an approximately five-fold greater risk (p 
<0.001) than that of people without AF (Wolf et al., 1991). This can be 
compared to the risk of stroke in patients with hypertension or coronary heart 
disease, who have a three- and four-fold increased risk of stroke, respectively, 
than patients without either of these conditions (Wolf et al., 1991). Results from 
the Framingham study identified AF as an independent risk factor for stroke 
(Wolf et al., 1991). In addition, AF accounts for approximately 10-15% of all 
ischaemic strokes (Wolf et al., 1991). The incidence of strokes attributable to 
AF increases from 1.5% at age 50–59 years to 23.5% at age 80–89 years 
(Wolf, Mitchell, Baker, Kannel, & D’Agostino, 1998). Furthermore, the risk of 
stroke is similar in all AF clinical sub-types; paroxysmal, persistent, long-
standing or permanent (Flaker, Belew, Beckman, Vidaillet, Kron, Safford, et al., 
2005). Strokes that occur in the presence of AF are often more severe resulting 
in greater likelihood of death or disability, and need for residential care than 
strokes that occur in patients without AF (Steger, Pratter, Martinek-Bregel, 
Avanzini, Valentin et al., 2004). 
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1.2.4.2 Quality of Life 
In the late 1940s, the World Health Organisation (WHO) extended the definition 
of health to encompass the presence of physical, mental, and social well-being, 
giving rise to the concept of quality of life (QoL) (WHO, 1947). The WHO’s 
Division of Mental Health officially defined the term QoL as “an individual’s 
perception of their position in life in the context of the culture and value systems 
in which they live and in relation to their goals, expectations, standards, and 
concerns” (WHO, 1993: 153). Reviews conducted to evaluate the QoL in 
patients with AF and the impact of rate- and rhythm-control strategies on QoL, 
found that most studies demonstrated that patients with AF report poorer QoL 
compared to the general population (Thrall, Lane, Caroll & Lip, 2006; Lane & 
Lip, 2008b). Among highly-symptomatic AF patients, QoL is improved following 
either rhythm- or rate-control treatment strategies, with such improvements in 
QoL most probably attributable to the relief of symptoms (Thrall et al., 2006; 
Lane & Lip, 2008b).  
   
QoL related to AF patients starting warfarin therapy was likewise studied. In a 
study with utility-based approaches using time trade-off (reflecting a person’s 
preference for a shorter but healthier life) and standard gamble methods 
(measuring what chance of death someone would be willing to take to be 
healthier), patients felt that warfarin therapy would slightly decrease QoL 
(Gage, Cardinalli, & Owens, 1996). Lancaster and colleagues recruited 333 AF 
patients into a randomised controlled trial to determine the effect of long-term 
warfarin therapy versus placebo, on patient’s QoL (Lancaster, Singer, 
Sheehan, Oertel, Maraventano, Hughes, et al, 1991). They found that there 
were no significant differences in validated measures of functional status, well-
being and health perceptions between warfarin-treated and control patients. 
Unless a bleeding episode occurred, patients did not associate warfarin therapy 
with a decrease in health-related QoL. 
 
Das, Wilcoxson & Corrado (2005) argue that strokes are more likely to cause 
neurological impairment than death and therefore stroke prophylaxis should 
improve QoL more than longevity. In the early stages of treatment, OAC may 
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affect QoL from bleeding complications and in the longer term QoL may be 
affected by the inconvenience of clinic visits, blood tests and restricted lifestyle 
(e.g. diet and alcohol) (Das et al., 2005). Therefore understanding the impact of 
stroke and OAC therapy on QoL could play a major role during clinical 
decisions, as patients may value the same level of functional status differently 
(Das, et al. 2005).  
 
Based on this premise, Das, Wilcoxson, Corrado and West (2007) conducted a 
cross-sectional study comparing patients who had been taking warfarin for less 
than one year with those who were on warfarin for more than one year, to 
assess the perceived change in QoL with the duration of anticoagulation. 
Concurrently they also compared QoL in patients taking warfarin with people 
from the general population (Das et al., 2007), using an abbreviated version of 
the SF-36,  which provided composite mental and physical QoL scores. There 
were no differences in mental or physical QoL in older patients with AF treated 
with long-term warfarin compared with the general population and no difference 
in QoL with duration of anticoagulation (Das et al., 2007). However they found 
that increasing age had an effect on the mental QoL and that physical QoL was 
affected by the patient’s stroke risk (assessed by the CHADS2 score (the 
CHADS2 score is a risk score commonly used to assess the risk of stroke in a 
patient suffering from AF and will be further discussed in section 1.3.3.1) (Das 
et al, 2007). A limitation of the study was that older patients who had previous 
complications arising from warfarin treatment were excluded. Thus one cannot 
say if warfarin related complications would have an effect on patient’s QoL.  
 
Health-related QoL can be defined as a subjective measure of how physical 
impediments, as well as psychological and emotional discomfort, impact a 
person’s day-to-day life. A medication’s net impact on a patient’s QoL can be 
thought of as a balance between the potential side effects of a medication, the 
burden of complying with an appropriate dose of the medication, and the 
medication’s ability to prevent the targeted adverse health outcomes (Das, 
Billet, Cohen & Arnsten, 2005). Research demonstrates that generally AF 
patients value the potential of warfarin to prevent stroke over the risk of 
adverse drug effects or inconvenience of the drug regimen (Devereaux, 
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Anderson, Gardner, Putnam, & Flowerdew, 2001; Kneeland & Fang, 2010). 
Physicians  may tend to over-emphasize the impact of long-term warfarin on 
QoL, Differences between physician and patient perceptions of the risks, 
benefits, and lifestyle burden of long-term warfarin may have important 
implications in under-prescribing and medication compliance patterns (Das et 
al., 2005; Kneeland & Fang, 2010; Kutner, Nixon, & Silverstone, 1991; 
Protheroe, Fahey, Montgomery & Peters, 2000). 
 
 
The few qualitative studies, included in the meta-synthesis  presented in 
Chapter 2, have identified several domains that relate to the impact of long-
term warfarin therapy on patient’s health-related QoL. These are the 
inconvenience of taking the medication and frequency of  blood monitoring, 
dietary and alcohol restrictions, perceived efficacy and safety of the medication, 
drug-drug interactions, anxiety related to potential and actual side effects of the 
medication, patient autonomy, quality of information given to patients by 
physicians, shared decision-making before initiating the medication, symptom 
alleviation (or prevention), and impact of the medication on physical activities 
(Dantas, Thompson, Manson, Tracy & Upshur, 2004; Prins, Marrel, Carita, 
Anderson, Bousser, Crijns, et al., 2009; see Chapter 2).  
 
While available data argue against attributing a significant negative QoL impact 
to long-term warfarin therapy, all of the studies have limitations. First, we do not 
know whether QoL would have been more negatively impacted in patients who 
were not selected to start warfarin; similarly, little is known about QoL changes 
in patients who discontinued warfarin. Second, most studies were of patients 
who were already taking warfarin,  who may be more compliant or agreeable to 
chronic therapy. Greater variability in QoL may be more likely in unselected 
patients (Sweeney, Gray, Steele, & Evans, 1995; Protheroe et al., 2000). Third, 
the majority of studies have evaluated older patients and potentially lack 
generalizability to younger patients who might experience a more pronounced 
detriment to their QoL when forced to limit activities, like contact sports or 
travelling, due to risk of bleeding and frequent blood-tests, respectively 
(Lancaster et al., 1991). Finally, the impact of experienced side effects (i.e., 
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bleeding), even if minor, likely plays a significant role in determining patient’s 
QoL while taking warfarin and needs a more robust assessment in future QoL 
analyses.  
 
1.2.4.3 Depression and Anxiety in AF 
The relationship between AF, depression and anxiety has not been extensively 
studied. Thrall, Lip, Caroll and Lane (2007) assessed depression and anxiety 
(using the Beck Depression Inventory (BDI) and State-Trait Anxiety Inventory 
(STAI), respectively) in 101 AF patients and 97 patients with hypertension in 
sinus rhythm (as “disease control”), in a cross-sectional study (Thrall, Lip, 
Carroll, & Lane, 2007). AF patients, displayed significantly higher levels of trait 
anxiety at baseline compared to ‘disease-controls’; there were  no significant 
differences in depression, state anxiety, or  QoL between groups at baseline. 
Symptoms of depression and anxiety persisted in AF at 6 months in 36.8% and 
33.3%, respectively. Multivariate analyses revealed that baseline depression 
scores provided the best independent prediction of 6-month QoL (Thrall et al, 
2007).  
 
In a more recent study, Lane, Langman, Lip and Nouwen (2009) explored how 
health-related QoL, depression, and anxiety change over the first 12 months 
following diagnosis of lone AF (without any other risk factors for stroke) . Data 
from 70 lone AF patients (mean age 71.4 [S.D. 9.1]; 64% men) was collected 
using the BDI, STAI, and SF-36, at baseline, six and 12 months after diagnosis. 
Consistent to the findings of Thrall et al. (2007), Lane et al. (2009) found that 
lone AF patients do not appear to experience significant levels of depressive 
symptoms following diagnosis. The predominant affective response appeared 
to be anxiety and there were no significant changes in depression and anxiety 
over the first year (Lane et al., 2009).  
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1.3 Anti-thrombotic therapy for atrial fibrillation 
1.3.1 Antiplatelet therapy vs. control 
Eight randomised controlled trials examined the effects of antiplatelet therapy 
(predominantly aspirin) compared with placebo on the risk of thromboembolism 
in patients with AF (Hart, Pearce & Aguilar, 2007). In seven trials where aspirin 
alone was compared with placebo/no treatment, aspirin was associated with a 
non-significant 19% (95% CI: -1%-35%) reduction in the incidence of stroke. 
However when data from all comparisons of aspirin and placebo/control were 
added in the meta-analysis, this showed a significant reduction of 22% (95% 
CI: 6%-35%) associated with aspirin.  
 
1.3.2 Anticoagulation therapy with warfarin vs. control 
For nearly 50 years, vitamin K antagonists, such as warfarin have been the 
mainstay of oral anticoagulation for stroke prevention in AF. Evidence from six 
randomised controlled clinical trials, five in primary prevention and one 
secondary prevention, supports the use of warfarin as anticoagulant treatment 
for thromboprophylaxis in AF patients (Hart et al., 2007; Lip & Lim, 2007). A 
meta-analysis of these trials revealed that adjusted-dose warfarin was 
associated with an overall 64% (95% CI, 49%-74%) reduction in the relative 
risk of stroke compared to placebo (Hart, et al, 2007). Further, all-cause 
mortality was also significantly reduced (26%; 95% CI, 3%-43%) with adjusted-
dose warfarin compared to placebo or control (Hart et al., 2007). However, 
warfarin was associated with a relatively small absolute increase in major extra-
cranial haemorrhage (≤0.3% per year) (Hart et al, 2007; Lip & Lim, 2007). 
 
1.3.3 Anticoagulation therapy with warfarin vs. antiplatelet therapy 
Direct comparison between the effects of warfarin and aspirin therapies was 
undertaken in 12 trials (Hart et al., 2007), demonstrating 39% (95% CI: 22%-
52%) relative risk reduction in stroke with adjusted-dose warfarin therapy 
compared to antiplatelet therapy (Hart et al., 2007).  In addition, the 
Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study found that 
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warfarin (INR 2.0-3.0) was superior to aspirin 75mg (daily) in reducing the 
primary endpoint of fatal or disabling stroke (ischaemic or haemorrhagic), 
intracranial haemorrhage, or clinically significant arterial embolism by 52%, with 
no difference in the risk of major haemorrhage between warfarin and aspirin 
(Mant, Hobbs, Fletcher, Roalfe, Fitzmaurice, Lip et al., 2007). However, despite 
the evidence of the significant benefit of warfarin over aspirin/anti-platelets and 
no therapy in the reduction of stroke, the inherent difficulties associated with 
warfarin, such as drug-, diet-, and alcohol-interactions, and lifestyle changes 
because of regular monitoring and dose adjustments (Bungard, Ghali, Teo, 
McAlister, & Tsuyuki, 2000), and patients’ beliefs about warfarin, have led to 
the development of novel oral anticoagulants (NOACs) which sought to 
minimise these difficulties. 
 
1.3.4 Novel oral anticoagulants (NOACs) 
1.3.4.1 Dabigatran 
The randomised evaluation of long-term anticoagulant therapy (RE-LY) trial 
(Connolly, Ezekowitz, Yusuf,  Eikelboom, Oldgren, Parekh, et al., 2009) 
compared blinded-dose dabigatran (150mg bid or 110mg bid) to open-label 
dose-adjusted warfarin in 18,113 AF patients with one or more risk factor for 
stroke. Dabigatran 150mg bid was superior to warfarin in reducing the risk of 
stroke and systemic embolism, albeit with similar rate of major bleeding, while 
dabigatran 110mg bid significantly reduced the risk of major bleeding but had 
similar efficacy to warfarin in reducing stroke and systemic embolism (Connolly 
et al, 2009).  
 
High-dose dabigatran was also associated with a significant increased risk of 
major gastrointestinal haemorrhage (1.51%) compared with dabigatran 110 mg 
(1.12%) or warfarin (1.02%) (Connolly et al., 2009). In addition, both doses of 
dabigatran had significantly higher discontinuation rates than warfarin (Connolly 
et al., 2009). The main influence for the increased discontinuation of dabigatran 
compared to warfarin was its tendency to cause dyspepsia, demonstrating that 
warfarin appeared to be better tolerated than dabigatran (Connolly et al., 2009) 
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1.3.4.2 Rivaroxaban 
The oral direct factor Xa inhibitor, rivaroxaban, was compared to warfarin in the 
Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with 
Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET-AF) study (Patel, Mahaffey, Garg, Pan, Singer, Hacke, et 
al., 2011). This double-blind, randomised, event-driven non-inferiority trial 
compared rivaroxaban (20mg once daily or 15 mg once daily in patients with 
moderate renal impairment) with dose-adjusted warfarin (target INR 2.5) in 
14,264 patients (Patel et al., 2011). Rivaroxaban was non-inferior to warfarin 
for the primary efficacy endpoint of prevention of stroke and systemic 
embolism, however it was not superior to warfarin (Patel et al., 2011). Major 
and non-major clinically relevant bleeding was similar with rivaroxaban and 
warfarin, however the rivaroxaban treatment group demonstrated significantly 
less fatal bleeding and intracranial haemorrhage (0.5 versus 0.7 per 100 patient 
years; p<0.05)). Nevertheless, significantly more patients receiving rivaroxaban 
had a haemoglobin decrease and required a blood transfusion (Patel et al., 
2011). Premature discontinuation rates on rivaroxaban and warfarin were 
comparable, at approximately 23% (Patel et al., 2011). 
  
1.3.4.3 Apixaban 
The Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation (ARISTOTLE) trial was a randomised, double-blind, 
international trial comparing apixaban 5mg twice daily with warfarin (INR 2.0-
3.0) in over 18,000 patients (Granger, Alexander, McMurray, Lopes, Hylek, 
Hanna, et al., 2011). The rate of stroke or systemic embolism in ARISTOTLE 
was significantly lower with apixaban compared to warfarin (1.27% vs. 1.60% 
per year, respectively) primarily driven by a reduction in haemorrhagic stroke 
(Granger et al., 2011), Apixaban also significantly reduced all-cause mortality 
compared to warfarin (3.52% vs. 3.94% per year, respectively). Apixaban was 
also found to be safer than warfarin in, significantly reducing the risk of major 
bleeding (2.13% vs. 3.09% per year, respectively) (Granger et al., 2011). Drug 
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discontinuation also occurred significantly less frequently with apixaban 
compared to warfarin (25.3% vs. 27.5%; p= 0.001).  
 
Although the new OACs have been recently approved for use in patients with 
AF in Europe, they may bring a new set of challenges for physicians, mainly 
concerning the lack of agent to reverse the anticoagulant effect, long-term 
safety, and ‘real-world’ clinical experience. In addition, some AF patients 
(particularly those with significant renal impairment) are not eligible for the new 
OACs (Camm, et al.,  2012).  Although the new OACs generally have a 
predictable anticoagulant response that allows for convenient, fixed-dose, and 
unmonitored treatment, regular monitoring of warfarin may also be seen as a 
benefit as it can help in the assessment of patient adherence to treatment, 
whereas with the new OACs it is more difficult to ascertain medication 
adherence. Therefore, warfarin still has a clearly defined place in therapy, as 
the established gold standard antithrombotic for stroke prevention in atrial 
fibrillation. The efficacy and safety of warfarin has been established, and it is 
readily reversed by vitamin K. Furthermore, the challenges posed by blood 
monitoring are also offset by the benefit they provide in the opportunity to 
assess patient adherence.  
 
1.3.5 Current recommendations for OAC 
1.3.5.1 Stroke Risk Stratification 
The traditional risk factors for stroke in AF are previous stroke or transient 
ischaemic attack (TIA), increasing age (≥75 years), hypertension, diabetes 
mellitus, and congestive heart failure or left ventricular systolic dysfunction and 
these risk factors comprise the well-known CHADS2 score (Gage, Waterman & 
Shannon, 2001). The CHADS2 stroke risk stratification scheme assigns one 
point to each risk factor, except for previous stroke which gets two points. 
Scores range from 0-6, with higher scores denoting greater risk of stroke (see 
Table 1 and 2). The CHA2DS2-VASc (see Table 1 and 2) is a refinement of the 
CHADS2 schema, but also incorporates female gender, age 65-74 years, and 
vascular disease (previous MI, peripheral vascular disease, and aortic plaque), 
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as additional risk factors (Lip, Nieuwlaat, Pisters, Lane, & Crijns, 2009). The 
CHA2DS2-VASc score assigns one point to: congestive heart failure, 
hypertension, diabetes mellitus, vascular disease (including MI), age of 65-74 
years, sex category and two points to prior stroke and age ≥75years (Lip et al., 
2009), with total scores ranging from 0-9. CHA2DS2-VASc clearly identifies truly 
‘low risk’ patients (Lip et al., 2009; Coppens, Eikelboom, Hart, Yusuf, Lip, 
Dorian et al., 2013). Patients with CHA2DS2-VASc of 1 or more are eligible for 
OAC unless the only risk factor is female sex (Camm et al., 2012). At the time 
of this programme of work, none of the new OACs were available to prescribe 
for stroke prevention in AF, so warfarin was the only OAC available. 
 
Recent guidelines for antithrombotic therapy in AF recommend that stroke risks 
should be based on the presence (or absence) of risk factors for stroke and 
thrombo-embolism, rather than on an artificial division into high, moderate, or 
low risk categories (Camm et al., 2010; 2012).   
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Table 1: CHADS2 and CHA2DS2-VASc scoring systems (adapted from Gage 
et al., 2001 and Camm et al., 2010) 
 
CHADS2 Score Condition/Risk Factor CHA2DS2-VASc Score 
C 1 Congestive heart failure C 1 
H 1 Hypertension (including 
treated hypertension) 
H 1 
A 1 Age (≥75 years) A 2 
D 1 Diabetes D 1 
S 2 Prior stroke or TIA S 2 
 † Vascular disease V 1 
 † Age (65-74) A 1 
 † Sex category (female 
sex) 
Sc 1 
Total score 6   9 
† not included in the CHADS2 score 
 
Table 2: CHADS2 and CHA2DS2-VASc score and stroke rate (adapted from 
Camm et al 2010) 
 
CHADS2 
Score 
Patients 
(n=1733) 
Adjusted 
stroke rate 
(%/year)  
CHA2DS2-
VASc Score 
Patients 
(n=7329) 
Adjusted 
stroke 
rate 
(%/year) 
0 120 1.9 0 1 0 
1 463 2.8 1 422 1.3 
2 523 4 2 1230 2.2 
3 337 5.9 3 1730 3.2 
4 220 8.5 4 1718 4.0 
5 65 12.5 5 1159 6.7 
6 5 18.2 6 679 9.8 
   7 294 9.8 
   8 82 6.7 
   9 14 15.2 
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1.3.5.2 Optimal International Normalized Ratio (INR) 
To be effective and to reduce the risk of bleeding, control of warfarin is 
essential.  Anticoagulation control is measured by the International Normalised 
Ratio (INR), a measure of the clotting time (derived from the ratio between the 
actual prothrombin time and that of a standardized control serum). For patients 
with AF, their INR needs to be between 2.0 and 3.0 (Camm et al., 2010; Fuster 
et al., 2006; NICE, 2006). If INR is lower than 2.0, it means that the blood is 
‘thicker’ and there is a higher risk of stroke. If the INR is more than 3.0, it 
means that the blood ‘too thin’ and there is higher risk of bleeding. Warfarin and 
other vitamin K antagonists are difficult to control because of high inter-
individual and intra-individual variations as well as significant drug, food and 
alcohol interactions (Camm et al., 2010; Fuster et al., 2006; NICE, 2006). On 
average, trials found that patients need to remain in the therapeutic INR range 
of 2.0-3.0 for more than 60% of the time to for the reduction of stroke risks to 
outweigh the risk of bleeding (Connolly, Pogue, Eikelboom, Flaker, 
Commerford, Franzosi et al., 2008) and preferably >70% of the time (Morgan, 
McEwan, Tukiendorf, Robinson, Clemens & Plumb, 2009).  
 
1.3.5.3 Bleeding Risks 
The main side effect of OAC, particularly with warfarin, is the risk of bleeding. 
Guidelines advocate that bleeding risks should be assessed before patients are 
started on OAC therapy. Using a ‘real-world’ cohort of 3978 European patients 
with AF from the Euro Heart Survey, HAS-BLED (hypertension, abnormal 
renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly 
(>65), drugs/alcohol concomitantly), a new bleeding risk schema was 
constructed which has demonstrated good consistent predictive accuracy 
(Pisters, Lane, Nieuwlaat, de Vos, Crijns & Lip, 2010) (See Table 3). Scores 
range from 0-9. Patients who achieve a score of ≥3 are at a higher risk of 
bleeding and physicians should use OAC therapy with caution and ensure 
regular review of the patient following initiation of OAC therapy (Pisters et al., 
2010). 
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Table 3: HAS-BLED scoring system (adapted from Camm et al., 2010) 
 
Letter Clinical characteristic Score 
H Hypertension 1 
A 
Abnormal renal and liver 
function (1 point each) 
1 or 2 
S Stroke 1 
B Bleeding 1 
L Liable INRs 1 
E 
Elderly (e.g. age >65 
years) 
1 
D 
Drugs or alcohol (1 point 
each) 
1 or 2 
  Maximum 9 points 
 
 
1.4 Barriers to oral-anticoagulation therapy 
Despite the benefit of OAC for stroke thromboprophylaxis in AF, such treatment 
is underutilised (Bungard, et al., 2000; Ogilvie, Newton, Welner, Cowell, & Lip, 
2010), with only 15% to 44% of patients without contraindications being 
prescribed warfarin (Bungard, et al., 2000). The reasons for this underutilisation 
are numerous but the barriers to anticoagulation can be divided into three main 
categories: patient, physician-, and health-care related barriers (Bungard et al, 
2000; Gattellari, Worthington, Zwar, & Middleton, 2008a; Lane & Lip, 2008a; 
Pugh, Pugh & Mead, 2011; see Chapter 2).   
 
1.4.1 Patient barriers 
Bungard et al (2000) reviewed surveys that identified several patient-related 
barriers, which could influence physicians’ decisions in prescribing warfarin to 
patients. These barriers including age, perceived embolic risk and perceived 
risk for haemorrhage were consistently identified as influencing the decision in 
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prescribing anticoagulation in several studies (Bungard et al., 2000; Gattellari et 
al., 2008a; Pugh, et al., 2011) and will be explored in more detail in this section. 
 
1.4.1.1 Age 
The literature suggests that advancing age often influences physicians’ 
decision to not prescribe warfarin in older patients (Partington, Abid, Teo, 
Oczkowski, & O’Donnell, 2007; Pugh et al., 2011). This could be due to age per 
se increasing the risk of bleeding (Cosmo & Palareti, 2009). However, the 
BAFTA trial revealed that warfarin in patients over the age of 75 years, was 
associated with a significant reduction in fatal strokes, with no significant 
differences in the risk of major bleeding between the warfarin and aspirin trial 
cohorts (Mant et al., 2007). Therefore the patients that are most likely to benefit 
from OAC are not receiving treatment. In addition, the increased likelihood of a 
greater risk of falls, decline in cognitive ability, and multiple comorbidities in 
older people, also increase the risk of bleeding, with the latter two also 
complicating OAC management, and reducing a patient’s ability to adhere to 
the warfarin regimen which requires regular monitoring, dose-adjustment and 
lifestyle changes.  
 
1.4.1.2 Patient beliefs and perceptions 
Patients’ beliefs about their healthcare are important factors that influence their 
decision to accept, decline, or comply with anticoagulant therapy, particularly 
warfarin (Howitt & Armstrong, 1999; Protheroe, et al., 2000). Some of the 
patient beliefs and perceptions that act as barriers to warfarin prescription 
identified in the literature are fear of bleeding risks caused by warfarin, the fact 
that warfarin was also used as rat poison and the responsibility warfarin brings 
with it regarding diet, alcohol consumption, and lifestyle change (Dantas et al., 
2004; Lipman, Murtagh & Thomson, 2004).  
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1.4.1.2.1 Illness beliefs and perceptions 
Beliefs about illness will determine the action a person chooses to take, which 
information they give to a physician, the kind of treatment they want, whether 
they adhere to that treatment, and their emotional, behavioural, and cognitive 
responses to the illness (Leventhal, Brissette, & Leventhal, 2003; Leventhal, 
Nerenz, & Steele, 1984). Illness representations are people’s organised sets of 
beliefs about the experience, impact, effect and outcome of an illness and 
hence are not necessarily accurate or coherent with the evidence-base. They 
are unique to each individual and will be shaped by many factors, including 
their personal history, experience of different illnesses, and social and cultural 
learning. Five main dimensions of illness representations have been 
established: identity, timeline, cause, control, and consequences (Leventhal et 
al., 2003; Leventhal et al., 1984).  
 
The concept of illness identity refers to the way a person labels the illness and 
symptoms, such as what AF and OAC are and what they involve (Leventhal et 
al., 2003; Leventhal et al., 1984). The more various symptoms match a 
person’s model of a particular illness the more likely it is they will diagnose 
themselves as having that illness (Leventhal et al., 2003; Leventhal et al., 
1984). The timeline is the length of time that a person believes the illness will 
last and the pattern it will take, e.g. chronic, acute, remitting, or cyclical. This 
will affect their adjustment to the illness and adherence to treatment (Leventhal 
et al., 2003; Leventhal et al., 1984). The cause is what a person thinks caused 
their symptoms or illness (Leventhal et al., 2003; Leventhal et al., 1984). 
However, they might not be medically accurate. Beliefs about control concern 
whether the person believes their illness can be prevented, controlled or cured 
(Leventhal et al., 2003; Leventhal et al., 1984). People who think their illness is 
controllable are more likely to take an active part in their treatment and 
rehabilitation (Scharloo, Kaptein, Schlosser, Pouwels, Bel, Rabe, et al., 1999). 
Conversely, thinking an illness is uncontrollable is associated with using 
passive coping strategies, such as avoidance, and increased hospital 
admissions (Scharloo et al., 1999). Beliefs about consequences are concerned 
with the effect of the illness (Leventhal et al., 1984; Leventhal et al., 2003). 
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Perceived consequences are usually closely linked to the severity of 
someone’s symptoms. Therefore asymptomatic illnesses, such as AF, may be 
often viewed as having no consequences. People can also have beliefs and 
representations about treatment procedures which, in turn, will affect how likely 
they are to adhere to particular treatments. 
 
Furthermore, managing an illness or treatment which is abstract (i.e. something 
that patients cannot perceive or feel, e.g. asymptomatic atrial fibrillation), might 
be harder than managing an illness or treatment when a person has concrete 
(i.e. when patients can perceive or feel symptoms, such as palpitations in 
symptomatic atrial fibrillation)  experience of it (Leventhal et al., 1984; 
Leventhal et al., 2003). Therefore, asymptomatic AF patients might be less 
likely to adhere to treatment as they perceive no concrete symptoms. This 
could also be linked to the issue of motivation: if people do not have symptoms, 
they may be more likely to favour an immediate reward (not taking on the 
burden of OAC) over the long-term consequences (risk of stroke). 
 
Chronically ill patients have increased levels of anxiety and depression when 
they believe their illness has a psychological cause, serious consequences 
(Grace, Krepostman, Brooks, Arthur, Scholey, Susken, et al., 2005; Hirani, 
Pugsley, & Newman, 2006; Jopson & Moss-Morris, 2003), poor controllability 
(Grace et al., 2005; Petrie, Weinman, Sharpe, & Buckley, 1996), is chronic 
(Fabbri, Kapur, Wells, & Creed, 2001; Grace et al., 2005; Petrie et al., 1996), 
and identified with a higher number of symptoms (Fabbri et al., 2001; Steed, 
Newman, & Hardman, 1999). Beliefs that an illness has significant 
consequences and poor controllability are related to increased fatigue 
(Treharne, Lyons, Hale, Goodchild, Booth, & Kitas, 2008), pain (Hirani et al., 
2006), decreased vitality (Jopson & Moss-Morris, 2003) and poorer physical 
functioning (Scharloo et al., 2007). Modifying illness beliefs through education, 
cognitive therapies, and emotional regulation interventions will lead to positive 
clinical outcomes, including improved functional status, symptom management, 
psychological well-being, and better adherence to treatment recommendations 
(Cameron, & Jago, 2008; Kaptein, Scharloo, Fischer, Snoel, Cameron, Sont, et 
al., 2008; McAndrew, Musumeci-Szabo, Mora, Vileikyte, Burns, Halm, et al., 
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2008; Petrie, Broadbent, & Meechan, 2003). Thus, identifying the individual 
patient’s experiences and physician’s interpretation of patients’ beliefs and 
experiences of the consultation is critical for developing interventions to 
promote adaptive illness beliefs.  
 
A few investigators described illness beliefs in patients with coronary artery 
disease (CAD) or heart failure (HF). Patients awaiting elective coronary artery 
bypass graft (CABG) surgery (Hermele, Olivo, Namerow, & Oz, 2007) and 
those treated with elective percutaneous coronary intervention (PCI) (Astin, 
Closs, McLenachan, Hunter, & Priestly, 2009) viewed their illness as less 
chronic compared to patients with HF (Cherrington, Lawson, & Clark, 2006) 
and patients attending cardiac rehabilitation (Yohannes, Yalfani, Doherty, & 
Bundy, 2007). Patients who completed a cardiac rehabilitation programme after 
myocardial infarctions (MI) (Yohannes et al., 2007) reported lower personal 
control beliefs compared to patients with heart failure (Cherrington et al., 2006) 
or those treated with PCI (Astin et al., 2009). Treatment control beliefs were 
highest in patients undergoing elective PCI (Astin et al., 2009) and awaiting 
CABG surgery (Hermele et al., 2007). Heart failure patients perceived greater 
consequences (Cherrington et al., 2006) of their illness compared to patients 
with CAD (Astin et al., 2009; Grace et al., 2005; Hermele et al., 2007; Safford, 
Berk, & Jackson, 2009) and endorsed more emotional distress related to their 
illness compared to patients awaiting CABG surgery (Hermele et al., 2007).  
 
Studies of illness beliefs directly related to AF are sparse. The belief that AF 
was related to a higher number of symptoms was associated with greater 
psychological distress (Steed et al., 1999) and sharper declines and slower 
improvement in physical health scores over 12 months after diagnosis (Lane, et 
al., 2009). In addition patients perceived psychological factors, age, and 
heredity caused AF and reported that AF induced worry, anxiety and 
depression (McCabe, Barnason & Houfek, 2011a). 
 
Research has pointed out that arrival at the doctor’s surgery is often the last 
stage in the construction of sickness. For example, according to Scambler 
(1991), the majority of patients consult widely with lay (non-medical) contacts 
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before deciding to visit the doctor. Patients rely upon lay beliefs about the 
nature of their illness (i.e. a diagnosis function) in conjunction with lay beliefs 
about the nature of alternative remedies (i.e. a treatment function). During 
diagnosis, patients attempt to identify the nature of the illness by relating 
symptoms to the originating illness or disease. During treatment, consumers 
attempt to select the health remedy most appropriate to the illness identified 
during diagnosis. 
 
In a study which draws on a large national study of health and lifestyles in the 
UK, Blaxter (1990) has provided a detailed picture of some of these variations. 
This study also shows that health is not a single or unitary concept, but one that 
has a number of dimensions as applied to different areas of life and lifestyles 
(Blaxter 2003, 2004). Blaxter’s (1990) discussion of lay beliefs is drawn from 
responses to open-ended questions about health put to 9,000 respondents in 
England, Wales and Scotland. Overall, these responses show that for lay 
people ‘health can be defined negatively, as the absence of illness, functionally 
as the ability to cope with everyday activities, or positively as fitness and well-
being’ (p. 14). However, there are two important additions to this general 
picture. The first is that health has a moral dimension, reflecting not only the 
adoption or maintenance of a healthy lifestyle, but also how people respond to 
illness and deal with its aftermath. Illness runs the risk of devaluing a person’s 
identity, either because of its causation (e.g. smoking, sexual contact, failure to 
‘keep well’) or because of inappropriate behaviour in the face of symptoms. 
Moral dimensions of health have been found in a number of other studies, such 
as Conrad’s (1994) study of students in the USA and Williams’ (1984) study of 
middle-aged and older people with arthritis in England. From this viewpoint 
illness is not simply a deviation from biological norms, as in the medical model, 
but a significant departure from social norms. 
 
Second, Blaxter (1990) shows that health, illness and disease are not always 
mutually exclusive in lay thought. Respondents in her study often reported that 
they saw themselves as healthy despite having serious conditions such as 
diabetes. There is clearly a strong motivation towards feeling and being seen to 
be healthy, if at all possible. 
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Cohen et al. (2001) emphasises the importance of understanding the ways in 
which the meaning of medication is culturally constructed in as much as 
medicine is ‘socially embedded’ (p. 442) in differing thresholds of normality and 
abnormality which reflect wider social relations. Acknowledging that while there 
are specific cultural features characterising this class of drug (in their link to 
lifestyle and behavioural expectations for example), they believe that ‘all 
classes of prescribed medications’ can be understood as being mediated and 
their use shaped and constructed by cultural repertoires and social relations 
‘beyond an individual consumer’s body’ (p. 449). As they say:  
 
Medications themselves are much more than material objects 
with physiological effects; they are also representations that 
carry meanings and shape social relations as they evolve in 
conjunction with individuals and collectivities (p. 442). 
 
The internal and external physiological effects (bleeding and bruising) of 
warfarin are therefore extremely important for a large number of people both 
positively as a therapeutic agent but also more negatively as a potential source 
of serious side effects and risks. It is important to understand how the drug is 
experienced and how these effects are understood by those taking it, especially 
for a chronic disorder.  
 
1.4.1.2.2 Psychological influence on symptom perception 
Psychological factors can also affect the perception and interpretation of 
symptoms in a number of ways including the role of attention in whether people 
notice their symptoms, the effect of the environment on symptom perception 
and interpretation, individual differences in the interpretation of symptoms, and 
the influence of emotions on symptom perception and interpretation (Sarafino, 
2006). The degree of attention we pay to our internal physical state has a 
strong influence on the perception of symptoms. Broadbent’s (1958) theory of 
attention assumes we have a limited capacity to pay attention to different 
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stimuli at the same time. Therefore, changes in our internal states have to 
compete with what is going on around us for attention. 
 
Research evidence confirms the importance of attention in the perception of 
symptoms (Broadbent & Petrie, 2007). People are more likely to report 
symptoms if they are unemployed, living alone, or when  in boring situations in 
laboratory research (Pennebaker, 2000; Pennebaker & Epstein, 1983). People 
will also report more symptoms if they are instructed to attend to their internal 
physical stimuli rather than external stimuli (Broadbent & Petrie, 2007; 
Pennebaker & Lightner, 1980). The implications of this for healthcare are that 
taking a person’s attention away from internal stimuli by using strategies such 
as distraction can lower the perception of symptoms. Distraction might 
therefore be useful for managing symptoms like the elevated heart rate from 
AF. 
 
Individuals will also have sets of beliefs, about which illnesses they are 
vulnerable to, which symptoms indicate potential illness, and which illnesses 
comprise a threat to their overall health (Broadbent & Petrie, 2007). Schemas 
people have about their health and illness will therefore be influenced by their 
past experience of illness and others’ attitudes to illness.  
 
Thus qualitative studies that adopt an idiographic focus on the experiences of 
the patients are critical in understanding these beliefs. Schemas will usually 
operate unconsciously to influence what symptoms people attend to and how 
they interpret them.  Broadbent and Petrie (2007) argue that this might be due 
to the fact that patients scan their symptoms for any that fit with the illness they 
are learning about. 
 
Emotion is also strongly associated with the perception and reporting of 
symptoms. Strong emotion is accompanied by physiological changes that can 
be misinterpreted as symptoms. Research into anxiety has established that this 
results in a narrowing of attentional focus and a bias towards the perception of 
threat (Bar-Haim, Lamy, Pergamin, Bakerman-Kranenburg, & van Ijzendoorn, 
2007). Anxiety will therefore make people hyper-vigilant, in which case they will 
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scan themselves and the environment for any potential threat (Bar-Haim et al., 
2007). Anxiety may influence people’s perceptions and result in the reporting of 
more concurrent, or momentary, physical symptoms, patients with a depressed 
mood report having experienced more symptoms in the past (Howren & Suls, 
2011) 
 
1.4.1.3 Patient knowledge and understanding 
Another issue concerning older patients is knowledge surrounding AF and OAC 
treatment. In Dantas’ et al. (2004) study, older patients above 75 years of age 
demonstrated poor knowledge regarding warfarin treatment with less than half 
the sample being able to name a warfarin related benefit, risk or lifestyle 
change. Researchers found that in most cases family members or spouses that 
accompanied the patients were more knowledgeable and play an important role 
in warfarin management. Furthermore, this study sample was from a patient 
population of an academic primary-care practice that was both well-educated 
and of medium-high socio-economic status, thus a more heterogeneous 
sample may demonstrate even less treatment related knowledge. The AF 
Aware group (Aliot, Breithardt, Brugada, Camm, Lip, Vardas et al., 2010) 
examined the level of understanding, perception, and attitudes of 
cardiovascular risks associated with AF in 825 patients and demonstrated that 
one in four patients felt unable to explain AF and 55% considered AF life-
threatening. 
 
A prospective study of 122 Chinese AF patients attending an anticoagulation 
clinic evaluated patient’s treatment-related knowledge and its relationship to 
anticoagulation control (Tang, Lai, Lee, Wong, Cheng & Chan, 2003). Overall 
knowledge of OAC was poor. Patients generally knew the colour of their 
warfarin tablets but were deficient in knowledge related to consequences of 
over- and under-anticoagulation, drugs that interact with warfarin and 
management of a missed dose (Tang et al., 2003). However, many of the 
patients were unable to read and thus may not have received any appropriate 
educational information. This study also found a positive correlation between 
patients’ knowledge of warfarin treatment and the number of INR values within 
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range (r 0.20; p=0.024) (Tang et al., 2003). Therefore, patient knowledge has 
an important impact upon INR control; patients were more likely to have INR 
scores within range if they also scored higher on their educational 
questionnaire (Tang, et al, 2003).  
 
Lip et al. (2002) studied patient knowledge related to their anticoagulation and 
their perceptions of AF in 119 chronic AF patients attending a hospital clinic. 
They found that 37% of the sample population were not aware of their heart 
condition and almost half were not aware of the reason they were taking OAC. 
In a pilot study to increase knowledge of AF patients regarding their condition 
and OAC treatment, Lane and colleagues report similar findings with 51% of 
patients unable to name their cardiac condition at baseline and only about half 
the patients perceived AF as a serious condition or were aware that AF 
predisposes to thromboembolism at baseline (Lane, Ponsford, Shelley, Sirpal & 
Lip, 2006). After a brief educational intervention there was an 18% increase of 
participants that were aware that anticoagulants prevented blood clots. In 
addition, there was minimal change in number of patients who were aware of 
the benefit of stroke prevention associated with anticoagulants (6% increase). 
The educational intervention significantly improved patient’s knowledge of the 
target INR range and factors that may affect INR levels (p=0.001 and p=0.014, 
respectively) for those who completed both questionnaires.  
 
Therefore, in order to optimize AF management and allow patients to 
participate in maintaining their health, in consultation with health professionals, 
they need to be appropriately educated about the condition and the treatment 
options. 
 
1.4.1.4 Decision-making 
Dantas et al. (2004) argued that patients tend to have limited input into the 
decision to initiate warfarin therapy. Moreover, the majority of patients in their 
study appear to lack a comprehensive understanding of the risks and benefits 
associated with the treatment. A study was conducted to explore patients’ 
perceptions of their roles during decision making, 12 patients were interviewed 
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and data analysed using a grounded theory approach (Waterworth & Luker, 
1990). From their analysis researchers came up with one major theme, called 
‘toeing the line’ (Waterworth & Luker, 1990). This theme suggests that patients 
are sometimes more concerned about doing what is right, rather than 
participating in decisions concerning their own care. Thus, Waterworth & Luker 
(1990) argued that if health professionals adopt practices which encourage 
involvement, patients might be influenced to comply so they do not go against 
their perceptions of the recommendation(s) of the doctor. This is similar to a 
response bias. In the qualitative study conducted by Dantas et al. (2004), 
patients reported that they had no involvement in the decision making process 
and that decisions to initiate warfarin were mostly taken by physicians. These 
reports were often accompanied by a high level of trust in the medical expertise 
of the physician (Dantas et al., 2004). 
 
1.4.1.4.1 Models of involvement in decision making 
Although several policy documents have advocated patient participation in 
decisions about their own health care, they have been criticised for failing to 
adequately delineate what they mean by the term participation (Entwistle, 2000; 
Rhodes & Nocon, 1998). For example, policies may not differentiate between 
public participation in health services and patient participation in decisions 
about their own health care. Furthermore, reference to the academic literature 
may increase the confusion as several models of participation in treatment 
decision-making can be identified. 
 
One of the models discussed in the academic literature is a non-participatory 
model, paternalism, which is sometimes referred to as the traditional medical 
model (Charles, Gafni, & Whelan, 1999; Coulter 2002; Emanuel & Emanuel 
1992). It is important to identify this model because the more 'participatory' 
models tend to be explained as a contrast to the paternalistic model. In the 
paternalistic model the physician decides what is wrong with the patient and 
what treatment will be implemented. The patient's role in decision making is 
limited to agreeing with what has been recommended by the physician. 
However, a paternalistic approach is beneficial in certain circumstances where 
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patients whose action or choice is insufficiently voluntary to be genuinely his or 
hers. Such circumstances may include older people suffering from severe 
cognitive impairment and where no family member is available to make the 
decision for them. 
 
Various decision-making models, which incorporate components of patient's 
participation in decision-making are described in the literature. Emmanuel and 
Emmanuel (1992) describe three treatment decision-making models in addition 
to the paternalistic model: the informative model, the interpretive model, and 
the deliberative model. In the informative model the physician provides all the 
relevant information to the patient, for the patient to decide on a treatment 
option (while considering their own values and preferences). In the interpretive 
model the physician gives the patients all the information but in addition aims to 
get the patient to disclose his/her values and then matches an intervention to 
the patient's values. In the deliberative model, the physician aims to help the 
patient identify their health related values and an intervention that will yield the 
best return in terms of these values. In this deliberative model, the physician 
also persuades the patient as to the best health related values for their 
situation. 
 
Charles and her colleagues also discuss three models of treatment decision-
making in addition to paternalism: the informed model, the physician as agent 
model and the shared model (Charles et al 1999; Gafni, Charles, & Whelan, 
1998; Charles, Gafni, & Whelan, 1997). However, they rejected the physician 
as agent model (where the patient discloses all information about their values 
to the physician and the physician considers the options based on these 
values) due to the difficulties in patients being able to recognise and voice all 
their values (Gafni et al., 1998). The informed model was described as the 
physician giving all the information to the patient and the patient being 
responsible for the decision (this is similar to the informative model described 
by Emmanuel and Emmanuel, 1992). The shared model was where the patient 
and health professional share information with one another, debate the pros 
and cons of the options (with each party giving their views and preferences) 
and reach a shared decision. A further model that is presented in the literature 
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is evidence-based patient choice where patients are given research-based information 
about the risks and benefits of at least two treatment options and have some input into 
the decision-making process (Entwistle, Sheldon, Sowden, & Watt, 1998; Hope, 1996). 
 
Wirtz, Crib, and Barber (2006) discussed four models of patient-physician decision-
making that encompass most of the models discussed before (see Figure 1). In the 
paternalistic decision model, where the patient is seen predominantly biomedically, i.e. 
as a body, the physician chooses the treatment after evaluating information about the 
illness of the patient and the treatment options (Wirtz et al., 2006). The shared 
decision and interpretative models both perceive the patient as a sentient being with 
experience and values (Wirtz et al., 2006). However, in the shared decision model, 
patients and physicians share information and a treatment decision is made where 
both parties agree, whereas the interpretative model is similar to the paternalistic 
model, with the added consideration of the patient’s values and preferences (Wirtz et 
al., 2006). In the fourth model, the informed decision, the patient decides on his or her 
own after the physician discloses information about benefits, risks and alternative 
treatments (Wirtz et al., 2006).  
Figure 1: Models of patient-physician decision making process (adapted from Wirtz et 
al, 2006)   
 
Paternalistic decision  
The doctor chooses the 
treatment after evaluating 
information about the illness 
of the patient and the 
treatment options. 
Interpretative decision 
Similar to the paternalistic 
model, with the added 
consideration of the patient’s 
values and preferences. 
Shared decision 
Patients and physicians 
share information and a 
treatment decision is made 
where both parties agree. 
Informed decision 
The patient decides on his or 
her own after the doctor 
discloses information about 
benefits, risks and alternative 
treatments. 
Patient predominantly, as 
biomedical body 
Patient as sentient being 
with experiences and 
values 
Patient as autonomous 
decision-maker 
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A participatory process of decision-making that refers specifically to decisions 
about taking medication is concordance (Horne et al., 2005). Concordance can 
be defined as an agreement reached after negotiation between a patient and a 
health professional that respects the beliefs and wishes of the patient in 
determining whether, when and how medicines are to be taken (Horne et al., 
2005). The concordance decision-making process recognises that patients and 
health professionals may have different views about taking medication and 
gives each viewpoint equal importance (Britten, 2003). It is a move away from 
the more paternalistic notion of compliance to drugs and relies on patients and 
health professionals sharing information, debating the pros and cons of options 
and patients' involvement in the treatment decision (Elwyn et al., 2003). In 
order to achieve a concordant process of decision-making physicians may 
need to use the same competencies as for a shared decision-making approach 
(Elwyn et al., 2003). 
 
In view of this, a recent three step model of shared decision making to guide 
clinical practice was proposed (Elwyn, Frosch, Thomson, Joseph-Williams, 
Lloyd, Kinnersley et al., 2012). Elwyn and colleagues suggest three key steps 
of shared decision making for clinical practice (see Table 4), namely choice 
talk, option talk and decision talk, where the clinician supports deliberation 
throughout the process (Elwyn et al. 2012). Choice talk refers to the step of 
making sure that patients know that reasonable options are available. Option 
talk refers to providing more detailed information about options and decision 
talk refers to supporting the work of considering preferences and deciding what 
is best (Elwyn et al. 2012). The model outlines a step-wise process, however 
Elwyn et al. (2012) note that such a model is not prescriptive as clinical 
interactions are by necessity fluid. 
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Table 4: Summary of shared-decision making model proposed by Elwyn et al. 
(2012): choice talk, option talk, preference talk (adapted from Elwyn et al., 
2012) 
 
Choice talk Option talk Preference Talk 
 Step back  
 Offer choice  
 Justify choice - 
preferences matter  
 Check reaction  
 Defer closure 
 Check knowledge  
 List options  
 Describe options – 
explore preferences  
 Harms and benefits  
 Provide patient 
decision support  
 Summarize 
 Focus on 
preferences  
 Elicit preferences  
 Move to a decision  
 Offer review 
 
 
There are many similarities between some of the models presented above 
(although they are given different labels), but there are also significant 
differences. To some extent a similarity between the models is that they are a 
contrast to (and in some cases a rejection of) the non-participatory nature of 
paternalistic model (Charles et al., 1997; Charles et al., 1999; Emanuel & 
Emanuel, 1992; Gafni et al., 1998; Hope, 1996). Each model, to varying 
degrees, aims to involve patients in the treatment decision making process and 
may represent an attempt to overcome the paternalistic position where the 
physician is the expert and therefore able to decide what is best for an 
individual patient.  
 
Several studies (see Table 5) have examined patient preferences for 
antithrombotic therapy in AF patients (Gage, Cardinalli, Albers, & Owens, 1995; 
Gage, Cardinalli & Owens, 1998; Gage, Cardinalli & Owens, 1996; Man-Son-
Hing, Laupacis, O’Connor, Biggs, Drake, Yetisir et al., 1999; Howitt & 
Armstrong, 1999; Man-Son-Hing, Laupacis, O’Connor, Wells, Lemelin, Wood et 
al.,1996; McAlister, Man-Son-Hing, Straus, Ghali, Anderson, Majumdar et al., 
2005; Protheroe, et al., 2000; Sudlow et al., 1998; Thomson, Eccles, Steen, 
Greenaway, Stobbart, Murtagh et al., 2007; Thomson, Parkin, Eccles, Sudlow 
& Robinson, 2000) and in patients at high risk of developing AF, but without AF 
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(Devereaux, et al., 2001; Fuller, Dudley & Blacktop, 2004; Man-Son-Hing, 
O’Connor, Drake, Biggs, Hum & Laupacis, 2002; Holbrook, Labiris, Goldsmith, 
Ota, Harb & Sebaldt, 2007; Alonso-Coello, Montori, Sola, Schunemann, 
Devereaux, Charles et al., 2008). Use of decision aids, such as audio booklets 
(Man-Son-Hing et al.,1999, 2002; McAlister et al., 2005; Holbrook et al., 2007) 
decision boards (Devereaux et al., 2001; Fuller et al., 2004; Holbrook et al., 
2007; Howitt & Armstrong, 1999; Man-Son-Hing et al., 1996, 1999) and 
interactive videos or computer programs (Gage et al., 1995, 1996,1998; 
Holbrook et al., 2007; Thomson et al., 2007) were prominent in these studies. 
These decision aids were developed to facilitate a shared decision making 
process and ensure that treatment choices were consistent with patients’ 
personal preferences and values. They contained information on the likelihood 
of clinically important outcomes, including stroke and major haemorrhage 
associated with OAC with warfarin, aspirin or no treatment and researchers 
asked patients to indicate their treatment choice based on the information 
presented (Lip, Andreotti, Fauchier, Huber, Hylek, Knight, et al., 2011). 
 
Patients in these studies placed greater emphasis on reducing the risk of stroke 
than the risk of bleeding. This could be due to the lack of knowledge on 
consequences of major bleeding. However, some studies (Fuller et al., 2004; 
Protheroe et al., 2000) suggest that there was a decrease in patients choosing 
to accept OAC when information on intra-cranial haemorrhage risk was also 
included. Decision aids provided an opportunity to improve patient knowledge 
of AF and OAC which empowered patients to make a decision (Holbrook et al., 
2007; Man-Son-Hing et al., 1996, 1999, 2002; Thomson et al., 2000). However, 
research also suggested that the use of decision aids resulted in less patients 
opting for OAC (Fuller et al., 2004; Holbrook et al., 2007; Howitt & Armstrong, 
1999; Man-Son-Hing et al., 1999; Protheroe et al., 2000; Thomson et al., 2000) 
than the current guidelines would recommend (Lip et al., 2011). 
 
However, several issues were raised whilst drawing general conclusions from 
these studies. The main issue is the heterogeneity of methods amongst the 
studies (see Table 5) including the different methods to elicit patient preference 
and how patients in the intervention groups were educated. In addition it is 
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important to distinguish between studies of patients with and without AF, (see 
Table 5) as perceptions,values and beliefs that influence preference may differ 
between patients with AF who need to decide about lifelong therapy and those 
in a hypothetical situation (Lip et al., 2011). In addition enrolled patients with 
previous experience of OAC or who were already on OAC during these studies 
might have chosen their current therapy over other treatment choices to 
prevent cognitive dissonance (i.e. distress/conflict between preferences and 
actual treatment choice) (Fuller et al., 2004; Holbrook et al., 2007; Howitt & 
Armstrong, 1999; Lip et al., 2011; Man-Son-Hing et al., 2002; Protheroe et al., 
2000; Thomson et al., 2007).  
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Table 5: Summary of the studies on the use of patient decision aids in AF patients (Adapted from Lip et al., 2011) 
 
Author, year, 
country 
Sample size, 
mean (SD) 
age 
Study design 
Method of eliciting 
patient preference 
Outcomes 
Studies in patients with AF 
Gage et al., 
1995, US 
n=57; 70 
Cross-sectional, 
Markov decision 
model 
Interviews, computer-
based TTO 
 High utility for daily aspirin (0.998) or warfarin (0.988) 
 Disutility associated with severe stroke (0.39) or extra-cranial 
haemorrhage (0.76) 
Gage et al., 
1996, US 
n=70; 70.1 
(7.3) 
Cross-sectional, 
longitudinal 
Interviews, computer-
based TTO 
 High utility for daily aspirin (1.0) or warfarin (0.997) 
 Disutility associated with moderate-to-severe stroke (0.07 and 
0.0, respectively) 
Man Son Hing 
et al., 1996, 
US 
n=64; 68.9 
(9.0) 
RCT Interviews, PTOT  52% willing to take warfarin for  absolute risk reduction ≤1/100 
Gage 1998, 
US 
n=69; 70 
Cross-sectional,  
Markov decision 
model 
Interviews, computer-
based TTO 
 Disutility association with stroke 
Sudlow et al., 
1998, UK 
n=176; ≥50 Cross-sectional 
Questionnaire and 
interview 
 89% willing to take warfarin to prevent stroke 
Man Son Hing 
et al., 1999, 
US 
n=287; control 
67, 
intervention 
65 
RCT PTOT vs Usual care 
 Proportion choosing warfarin greater in control group 
 PTOT increased ability to make decision choice 
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Howitt & 
Armstrong, 
1999, UK 
n=56 Cross-sectional 
Qualitative interview, 
PTOT 
 20 choose not to take warfarin despite knowledge of stroke risk 
Protheroe et 
al., 2000, UK 
n=97;77 (3.9) 
Observational, 
Markov decision 
model 
Individualised decision 
analysis 
 61% preferred warfarin based on individualised stroke risk 
Thomson et 
al., 2000, UK 
n=57; 73 
Cross-sectional, 
Markov decision 
model 
Interview, standard 
gamble 
 High utility for daily warfarin (0.94) 
 Disutility associated with severe stroke (0.19) 
McAlister et 
al., 2005, US 
n=43.4; 72 
Cluster 
randomised trial 
Self-administered, PTOT 
 PTOT increased patient ability to choose ‘appropriate’ 
antithrombotic therapy in short-term only 
Thomson et 
al., 2007, UK 
n=109; 73 (6) RCT 
Computerised decision 
aid vs. guideline evidence 
 Computerised decision aid let to significantly fewer patients 
choosing warfarin 
Studies in patients at high risk of AF but without AF 
Devereaux et 
al., 2001, 
Canada 
n=61; 40-74 
Prospective 
observational 
Interview, PTOT 
 74% willing to take warfarin if just one stroke in 100 patients 
were prevented over 2 years 
 57% willing to accept 22 extra bleeds in 100 patients over a 2-
year period on warfarin 
 Most patients willing to take aspirin if it prevented just 1 stroke in 
100 patients over 2 years 
Fuller et al., 
2004, UK 
n=81; 81 Cross-sectional 
Qualitative interview and 
questionnaire, PTOT 
 Avoiding of stroke paramount 
 >50% would decline warfarin when presented with stroke risk 
information plus increasing ICH risk 
 Need for daily tablets, regular blood tests, and restrictions on 
alcohol, reduced number willing to take warfarin slightly 
Man Son Hing 
et al., 2002, 
Canada 
n=198; 71 (7) RCT 
Qualitative vs. 
quantitative, PTOT 
 Patients more likely to choose aspirin 
 Patients at moderate-stroke risk more likely to choose warfarin 
 No significant difference in treatment choice between groups 
Holbrook et 
al., 2007, 
Canada 
n = 98; 73.6 
(6.1) 
RCT 
Interview, decision board 
vs. decision booklet with 
audiotape vs. interactive 
 When treatment names were blinded, 40% chose warfarin, 42% 
chose aspirin and 18% no treatment 
 Un-blinding of treatment led to fewer people choosing warfarin 
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computer programme or no treatment 
 Most people chose aspirin 
Alonso-Coello 
et al., 2008, 
Spain 
n ≥96; ≥60 Cross-sectional 
Interview, PTOT and 
visual analogue scale 
 Data not yet published 
Legend: 
AF - atrial fibrillation;  
SD - standard deviation;  
UK - United Kingdom;  
US - United States of America;  
ICH - intra-cranial haemorrhage;  
PTOT - probability trade-off technique;  
RCT - randomised controlled trial;  
TTO - time-trade off  
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1.4.1.5 Patient Adherence to OAC 
Data from the Anticoagulation and Risk factors in Atrial Fibrillation (ATRIA) 
Study suggest that over one in four patients newly started on warfarin therapy 
for atrial fibrillation discontinue therapy within one year (Fang, Go, Chang, 
Borowsky, Pomernacki, Udaltsova, et al., 2010). These results are consistent 
with data from clinical trials showing a 22% discontinuation in the first year and 
33% during a mean study period of 2.7 years in patients randomized to warfarin 
versus alternative agents (de Schryver, van Gijn, Kappelle, Koudstaal, Algra & 
Dutch TIA and SPIRIT study groups, 2005; Mant et al., 2007), as well as an 
observational study demonstrating that 26% of patients older than 79 years 
newly started on warfarin had stopped therapy within the first year (Hylek, 
Evans-Molina, Shea, Henault, Regan, 2007). However, in another more recent 
study conducted in the US, non-persistence with treatment on warfarin was 
reported in 46.5% of the AF patients on warfarin during at least one year 
(Song, Sander, Varker, & Amin, 2012). Song et al. (2012) found that this was 
similar to other long-term medications commonly prescribed to the AF 
population in their study. Although a high frequency of haemorrhagic events 
partially explained the significant discontinuation rate in one study (Hylek et al., 
2007), discontinuation rates were large even in studies without many major 
bleeding episodes (Mant et al., 2007; Fang et al., 2010). Similarly, in Song et 
al.’s (2012) study 42.6% of AF patients on warfarin permanently 
discontinued the OAC treatment within one year. This was also consistent with 
the discontinuation rate of 32.9%-52.0% of other long-term medications in this 
study (Song et al., 2012). 
 
Although a higher risk of haemorrhagic complications is associated with old 
age, studies have found that younger age is a risk factor for poor warfarin 
adherence (Arnsten, Gelfand, & Singer, 1997; Gallagher, Rietbrock, Plumb, & 
van Staa, 2008). Patients with fewer risk factors for stroke were also found  to 
have lower adherence rates with warfarin (Arnsten et al., 1997; Gallagher, et 
al., 2008; Go et al., 1999). Prevalence and risk factors of inconsistent warfarin 
use was examined in the INR Adherence and Genetics (IN-RANGE) study 
(Kimmel, Chen, Price, Parker, Metlay, Christie, et al., 2007; Platt, Localio, 
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Brensinger, Cruess, Christie, Gross et al., 2008) by monitoring patient 
adherence through the use of electronic pill bottle caps for almost eight months. 
The study revealed that 92% had at least one missed or extra bottle opening 
and 36% of the participants missed more than 20% of the prescribed bottle 
openings. In addition, findings show a link between poor adherence and 
several risk factors, including education beyond high school and being actively 
employed, but also to lower mental health functioning and poor cognitive 
functioning (Platt et al., 2008). 
 
Active employment has also been found to be a risk factor for poor adherence 
for both anticoagulation as well as other diseases (Ediger, Walker, Graff, Lix, 
Clara, Rawsthorne, et al., 2007; Palareti, Legnani, Guazzaloca, Lelia, Cosmi, 
Lunghi, et al., 2005). This might be due to the fact that patients who are 
employed might have greater competing time interests, than patients who are 
unemployed or pensioners. On the other hand, while poor adherence was 
associated with active employment, so was extreme poverty. Data from an 
underserved urban population in the US showed an association between an 
annual income greater than $10,000 and higher self-reported adherence rates 
(Davis, Billett, Cohen, & Arnsten, 2005). 
 
Investigation into psychosocial determinants specific to warfarin adherence has 
been limited, but evaluation of medically ill patients in general has identified 
multiple associated factors including depressive symptoms, perceived lack of 
social support, poor cognitive function, and poor health related QoL (Nikolaus, 
Kruse, Bach, Specht-Leible, Oster & Schlierf, 1996; Schauer, Moomaw, Wess, 
Webb & Eckman, 2005; Schillinger, Wang, Rodriguez, Bindman & Machtinger, 
2006; Wang, Bohn, Knight, Glynn, Mogun & Avorn, 2002). In a study of patients 
on warfarin for non-valvular atrial fibrillation, patients with presumed 
psychosocial risk factors for non-adherence, in particular substance abuse, had 
increased risk for adverse medical outcomes, though adherence rates were not 
directly assessed (Schauer et al., 2005). It was found that only 9.7% of studied 
patients with new atrial fibrillation filled a prescription for warfarin within 30 days 
of diagnosis (Johnston, Cluxton, Heaton, Guo, Moomaw & Eckman, 2003). In 
Johnston et al.’s (2003) cohort study, alcohol and drug abuse, psychiatric 
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disease, homelessness, and lack of caregiver support were inversely related to 
warfarin use, though the study could not differentiate between patients who 
were given a prescription and failed to fill it versus those who never received a 
prescription. Cognitive functioning has inconsistent associations with 
adherence, but such studies might be confounded by caregiver involvement 
(Nikolaus et al., 1996; Schillinger et al., 2006). 
 
In addition to psychosocial determinants of warfarin use, a few studies have 
investigated attitudinal correlates to warfarin adherence. A study of patients in 
an academic anticoagulation clinic evaluated self-reported compliance and 
found that in addition to being homeless, non-married, and having a higher pill-
burden, patients’ perceptions of barriers to taking warfarin correlated to poor 
compliance (Orensky, & Holdford, 2005). Interestingly, Orensky and Holdford 
(2005) elected to use the word ‘compliance’ throughout their study, denoting 
the possible adoption of a paternalistic attitude or a lack of awareness about 
this issue. Barriers measured in this study included the perception of taking too 
many pills, the perception that taking warfarin increases worry about bad health 
outcomes, and the perception that taking warfarin increases bruising and 
bleeding. Qualitative data also hint at the potential impact of high pill burden as 
a perceived barrier to warfarin adherence (Dantas et al., 2004). In another 
analysis, trends linking several attitudinal assessment scores with warfarin non-
adherence were found (Cruess, Localio, Platt,Brensinger, Christie, Gross, et 
al., 2009). Of these attitudinal scores, higher ‘Information Discomfort,’ 
specifically a measure of ‘patient reluctance to hear information about their 
medical conditions and treatments,’ was independently associated with poor 
adherence (Cruess et al., 2009). 
 
1.4.2 Physician barriers 
1.4.2.1 Stroke risk reduction; Physicians’ vs. patients’ beliefs 
Devereaux and colleagues (2001) conducted an observational study, using 
educational information and clinical scenarios, to compare physicians’ (n=63) 
and patients’ (n=61) perceptions on the degree of bleeding on OAC  and the 
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reduction in the risk of stroke, that was acceptable for warfarin to be prescribed 
or taken as treatment (Devereaux et al., 2001). Researchers found that 74% of 
patients were willing to accept warfarin if one stroke in 100 patients was 
prevented, however 62% of physicians refused to prescribe warfarin based on 
the same risk reduction. Similarly, patients were more willing to accept a higher 
risk of bleeding (22 additional episodes of bleeding in 100 patients over a 
period of two years); there was little consistency amongst physicians on the 
acceptable level of risk of excess bleeding (Devereaux et al., 2001). This study 
demonstrated that patients were more willing to accept the risk of bleeding 
associated with OAC in order to prevent a stroke whilst physicians were more 
concerned with the risk of treatment-associated bleeding (Devereaux et al., 
2001).  
 
Similarly, in a recent national survey with Australian family physicians, 
researchers showed that experience of bleeding events and fear of bleeding in 
patients appear to influence warfarin prescription (Gattellari, Worthington, Zwar, 
& Middleton, 2008b). Furthermore, the experience of a major bleed in a patient 
with AF on warfarin, led physicians to feel responsible for this outcome. 
However, when patients experienced a stroke from not prescribing warfarin, 
which was a more common experience, it did not affect their sense of 
responsibility (Gattellari et al., 2008b).  
 
Omission bias and the closely related status quo bias are well-described and 
validated cognitive biases that result from a preference for omission or inaction 
and preservation of the status quo (Aberegg, Arkes & Terry, 2006; Ritov & 
Baron, 1999). This preference can lead decision makers to choose the risks 
and benefits of the status quo even when the relative risks and benefits of 
changing the status quo through action are objectively superior. Similarly, 
decision makers may inappropriately judge harms due to omission as less 
severe or blameworthy than harms that result from action (Aberegg, Arkes & 
Terry, 2006; Ritov & Baron, 1999). These biases stem from heuristics that 
guide everyday choices but may be barriers to optimal decision making when 
applied in contexts such as medicine in which they are not relevant. 
Researchers argued that clinicians could feel more responsible for bleeding 
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episodes rather than stroke episodes because of harm arising from ‘acts of 
commission’ as they are feel that they ‘caused’ the bleeding episode from a 
direct consequence of prescribing warfarin (Aberegg et al., 2006; Ritov & 
Baron, 1999). Tendencies toward this bias may be reinforced by the time-
honoured clinical dictum “first do no harm,” which emphasizes risk avoidance 
and may serve as a justification for “doing nothing” or “holding course.” Thus 
even when stroke risk reduction outweighs bleeding risks, physicians may 
abandon potential harmful therapies (Aberegg et al., 2006).  
 
1.4.2.2 Fear of litigation 
The difference between physicians and patients in their thresholds for 
prescribing and accepting warfarin, discussed in the previous section, could 
also be partly due to physicians’ fear of litigation when prescribing warfarin. In a 
survey conducted with general practitioners (GPs), it was found that 29% of the 
participants (126/440) reported fear of litigation as a factor that limited their 
ability to manage warfarin (Rodgers, Sudlow, Dobson, Kenny, & Thomson, 
1997). Clinical uncertainty about patient management in AF could be one of the 
reasons behind this fear. In a qualitative study conducted to improve 
understanding of physicians’ decision making in AF and the use of 
antithrombotics, when physicians were faced with complex scenarios, a small 
proportion of the participants seemed content to exercise patient-centred 
decision making to a point where the physician appeared to abdicate 
responsibility (Anderson, Fuller, & Dudley, 2007). Lipman and colleagues 
(2004) demonstrated that GPs’ way of making decisions about anticoagulation, 
whilst including research evidence, is strongly influenced by many other 
factors, which also influence their perception and interpretation of the research 
itself (Lipman, et al., 2004). They argue that decisions emerge from a complex 
social process and these are only partly influenced by a rational or objective 
evaluation of the risks and benefits of treatment (Lipman et al., 2004). 
Conversely to the fear of litigation, clinical uncertainty in AF patient 
management is commonly reported in the literature as a barrier influencing 
warfarin prescription (Bungard et al., 2000; Lipman et al., 2004; Murray et al., 
2011). Clinical uncertainty, including not being aware of the current literature 
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and guidelines or being aware of the literature but not accepting the results, 
was an often reported barrier (Bungard et al., 2000; Lipman et al., 2004; Murray 
et al., 2011). Rodgers et al., (1997) found that the GPs in their survey believed 
that guidelines on whom to anticoagulate (78%), availability of consultant 
advice (77%) and further training (48%) would facilitate their willingness in 
prescribing warfarin.  
 
1.4.2.3 Physicians’ knowledge of guidelines 
Clinical practice guidelines have become a common tool for promoting best 
care. Their impact on practice is however, highly variable (Grimshaw, Thomas, 
MacLennan, Fraser, Ramsay, Vale, et al., 2004; Lomas, Anderson, Domnick-
Pierre, Vayda, Enkin & Hannah, 1989;). A meta-synthesis was recently 
conducted to explore and synthesise qualitative research on GPs’ attitudes to 
and experiences of clinical practice guidelines (Carlsen, Glenton, & Pope, 
2007). Researchers included English, Spanish or Scandinavian qualitative 
studies whose participants were GPs and that focused on experiences and 
attitudes towards the use of clinical practice guidelines (Carlsen et al., 2007). 
Using narrative synthesis framework as their method of analysis, synthesis of 
the studies revealed six broad themes. The first theme, ‘Questioning the 
guidelines’ showed that  in most studies, GPs indicated that they were sceptical 
about the evidence base for guidelines, arguing that population-based trials 
and a narrow inclusion criteria in the studies mentioned in guidelines could 
weaken the applicability to individual patients (Carlsen et al., 2007).  The 
second theme, ‘GPs’ experience’, revolved around the anxiety GPs 
experienced when faced with guideline recommendations because their 
experience is  different than what is stated and that patients in clinics were 
more complicated than what is portrayed. GPs’ desires and empathy for 
patients that are suffering was mentioned as a factor that influenced them 
against recommendations (Carlsen et al., 2007). Additionally, the third theme, 
‘Preserving the physician–patient relationship’, non-adherence to guidelines 
was also influenced by the fear of jeopardising the relationship with the patient 
(Carlsen et al., 2007). As noted above, researchers also found that the 
emotional burden of missing a diagnosis and fear of litigation was an issue with 
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GPs. This was the main concept of the fourth theme, ‘Professional 
responsibility’ (Carlsen et al., 2007). The final two themes, ‘Practical issues’ 
and ‘Guideline format’, discuss issues that GPs believe influence the use of 
guidelines, including lack of time to read, assess guidelines and negotiating 
with patients, lack of skills with new procedures and that guidelines needed to 
be short and simple and include patient leaflets (Carlsen et al., 2007). 
 
The lack of knowledge on guidelines leads to an overestimation of the 
associated risks of bleeding and underestimation of the stroke risk during 
clinical practice, and is identified in the literature as one of the barriers to 
warfarin prescription for anticoagulation in AF (Boulanger, Kim, Friedman, 
Hauch, Foster & Menzin, 2006; Lane & Lip, 2008a; Murray et al., 2011; Taggar 
& Lip, 2008; Tay, Lip, & Lane, 2009). Similarly, in the Euro Heart Survey, 
researchers found that some of the key risk factors in patients with AF such as 
prior stroke and age >75, which are associated with a significant increase in the 
risk of stroke, were not associated with anticoagulant prescription (Nieuwlaat, 
Capucci, Lip, Bertil Olsson, Prins, Nieman, et al., 2006). Investigators in the 
Euro Heart Survey argued that stroke risk stratification schemes, to determine 
which drug is most appropriate were scarcely employed and that future 
education and guidelines should focus on providing one uniform and easy to 
use stroke risk stratification scheme (Nieuwlaat, et al., 2006). 
 
In a retrospective study to investigate the determinants of warfarin use in 
patients with AF (Choudhry, Soumerai, Normand, Ross-Degnan, Laupacis & 
Anderson, 2006),  warfarin was prescribed more often to patients who were 
male, younger, and had already received a prescription for warfarin in the past. 
Furthermore patients who were given warfarin were more likely to have stroke 
risk factors with less bleeding risk factors and were less likely to have been 
hospitalized for other reasons in the previous year (Choudhry, Anderson, 
Laupacis, Ross-Degnan, Normand & Soumerai, 2006). Researchers also 
argued that only 55.6% of the patients who had at least one major stroke risk 
factor received warfarin.  Furthermore, older patients (>90 years) and patients 
with comorbidities were associated with significantly less likelihood of being 
prescribed warfarin, possibly because of risks associated with old age 
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(cognitive function and risk of falls) and risk of bleeding associated with the 
comorbidities (Choudhry et al., 2006).   
 
Choudhry and colleagues (2006) found that patients in Canada who received 
care from family physicians with cardiology consultations were more likely to be 
prescribed warfarin (53.2%) than patients who are treated by family physicians 
(also defined as general practitioners in the study) alone (42.3%). Interestingly, 
even patients whose primary provider was a cardiologist were less likely to 
receive warfarin than patients of family physicians, even in the absence of 
cardiology consultation (Choudhry et al., 2006). They argue that cardiologists 
may be more knowledgeable about the care required for AF (Ayanian, 
Hauptman, Guadagnoli, Antman, Pashos & McNeil, 1994) and thus would only 
be more willing to prescribe warfarin if patients have another physician who is 
able to supervise therapy. Another reason given was that the involvement of 
more physicians, regardless of specialty, may result in higher quality care, and 
that patients who agree to see a cardiologist may be more likely to accept 
warfarin (Choudhry et al., 2006; Rutten, Hak, Stalman, Verheij, & Hoes, 2003).  
 
These results suggest that some medical practitioners are either not aware of 
the current guidelines for thromboprophylaxis for AF or they are actively 
choosing not to prescribe warfarin to eligible patients. Nevertheless, according 
to more recent results from the Euro Heart Survey (Nieuwlaat, et al., 2006), 
only 33% of eligible patients were not prescribed warfarin. Nieuwlaat et al. 
(2006) argue that the increase in warfarin prescription in this survey could be 
due to several factors, including the fact that the cohort was not representative 
of average Europeans and the use of a relatively high proportion of university 
and specialized centres in the survey. Conversely, an interesting finding of this 
survey was the fact that 40% - 50% of patients, who fall in the low risk 
category, were prescribed warfarin. This means that a high proportion of 
patients were being exposed to a relatively high bleeding risk, when anti-
platelet therapy would suffice (Nieuwlaat, et al., 2006).  
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1.4.3 Health-care system barriers 
1.4.3.1 Consultation time constraints 
On average, patient visits in the US last about 16 minutes (Fiscella & Epstein, 
2008; Mechanic, McAlpine, & Rosenthal, 2001; Tarn, Paterniti, Kravitz, 
Heritage, Liu, Kim, et al., 2008). The average amount of time spent with 
patients in the UK is even less than that (Deveugele, Derese, van den 
Brink-Muinen, Bensing, & De Maeseneer, 2002). Analysis of videotaped 
consultations of general practitioners in six European countries revealed that 
the overall mean length of consultation was 10.7 minutes, ranging from 7.6 
minutes to 15.6 minutes; in the UK, the mean length of consultations was 9.4 
minutes (SD 4.7). The literature suggests that this is not enough time to 
transmit higher quality information, to establish rapport, to effectively address 
patient needs and tackle multiple complex problems (Braddock, Edwards, 
Hasenberg, Laidley & Levinson, 1999; Fiscella & Epstein, 2008; Tarn et al., 
2008). By analysing tape recordings, Tarn et al. (2008) found that most of the 
time available is allocated to justification and purpose of the prescribed 
medication, directions of use and side effects. Furthermore, this time would 
need to be increased if physicians also talked about guidelines and if the 
patient was accompanied by family or friends (Tarn et al., 2008). In addition, 
more time is needed when consultations are done across different race, 
ethnicity, language and educational level (Fiscella & Epstein, 2008; Lott, 2002; 
Saha, Komaromy, Koepsell & Bindman, 1999). Such barriers severely limit 
patients’ ability to understand information together with the physicians’ capacity 
to confirm patients’ understanding and ability to taketake an informed decision 
(Braddock, Fihn, Levinson, Jonsen, & Pearlman, 1997; Braddock et al., 1999; 
Fiscella & Epstein, 2008).  
 
1.4.3.2 Health-care system influences on OAC monitoring 
In a survey conducted in the UK by Rodgers et al., (1997) several health care 
system barriers were found that limited the ability of GPs to manage warfarin, 
including lack of time (57%), delay in receiving laboratory results (40%) and 
space constraints (22%). Results from the Euro Heart Survey also showed that 
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the absence of an OAC monitoring outpatient clinic leads to a lower probability 
of warfarin being prescribed, and also an increased frequency in the 
prescription of an antiplatelet drugs (Nieuwlaat et al., 2006). 
 
A systematic review and meta-regression was conducted to describe and 
explore the effects of different settings on anticoagulation control (van 
Walraven, Jennings, Oake, Fergusson, & Forster, 2006) and evaluated 67 
studies involving 50,208 patients with 57,155 patient-years of follow-up. The 
overall percentage of time spent in the therapeutic range was 63.5% (95% CI, 
61.6-65.6%). However, anticoagulation control varied extensively among study 
groups, with study setting, drug type, and self-monitoring being the most 
important factors influencing anticoagulation control. In their meta-regression, 
van Walraven et al (2006) found that anticoagulation setting had the greatest 
effect on anticoagulation control with studies in community practices having 
significantly lower control than either anticoagulation clinics or clinical trials 
(−12.2%; 95% CI = −19.5 - −4.8; p < 0.0001). Self-management was also 
associated with a significant improvement of time spent in the therapeutic 
range (+7.0%; 95% CI = 0.7 - 13.3; p = 0.03).  
 
Similarly, another meta-analysis was conducted to evaluate the effect of 
specialty clinic versus usual care by community physicians on anticoagulation 
control, measured as the proportion of time spent in therapeutic INR range, for 
AF patients that received warfarin anticoagulation in the United States (Baker, 
Cios, Sander, & Coleman, 2009). Authors assessed eight studies involving 
22,237 warfarin-treated AF patients with 41,199 years of follow-up. AF patients 
in the 14 groups spent 55% (95% CI = 51 - 58) of their time within the 
therapeutic INR range. In the studies found by Baker et al (2009) patients in 
anticoagulation clinics spent on average 63% (95% CI = 58 - 68) of their time in 
the therapeutic range versus 51% (95% CI = 47 - 55) for patients in community 
practice. Therefore when compared patients treated in the community setting 
spent 11% (95% CI = 2 - 20) less time in therapeutic INR range (Baker et al, 
2009).  
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1.5 Rationale 
Several studies have shown that although warfarin is the recommended 
antithrombotic treatment for AF patients at moderate to high-risk of stroke, it is 
still underutilized. Reasons why physicians choose not to prescribe warfarin to 
eligible patients is very limited and there are no qualitative studies that explore 
the experiences that influence physicians’ decisions to prescribe or withhold 
warfarin in AF patients. Additionally, there is also a paucity of qualitative 
literature that explores the factors that influence AF patients’ acceptance or 
refusal of warfarin.  
 
The importance of treating the patient and not just the disease is recognised by 
the NHS (NHS Department of Health, 2010). Each person is a unique mix of 
thoughts, emotions, personality, behaviour patterns, and their own personal 
history and experiences. Thus by utilising qualitative methods, studies can 
focus on an exploratory in-depth approach that allows the idiographic analysis 
of the participants’ experiences in making sense of what is going on in the 
consultation and AF and OAC with warfarin.  
 
The study will be divided into two related projects. Study 1 will explore the 
experiences, beliefs and attitudes of patients diagnosed with AF during their 
initial consultation and what influenced them to accept, refuse or discontinue 
warfarin as their blooding thinning medication. Study 2 will explore physicians’ 
experiences, beliefs and attitudes during their initial consultation with a patient 
diagnosed with AF and their reasons for prescribing/withholding such 
medication.  
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1.4 Aims  
The overall aim of the programme of work is to explore patients’ and 
physicians’ experiences of AF and anticoagulant therapy in two related studies.   
 
Study 1 
To explore the experiences, beliefs and attitudes of patients diagnosed with AF 
during their initial consultation and what influences them to accept, refuse or 
discontinue warfarin as their blooding thinning medication. 
 
Research Questions 
What are the experiences, beliefs and attitudes of patients diagnosed with AF 
during their initial consultation? 
What are the experiences, beliefs and attitudes that influence patients' 
decisions to accept, refuse or discontinue warfarin as their blood thinning 
medication? 
 
Study 2 
To explore physicians’ experiences, beliefs and attitudes during their initial 
consultation with a patient diagnosed with AF and their reasons for 
prescribing/withholding such medication.  
 
Research Questions 
What are physicians’ experiences, beliefs and attitudes during their initial 
consultation with a patient diagnosed with AF? 
 
What are the experiences, beliefs and attitudes that influence warfarin 
prescription by physicians? 
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Chapter 2: Patients’ and health professionals’ views and 
experiences of atrial fibrillation and oral-anticoagulant therapy: 
a qualitative meta-synthesis 
2.1 Introduction 
AF is the most common arrhythmia in clinical practice and is associated with 
increased morbidity and mortality (Camm et al, 2010; NICE, 2006;).  AF is an 
independent risk factor for stroke conferring a risk five times that of matched 
controls (Wolf et al, 1991). Hence, stroke risk reduction with antithrombotic 
therapy is a crucial component of AF management (Camm et al, 2010; Lane & 
Lip, 2008a). Guidelines recommend life-long OAC for patients with one or more 
risk factors for stroke (Camm et al., 2010). However, such therapy remains 
underutilised (Ogilvie et al., 2010; Ogilvie, Welner, Cowell, & Lip, 2011). 
 
There are a number of complex factors which make prescription, and 
adherence, of OAC challenging. Physicians may display uncertainty about 
balancing the risk of stroke and the risk of bleeding, which may be passed onto 
patients (Bungard, et al., 2000). Two recent systematic reviews emphasised 
the impact of physicians’ apprehension about feeling responsible for a major 
bleed which seemed to outweigh their concern about risk of stroke (Choudhry 
et al., 2006; Pugh, et al., 2011). This may be related to the Hippocratic Oath to 
‘first do no harm’ (Aberegg, Arkes & Terry, 2006): responsibility is attributed to 
harm perceived by ‘acts of commission’, i.e. prescribing OAC, which are not felt 
with ‘acts of omission’, i.e., increasing the risk of stroke by not prescribing OAC 
(See section 1.4.2.1).  
 
In addition to factors relating to health professionals, very little is known about 
patients’ understanding of AF and OAC treatment. What we do know is that 
patients with AF report poorer QoL compared to the general population (Thrall, 
et al., 2006; Lane & Lip, 2008b), and greater levels of anxiety (Thrall et al., 
2007). 
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This meta-synthesis will address the need to consolidate existing evidence 
about patients’ and physicians’ experience of AF and OAC. The complexity 
inherent in this field make the need for patient-centred care, effective 
communication skills, and individually-tailored education, as recommended by 
AF guidelines (NICE, 2006; Camm et al., 2010), particularly significant. The 
benefit of incorporating qualitative evidence like that presented in this meta-
synthesis within the larger hierarchy of evidence is that it can add depth; it can 
bring the focus back to the individual to ensure that population-based findings 
retain their applicability to the individual case (Carlsen, et al., 2007). 
Consequently a meta-synthesis of qualitative evidence examining patients’ and 
health professionals’ experiences and beliefs about AF and OAC therapy was 
conducted to determine what is already known, implications for practice and to 
indicate where further research should be focused.  
 
2.1.1 Aim 
The aim of the meta-synthesis was to explore and review the qualitative 
literature  on patients and healthcare professionals perspectives on the 
experiences of AF and OAC therapy. This was achieved by synthesising 
studies that adopted a qualitative approach for data collection (such as 
interviews and focus groups) and data analysis (including thematic analysis, 
framework analysis, grounded theory etc), to explore experiences of patients’ 
and/or health professionals’ experiences of atrial fibrillation and/or 
anticoagulation by warfarin. 
2.2 Method 
Meta-synthesis of qualitative evidence is modelled on traditional systematic 
review methodology (Shaw, 2011) and follows the methodological techniques 
described in Taylor, Shaw, Dale & French (2011). A systematic search 
strategy, screening and quality appraisal were employed. 
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2.2.1 Systematic search 
Search terms were developed from two main bibliographic database 
categories: ‘atrial fibrillation’ and ‘anticoagulant therapy’; a qualitative 
methodology filter was used to ensure the retrieval of qualitative studies (Shaw, 
Booth, Sutton, Miller, Smith, Young, et al., 2004: see Appendix A for the full 
search strategy). Web of Knowledge, Ingenta connect, ScienceDirect 
(EBSCO), Swetswise, Sage Journals online, PsycInfo and the Cochrane 
Library were searched to include publications up to 26th August 2011. The UK 
electronic theses online service (EThOS) and Google scholar were searched to 
identify UK dissertations and grey literature. 
 
2.2.2 Screening 
Studies retrieved were screened using the following inclusion criteria: studies 
that explored views or experiences of patients or carers and/or health 
professionals (e.g. physicians and/or nurses and/or pharmacists) about AF 
and/or OAC using qualitative methods (defined as using qualitative techniques 
for recruitment strategies, data collection, and data analysis). Once screened, 
duplicates were removed and reference checking and citation searches were 
conducted. Authors were contacted directly if pertinent data or methodological 
information such as the method of data analysis used were missing. 
 
2.2.3 Critical appraisal 
The quality of studies was appraised using the Critical Appraisal Skills 
Programme (CASP) Tool for qualitative research (Public Health Resource Unit, 
England [CASP], 2006), independently by each member of the research team 
(CBX, RS, DAL), who then met to discuss their quality appraisal and agree on 
the quality of the studies (see Appendix B). Papers were deemed to be of low 
quality when any or all of the following issues were identified: incomplete 
description of the methods used, missing qualitative data linking to authors’ 
interpretations and conclusions, and omission of discussion of the 
trustworthiness of the study. Papers with missing data although deemed to be 
of low quality were not excluded but their findings were given less “weight” 
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during the synthesis process (Dixon-Woods, Bonas, Booth, Jones, Miller, 
Sutton, et al., 2006).    
 
2.2.4 Synthesis of the studies 
Synthesis of studies (i.e. the method of analysis) followed the principles 
outlined by Malpass et al. (2009). Articles were read in-depth and their findings, 
including the original authors’ interpretations and conclusions were recorded in 
data extraction forms. Key themes and categories were identified (first-order 
constructs) and grouped through descriptive coding to form second order 
constructs (See Table 6 for an example). First order constructs are study 
participants’ interpretations of their experience (direct quotes from participants 
and or authors comments) and they represent sub-themes; second order 
constructs are the grouped themes of all the studies developed through 
descriptive coding; second order constructs represent the themes.  
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Table 6: Examples of first-order constructs and the development of second-
order constructs 
 
First-order constructs  
Developing 
second-order 
constructs 
Lipman et al, 2004 Anderson et al, 2007 
“I like to advise… identify 
what the patient thinks 
they need, what I think 
they should have, and 
then if it’s acceptable we 
come to an agreement 
and we try to take it 
forward, its negotiation, try 
more and more nowadays 
to do that in a 
consultation…” (GP1) 
“I would almost put the 
decision or the ball in his 
court and I would go down 
the lines of describing to 
him his absolute and 
relative risk reductions 
with aspirin and warfarin… 
and I’d see what he’d 
prefer to do” (Physician) 
 
 
The physician’s 
perspective of the 
decision making 
process 
 
Dantas et al, 2004 Bajorek et al, 2006  
 
 
The patient’s 
perspective of the 
decision making 
process 
 
 
“I can recall that I had no 
objection. I said, "You are 
the experts, you are the 
doctors. If I get any help, I 
mostly will appreciate 
it.".... I don't think I would 
trust myself that much (to 
make the right decision).” 
(P15) 
 
Nurses believed that 
patients were generally 
familiar with what type of 
medication warfarin was (a 
‘blood thinner’), although 
they did not always 
understand why it was 
prescribed for them. 
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The synthesis then involved the interpretative activity of translating studies into 
each other, i.e. comparing and contrasting second order constructs to identify 
third-order constructs, which are the researchers interpretations, of the study 
authors’ interpretations of the participant interpretation of their experience. 
These higher ordinate themes, or third order constructs, represent the 
collective meanings of findings from individual papers to enable a theoretical 
interpretation of the phenomenon. This whole process was facilitated by the 
use of mind maps (See Figure 2) and discussions (led by CBX) with the 
research team (CBX, RS, DAL) to think through interrelations between first- 
and second-order constructs within and between papers to ensure the 
development of third-order constructs remained true to the data throughout the 
synthesis.  
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Figure 2: Example of a mind map used in the development of third-order 
constructs 
 
 
 
 
Figure 2 Legend: 
 
 
: Direction of process 
 
: Description of “action” or Influences on “action” 
 
:Diverging perspectives 
 
: Action or perspective 
AF is documented 
through ECG
Patients feel symptoms 
and get stressed 
because of 
misdiagnosis
Patients relieved that 
there was a cause
Brief consultation, with 
insufficient information on AF 
and OAC
Patient’s perspectiveDoctor’s perspective
The doctor took the 
decision (trusting the 
expert, and not 
voicing concern)
It is a shared 
Decision
D
ecid
in
g
 o
n
 O
A
C
 
th
era
p
y
Challenges surrounding OAC 
prescription and acceptance
Patient 
beliefs
Education on OAC
Lifestyle 
changes
Communication 
between health 
professionals
Balancing the need for 
OAC with lifestyle of 
older people
(mobility, cognition)
Feelings of liability 
Lack of clear 
guidelines and 
further training 
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2.3 Results 
The topic-based search terms yielded over 100,000 references but with the 
inclusion of the qualitative methodology filter this number was reduced to 12 
unique studies (see Figure 3 for the PRISMA flow diagram, which helped in 
depicting the flow of information through the mapping of the number of records 
identified, included and excluded, and the reasons for exclusions).  
 
 
Two studies were excluded: one explored experiences of patients with an 
implantable atrial defibrillator (Deaton, Dunbar, Moloney, Sears, & Ujhelyi, 
2003); another was a method-based paper about using qualitative research to 
discontinue one arm of a trial (Murtagh, Thomson, May, Rapley, Heaven, 
Graham,  et al.,  2007). These two studies were excluded since the aims 
explored by the relevant authors were not conducive to the aims of the meta-
synthesis. Ten studies met the inclusion criteria and were included in this meta-
synthesis (see Table 7 for summary of study characteristics).  
 
 2.3.1 Critical appraisal 
Quality of studies was assessed using the Critical Appraisal Skills Programme 
(CASP) Tool for qualitative research (Public Health Resource Unit, England 
[CASP], 2006). The papers reviewed were judged to be of generally good 
quality. Only Howitt and Armstrong (1999) and Murray et al. (2011) were 
deemed to be of lower quality. Common weaknesses within both studies 
included the lack of a clear description of analytic method and insufficient raw 
data from participants to support interpretations. However, this may have been 
caused by the journals’ restrictions with regards to word limit. 
 
No papers were excluded on the basis of critical appraisal discussions. 
However, the appraisal exercise was completed to highlight potential limitations 
with individual papers.  
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2.3.2 Theoretical frameworks of studies 
The studies used various methodological frameworks and methods: thematic 
analysis (Howitt & Armstrong, 1999; McCabe, Schumacher & Barnason, 2011b; 
Murray et al., 2011; Wild, Murray & Donatti, 2011), thematic analysis with a 
phenomenological approach (Bajorek, Krass, Ogle, Duguid, & Shenffield, 2006; 
Bajorek, Ogle, Duguid, Shenffield & Krass, 2007), content analysis (Dantas et 
al., 2004; Fuller et al., 2004), framework analysis (Lipman et al., 2004; Murray 
et al., 2011), grounded theory (Anderson et al., 2007). 
 
It may be argued that the synthesis of research with different epistemological 
standpoints is not desirable as each individual study is theoretically unique 
(Sandelowski, Docherty, and Emden 1997). However, researchers commented 
that combination of findings from different epistemological approaches can 
enhance the synthesis (Finfgeld, 2003; Yardley & Bishop, 2010; Zimmer, 
2006).  
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2.3.3 Findings 
The four third-order constructs identified are presented in series (see Table 8).  
 
Figure 3: PRISMA diagram depicting the selection of relevant studies 
Articles identified by databases using category 
terms “atrial fibrillation” and “anticoagulant therapy”: 
(246,781 AND 435,030) 
N= 11191 
Articles identified through 
other sources: 2 
Full-text articles 
screened: 
N= 12 
Articles identified by inclusion of 
qualitative filter: 
N= 10 
Reason for exclusion: 
Experiences other than ones 
in inclusion criteria: 1 
Qualitative reasons for 
terminating of trial: 1 
Included studies 
N=10 
Qualitative filter: “Qualitative*”, 
“Finding*”, “Interview*” and Thesaurus 
terms “Interviews” 
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Table 7: Summary of the characteristics of included studies 
 
Author, year, country, 
journal 
Aim Demographics [mean age 
(SD),% male] 
Methods of data collection and 
analysis 
 
Howitt & Armstrong 
(1999) 
UK. British Medical 
Journal 
To determine the extent to which 
implementation of an evidence based 
treatment, anti-thrombotic treatment in 
AF, is possible in general practice. 
 
 N = 56 patients [†] 
 
 
 Face to face semi-structured interviews 
 Thematic analysis (information through 
email) 
 
Dantas et al (2004), 
Canada. BMC Family 
Practice 
To examine the experience and 
perspective of patients on long-term 
warfarin therapy for AF, and compare to 
physician-identified barriers reported by 
Bungard et al 2000. 
 
 N = 21 patients [74yrs(†), 
57%]  
 Face to face semi-structured interviews  
 Content analysis 
Lipman et al (2004), UK. 
Family Practice 
To explore how GPs with an active 
interest in research or evidence based 
medicine make decisions about 
anticoagulation in patients with AF 
 
 N = 11 GPs [43yrs(†), 82%]   Face to face semi-structured interviews  
 Framework method 
Fuller et al (2004), UK. 
Age and Ageing 
 
To examine treatment choices of older 
patients when given information about the 
cumulative benefits of warfarin on stroke 
risks over a 10 year period, and 
qualitatively examine the themes that 
surrounded these decisions 
 
 N = 81 patients [81yrs(†), 
55%] 
 Face to face discussions 
 Content analysis 
Bajorek et al (2006), 
Australia. Australian 
Journal of Advanced 
Nursing 
 
 
 
To explore the nurses’ experiences 
surrounding the long-term use of warfarin 
in elderly patients 
 N = 11 nurses [42.5yrs 
(10.4), 0%] 
 Focus-group interviews 
 Thematic analysis with a 
phenomenological approach 
  
 
 
8
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Anderson et al (2007), 
UK. Quarterly Journal of 
Medicine 
To improve understanding of physicians’ 
behaviour and attitudes in respect to  
decision making in AF and the use of anti-
thrombotics 
 
 N = 14 [†] 
 5 cardiologists (2 
Consultants, 3 SpRs) [†] 
 9 physicians in geriatric or 
general medicine (4 
Consultants, 5 SpRs) [†] 
 
 Face to face semi-structured interviews 
 Grounded theory 
Bajorek et al (2007), 
Australia. Medical Journal 
of Australia 
 
To explore the attitudes of doctors, other 
health professionals, patients and carers. 
 
 N = 63 participants (8 
groups) 
 Group 1: 6 patients, 1 career 
[78.9yrs (4.1), 43%] 
 Group 2: 8 patients, 2 carers 
[76yrs (9.2), 50%] 
 Group 3: 5 consultants, 1 
registrar [42yrs (10.7), 33%] 
 Group 4: 3 consultants, 3 
registrars [41yrs (13.8), 
66%] 
 Group 5: 8 GPs [51.8yrs 
(11.1), 75%] 
 Group 6: 11 nurses [42.5yrs 
(10.4), 0%] 
 Group 7: 9 hospital 
pharmacists [39.6yrs (11.8), 
11%] 
 Group 8: 6 community 
pharmacists [50.5yrs (16.9), 
83%] 
 
 Focus-group interviews 
 Thematic analysis with a 
phenomenological approach 
 
Wild et al (2009), UK, 
USA, Spain. Expert 
Reviews 
Pharmacoeconomics 
Outcomes Research 
To explore patients’ perspectives 
of VKA therapy in respondents with atrial 
fibrillation or venous thromboembolism 
 
 N = 60 patients [60yrs (†), 
57%] 
 
 20 patients from each 
country, 47% with AF/53% 
with VTE 
 Face to face semi-structured interviews  
 Analysed with ATLAS using thematic 
analysis 
  
 
 
8
1
 
 
McCabe et al (2011b), 
USA. Journal of 
Cardiovascular Nursing 
To describe the experience of living with 
recurrent symptomatic AF. 
 N = 15 patients [59.8yrs 
(14.5), 53%] 
 
 Patients who are undergoing 
treatment with an anti-
arrhythmic drug or 
scheduled for ablation 
therapy for AF 
 
 Face to face semi-structured interviews 
and field notes 
 
 Thematic analysis 
 
Murray et al (2011), 
Canada, Canadian 
Journal of Cardiology 
i) To determine the attitudes and clinical 
practice gaps in knowledge, skill, and 
competence among community-based 
physicians  
ii) To provide evidence to guide the 
development of educational interventions 
to effectively address the clinical practice 
gaps 
 
 Family physicians: 6 (21%) 
[†] 
 Cardiologists: 8 (29%) [†] 
 Internists: 2 (7%) [†] 
 Emergency physicians: 6 
(21%) [†] 
 Neurologist: 1 (4%) [†] 
 Patients with AF: 5 (18%) [†] 
 Semi-structured telephone interviews 
 Analysed with N-Vivo7.0 using open 
coding and later selective coding. 
Legend: † - not reported; AF – Atrial fibrillation; SD – Standard deviation; VKA – Vitamin K antagonists 
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Table 8: Map of second and third-order constructs 
 
Second-order constructs Third-order constructs 
Being diagnosed 
 
Diagnosing AF and the 
communication of information 
 
The lack of education within the 
consultation 
The patient’s perspective Deciding on OAC therapy 
 The physician’s perspective 
Patient beliefs Challenges revolving around 
patient issues 
 
Accepting lifestyle changes 
The need for on-going patient 
education and support 
Communication between health 
professionals 
Healthcare challenges 
 
Limited time allocated to patients  
Raising awareness through clear 
guidelines and the need for further 
training 
 
2.3.3.1 Diagnosing AF and the communication of information 
Only McCabe, Schumacher & Barnason (2011b) explored patients’ pre-
diagnosis experiences. They found that some were diagnosed accurately and 
quickly, whilst for others the process was slow because arrhythmia is difficult to 
document on an ECG and AF symptoms are not always clear which led to 
some patients being misdiagnosed with stress. Murray et al (2011) also found a 
lack of agreement on the severity of AF and physicians expressed a lack in 
confidence in detecting paroxysmal AF (i.e. self-terminating episodes of AF 
typically lasting <48 hours but no longer than 7 days) due to its intermittent 
nature. Nevertheless, once AF was diagnosed, patients reported a sense of 
relief despite this sometimes being shocking news (McCabe et al, 2011b).  
 
“The doctor came in and said: “The good news is you’re not crazy. 
The bad news is there is something wrong.” I’m like - I told you - 
you should have believed me in the first place. It was almost a 
relief - not that something was wrong with my heart, but that at 
least I know something’s wrong. It may be fixed versus going on 
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feeling yucky and not getting an answer.” (Patient) (McCabe et al, 
2011b) 
 
Participants from three studies (Bajorek, Ogle, Duguid, Shenfield & Krass, 
2007; Dantas et al, 2004; McCabe et al, 2011b) found that additional 
information on possible treatments to control AF symptoms and OAC was 
lacking. According to their participants’ accounts, educational efforts aimed at 
increasing knowledge about AF and warfarin were minimal and insufficient.  
 
“Nobody really explained to me in full what Coumadin is all about, 
but I did some reading about it. I know it's a blood thinner, an anti-
coagulant... helps with the atrial fibrillation that I have, because 
apparently blood stays longer than it should in the atrium, and if it 
thickens it can go to your brain and you can have a stroke.” 
(Patient 8) (Dantas et al., 2004) 
 
This viewpoint is corroborated by health professionals in Bajorek et al (2007) 
study who suggest that the educational information provided is often 
inadequate to the point that existing educational resources, referring to the 
standard manufacturer-produced warfarin booklet, are not readily employed. 
Furthermore Lipman et al. (2004) explored with General Practitioners (GPs) 
what educational information on OAC was discussed during consultations. 
More than half reported that they gave a limited amount of information about 
risks of warfarin to the patient.   
 
“... I don’t use risk tools, facts and figures it’s a... more of a 
generality of erm... ‘It’s just going to reduce your risk of stroke and 
it should prolong your life’ and erm... ...you know maybe I 
shouldn’t but I don’t have... I don’t use NNTs [Number Needed to 
Treat]” (GP10) (Lipman et al., 2004) 
 
Indeed, GPs were found to have different communication styles with varying 
rates of success. Some GPs preferred discussing statistics about risks 
associated with warfarin to help the patient reach a decision about warfarin 
uptake, while others preferred to discuss the benefits of warfarin without using 
probabilities or statistics to provide a rationale for their recommendation 
(Lipman et al., 2004). 
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Patients commented that information during the consultation is often rushed. 
The following patient suggested that written information should be given, which 
could be further explained by the GP. 
 
“The cardiologist . . . says you should cut out certain food, 
vegetables, or reduce the quantities . . . I found it very difficult to 
sit on the other side of his desk and try and make notes of what he 
was saying. Now to him it is a regular thing, it is a routine thing . . . 
for me it is the first time I hear this. For 50 years I have been 
eating this or that . . . I don’t think it should be left verbally . . . 
(You) should be given a briefing sheet or something to take away . 
. . (then) see your GP and he follows this up with verbal advice.” 
(Patient) (Bajorek et al., 2007) 
 
A further complication is that diagnosis or treatment advice may be given in 
secondary care. This is not always the best context for patients to take in the 
information provided (Bajorek, Krass, Ogle, Duguid & Shenfield, 2006). 
 
“Education in the hospital ward…you are asking a lot when 
somebody is in a four bedded room…(pharmacist) trying to explain 
something to you…you can’t hear, you can’t sleep very 
well…probably not the best place for you to have all this stuff 
explained to you…only so much we can do, it’s just too hectic.” 
(Nurse) (Bajorek et al., 2006) 
 
2.3.3.2 Deciding on OAC therapy 
Following information provision at diagnosis is the decision-making process 
regarding OAC therapy. Again the literature reveals a mix of strategies. Three 
studies explored OAC therapy decision-making with patients (Dantas et al, 
2004; Bajorek et al., 2006; Bajorek et al., 2007), and in each, patients reported 
that the decision was taken by the physician and that they were happy with this 
approach.  
 
“I can recall that I had no objection. I said, "You are the experts, 
you are the doctors. If I get any help, I mostly will appreciate it.".... 
I don't think I would trust myself that much (to make the right 
decision).” (Patient 15) (Dantas et al., 2004) 
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However, other health professionals (nurses, hospital pharmacists) caution 
against this didactic consultation style, where a patient accepts a drug based 
on the trust they have in the expert (Bajorek et al., 2006; Bajorek et al, 2007). 
The argument was postulated that patients should be responsible for their 
health and voice their concerns, rather than abdicating responsibility for health 
care decisions to their physician.  
 
“A lot of the older patients – ‘my doctor says it is good for me so I’ll 
take it…they are an expert’…are pretty bad because they don’t 
ask questions.” (Nurse) (Bajorek et al., 2006) 
 
Some patients wanted sufficient information to make an informed decision but 
also required time to reflect on it before discussing it further with their GP. 
 
“I would personally prefer that I read the book first and then come 
back and say “I am not sure about this or that; could you explain 
this to me?” (Patient) (Bajorek et al., 2007) 
 
Dantas et al. (2004) found that some patients had commenced OAC while 
hospitalised because of an emergency or another illness and therefore 
preventing an active informed decision. Under these circumstances patients 
often ended up being presented with warfarin as their only therapeutic option 
which is perceived as a problem by some (Dantas et al, 2004; Bajorek et al., 
2006; Bajorek et al., 2007).  
 
“When I went into the (clinic) to see my doctor, they admitted me 
to the cardiac emergency, and they kept me there all day... I was 
in for just about a week... and when I was discharged the doctors 
explained that they were putting me on to certain medications, and 
Coumadin was one of them.” (Patient 10) (Dantas et al., 2004) 
 
“They just don’t voice a concern about taking it because they don’t 
see they have any other option…just part of the treatment that’s 
been prescribed…they have to put up with it.” (Nurse) (Bajorek et 
al., 2006) 
 
In contrast some physicians perceived this decision-making process as more of 
a negotiation (Lipman et al., 2004; Anderson et al., 2007). All GPs and senior 
physicians in these studies argued that patients’ ideas, concerns and 
expectations about OAC therapy should be central to consultations but the 
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conclusion was that there was “a range of views as to the extent to which 
physicians would allow patients to be the ‘final’ decision-maker” (Anderson et 
al., 2007). 
 
“I like to advise… identify what the patient thinks they need, what I 
think they should have, and then if it’s acceptable we come to an 
agreement and we try to take it forward, it’s negotiation, try more 
and more nowadays to do that in a consultation…” (GP1)(Lipman 
et al., 2004) 
 
“I would almost put the decision or the ball in his court and I would 
go down the lines of describing to him his absolute and relative 
risk reductions with aspirin and warfarin… and I’d see what he’d 
prefer to do” (Physician) (Anderson et al., 2007) 
 
However GPs feel responsible for the outcome (stroke or bleeding event) when 
a patient doesn’t take the “right” treatment decision (Lipman et al, 2004). This is 
more often the case with the ‘family-doctor’ relationship built over time, than 
hospital physicians (Lipman et al, 2004). These feelings often prevent GPs 
from prescribing warfarin for fear of causing bleeds.  
 
“Well it’s my fault for putting it in a way that . . . that perhaps didn’t 
put the benefits and harms quite in context. I’ve made a mistake in 
how I’ve described the risk for that individual patient because they 
made a decision which I think is probably the wrong decision . . .” 
(GP4) (Lipman et al, 2004) 
 
2.3.3.3 Challenges revolving around patient issues 
Researchers found that patients’ beliefs were influenced by their ‘experiential’ 
knowledge (Pinder, 2008) that is knowledge gained through first-hand 
experience. This knowledge often had a negative influence on warfarin 
acceptance (Howitt & Armstrong, 1999; Dantas et al., 2004; Fuller et al., 2004; 
Lipman et al., 2004).  A common patient belief mentioned in these six studies 
was the awareness of warfarin being used as rat poison.  
 
 
“‘Hang on doctor’ he said ‘That’s the stuff they use to poison rats 
with isn’t it’, I said ‘That’s . . . well it is and how do you . . . ’ and he 
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said ‘Oh I was a rat catcher for the council, I don’t want that 
because I’ve seen too many things happen to rats with that’.” 
(GP1) (Lipman et al., 2004) 
 
Similarly, older participants in Fuller et al’s (2004) study saw friends or family 
members have haemorrhagic strokes, and associated the increased risk of 
bleeding from OAC therapy with a possible haemorrhagic stroke. This could 
easily be misconstrued as the same medication that is lowering the risk of an 
embolic stroke is increasing the risk of a haemorrhagic stroke. 
 
“Bleeding into the brain – isn’t that fatal? Happened to someone I 
know” (Patient 72, aged 78) (Fuller et al, 2004) 
 
Howitt & Armstrong (1999) argued that patients who refused to take warfarin 
did not perceive themselves as vulnerable. Such patients believed that a stroke 
can only happen to people with an unhealthy lifestyle. This constitutes an 
avoidant coping mechanism, or denial, lived out in their agreement to take only 
aspirin.  
 
“People who have strokes are overweight, drink and smoke. I don't 
think it will happen.” (Patient 16, final treatment aspirin) (Howitt & 
Armstrong, 1999) 
 
There are other issues related to lifestyle which resulted in refusal of, or a 
negative perception of, warfarin: the need for regular blood tests to monitor 
anticoagulation control, the amount of time it takes to do the tests, abstinence 
of alcohol, and an ever increasing amount of tablets (Dantas et al., 2004; Fuller 
et al., 2004; Lipman et al., 2004; Bajorek et al., 2006; Wild, Murray & Donatti, 
2009; McCabe et al., 2011b) 
 
“I’ve had one patient who has refused to go on warfarin . . . 
because he doesn’t want to take it, he doesn’t want to have that 
commitment to taking medication, to being monitored you know to 
possibly having the side effects that he might have, even though 
he is aware of the potential benefits, now if that’s . . . if that’s his 
decision that’s fine by me, it’s not my life, I’m not taking warfarin 
for the rest of my life you know.” (GP11) (Lipman et al, 2004) 
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Monitoring was reported as particularly disruptive when planning holidays or 
working. These patients were more likely to feel inconvenienced than those 
who were monitored less frequently (Wild et al., 2009). Patients’ resistance to 
follow-ups was also reported as a challenge (Murray et al., 2011).  
 
“I have to miss work to get my blood work done or go visit the 
doctor to get a prescription and depending on their hours, 
sometimes I have to leave.” (Patient US Group 6) (Wild et al., 
2009)  
 
However, some patients viewed the regular blood monitoring positively as it 
confirmed their warfarin control (Dantas et al, 2004; Wild et al., 2009). 
 
“I like getting it checked. It makes me feel more comfortable, as far 
as know I’m okay.” (Patient US Group 11) (Wild et al., 2009) 
 
2.3.3.4 Healthcare challenges 
Communication between primary and secondary care was a key challenge 
identified in the synthesis (Lipman et al, 2004; Bajorek et al, 2007; Murray et al, 
2011). The lack of communication between hospital physicians and GPs meant 
neither took responsibility for patient education, which in turn has significant 
consequences for patient adherence (Lipman et al, 2004; Bajorek et al, 2007). 
 
“Decision making for who goes on warfarin is taken often by one 
person, monitoring of warfarin is taken by another person and in 
our practice people are monitored in 5 different systems, alright 
and er . . . ongoing responsibility for patient education is 
nonexistent . . . the potential risks of warfarin to me are so large in 
terms of errors basically.” (GP2) (Lipman et al, 2004) 
 
“It may create conflict with the patient too . . . especially if the other 
health professional said something (different)” (GP) (Bajorek et al, 
2007) 
 
The common problem of limited personnel and time pressures on consultation 
time was identified by health professionals, nurses and GPs, as a barrier to 
investment in patient education (Bajorek et al, 2006; Bajorek et al, 2007). 
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“The doctors all roll up at 9 o’clock in the morning to do their 
rounds - ‘yep they can go home…there are five other people down 
in A&E waiting to come up, let’s ship them down to transit lounge.’ 
- they get home and open up this little plastic bag with all their 
drugs…pharmacist hasn’t had a chance to talk to them…we 
haven’t seen what they‘re on…pressure to get them out.” (Nurse) 
(Bajorek et al., 2006) 
 
The nurse above and GP below suggested that since time is limited, 
responsibility to educate patients could be shifted to pharmacists, either at the 
hospital or in the community which may improve compliance. In addition, 
Bajorek et al. (2007) argued that such a strategy could aid patient surveillance 
and education. 
 
“If they are in there looking at the patient in-house . . . then that is 
probably quite useful . . . I usually don’t have the time. . . If the 
pharmacist is actually sitting down with them and looking at how 
they are managing their tablets at home. . . [monitoring] 
compliance [and] suggesting that the dosette is the way to go with 
this patient . . . It’s a very practical way actually.” (GP) (Bajorek et 
al, 2007) 
 
2.4 Discussion and Conclusion 
2.4.1 Discussion 
This meta-synthesis has enabled consolidation of the knowledge about 
patients’ and physicians’ understanding of AF, risk perception management in 
relation to OAC therapy and the settings in which AF is diagnosed and 
treatment discussed. AF guidelines (NICE, 2006; Camm et al., 2010) prioritise 
patient-led care which requires better rapport between physicians and patients 
than is currently represented in the literature.  
 
Shared decision-making is imperative for patient-led care. Patients’ 
experiences during the decision-making process synthesised here suggest a 
mixture of the paternalistic and interpretative models (Wirtz et al., 2006). While 
the physicians’ experiences clearly indicate that a shared decision making 
model is being used. This contradiction warrants further study but could be 
related to the patients’ trust in the expertise of the physician and may explain 
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why patients submit to physicians’ decisions. Evidence suggests that the 
concept of trust between patients and physicians is vital for a successful 
relationship (Kao, Green, Davis, Koplan & Cleary, 1998; Pearson & Raeke, 
2000), which in turn is crucial for treatment adherence. Trust, in this case, is 
manifest in a positive acceptance of the sick role and belief that physicians will 
care for their interests (Hall, Dugan, Zheng & Mishra, 2001). In critical 
consultations, where potential risk and negative outcomes are discussed, what 
is interpreted as trust in the physician could also be due to the need to escape 
the responsibility of a difficult decision.  
 
Participants, both patients and health professionals commented that lack of 
time was an issue within the health-care system both with regard to patient 
education and physician workload. Deveugeule et al. (2002) found that the 
mean length of consultations in the UK was almost 10 minutes. Similar to the 
findings of this synthesis, the literature suggests that this is not enough time to 
establish rapport with the patient, transmit information, and address the 
patient’s needs (Fiscella & Epstein, 2008; Tarn et al., 2008), which could have 
an effect on patient adherence to treatment. Findings from this study also 
demonstrate that doctorsoften refrain from changing the decision taken by 
other doctors (especially doctors in primary care changing the decision of 
doctors from secondary care) or prescribing OAC for fear of being held 
responsible. This was similar to findings from Carlsen’s et al (2007) meta-
synthesis, where the emotional burden of missing a diagnosis was tied to fear 
of litigation with GPs.  
 
Similar to the findings of this synthesis, Carlsen et al (2007) meta-synthesis 
about GPs’ attitudes to clinical practice guidelines, found that GPs were 
sceptical about evidence-based guidelines in general. GPs in this meta-
synthesis argued that population-based trials and a narrow inclusion criteria in 
the studies mentioned in guidelines could weaken the applicability to individual 
patients (Carlsen, Glenton & Pope, 2007). Healthcare professionals in this 
synthesis raised similar concerns, mentioning that RCTs do not always reflect 
the ‘common 80 year old’ patient. Sackett and colleagues also point out that the 
practice of evidence-based medicine means integrating individual clinical 
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expertise with the best available clinical evidence from systematic research 
(Sackett, Rosenberg, Gray, Haynes, & Richardson, 1996). This issue 
strengthens the need to incorporate qualitative studies not only before or after 
interventions or RCTs, but as an on-going parallel study. Such a combination of 
studies could provide the breadth covered by quantitative studies with the 
depth that only a qualitative study can provide (Yardley, 2007), thus adopting 
the holistic approach desired by guidance agencies including NICE (Kelly et al, 
2009). 
 
 
Developments in health psychology have resulted in several theoretical models 
for understanding variations in adherence to treatment (Horne & Weinman, 
1998). In explaining how beliefs might influence patients’ decisions on 
adherence with prescribed medications, Horne (1997) proposed that although 
beliefs about medicines in general influence the patients’ initial orientation 
toward medicines, adherence behaviour is likely to be more strongly related to 
personal views about the specific prescribed medication. In particular, 
adherence decisions are influenced by a cost–benefit assessment in which 
personal beliefs about the necessity of the medication for maintaining or 
improving health are balanced against concerns about the potential adverse 
effects of taking it (Horne, 1997). This means that within studies which have 
examined OAC therapy, patients’ concerns, such as the knowledge of OAC 
side effects and the need for lifestyle change, outweigh the necessity of the 
medication in the reduction of thromboembolism. This may be due to the 
complexity of OAC management where the patient has to balance the current 
risk of stroke with future risk of bleeding. In addition, unlike other medications 
such as hypertension or diabetes where the medication can (with the addition 
of other medications and appropriate self-care) ultimately ‘control’ the condition, 
OAC therapy does not  guarantee that the patient will not experience a stroke, 
however, it does reduce the  stroke risk considerably.  
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2.4.2 Conclusion 
This meta-synthesis clearly identifies the key challenges facing AF patients and 
healthcare professionals who manage their treatment, namely the importance 
of an early and accurate diagnosis, necessity of sufficient education pertaining 
to AF and available treatment, particularly OAC, and identification of patient 
barriers to treatment to improve adherence. In addition the synthesis of the 
qualitative studies emphasises the differing experiences, perceptions and 
attitudes of health professionals and patients towards AF and OAC 
commencement. This qualitative meta-synthesis further highlights that central 
to all these issues is the effective communication of information in a variety of 
formats by different health professionals, and the need for an individualised 
approach based on discussions with patients regarding their preferences for 
decision-making and treatment options rather than a ‘one-size fits all’ approach.  
 
2.4.3 Practice and Research implications 
Adopting a model of mixed evidence, utilising qualitative research with 
quantitative randomised control trials, enables a holistic approach to evidence-
based health care that contextualizes the biomedical data by also making 
sense of the social determinants of health which are critical when designing 
interventions for individuals leading complex lives (Kelly, Stewart, Morgan, 
Killoran, Fischer, Threlfall, et al, 2009). 
 
In contrast to patients’ experiences, findings show that physicians indicate that 
a shared decision model is being adopted, highlighting the need to further 
explore this dichotomy of experiences from the physicians’ and the patients’ 
own perspectives. Qualitative methodologies focusing on the individual lived 
experience of patients and physicians could help to illuminate the differing of 
opinions highlighted in this meta-synthesis.  
 
Additionally NHS policy should focus on increasing time allotted to initial patient 
consultations and improve physician education with regards to  teaching 
adequate communication techniques and skills geared towards adopting a 
more shared decision making process in the available patient contact time. 
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Patients should be regarded as active decision makers who will be more 
motivated to use their medication if imparting of information targets the 
necessity of OAC outweighing their concerns about taking it. However further 
research on patients’ and physicians’ lived experiences are required to 
corroborate this. Such research could have an impact on practice, by 
encouraging health professionals to understand and attend better to the needs 
and concerns of the patient. The following chapters, aim to expand this further 
by exploring patients’ and physicians’ lived experiences of AF and OAC.  
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Chapter 3: Methodology  
3.1 Introduction 
As outlined in the review of the literature, several studies have shown that 
although warfarin is still the recommended antithrombotic treatment for AF 
patients at moderate to high-risk of stroke, it is still underutilized. The qualitative 
literature regarding the experiences that influence physicians’ decisions in 
prescribing warfarin to patients with AF is very limited. Additionally, there is a 
paucity of qualitative literature that explores the experiences that influence 
patients to accept or refuse warfarin as their blood thinning medication. The 
systematic literature search conducted as part of the meta-synthesis of 
qualitative studies portrayed in Chapter 2, highlights this paucity with only 10 
studies available. The studies synthesised adopted various method qualitative 
methods, including: thematic analysis (Howitt & Armstrong, 1999; McCabe, et 
al., 2011b; Murray et al., 2011; Wild et al., 2011), thematic analysis with a 
phenomenological approach (Bajorek et al., 2006; Bajorek et al., 2007), content 
analysis (Dantas et al., 2004; Fuller et al., 2004), framework analysis (Lipman 
et al., 2004; Murray et al., 2011), grounded theory (Anderson et al., 2007). 
Although the studies conducted by Bajorek and colleagues (2006; 2007) 
conducted a thematic analysis with a phenomenological approach, they 
focused more on descriptive analysis rather than being interpretative. 
Conversely, this study was conducted using an IPA approach which apart from 
focusing on the phenomenological aspect, it also gives importance to the 
hermeneutic philosophical approach while maintaining an idiographic nature. In 
addition, Bajorek et al. (2006; 2007) conducted focus groups as their data 
collection method, while this study used individual interviews. There are 
advantages and disadvantages for both data collection methods. However 
individual interviews were used because of the sensitive nature of the 
phenomenon in question. The researchers felt that participants should not feel 
threatened by speaking openly about what happened in their consultation. Thus 
an individual interview offered a safer environment to build rapport between the 
researcher and participant. 
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This chapter includes the operational definitions, the rationale for the research 
methodology, the philosophical framework, research design, ethical issues and 
operationalisation of the interview guide. The project was divided into two 
interlinked studies. Study 1 explored the experiences that influence patients’ 
decision to accept or refuse warfarin as their OAC medication. Study 2 
explored the physicians’ experiences of warfarin prescription and their reasons 
for prescribing/withholding such medication.  
  
3.2 Aims and research question 
The overall aim of this empirical work is to explore patients’ and physicians’ 
experiences of AF and OAC.   
 
Study 1 
The aim of this study was to explore the experiences, which motivate patients 
to accept/decline/discontinue warfarin as their OAC medication. 
 
Research question 
What are the experiences which motivate patients to accept/decline/discontinue 
warfarin as their OAC medication? 
 
 
Study 2 
The aim of this study was to understand and describe the experiences that 
influence warfarin prescription by physicians. 
 
Research question 
What are the experiences that influence warfarin prescription by physicians? 
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3.3 Objectives  
To achieve the study aims, Study 1 will: 
 Explore the experiences and attitudes that have an effect on the 
patients’ decisions to accept, decline, or discontinue warfarin. 
 
 Explore the effect that these decisions have on patients’ everyday 
experiences following diagnosis of AF.  
 
Study 2 will: 
 Describe the experiences of cardiologists, general physicians, general 
practitioners and cardiology registrars in prescribing warfarin.  
 
 Explore case scenarios with cardiologists, general physicians, general 
practitioners and cardiology registrars to discover what influences their 
decisions in prescribing warfarin to patients with AF.  
 
 
3.4 The research approach 
To answer the research question, it is imperative to listen to the participants’ 
own experiences as they live their own life story and to determine their 
meaning of this phenomenon. To explore this lived experience, a qualitative 
stance was chosen for this empirical work.  
 
3.4.1 Rationale for choosing a qualitative approach  
Qualitative research is interested in exploring human experiences (Ashworth, 
2003). This type of research approach takes into account how the individuals 
experience events and make sense of the world, rather than imposing pre-
conceived ideas and assumptions (Smith, Flowers & Larkin, 2009). Such an 
‘insider’ or ‘user’ approach which explores the nuances of phenomena is 
becoming more popular in health psychology (Chapman, Parameshwar, 
Jenkins, Large, & Tsui, 2007; French, Maissi, & Marteau, 2005; John, Hale, 
Treharne, Carroll & Kitas, 2009; Pothoulaki, MacDonald, & Flowers, 2012) 
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Qualitative researchers focus on the meanings of the experience that are 
important to research participants. This is in direct contrast to quantitative 
research that aims to examine existing theory through testing variables that are 
pre-defined by the researcher (Willig, 2001). According to Willig (2001) the goal 
of qualitative research is not to predict, but rather to define and clarify events 
and experiences.  
 
In contrast to quantitative research, qualitative research, which is typically 
inductive, allows for new insights from research participants to be discovered. 
Quantitative researchers aim to test a pre-defined hypothesis on a large cohort 
(Smith, 2003) in order to generalise results in support of a truth about 
experience (Parker, 1994; Willig, 2001). In contrast, qualitative researchers do 
not aim to conduct studies that can be replicated or generalised to all people 
who have shared a similar experience but instead aim to understand the view 
of a small number of participants, from their individual reference (Smith, 2003). 
Thus, instead of attempting to test and measure variables to try to reach a 
“scientific law”, qualitative researchers believe that rather than the seeing the 
world in a universal way where people live in their different ways, the world 
should be seen individually from each person’s existence and perspective 
(Ashworth, 2003). A qualitative approach is thus more suited to explore the 
patients’ and physicians’ own individual experiences and perspectives, 
especially to understand the dichotomy of findings with regards to decision 
making outlined in the introduction. 
 
Another clear difference between quantitative and qualitative research is the 
concentration on objectivity and subjectivity. Quantitative research attempts to 
produce objective findings through controlled experiments and the 
measurement of confounding variables that could affect the ‘validity’ of the 
research such as attempting to avoid demand characteristics and experimenter 
effects and to try to maintain ecological validity (Parker, 1994). In contrast, a 
qualitative approach embraces subjectivity through reflexive practice (Elliott, 
Fischer & Rennie, 1999; Parker, 1994). Reflexivity is the practice of being 
aware about the research process through a continuous cycle of self-
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observation and self-evaluation in order to understand actions and the 
reactions and decision making throughout the research process. This reflective 
practice helps in maintaining subjectivity as it is impossible to avoid own fore-
understandings and prejudgements becoming part of the research (Finlay, 
2003a).  
 
Qualitative research can be considered more naturalistic because instead of 
attempting to conduct research in an entirely controlled environment set up by 
the researcher it acknowledges and works with the effects that the research will 
have on the participants, researchers and the overall findings (Parker, 1994). 
Additionally, qualitative research methods enable health sciences researchers 
to delve into questions of meaning, examine institutional and social practices 
and processes, identify barriers and facilitators to change, and discover the 
reasons for the success or failure of interventions (Sokolowski, 2000).  
 
Qualitative research can be loosely split into two main branches: approaches 
that explore individual experiences and a person’s individual lifeworld (a 
phenomenological position); and approaches that explore how people’s 
language constructs or defines the social world (social constructionist 
approaches). Phenomenological approaches are interested in the subjective 
experience within the socio-cultural context in which people live, thus 
experience is the unit of study in this approach. By comparison, social 
constructionist approaches are loosely deterministic in that they examine 
language and communication practices in order to determine how they facilitate 
or inhibit people’s ability to function in the social world. Language therefore 
rather than experience is the unit of study here. The current research took a 
phenomenological approach as the focus of the current research programme 
was to investigate the lived experience of patients and physicians as 
understood within the constraints of the UK health care services. 
  
3.4.2 Phenomenology 
Phenomenology is “the study of human experience and the way in which things 
are perceived as they appear to consciousness” (Langdridge, 2007, pp.10). 
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Phenomenology, rooted in early 20th-century European philosophy, involves 
the use of rich descriptions and close analysis of lived experience to 
understand how meaning is created through embodied perception (Sokolowski, 
2000). The aim of phenomenological research “is to capture as closely as 
possible the way in which the phenomenon is experienced within the context in 
which the experience takes place.” (Giorgi & Giorgi, 2003, pp. 28). Central to 
phenomenology is the individual ‘lived experience’ and a person’s perception of 
their lifeworld or, expressed another way, as the meanings people place on 
their experiences (van Manen, 1990). van Manen (1990) defined lifeworld 
through four interconnected fundamental themes: lived space (spatiality), lived 
body (corporeality), lived time (temporality), and lived human relation 
(relationality or communality). Lived space concerns with the way participants 
experience spatial dimensions of their day-to-day experience. For example,  
van Manen (1990) argues that spatiality does not mean the space inside the 
hospital, but rather the experience of entering the hospital. Another example 
could include how patients on OAC would have more existential spatial 
awareness of the potential hazards that could lead to internal bleeding, such as 
falling. The concept of the potential bleeding could then influence the lived body 
existential. The lived body existential includes aspects of habits, feelings, 
perceptions and experiences of the participants’ own body. The theme of lived 
time revolves around the temporal perspectives of past, present and future, the 
participants’ experience of subjective time rather than objective time. For 
example, how patients and physician perceive and experience time during the 
consultations. The fourth existential, lived human relation, is concerned with the 
lived relation participants have with others in the interpersonal space that they 
share, for example the experience of the relationship formed between the 
patient and their health professional.  
 
In order to locate the epistemology of the current research it is important to 
discuss some of the theoretical underpinnings of phenomenology. Therefore, 
this section briefly explores the theoretical underpinnings of phenomenological 
psychology. As will be seen, although the phenomenological movement is 
rooted in the early philosophy of Husserl, over time variations of 
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phenomenology have been taken up, embracing the ideas of existentialism and 
hermeneutics. 
 
Phenomenology proposes that central to any experience is intentionality, which 
is a key feature of consciousness (Moran & Mooney, 2002). In fact, this theory 
of intentionality is central to phenomenology. Intentionality here means that all 
experience has an object-relatedness and thus whenever we are conscious, it 
is always to be conscious of something. As human experiences are always 
already related to the world, it is mistaken to overlook this basic fact (Moran & 
Mooney, 2002). Phenomenology focuses on the inherent social situatedness of 
human experience (experience is already interpreted when lived). Therefore, it 
emphasises the investigation of the person-in-context and therefore the need to 
keep together the person and the world. This is different from other 
approaches, mainly that of Rene Descartes, whose subject-object division 
evolved into rationalism and empiricism where the focus is always on one of 
these aspects at the expense of the other. How can we ever come to 
understand the world of another person who is just as much trapped in their 
own subjectivity? Phenomenology therefore may be seen as a movement away 
from this Cartesian dualism of reality being somewhere ‘out there’ or 
completely separate from the individual (Koch, 1996). Phenomenology offers 
the researcher an explanation of how the experiencing participant and the 
object experienced are not externally linked but internally unified, Idhe stated 
that: 
 
“...every experiencing has its reference or direction towards what 
is experienced, and, contrarily, every experienced phenomenon 
refers to or reflects a mode of experiencing to which it is present.” 
(Idhe, 1986, pp.42-43) 
 
In phenomenological research, the researcher attempts to explore the lived 
experience as perceived by the participant. This requires a certain level of what 
Husserl termed epoché, or ‘bracketing off’ one’s own perceptions and 
preconceived ideas about the phenomenon to be open to discovering the 
phenomenon as experienced by a participant (Spinelli, 1989). However, it is 
debateable as to how much a researcher can bracket off their ideas. The 
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phenomenological movement is essentially split between early 
phenomenologists who believe that experience is transcendental (e.g. Husserl), 
and later phenomenologists who believe it is existential (e.g. Heidegger and 
Merleau-Ponty, Langdridge, 2007; Moran & Mooney 2002;). 
 
Transcendental phenomenology relates to the belief that a person can step 
outside of their experience and ‘view the world from above’, and thus believe 
that epoché is possible (Husserl, 1936). Through the epoché we can identify 
the essence of a phenomenon and it is that essence which transcends the 
individual, subjective experience. This notion, however, has been a bone of 
contention, with the majority of those that followed Husserl rejecting this type of 
philosophy.  
 
Heidegger gave the phenomenological movement an existential turn when he 
asserted that the person remained an important part in the relationship 
between the subjective lived experience and the world in which we live (Moran 
& Mooney, 2002). Existential phenomenologists believe that experience is 
embodied and we exist only through ‘being-in-the-world’. Existential 
phenomenologists therefore believe that a person cannot completely achieve 
epoché. Existential phenomenology also recognises both the temporal and 
social nature of experience. Our sense of being-in-the-world is understood 
through our concept of time where “we all live in time in a verb-like way, as 
meaning-making machines seeking to realize ourselves” (Langdridge, 2007, 
pp.39). Furthermore, we exist in a world with others and therefore all 
experiences occur in relation to other people (e.g. relationship between patients 
and physicians); ‘being-in-the-world’ can thus be thought of as being-in-the-
world-with-others. It is also important to remember the idiographic nature of 
experience. Each person’s experience of a phenomenon will be different thus 
there is no ‘correct’ interpretation. We cannot know the truth about a 
phenomenon because one person’s truth will not necessarily be the same as 
another’s (Spinelli, 1989).  
 
Similarly, Finlay (2003a, pp.107), drawing on the ideas of Heidegger, notes 
“each person will perceive the same phenomenon in a different way, each 
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bringing to bear his or her lived experience, specific understandings and 
historical background.” Moreover, experience is ever-changing, as an example 
from Spinelli (1989), the first time I see a painting in a gallery that I have been 
meaning to see for a while will be a different experience when I see it for a 
second time: “Our interpretations of the world, therefore, are not only unique, 
they are also unfixed (‘plastic’) in their meaning” (Spinelli, 1989, p.9). 
 
Phenomenological psychology also employs the use of hermeneutics (meaning 
the ‘art of interpretation’ – Smith et al., 2009). Phenomenological research is 
considered a co-creation between the researcher and the participant and the 
meanings that both bring to the data through their individual subjectivities 
(Finlay, 2003b). Thus, phenomenology acknowledges the important role that 
the researcher and their fore-understandings play in the interpretation of the 
research (Finlay, 2003b, Smith et al., 2009) yet, at the same time, recognises 
the need to remain open to the insights obtained through the participants’ 
experience. The researcher’s fore-understandings may work to block the 
participants’ meanings from appearing yet also serve to open up the 
interpretation. Thus, ‘tension’ between reduction and reflexivity occurs in 
phenomenological research whereby the researcher must ‘bracket’ their fore-
understandings yet also utilise them as a ‘source of insight’ (Finlay, 2008).  
 
This complex nature of interpretation may best be understood as a hermeneutic 
circle, whereby one needs to look at the whole to be able to understand the 
part and vice versa (Smith et al., 2009). Interpretation is seen as moving back 
and forth between the part and the whole to reach the interpretation (seeing the 
participant and the data in a holistic way; understanding the whole account in 
the transcript, but also paying attention to the smaller details within the account 
where inconsistencies or other patterns might emerge). Each time one looks at 
the part, one’s understanding of the whole becomes strengthened and with 
each strengthening of the whole, new questions and new understandings of the 
part becomes apparent. Similarly before data is collected, the researcher 
already has fore-understanding of the phenomenon under investigation, which 
inevitably becomes modified through hearing the experience of a participant. 
This new understanding causes new questions and understandings of the 
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participant’s experience to be formed. Thus the research process involves a 
constant moving back and forth between the researcher’s and participant’s 
subjectivity until a plausible interpretation is reached (Finlay, 2003a; Smith, 
2007; Smith et al., 2009). Thus researchers should proactively manage their 
interactions with their participants and the world and to actively explore how 
these encounters impact on their pre-existing beliefs and knowledge in order to 
grasp the phenomenon under study (Shaw, 2010) 
 
The complex role of the researcher’s understandings in the interpretation of 
data renders it essential for the phenomenological researcher to be reflexive 
throughout the research. Finlay (2003) defines reflexivity as the process of 
frequent reflections on both the phenomena being studied and our own 
experiences of it, so as to move beyond the bias of our fore-knowledge and our 
investment in particular research outcomes. Lamb and Huttlinger (1989, p. 766) 
state that reflexivity is “self-awareness and an awareness of the relationship 
between the investigator and the research environment”. The researcher must 
constantly reflect on their own experiences and understandings regarding the 
phenomenon under investigation from the outset and throughout the research 
process through reflexive notes or a reflexive journal 
 
To summarise, phenomenological psychology acknowledges that lived 
experience, and the meanings we place on that experience, are the result of 
‘being-in-the-world-with-others’. Experience is embodied, on-going and a result 
of our interactions with the world and others. Phenomenological psychology 
also involves a process of interpretation (hermeneutics) and acknowledges the 
intersubjectivity between the researcher and participant. In the next section 
(section 3.4.3), interpretative phenomenological analysis, the particular 
phenomenological psychology approach chosen for this research will be 
explored. 
 
3.4.3 Interpretative Phenomenological Analysis  
Interpretative Phenomenological Analysis (IPA) is a relatively recent qualitative 
phenomenological approach developed by Jonathan Smith (1996) for 
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psychological research.  Since its inception, it has become one of the most 
widely known and well-used qualitative methodologies in health psychology 
(Brocki & Wearden, 2006; Chapman et al., 2007; French et al., 2005; Smith, 
2011). 
 
As with all phenomenological approaches, the focus of IPA is the detailed 
examination of individual experiences of a particular phenomenon and the 
meanings participants attribute to these experiences. The aim of IPA is to 
conduct this examination in a way which as far as possible enables that 
experience to be expressed in its own terms, rather than according to 
predefined category systems (Smith et al., 2009).  
 
The current research project aims to understand participants’ meanings of AF 
and OAC (prescription/acceptance/refusal) through their lived experiences of it 
and therefore a phenomenological approach is suited. Grounded theory, an 
approach that originated from sociology is appropriate for phenomenological 
research but its emphasis on generalising findings to whole populations means 
that any differences in individual accounts may be missed (Charmaz, 2003). As 
Willig (2001) shows, grounded theory aims to identify and explicate 
contextualized social processes which account for phenomena. By contrast, 
IPA is concerned with gaining a better understanding of the quality and texture 
of individual experiences (i.e. it is interested in the nature or essence of 
phenomena).  
 
As discussed previously (see section 3.4.2) phenomenological research 
(including IPA) allows a more individual approach. So rather than aiming for 
nomothetic, generalised research findings, IPA is concerned with idiographic 
experiences and understandings and how the individual interprets phenomena, 
rather than how it is socially constructed. Only when each individual’s 
experience has been interpreted can the researcher move to a shared 
understanding across the group (Smith, 2004). The idiographic nature of IPA 
allows the researcher to identify participants’ distinct meanings and 
experiences of a phenomenon but also allows for the identification of the areas 
where these meanings and experiences are shared by a group of participants 
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(Shaw, 2001; Reid, Flowers & Larkin, 2005; Smith et al., 2009). 
Phenomenologists explicitly seek out idiographic meanings in an attempt to 
understand the individual, which may or may not offer general insights 
(Ashworth & Ashworth, 2003). However, Halling (2008) accepts both the 
particular and general by arguing that idiographic research can also be 
universal in that it may well identify common structures of experience. He 
suggests that phenomenologists engage in three levels of analysis: looking at 
the particular within an individual’s experiences; looking at what is common 
about the experience across people; and looking at what in the phenomenon 
helps us understand human existence in a broader philosophical sense 
(Halling, 2008). He also suggests that, similar to previous arguments on the 
relationship between the part and the whole and the researcher-participant 
subjectivities (see section 3.4.2), researchers need to move back and forth 
between experience and reflection at these different levels (see section 3.4.2). 
Nonetheless, it is also important to consider that although IPA focuses explicitly 
on the individual experience, it also  recognises the role of sociocultural and 
historical influences in the way people experience and understand their lived 
world (Eatough & Smith, 2008) 
 
Related to this, another difference between IPA and other approaches to data 
analysis is the focus of IPA on cognitions, which it shares with mainstream 
cognitive psychology.  It is concerned with the process participants go through 
in order to make meaning. However unlike mainstream cognitive psychology, 
which uses positivist measures of cognitive functioning to predict cognitive 
performance, IPA enables the researcher to explore participants’ own 
cognitions through the interpretations of their own meanings and 
understandings (Smith, 2004). In this way, IPA provides us with “a deeper 
understanding than traditional psychological methods” (Reid et al., 2005, 
pp.20). For example, IPA asks how people make sense of what is happening in 
a particular phenomenon, thus incorporating the person’s own cognitions. A 
focus on cognitions is also another way in which IPA is distinct from discourse 
analysis. Smith et al. (2009) describes IPA as a middle ground between the 
opposing stances of social cognition (which draws on positivist approaches to 
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look at cognitions) and discourse analysis (which uses qualitative data but does 
not consider cognitions). 
 
By discussing the researcher’s own interpretations of the participants’ own 
meaning (a double hermeneutic approach), IPA is explicit about what the 
researcher brings to the analysis (Smith et al., 2009). Reflexivity is also 
apparent in grounded theory with the use of memos throughout the analysis but 
the final presentation of results does not include this focus, instead the 
research findings are presented as completely data-driven. Discourse analysis 
also does not present research findings as a meaning-making process between 
the researcher and the participant but links participants’ discourses with 
institutions and current social explanations and practices (Willig, 2003). An 
interpretative approach to data analysis, therefore, does not mean that themes 
can simply ‘emerge’ or ‘be discovered’, rather data analysis requires the 
researcher to ‘actively’ work with the data (Braun & Clarke, 2006). The use of 
the term “emerging”: 
 
“...can be misinterpreted to mean that themes reside in the data, 
and if we just look hard enough they will ‘emerge’ like Venus on 
the half shell. If themes ‘reside’ anywhere, they reside in our 
heads from our thinking about our data and creating links as we 
understand them.” (Ely et al., 1997, pp. 205-206 cited in Braun & 
Clarke, 2006) 
 
IPA goes beyond simply using participants’ own words to describe a particular 
phenomenon it then uses these words to interpret the meanings expressed by 
the participants. IPA uses a double hermeneutic as the researcher is making 
sense of the participant making sense of their experiences (Smith et al., 2009).  
 
Smith (2004) outlines three characteristic features of IPA; it needs to be 
‘idiographic, inductive and interrogative’. IPA’s commitment to the individual 
account has already been discussed. IPA is inductive as it allows unanticipated 
areas of experience to be explored (Smith, 2004). In this sense, it is important 
to employ a semi-structured approach using open-ended questions, which 
allow participants to discuss areas of importance for them. Once the results of 
an IPA study are obtained, they are then discussed with reference to the 
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existing psychological literature on that topic. In other words, the results of the 
IPA study are then used to inform, support or problematise findings from 
previous work and it is in this way that IPA is interrogative (Smith, 2004). 
 
Reid et al. (2005) also outlines three characteristic features for a successful 
IPA study: they believe it must be ‘interpretative’, ‘transparent’ and ‘plausible’. 
To be interpretative the researcher must subjectively and reflexively work with 
the data to interpret the meanings the participants hold, these interpretations 
can be based on theoretical perspectives as long as they are transparently 
linked to the participants’ words (“grounded within the data”). Furthermore the 
analysis needs to be plausible to the participant: those working on the data and 
to those reading the analysis, in other words the interpretations need to 
resemble what it is actually like to live those experiences. 
 
3.4.4 The researcher’s beliefs 
In interpretative phenomenology, fore-knowledge and beliefs are integral to 
interpretation and should be acknowledged for their influence on the 
interpretation of data (Plager, 1994). Thus the following section, the researcher 
will discuss his fore-knowledge and beliefs with regards to AF and OAC. This 
section will be written in the first person.  
 
I am a 28 year old Maltese male, who is a Roman Catholic by religion. As a 
young boy I used to spend a lot of my free time with my grandfather, and from 
there I learnt to respect and to feel at ease talking with but most importantly 
listening to older people. Personally I have never experienced AF or OAC, nor 
have members of my family. However, when my grandfather died, the family 
took it in turns to go and sleep at our grandma’s house, so she would not feel 
lonely. During one of my stays, she had a minor stroke during the night, and I 
remember that she woke me up and was asking me questions that did not 
make sense. After calling my parents, my mum realised it was a possible TIA 
and we called for the ambulance. That was my first ‘real-life’ experience with 
stroke. In addition, my father has a heart condition and when he had his first 
heart attack and went to emergency care; I was struck by the attitude taken by 
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the healthcare professionals. The lack of information and empathy shown was 
disconcerting.  
 
Thus when I started this journey I was motivated to explore such attitudes and 
to understand whether these attitudes were experienced elsewhere. 
Furthermore, since AF increased the risk of stroke, I was driven to understand 
this condition more. During some of the AF clinics I observed, physicians I used 
to be paired with seemed very helpful and empathic to the patients. Some 
patients seemed to be concerned about the new heart condition, especially 
when they felt no symptoms. This reminded me of the abruptness of medical 
emergencies that had happened to my grandma and my father. In addition I 
could understand how patients who were not feeling any symptoms might only 
perceive the burden of taking OAC, rather than the benefits. When I started 
informing myself on the literature of AF and OAC I felt that physicians might be 
doing the right thing when they were taking the decision themselves to 
prescribe warfarin as it was after all for the patient’s benefit. Thus I could 
understand how physicians could easily take a paternalistic role and prescribe 
the medication. Thus throughout the course of this study, my personal thoughts 
and reflections have changed as I have become more aware of the patients’ 
own lived experiences. I understood how convincing a patient to abide by your 
decision would impact on his perception of both the relationship with the 
physician and the treatment, especially when I was discussing some of these 
issues with physicians. Returning to my health psychology mind-set I started to 
think more along the lines that patients have the right to decide what medicines 
they are taking as they are the ones that are going to live with their choice and 
warfarin could be a potentially dangerous drug. 
 
3.5 Research Design 
This project adopted a qualitative design using IPA, as it was coherent with the 
theoretical underpinnings of phenomenology as described above. The 
programme of research was divided into two interlinked studies examining the 
experiences that influence patients to accept or refuse warfarin and physicians’ 
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experiences of warfarin prescription and their reasons for prescribing/ 
withholding such medication.  
 
3.5.1 Ethical Considerations 
Ethics approval was sought and granted by the South Birmingham Research 
Ethics Committee on the 23rd September 2009. The School of Life and Health 
Sciences Ethics Committee, Aston University approved the study on 11th 
December 2009.  To conduct a study within the NHS, Research and 
Development approval was also needed, and this was obtained on the 11th 
January 2010. 
 
Participants’ informed consent is considered very important in research 
methods (Munhall, 2001; Rubin & Babbie, 2001). After going through the 
Participant Information Sheet (see Appendix C, D) and any questions 
participants had about the study were answered by the researcher, and all 
participants in this study provided written informed consent (see Appendix  E, 
F). Participants were told why they have been chosen to take part in the study. 
They were also informed about the nature of the interviews, namely that the 
interviews would be held at times convenient to them, that they would be 
conducted in a quiet office in City Hospital and that all travelling expenses to 
and from the hospital for the study would be reimbursed. Addressing 
participants’ privacy and comfort was thus considered a priority.  
 
Since the interviews were going to explore personal and work related matters, 
participants were also informed about issues of confidentiality. They were told 
that their name was not going to appear in any part of the study but rather a 
pseudonym would be used instead. Furthermore, participants were assured 
that the information gathered would not identify a given response with a given 
respondent (Rubin & Babbie, 2001). They were also informed about the total 
duration of each interview and that it would be digitally recorded.   
 
Furthermore participants were advised that their participation was voluntary 
and that they had a right to accept or refuse to take part or to withdraw from the 
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study up to two weeks after the interview. Another ethical issue was the 
sensitive nature of the interview itself. Since the study was dealing mainly with 
older individuals, feelings of distress and sadness, could ensue from the 
particular nature of the questions. In the event of the participant becoming 
distressed several actions could be taken such as taking a break, changing the 
conversation if the participant wishes it, or stopping it altogether. In addition 
every participant was debriefed at the end of the interview (see Appendix G, H). 
 
3.5.2 Inclusion criteria and sampling 
IPA allows the researcher to obtain detailed accounts of individuals’ 
experiences of living with a particular condition (Shaw, 2001) and therefore 
participant samples were purposive and participants were recruited for their 
‘expertise’ on a particular subject, as they can offer researchers an 
understanding of their thoughts, commitments and feelings through telling their 
own stories, in their own words (Reid et al., 2005). 
 
Reid et al. (2005) described how to conduct comparison studies by looking at a 
phenomenon from multiple perspectives; the researcher can thus obtain a more 
thorough account of it. Smith et al. (2009) commented on the use of such 
‘bolder designs’. They argue that such multiple-perspective designs of one 
phenomenon can help researchers to develop a more detailed and multifaceted 
account of that phenomenon as well as serving as a form of triangulation of 
data (Smith et al., 2009). 
 
Conforming to this, the project opted to explore multiple perspectives: Study 1 – 
patients with AF who accepted, refused, or discontinued OAC therapy; and 
Study 2 – physicians in different specialties (cardiology, general practice, and 
general medicine) and at different levels (registrar and consultant). 
 
Small sample sizes are normally recommended for phenomenological research 
as the aim is to provide detailed, in-depth accounts of participants’ lived 
experience (Smith et al., 2009). The sampling method used for this particular 
study was purposive. This is a non-probability sampling method which is quick 
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and provides an opportunity to select participants with the characteristics of 
interest. This method is considered to be appropriate when conducting 
phenomenological studies (Polit, Beck & Hungler, 2001). Participants were 
carefully selected; in that they had to be individuals who had all experienced 
the phenomenon in question (see section 3.5.2.1.2 and section 3.5.2.2.1). 
Participants needed to give more than just an opinion or view about the topic 
under study; they had to be willing and able to give detailed descriptions of their 
own personal experience.  
 
The sample size in this project was determined on the basis of informational 
needs and for the aim of the study to be achieved (Morse, 1994). Smith and 
colleagues (2009) stated that there is no right answer to the question of sample 
size; however, they suggested using between three and six participants (Smith 
et al., 2009). Thus the aim was recruit four participants in each of the groups 
listed in Table 9, to make a sample of 32 participants in total. 
 
 
Table 9: Planned recruitment of patients and physicians 
 
Physicians Patients 
4 Consultant Cardiologists 4 Accepted OAC 
4 Consultant General Physicians 4 Refused OAC 
4 Cardiology Registrars 4 Discontinued OAC themselves 
4 General Practitioners 4 Discontinued OAC by physician 
 
 
3.5.2.1 Study 1: Patient participants 
3.5.2.1.1 Sampling 
 
This study planned to explore patients’ experiences in order to understand what 
led them to their decision to accept, decline or discontinue warfarin as their 
OAC therapy. Participants were eligible for inclusion if they were aged over 18 
years and had been diagnosed with AF. Participants were not excluded on the 
basis of gender or age. Patients diagnosed with severe cognitive impairment 
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were excluded from the study as participants had to recall, in detail, events 
from the past and present; decisions regarding cognitive ability were judged 
with the help of a physician who went through the potential participant’s 
medical notes. Initially, the study planned to explore the experience of a fourth 
group of patients (see Table 9); patients whose OAC was discontinued by their 
physician. However, no living patients were found that were eligible for 
inclusion into this group. Two cardiology registrars helped the researcher in 
finding such patients from medical notes. Patients whose physician had 
stopped OAC were mostly due to terminal cancer. Furthermore, the study 
aimed to recruit four patients into each of the remaining three groups 
(accepted, declined or discontinued warfarin), however, only three participants 
who discontinued OAC were found to be eligible and were willing to participate. 
 
In keeping with the requirements of an IPA study, the group under study should 
be homogenous (Smith et al., 2009). This has been stressed by several 
authors (Smith & Osborn, 2003; DeVisser & Smith, 2006) so as to focus the 
investigation as far as possible upon the phenomenon of interest, without it 
being confused by other factors. Smith et al. (2009) contends that the extent of 
‘homogeneity’ in a group varies from one study to another.  Smith et al. (2009) 
argue that participants are chosen on the basis that “they can grant us access 
to a particular perspective on the phenomena under study” (pg 49.). They 
further reason that since IPA is an idiographic approach, it is concerned with 
particular phenomena in particular contexts or outcomes (Smith et al., 2009). 
For example, a study by Kam and Midgeley (2006) explored how mental health 
professionals chose whether or not to refer a child for individual psychotherapy. 
They chose five referrers; counsellors, psychiatrist, psychologist, family 
therapist and social worker. The common phenomena between these 
participants was their experience with referrals of children to individual 
psychotherapy.  
 
Similarly, the phenomena in the present study was the experience of AF and 
OAC within the consultation, in particular: the exploration of what experiences 
influenced patients in accepting/refusing/discontinuing warfarin and what 
experiences influenced physicians in prescribing or withholding warfarin 
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treatment. Therefore, homogeneity across groups in Study 1 was defined as 
‘patients who had a consultation where they were diagnosed with AF and 
accepted, declined or discontinued warfarin treatment.’  
 
3.5.2.1.2 Recruitment process 
 
Patients were recruited from City Hospital. The clinicians working in the AF 
clinic suggested patients who met the inclusion criteria for the study. Initially, 
the clinicians talked to the patients about the study during the clinic and if they 
were interested, the researcher contacted them at a later stage, either by 
telephone or at their next meeting at the anticoagulation clinic or the AF clinic at 
City Hospital. The researcher explained the study in detail and also provided 
the participant information sheet (see Appendix C). The participant had at least 
two weeks to decide whether to take part in the study or not. After two weeks, 
the researcher contacted the potential participants. If the participant agreed to 
take part in the study, s/he was asked to sign a consent form and a meeting 
was scheduled for the interview (see Table 10 for patient characteristics). 
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Table 10: Patient Characteristics 
 
Accepted Age/Gender/Ethnicity 
CHA2DS2-VASc Score  
(% annual stroke risk) 
Lionel 78/M/White British 5 (6.7) 
Jonas 67/M/White British 2 (2.2) 
Fiona 70/F/White British 4 (4) 
Daniel 83/M/White British 4 (4) 
Refused Age/Gender/Ethnicity 
CHA2DS2-VASc Score  
(% annual stroke risk) 
Will 69/M/White British 3 (3.2) 
Greg 53/M/White British 2 (2.2) 
Josephine 58/F/White British 5 (6.7) 
Shona 77/F/Black Trinidadian 5 (6.7) 
Discontinued Age/Gender/Ethnicity 
CHA2DS2-VASc Score  
(% annual stroke risk) 
Katrina 80/F//White British 4 (4) 
Raj 72/M/Asian 4 (4) 
Robert 71/M/White British 2 (2.2) 
 
3.5.2.2 Study 2: Physician participants 
3.5.2.2.1 Sampling 
The study aimed to recruit four cardiologists, four general physicians, four 
general practitioners and four cardiology registrar level physicians that work at 
West Midlands hospitals and in general practices in primary care. Participants 
included were qualified medical physicians with experience in conducting 
consultations with AF patients. Participants were not excluded on the basis of 
gender or age. 
 
Following the aims outlined previously, homogeneity across Study 2 was 
defined as ‘physicians who were at a similar specialty level and had experience 
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of consultations with patients who had AF, and had undertaken decisions 
whether or not to prescribe warfarin’. 
 
3.5.2.2.2 Recruitment procedure 
A member of the supervisory team (GYHL) initiated contact with the physicians 
by sending e-mail invitations to colleagues to participate in this study. 
Participants interested in participation were then contacted by the researcher 
who explained the study in more detail and gave physicians a Participant 
Information Sheet (see Appendix D)  Participants were given two weeks to 
decide whether to take part in the study or not. After two weeks, the researcher 
contacted the participants and if they agreed to take part, they were asked to 
sign the consent form and a meeting was scheduled to conduct the interview at 
the participants’ convenience (see Table 11 for physician characteristics). 
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Table 11: Physician Characteristics 
 
Consultant 
Cardiologist 
Spoken Languages Ethnicity 
Age/ Years in  
Specialty level 
Sean 
English, Urdu, Punjabi, 
Hindi 
Asian 39/4 
John English 
White 
British 
45/20 
Melanie English 
White 
British 
50/24 
Peter English 
White 
British 
44/10 
Cardiology 
Registrars 
Spoken Languages Ethnicity 
Age/ Years in  
Specialty level 
Jeffrey English 
White 
British 
35/5 
Dheepak English, Hindi Asian 33/4 
Ted English 
White 
British 
32/6 
Chan English, Cantonese Asian 37/6 
Consultant 
General 
Physicians 
 
Spoken Languages 
 
 
Ethnicity 
 
Age/ Years in  
Specialty level 
Balu 
English, 3 South Asian 
(not specified) 
South 
Asian 
48/7 
Nilan English, Urdu Asian 46/9 
Tom English 
White 
British 
39/4 
Manpal English, Urdu Asian 42/9 
General 
Practitioners 
Spoken Languages  
Age/ Years in  
Specialty level 
Matthew English, Urdu, Punjabi Asian 40/12 
George English 
White 
British 
40/11 
Nick English 
White 
British 
60/31  
Samir English, Punjabi, Urdu Asian 37/9 
 
3.5.3 Data collection 
Both studies used semi-structured interviews as the method of data collection. 
Interviewing is the most widely used method of data collection within qualitative 
psychology (Brocki & Wearden, 2006; Gough, 2006; Smith, 2011). In 
phenomenological studies, the main data sources are typically in-depth 
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conversations, with researchers and informants as co-participants. 
Researchers help informants to describe lived experiences without leading the 
discussion (Gerrish & Lacey, 2006). 
 
The research interview is a specific form of human interaction in which 
knowledge evolves through a dialogue (Kvale, 1996). Semi-structured 
interviews were used to gather data as these facilitate rapport, allow greater 
flexibility of coverage, and allow the interview to explore new areas (Smith & 
Osborn, 2004). Semi-structured interview guides are practical as questions are 
planned beforehand in a standardised format, yet are flexible enough for 
participants to talk about their experiences and express their opinions (Rubin & 
Babbie, 2001). Semi-structured interviews, as the name entails, are in contrast 
to a structured interview format as the schedule is only designed as a guide, 
where questions may be adapted to the interview at hand (Kvale, 1996). Kvale 
(1996) argues that semi-structured interviews are more akin to a guided 
conversation where the interviewer explores topics when the interviewee 
introduces them.  
 
3.5.3.1 Operationalisation of the interview guide 
Semi-structured interview guides were developed for each individual study. 
These interview guides aided the researcher in focusing on the participant’s 
experiences of the phenomenon in question. The initial guide drafts for both 
patient and physician interview guides were developed based on previous 
findings in qualitative literature outlined in Chapter 2. 
 
3.5.3.1.1 Patient interview guide 
Initial interview guide drafts were developed specifically for each individual 
patient group in Study 1. These initial drafts contained between 22 and 24 
questions (see Appendix I). However, this initial list was shortened post-pilot 
into one main interview guide consisting of nine questions. This was done as 
most of the original questions were used  as prompts rather than actual 
questions to be asked. Therefore questions were grouped and marked as 
prompts (using letters) to facilitate the interview (see Table 12).  
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Table 12: Patients’ Interview Schedule 
 
1. Tell me something about yourself 
a. Lifestyle 
b. Family 
c. Work  
d. Health  
2. What are your experiences of living with your heart condition? 
3. What were your experiences of the first consultation with your doctor on 
your heart condition? 
a. Feelings 
b. Family reaction 
c. QOL 
4. What is your experience of the part of the consultation when you were 
told about warfarin? 
a. Feelings 
b. Family reaction 
c. QOL 
5. From your experience, how was the decision for warfarin taken? 
6. What experiences influenced you in ACCEPTING/ DECLINING/ 
DISCONTINUING warfarin? 
a. Previous experience? 
b. Family/Friends? 
7. Living with warfarin 
a. If warfarin was accepted - What are your experiences of living with 
warfarin 
b. If warfarin was accepted & discontinued – What were your experiences 
of living with warfarin 
8. From your experiences, did you find support? 
a. Family 
b. Friends 
c. Health care 
9. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
 
Thank you for your patience 
 
 
These open-ended questions aimed to elicit the patients’ lived experience of 
the first AF consultation with the physician, their feelings, and their family’s 
reactions. Furthermore, their experience of the communication style of the 
physician and the decision making process during their consultation was also 
discussed. The questions also explored the patients’ experiences after the 
consultation.  
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3.5.3.1.2 Physicians interview guide 
The initial draft of the interview guide contained 16 questions (see Appendix J). 
These questions were based on the barriers physicians reported in the 
literature explored in previous chapters and later condensed post-pilot into 
eight general questions after the pilot interview, so as not to impinge on the 
fluidity of the interview (see Table 13). The open-ended questions were used to 
elicit the physicians’ accounts of their initial consultations with patients 
diagnosed with AF, including: communication style, patient concerns, the 
decision making process and barriers experienced during the consultation. 
 
Case scenarios (see Appendix K) were also used to foster discussion and to 
aid physicians to focus on discussing their experiences with regards to decision 
making about OAC. These case scenarios were extracted from the literature 
(Gattellari, et al., 2008b; Watson & Lip, 2006), suggested to the researcher by 
an expert in the field of AF. Although the case scenarios from the literature had 
a ‘correct’ answer in relation to the presented cases, the researcher assured 
the physicians that the aim of their use during the interview was not to test the 
physicians’ knowledge but rather as an aid for discussion and to help them 
think about their own experiences with patients. During the interviews, the 
researcher asked the participant to read the cases and asked questions like, 
What would you do in such a case? Can you relate such a case to a previous 
experience of yours? 
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Table 13: Physicians’ Interview Schedule 
 
1. Can you tell me something about yourself? 
a. Can you tell me something about your line of work? 
 
2. What is your experience of the first consultations with patients with AF? 
a. Questions or concerns? 
b. What do you think your patients are feeling at that moment? 
c. How do you explore oral anticoagulation with the patient 
 
3. How do you decide about treatment? 
 
4. How do you deal with a situation where you do not agree with the 
patient’s decision? 
 
5. Could you take me through your thought process when deciding to 
prescribe warfarin to patients with AF? 
a. Could you share some actual case experiences that you had during your 
career? 
 
6. I have brought with me some case scenarios of AF patients, could you 
go through them one by one and explain to me your thoughts about their 
situation? 
a. What do you think would be going through the mind of the patient? 
b. Would you prescribe warfarin? 
c. Why? 
 
7. From your experiences, what barriers do you think physicians face when 
prescribing warfarin? 
 
8. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
 
Thank you for your patience 
 
 
 
3.5.3.1.3 Pilot Interview 
Before the actual studies were started, a pilot study was conducted to ensure 
that the questions were easy to follow and understand and that they were 
sufficiently appropriate to obtain the required data. The pilot work was also 
useful in determining the timing of the interview and data transcription (Polit & 
Hungler, 1995). The first interview of each group served as the pilot study for 
that particular group. The interview schedules were shortened (see sections 
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3.5.3.2.1 and 3.5.3.2.2)  after these pilot studies so that they would not impinge 
on the flow of the interview. The revised interview guides appeared to be 
appropriate and relevant to the research questions being asked and no 
changes were made thereafter.  
 
3.5.4 The semi-structured interview 
All interviews employed an interpretative phenomenological approach, i.e. they 
were partly biographical, open-ended, and asked participants to describe their 
experiences, and the researcher aided the participant to keep focus on their 
experience of the consultation. The latter was critical with physicians as they 
tended to talk more based on opinions. So the researcher had to use repetition 
and summarise what the participant was saying, and then prompting about their 
own experiences. 
 
All of the interviews with the patients were conducted in the researcher’s office 
in Arden House, City Hospital, Birmingham. Some patients requested to have 
their spouses present during the interview. Reasons participants brought up 
ranged from having to care for their spouse, or that the spouse would help the 
participant recall the details of events. In addition one female participant 
requested her spouse be present as she did not drive. The request for having a 
spouse present was not denied, as the researcher defends that spouses or 
family members might also be present during the consultation. Spouses in the 
interviews were treated as co-informants, sometimes adding to the information 
the participant was recounting on his experience. However the focus of the 
interview was always on the experience of the participant. Interviews with 
hospital general physicians and general practitioners were conducted in the 
participants’ own offices. One cardiologist preferred that the interview was 
conducted in his office. Another cardiologist preferred that the interview was 
conducted in an empty room next to the wards because of his busy schedule. 
The interviews of the other two cardiologists and the cardiology registrar level 
physicians were conducted in the researcher’s office. 
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The interviews were digitally recorded and transcribed verbatim within a day of 
the interview by the researcher. Each interview lasted on average about 70-90 
minutes, with 15 minutes for briefing about the study and obtaining written 
informed consent, 40-60 minutes for the recorded interview, and five minutes 
for debriefing. 
 
In the extracts presented, WORDS IN BLOCK LETTERS mean that the 
participant spoke louder, putting emphasis in his words. Opposing square 
brackets “][“ indicate that some text has been omitted. Round brackets 
containing text, i.e., (his father), either indicated text that was added to clarify 
the meaning of the quote or non-verbals (Sighs) that happened at that 
particular moment. 
 
3.5.5 Analysis of data 
IPA (Smith et al., 2009) was used to analyse the data collected. The initial 
analysis process described below was undertaken separately for each of the 
seven cohorts: physicians (cardiology registrars, cardiology consultants, 
general practitioners, and general physicians); and patients 
(accepting/declining/self-discontinuation of warfarin) (see Figure 4 for a flow 
diagram of the analysis process). Each individual transcript was read several 
times, until the researcher became very familiar with them. All emerging 
thoughts or reflections while reading the text were written in the left hand 
margin, these included short phrases on what the participant was saying or the 
meaning in that particular sentence and also possible descriptive themes. 
During this the researcher also highlighted metaphors, and linked 
contradictions within the participant’s own arguments. In addition the 
researcher noted the emphasis the participant placed on the use of certain 
words or phrases as well as non-verbal cues, for example when participants 
talked about their past experience of stroke or bleeding, they sometimes 
demonstrated visible emotion when recounting their experience. In addition, the 
researcher was also attentive to issues such as how patients made sense of 
their experiences of OAC, the consultation and the decision making process, 
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how physicians interpreted their patients’ experiences, and what experiences 
had an influence on physicians’ decisions.    
 
Initial interpretative themes were written in the right hand margin as suggested 
by Smith et al. (2009). These included interpretations of the phrases written on 
the left hand side. The analysis was designed in this way, so that on re-reading 
the interview, the researcher could first read the left-hand margin, then the 
quote, then the initial interpretative themes (see Appendix L for a scanned 
example from one of the general practitioner transcripts). Initial themes were 
then grouped together in clusters. Following the analysis of the first interview, 
the process was repeated for all interviews in the same group. The transcribed 
interviews resulted in a large amount of printed paper, and this procedure was 
very time-consuming. The first phase was completed when all the themes or 
concepts emerging for one participant were grouped in meaningful clusters (i.e. 
similar themes and contradictions were grouped). This analysis phase was 
repeated for all participants within a specific group. 
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Figure 4: Flow diagram of the analysis process 
 
The initial four stages where conducted within each group (e.g. cardiology 
consultants, general practitioners, patients who accepted warfarin, patients who 
refused warfarin etc.)  
First Phase 
 Interview transcript read and re-read  
 Thoughts or reflections written in the left 
hand margin 
 Initial interpretations written in right margin 
 Initial themes grouped into clusters 
 Process repeated for all interviews in the 
group 
Second Phase 
 Examination of theme clusters in search 
for shared themes that reflected the 
characteristics of all the participants in 
that group 
 Shared themes grouped together and 
created broad themes 
Third Phase 
 Re-analysis of the transcripts with each 
broad theme in mind  
 Verbatim extracts grouped under each 
theme 
 The same extract may fall under the same 
theme 
 Set up table with sub-themes, 
explanation, interpretation of quote, quote 
 Discuss table with supervisory team 
Fourth Phase 
 Exploration of patterns, connections and 
relationships between the participants in 
the same group 
 Facilitate through the use of mind-maps 
 Discuss mind-maps and group analysis 
with supervisory team 
Fifth Phase 
 
The four stages were 
repeated at group level 
(cardiologists, general 
practitioners, general 
physicians and registrars) 
to come up with super 
ordinate themes for the 
whole of the doctors’ 
study. This whole 
process was then 
repeated with the 
patients. 
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The second phase involved the examination of the clusters of themes to search 
for the shared themes that reflected the characteristics of all the participants in 
that group. All the shared themes where further grouped together and created 
broad themes that were relevant to more than half the participants in the group  
Smith et al. (2009).  
 
The third phase comprised the re-analysis of the transcripts with each theme in 
mind. Each transcript was re-examined while focusing on each theme to 
identify examples that explicate that theme through a more focused lens and 
included verbatim extracts under each theme. Throughout this procedure, the 
researcher continuously asked himself what extracts seems particularly 
essential for the experience being described. Some extracts fell under more 
than one theme. At the end of the third phase, a table was constructed for each 
theme with the sub-theme in the first column, a general explanation of that sub-
theme in the second column, the interpretation of the verbatim extract in the 
third column and the participant’s extract in the fourth column (see Appendix M 
for example table used to facilitate grouping of shared themes across 
participants in a group). 
 
The fourth phase consisted of an exploration of patterns, connections and 
relationships within and between the participants in the same group. The 
interrelationships between the broad themes were examined, aiding the 
researcher to better understand the life-world of the participants, to understand 
their experiences and to draw out the emergent analytic or super-ordinate 
themes. The analysis took on a highly reflexive practice on how each super-
ordinate theme contributed towards the “whole”. As discussed previously (see 
section 3.4.2 on discussion of part-whole relationship in hermeneutics) the 
constant interaction between the part and whole was crucial for the analysis  
process in this study; working on the constituent parts of the individual 
transcript and the whole interview, similarly at the individual participant and the 
whole group, and later at the specific group (e.g. patients who accepted OAC) 
and the whole cohort (e.g. the three patient groups). The researcher and 
supervisors also met regularly to reflect on how the different themes came 
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together, led by the researcher. To further facilitate these discussions of how 
themes came together to represent the groups, mind maps were created, 
having colour-coded themes and the interlinking relationships between themes, 
to aid explanation and discussion (see Appendix N for scanned example of 
mind maps from patient groups). This facilitated the discussion of the analysis 
of each group with the supervisors. These four phases were repeated for each 
of the patient (Study 1) and physician (Study 2) groups.  
 
In the fifth and final phase, the same procedure outlined above was conducted 
at group level. With the help of the mind-maps and tables, connections, 
relationships, similarities and contrasts among the groups were examined to 
form overarching themes. New mind maps were drawn to discuss group level 
analysis (see Appendix O for physicians’ group analysis mind map; see 
Appendix N for patients’ group analysis mind map). Devising such a design 
enabled the researcher to maintain not only an idiographic perspective, as 
needed in an IPA study (Smith et al., 2009) (as each theme can lead to the 
individual participant), but also enabled the interpretation of the lived 
experience at group level. This was an innovative adaptation of IPA, which 
Smith et al (2009) refers to as a bolder IPA design. Instead of having one 
homogenous group, several small homogenous groups form a patchwork of 
experiences from patients and physicians to enable a multi-experiential 
understanding of the phenomenon. 
 
3.5.6 Quality, trustworthiness, sensitivity and rigour  
Trustworthiness is an essential component of qualitative research, as findings 
should reflect the reality of the experience of participants. Benner (1994) 
suggested the use of repetition and reflection (for example the use of phrases 
such as ‘is that what you mean,’) during the data collection phase, which was 
an integral part of the interview technique in this study. Furthermore, such a 
prompt during the interviews served as an on-going process of verification from 
the participant. Additionally, supervision throughout the whole study and more 
frequently during the analysis stages was used to discuss and challenge the 
depth of the researcher’s analytic interpretations (Smith et al., 2009).  
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In addition, Yardley (2000) argued that a qualitative study should be assessed 
on its ability to accurately interpret and present the experiences and views of 
those involved in that particular study. So, rather than assessing research 
based on ‘reliability’ and ‘validity’ a qualitative researcher will aim for ‘sensitivity’ 
and ‘rigour’ (Yardley, 2000). Yardley (2000) proposed four broad principles for 
assessing the quality of qualitative studies, sensitivity to context, commitment 
and rigour, transparency and coherence, and impact and importance.  
 
The first principle, sensitivity to context, refers to the ways in which the 
research is sensitive to the context of the phenomenon being investigated. As 
Smith and colleagues (2009) point out, sensitivity in this study is demonstrated 
in its conception. The very choice of IPA as its methodology revolved around 
the need for sensitivity and the importance of taking an idiographic approach to 
the phenomenon studied. Furthermore, sensitivity to context was also shown 
during the interview process. Smith et al. (2009) argue that showing empathy, 
putting the participant at ease and negotiating the intricate power play between 
the researcher and the experiential expert are all ways that show sensitivity to 
context. The researcher took these into consideration during all the interviews 
conducted. Time was taken to explain the research in detail and to put the 
participant at ease, e.g. by telling the physicians in Study 2 that their real 
names and names of places that could lead back to their identity will not appear 
anywhere in study. In addition, the researcher always spent the first few 
questions to talk a bit about the participant’s life in general.  
 
With the patients, the researcher always made it a point to meet the 
participants at the entrance of the hospital, thus the walk back to the office 
served as an introduction and to build some rapport. Another method to 
demonstrate sensitivity to context in IPA studies is by grounding the 
interpretations in the data. According to Smith et al. (2009), it is important for 
findings to be presented in a way that ‘resonates’ with readers as an accurate 
account of participants’ experiences. Readers must also be presented with 
enough detail about participants and their circumstances to enable the reader 
to do this (Elliott et al., 1999). Care has been taken so that analytic and 
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interpretative claims are always backed up by participant extracts and 
interpretations were presented as possible readings while general claims were 
offered cautiously (Smith et al., 2009). 
 
The second broad principle proposed by Yardley (2000) is commitment and 
rigour. Conducting the research, analysis and write-up in a thorough manner 
and providing a detailed description of the whole process is one of the ways 
that this principle is demonstrated (Smith et al., 2009). Additionally the study 
took a rigorous approach in participant selection to conform to the IPA 
requirements (Smith et al., 2009). Yardley (2007) proposes that methodological 
competence is of paramount importance in demonstrating rigour. The 
researcher was already knowledgeable of IPA methodology at the start of the 
study, however he still opted to attend advanced workshops to become more 
versed in the method. In addition, triangulation serves as ways to ensure rigour 
(Reid et al., 2005). This can include any number of ways that are felt to be 
relevant to the particular investigation, including investigating a phenomenon 
from a number of viewpoints (different participant groups), using multiple 
qualitative methods, or asking another researcher to ‘audit’ or provide feedback 
on the study.  
 
Lincoln and Guba (1985) and Colaizzi (1978) advocated the use of member-
checking as a final step in validation for qualitative studies. However, there is 
no directive in interpretive research to prove or generalise, so the idea of 
validation is illogical (Chapman, Francis & McConnell-Henry 2011). Certainty 
has little resonance with the interpretative research. Revisiting a participant for 
clarification is a potential threat to the rigour of interpretive studies (Chapman, 
Francis & McConnell-Henry 2011). When asked to revisit a concept, a 
participant may overemphasise it, believing the researcher must think it 
important or relevant to the study. The desire of participants to say 'the right 
thing' is known as the 'halo effect'. 
 
By going away, examining and carefully considering the data, then returning to 
participants for clarification, researchers may then guide the participants in the 
directions they desire (Chapman, Francis & McConnell-Henry 2011). As the 
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balance of power is heavily in the researcher's favour, a participant is unlikely 
to resist the direction in which the researcher is leading them. Equally, returning 
to participants is antithetical to phenomenology's requirement that a recounting 
is presented in native, or original, form and that it considers a snapshot in time, 
not a generalisable right answer (Chapman, Francis & McConnell-Henry 2011). 
 
The preferred quality control procedure for IPA is that of an audit trail or 
triangulation of data analysis rather than any form of external "member 
checking" (Smith, 2003) as those checking the interpretations cannot have a 
full understanding or appreciation of the context in which the research 
interactions take place. As a result, the audit trail or the triangulation of data is 
not left to enable others to assess the interpretative decisions made, but to 
make transparent the procedure and to demonstrate the reasonableness of the 
analysis (Smith, 2003). 
 
In this study, triangulation was presented through the investigation of different 
viewpoints, such as physicians at different specialty levels and patients who 
accepted, or refused or accepted and then declined. Thus, as explained 
previously, by engaging in an ‘intra-study’ triangulation (i.e. triangulation by 
analysing multiple perspectives and experiences in each study) and at the 
same time, an ‘inter-study’ triangulation (i.e. triangulation by comparing the 
perspectives and experiences of physicians with patients), a more thorough 
understanding of patients’ and physicians’ experiences of AF and OAC therapy 
was obtained (Reid et al., 2005). In addition, the researcher had monthly 
supervision sessions that served as an audit of the research. In these 
supervision sessions, the researcher led the discussions and two further 
analysts contributed the discussions about what constituted a theme and how 
themes might interact with each other, thus providing triangulation in analysis. 
 
Transparency and coherence, the third broad principle proposed by Yardley 
(2000), refers to how clearly the stages of the research process are described 
in the write-up of the study (Smith et al., 2009). Transparency in this study can 
be seen in the detailed write-up of participant selection and recruitment, how 
the interview guide was developed and how the interview was conducted. In 
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addition, a detailed account of the data analysis process was outlined in the 
previous sections. Furthermore the detailed description of the research design 
and analysis presented show sensibility to the core philosophical assumptions 
that IPA requires (Smith et al., 2009). That is, the study showed sensibility 
towards being phenomenological, hermeneutic and idiographic. 
 
The final broad principle proposed by Yardley (2000) is the need for the study 
to show impact and importance. Yardley (2000) argues that the real validity of a 
qualitative study is its contribution to current knowledge (Smith et al. 2009). 
Multiple perspective IPA studies are still in their infancy and there is paucity of 
IPA research in general and specifically in AF patients. Therefore, a study such 
as this will provide an innovative methodological contribution. Furthermore the 
practical recommendations emerging from the participants’ own experiences 
and published meta-synthesis (refer to Chapter 2) have provided important new 
knowledge for the medical and patient community, policy makers and health 
workers.  
 
This chapter has established the philosophical perspective of the research and 
provided a clear rationale for the use of IPA as the methodology for addressing 
the research questions. Semi-structured interviews were identified as the most 
appropriate means of collecting data and details of interview preparation and 
process were discussed. In addition the process of data analysis through the 
use of IPA was explained.  Quality issues in qualitative research of this nature 
were discussed and consideration was given to the ethics of researching 
sensitive topics such as this. The following chapter focuses on the results from 
Study 1, the patients’ lived experiences of AF and OAC. 
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Chapter 4: Patients’ experiences of AF and OAC prescription 
4.1 Introduction 
This chapter includes the analysis of the lived experiences of patients during 
the consultations with their physicians when they were diagnosed with AF and 
their experiences with OAC treatment. Data were collected from three sub-
groups; patients who accepted warfarin as their OAC, patients who refused 
OAC during the consultation and patients who at first accepted OAC during the 
consultation and then decided to discontinue OAC themselves at a later stage. 
The study attempted to answer the following research question: What are the 
experiences, beliefs and attitudes that influence warfarin acceptance, refusal or 
discontinuation by patients? 
 
The patients in this study recounted their lived-experiences during the initial 
consultation with their physicians, their feelings about the diagnosis of AF, and 
what experiences influenced them to accept or refuse warfarin as their OAC 
medication. In addition, the patients explored what it meant to live with AF and 
take OAC life-long. Patients also commented on how the constraints brought 
about through living with warfarin compelled some to discontinue OAC, despite 
leaving them at an increased risk of stroke. Patients also discussed how their 
everyday experiences affected their perceptions of aspirin compared to 
warfarin. Some recommendations put forward from the participants for health 
care followed. 
 
Three over-arching themes emerged from the interviews with patients, each 
with two themes which were divided into two or more sub-themes as shown in 
Table 14. The following sections discuss in further detail the themes and sub-
themes that comprise the over-arching themes. Verbatim extracts and their 
interpretations are included in the text to highlight particular experiences that 
patients went through.  
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Table 14: Main themes emerging from patients’ own experiences of atrial 
fibrillation and oral anticoagulation 
 
Over-arching 
themes 
Themes Sub-themes 
Patients’ 
experiences of 
the initial 
consultation – 
“it’s not a 
consultation” 
Understanding the 
diagnosis 
Initial relief through knowledge 
Lack of take home material 
Reaching a 
Treatment 
Decision – the 
interplay of 
paternalistic and 
shared decision 
making 
What influences the decision to accept 
warfarin 
What influenced the decision to refuse 
warfarin 
Life after the 
consultation 
The challenges of 
living with OAC 
Food interactions 
Regular blood tests 
Support 
Experiences that 
lead to OAC 
discontinuation  
Balancing fear of stroke with negative 
experiences of OAC on QoL 
Being informed about patient rights 
Patients’ 
experiential 
reflections  
Perception of 
Warfarin vs. 
Aspirin 
Aspirin perceived as ‘old’ natural 
wonder-drug  
Warfarin perceived as dangerous/end-
of-life drug 
Patients’ 
recommendations  
Time & physicians’ communication 
skills in initial consultation 
On-going patient support 
Raising awareness about warfarin 
through the media 
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4.2 Patients’ experiences of the initial consultation – “it’s not a 
consultation” 
The first over-arching theme encapsulates the patients’ experiences during 
their initial consultations about AF and is sub-divided into two themes: (1) the 
diagnosis of AF and (2) the decision to accept or refuse oral anticoagulation 
treatment. 
 
4.2.1 Understanding the diagnosis  
This theme explored the patients’ recollection of their experiences of their initial 
consultation where they were given the diagnosis of AF by their physician. 
There were two sub-themes related to the diagnosis:  physician’s reassurance 
about the AF diagnosis and (2) the absence/paucity of educational material 
about AF to take away from the consultation. 
 
4.2.1.1 Initial Relief through knowledge 
Symptoms caused by AF were a source of anxiety for most of the symptomatic 
patients; nonetheless they provide an aid for the physician to focus on in 
diagnosis. Most symptomatic patients, such as Jonas, clearly remembered the 
moment they felt their first symptoms, which were a major cause of distress. In 
his experience, Jonas thought that he was going to have a heart attack, 
exacerbating his trauma which in turn led to the onset of panic attacks. It is also 
important to note that the following excerpt shows that Jonas was not sure that 
his heart condition was called AF. 
 
The first time in my life I had ever thought ‘you’re ill’. It’s hard to 
explain. I was frightened I was gonna fall out of bed. Erm… 
Everything was just really weird and I had to go into work that day. 
It was before I retired. I phoned up my gaffer and his son 
answered the phone and I said ‘I feel really ill and don’t know 
what’s the matter? I can’t come in today’ and he said ‘oh come in’. 
Give it 20 minutes and you’ll be alright’. I don’t know how I 
managed to drive to work, because I was having panic attacks. I 
think I got to work anyways and his father (his employer’s father) 
took one look at me and said to me get my car out, ‘There is only 
one place for him and that is the hospital’. That was how it was 
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found out. It wasn’t a heart attack; it was the fibrillation or what it’s 
called (Jonas, Accepted OAC) 
 
 
Likewise, Will described his experience as “distressing”. He almost relived it 
when discussing it as he could even remember what he was eating when he 
first experienced the symptoms. Unfortunately, Will was highly sensitive to his 
AF and every time he experienced symptoms, it felt like a traumatic event. This 
caused so much distress to him that he could not lie down for fear of triggering 
an event, which could possibly lead to sleep deprivation. For him, the fear of 
having a symptomatic event was even more distressing than being diagnosed 
with cancer, describing the AF symptoms as ‘mental torture’. In addition, 
because of the constant fear of the recurrent symptoms Will has even 
contemplated suicide.  
 
W– I was over here, at work. I WAS EATING A BANANA! It was 
so distinct I can you know… remember it clearly. Then they sent 
me home] [Then it happened again the next day and they rushed 
me here. That’s how they found out.][They said ‘Unfortunately Mr. 
Will, you’re very sensitive to it…’ 
Researcher – You’re very symptomatic 
W– yes yes that’s the word… I’m very sensitive to it.][I can’t lie 
down… I haven’t lied down for 20 odd years. I sleep in the chair, 
because if I lie down, in 20 minutes, the position of the heart… 
triggers the heart off.] [the biggest problem is my heart. Mhm. I’m 
still concerned on that. More than the cancer. I said to the 
surgeon, I’d rather have the operation 10 times rather than going 
into fast AF…] [It’s terrible… mental torture.] [I’m under a 
psychiatric team, cause I wanted to kill myself because of it… it’s 
terrible (Will, Refused OAC) 
 
In other symptomatic patients who had few recurrent episodes, such as 
paroxysmal AF, the length of time needed for a complete diagnosis was a 
source of stress. Katrina explains how several tests were conducted and 
although she knew that she “had something wrong” the physicians could not 
diagnose it. 
 
R  - Did you know that you had anything? 
K – Oh dear God no… I didn’t even know that I’ve got it. They also 
did an Echo in 2003, but they found nothing.] [I knew I had 
something wrong with my heart. I had told the doctor that 
sometimes my heart misses a beat and it didn’t feel right you 
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know. I couldn’t put my finger on it you know. Of course when I 
came to the (consultation) they managed to diagnose it. (Katrina) 
 
In asymptomatic patients, however, the diagnosis process was less systematic. 
Asymptomatic AF patients were usually diagnosed with AF during a routine 
check-up or when diagnosing other conditions, such as the experience of 
Lionel below. As with the other asymptomatic AF patients, Lionel was 
diagnosed only after a routine check-up for symptoms of anaemia by a private 
clinic.  
 
R – Do you remember when you first got to know about your heart 
condition? 
L – It was a long drawn out process. I kept going to the GP cause I 
didn’t feel well. Erm and… I suffered from migraines, almost twice 
a week and he used to ramble on my brains, but I used to tell him, 
it’s not my brain, I’m just not generally well. So I was in BUPA at 
the time, so I went to a private check-up you know. Then they 
discovered that I was anaemic and that I had an irregular 
heartbeat. That is how the condition was discovered. (Lionel, 
Accepted OAC) 
 
The initial consultation served as a relief for all patients in the study. During this 
short consultation, patients including Greg, Raj and Rob, initially were anxious 
when receiving the news that they suffered from a heart condition and later 
assured through adequate information given by the physician that AF is a 
common condition.  
 
I did yeah (get concerned) cause it’s your heart and it’s a big thing 
your heart eh? But I felt alright about it once he told me what it 
was. (Greg, Refused OAC) 
 
The patients describe being concerned during the initial consultation because 
they thought they were having a heart attack or they did not know what was 
happening. The added anxiety when the heart was mentioned was probably 
due to the fact that patients knew that the heart is central for life. Thus news 
concerning the heart brought about the possible threat of death.  
 
R – Yes that’s right… they discovered it when we called the 
ambulance 999. I felt very giddy and light headed, I thought I was 
going to pass out. Erm I thought I was having a heart attack. The 
ambulance came, and told me I have an irregular heartbeat. 
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Res – so you were told about the irregular heartbeat in the 
ambulance basically? 
R – Yes that’s right. They treated me in the bungalow, that when 
the doctor said that ‘You’ve got an irregular heartbeat’. 
Res – and how did you feel at that? 
R – In a way relieved, that erm… it wasn’t anything serious. (Raj, 
Discontinued OAC) 
 
The initial assurance provided did not have an influence on whether patients 
accepted or refused warfarin. However, time spent assuring the patient did 
impact on patient-physician relationship. Josephine perceived her physician as 
“an excellent doctor” because he spent the needed time to explain to her about 
her condition and reassure her.  
 
I’ve got an excellent doctor and he always explains everything to 
you. He’s told me which ventricle’s not working properly. And 
erm… we think the TIA  was due to it not being able to pump the 
blood well from the heart so it is clotting and then the one clot just 
came up and gave me this TIA. (Josephine, Refused OAC) 
 
Similarly, Raj had first felt the symptoms of AF when he was abroad. In the 
following quote, Raj’s wife explains that although the hospital structure was not 
well maintained, the impact of the social interaction with the health 
professionals was positive.  
 
R – we were on holiday in Goa] [I felt some palpitations and I was 
taken to hospital. I was told that erm… they put me in intensive 
care. I was with my wife.]  
[Wife - although the place was very badly maintained, the 
treatment was excellent. Doctors, nurses everybody. 
Res – When you came back to the UK, did you go to the hospital 
again? 
R – I recovered (from the bout of AF symptoms) quite well (in 
India) (Raj, Discontinued OAC) 
 
4.2.1.2 Lack of take home material 
Patients in this study commented that during and after the initial consultation 
there was a lack of take home educational material both on AF and OAC 
medication. Patients, such as Jonas, pointed out that during the initial 
consultation they were only informed about the name of the heart condition and 
the reason for initiating warfarin. Take home educational material could have 
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reinforced what the physician explained during his consultation and aided in 
lessening the cognitive burden posed by information overload during the 
consultation. Jonas only received further information on warfarin from the nurse 
only when he was going to start the warfarin clinic. He commented that such 
information would have been important for him immediately after the 
consultation. 
 
They didn’t tell me exactly what has happened apart from they 
gave it the name of atrial fibrillation. That was as much as I knew 
and what I know up till now. That it is an irregular heartbeat.][I 
would’ve liked to know a bit more at the time.  They told me why 
they were giving me warfarin. Which was to thin the blood, so clots 
wouldn’t form.] [It’s only after I came back here, I think it was a 
week after. I can’t remember the nurse’s name, but she was very 
nice. She described what the warfarin did. i.e. thin the blood. Then 
went through the different pills, the colour and things (Jonas, 
Accepted OAC) 
 
Shona and Robert had a similar experience during the initial consultation. 
When prompted on this issue they divulged that the only information they 
received was on the course of action for treatment following diagnosis.  
 
R – So you told me, that they told you it was fast heartbeat… did 
they give you any information about it? 
S – No… erm… no not really. They only thing they told was what 
they would do. (Shona, Refused OAC) 
 
However on further exploration of this issue with Robert, although educational 
material was not given to Robert, he understood and remembered the 
physician’s explanation during the consultation. However, he did not seem sure 
about what it meant, showing different levels of understanding.  
 
R – You told me before about ‘blood going up and down’ (the INR 
reading) do you know what that is? 
Rob – Not really, they say ‘look it increased so we’re going to 
change the number of tablets’. They experiment to find the exact 
level. 
Res – But did they explain to you what the level is? What it 
means? 
Rob – No, no (Robert, Discontinued OAC) 
 
Katrina was the only patient who commented that although no educational 
material was provided during the consultation, she took a booklet which was 
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available from the clinic. Indicating that although educational material might be 
present in the hospital, patients or physicians themselves might not be aware of 
them. 
 
Oh I like to read on what I’m taking. I read a lot on the irregular 
heartbeat on heart magazines in the clinic. I even took a booklet to 
read at home and read about it from there initially (Katrina, 
Discontinued OAC) 
 
4.2.2 Reaching a Decision – the interplay of paternalistic and shared decision 
making 
After being diagnosed with AF, patients shared with the researcher what 
experiences influenced them in accepting or refusing warfarin.  
4.2.2.1 What influences the decision to accept warfarin? 
The approach to the treatment decision was the main influence on the patients’ 
decision to accept warfarin. Patient experiences can be divided into two distinct 
approaches; a paternalistic approach or a decision based on a more inclusive 
discussion regarding antithrombotic medication choice. 
 
4.2.2.1.1 The paternalistic approach 
Conversely to the relief experienced from the physician reassurance in the 
initial diagnosis part of the consultation, some patients commented that their 
perception of the decision making process was that of a paternalistic approach. 
Patients commented that the physician either took the decision to initiate 
warfarin or the patient trusted the physician as the expert and did not voice 
his/her concerns. In addition some patients, like Lionel, had negative past 
experiences associated with AF. This had an impact on Lionel’s ability to 
understand and process the information given to him. Thus he was not able to 
discuss the issue of OAC treatment.  
 
L – It was a bit of a shock. I can’t say that it made me very worried. 
But it was a shock to realise that I had the same complaint as my 
mother. But I just accepted whatever they said and then got 
referred to the GP and prescribed medicines and I erm… just 
accepted it.] [I don’t worry about it. I know it’s dangerous and 
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erm… I know that presumably one day it will cause me to maybe, 
maybe have a stroke. (Lionel, Accepted OAC) 
 
Lionel commented that he felt that he had no alternative in the choice of OAC 
treatment as he was still coping with the fact that he was afflicted with the same 
condition that his mother suffered from. However, he later points out that OAC 
does not worry him, as he acknowledges that AF may cause stroke. In addition 
he was also put on the same drug (digoxin) his mother was taking before she 
died. Either the consultant failed to explore this issue with Lionel or Lionel 
preferred not to voice his past experience. 
 
When the cardiologist saw me, (the cardiologist) told me, ‘With the 
current medicine you’re on, you’re not doing so well’. Which was a 
surprise for me because I felt alright. Then (the cardiologist)said 
‘We’ll put you on digoxin’. This was the drug my mother was on 
before she died. (Cardiologist then said) ‘That means that we have 
to put you on warfarin as well’. And I was ‘Oh no… no not warfarin. 
I had heard tales about warfarin. You have to keep coming to 
hospital every week for a check-up. Oh no’… I expressed my 
concern. But (the cardiologist) just explained and that’s it. (Lionel, 
Accepted OAC) 
 
Lionel’s experience is an example of how challenging the decision process can 
be for a patient, i.e. weighing the risks and benefit of a treatment in light of his 
experiential knowledge from family and friends’ experiences. Lionel further 
explains that he felt he was left without any alternative. Since the consultant 
was going to change his medication and warfarin had to be initiated with this 
medication, he felt that he could not refuse. Lionel’s experience highlights that 
receiving bad news during a medical consultation challenges a patient’s ability 
to take a decision and the right to say “no”. In addition, Lionel experienced 
conflicting beliefs, or cognitive dissonance, when thinking about the 
cardiologist’s reason for the change in medications. Since his perceptions of his 
past medications were that they were “working”, he did not see the need for 
change.  
 
R – So you told (the cardiologist)that you didn’t want warfarin? 
L – Well I didn’t tell (the cardiologist) I didn’t want warfarin, I just 
expressed my dislike of having warfarin. So (the cardiologist) said 
that it was necessary, (the cardiologist) didn’t present me with any 
other alternatives. I’ve been quite happy, thinking about, I would’ve 
been quite happy to stay on the medicine I was on. But you don’t 
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think of what to say during the consultation, if you’ve had some 
bad news. You don’t know what to think. So I had to accept the 
reasons she gave, that the other medications weren’t working 
well… and you’re gonna go to warfarin. I wasn’t happy, but I didn’t 
realise that I could’ve said no. Of course I could’ve said no, I’m not 
stupid, but it never struck me that I could say no. The change of 
medication and the switch to warfarin was all too easy as far as 
the consultant was concerned. That’s my opinion now… 
R – Looking back 
L – Yes… I went back home and realised; I’ve got to go on 
warfarin.][I just accepted what the consultant said. Which now I 
think that one ought to challenge what they tell you. Cause you 
never know, there might be an alternative, or an alternative they 
don’t particularly favour. (Lionel, Accepted OAC) 
 
In addition, Katrina perceived the choice for taking the OAC medication as a 
“death or life” choice. Thus apart from provoking anxiety in Katrina, the 
perception of choice of medication was taken out of her hands. In the following 
quote, Katrina also emphasised her non-participation in the decision making. 
 
R – So did they tell you what it was when you went to the 
specialist? 
K – NO, I mean they just explained what it was. They put me on 
the tablets and that’s it.] [I said no I’m not going on it (warfarin), I 
know what warfarin is, I worked in hospital me self.] [I really felt it 
was a life or death decision, they just kept telling me you should 
take it. I felt like if I didn’t take it, something was going to happen 
to me tomorrow you know. (Sighs) 
R – So you didn’t feel free in your decision if I may say? 
K – No no, I don’t think so.   (Katrina, Discontinued OAC) 
 
Another indirect pathway towards a paternal approach to decision making was 
when patients accepted the medication out of trust in the physician’s expertise. 
Daniel commented on his trust with the physician. Although he presents himself 
as a passive patient, there is trust in his relationship with the physicians as he 
emphasised the point that he still asserts his opinion even though he does not 
want to participate in the decision making process. 
 
D – I was never given a choice, it was just prescribed for me, 
though I accept that.] [The exact words I do not remember. But I 
remember what I felt. I didn’t feel bothered or worried about it.][I 
think that in all the years I’ve been with my GP or [the] clinic, I 
haven’t had reason to complain. There is no one who has upset 
me by telling me what it is and all this business. I just leave it to 
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them. I always make it a point to tell them HOW I FEEL. (Daniel, 
Accepted OAC) 
 
Daniel further discussed the issue of trust later during his interview. According 
to Daniel’s experience although his physician did give the choice of medication, 
he wishes to be passive and does not want to engage in the decision making 
process in an interactive way. Jonas also emphasised that he perceived the 
physician as the expert. He compared the consultation to an analogy of a 
broken down car to explain his lack of knowledge on the subject matter. 
However, his analogy also highlights his opinion on shared decision making 
and the passivity a patient should adopt. On probing further, Jonas concludes 
that trusting the physician as the expert could also be the patient’s way of 
escaping responsibility for his health.  
 
J - He was the doctor… he was the doctor. To my way of thinking 
he knew what was best for me. I bloody sure I didn’t. I mean you 
could have an engine breakdown and I could look at this and say 
whatever. You’ve got to think to yourself, well he’s the mechanic, 
let him get on with it. Doctor said you’re on warfarin, fair enough if 
that is his opinion… that’s the way it goes.][I think it would have 
been nice to learn a bit more about it. 
R – So it would have been better if they gave you some 
information and then you made up your decision? 
J – Yeah make your own decision, and then at the end of the day 
it’s not the doctor’s fault. It’s your fault. (Jonas, Accepted OAC) 
 
Similar to Jonas’ and Daniel’s experience, Robert also highlighted his trust in 
the expert and accepted warfarin as advised.  
 
Res – So to summarise what you told me, and correct me if I’m 
wrong, you took on warfarin because it was the consultant’s 
advice 
Rob – That’s right, I took it right away. Well if the doctor tells you it 
is the best thing you can have, you take his advice. (Robert) 
(Robert, Discontinued OAC) 
 
However Robert, in the excerpt below, contradicts himself. He explains that the 
physician did describe why warfarin was better than aspirin in a way that he 
could compare the two medications through the use of an analogy. This shows 
that even though during the consultation the physician might have provided 
education on the medication, nonetheless, the perception of the patient towards 
the expertise of the physician influenced the acceptance of the medication. 
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Rob – When the doctor explained it to me, he said, ‘well look, to 
thin the blood this is a lot better than aspirin’. 
Rob Wife – you weren’t very keen on it because it could be 
unstable 
Rob – yeah but once it was stable then you can have 3 or 4 
weeks’ time before you need to go back to hospital again.] [The 
doctor had said ‘this is the best thing for you, it’s like the Rolls 
Royce of the blood thinners.’ I took it as it was the best thing I 
could have so I had it, you know what I mean. (Robert, 
Discontinued OAC) 
 
4.2.2.1.2 A decision based on a more inclusive discussion  
Although the paternalistic approach had a more dominant role in the patients’ 
experiences, an inclusive discussion that led to a decision was the second 
approach that some patients experienced during the consultation. Patients who 
perceived that they were included in the discussion for the choice of warfarin 
were aware about the need for warfarin and/or fearful of the risk of stroke. 
Fiona had started off on aspirin however when they proposed warfarin as a 
better alternative, the choice was left with her. Nevertheless, only when the 
difference between warfarin and aspirin was explained did she accept to initiate 
OAC. 
 
F – When it was explained to me what it was for, at first erm at the 
first clinic, they put me on aspirin. That was the starter. Then in 
clinic they said you can carry on the aspirin, but a better way was 
with the warfarin. I said ‘EXACTLY… what is it? What is the 
purpose for it?’ They said, ‘It helps to thin the blood and that will 
help prevent any clots’.  
R – So you were given an option whether to stay on aspirin? 
F – Yeah yeah yeah I could decide one way or the other. I said 
‘I’ve been on the aspirin’ and they said ‘Well yeah all right’… I said 
‘what difference will it make?’ They said it wasn’t making the same 
amount of difference that the warfarin was going to make. You 
know in the INR. (Fiona, Accepted OAC) 
 
Raj’s wife, who was a nurse, was present with him in the consultation when he 
was offered warfarin. Similar to Fiona’s experience, Raj’s wife mentioned that 
their cardiologist explained in detail why warfarin was needed and how it helps 
protect against stroke. Although Raj’s wife knew about warfarin, she lacked the 
knowledge of how a stroke can occur because of AF. The fear that Raj might 
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contract a stroke could have influenced Raj’s wife to suggest him to accept 
warfarin.  
 
R (wife) - well the cardiologist did say that you had to take warfarin 
because after the heart stops from the atrial fibrillation, erm, there 
could be a blood clot that starts off after your pulse becomes 
regular again. It can break up and you can have a stroke or… 
which I didn’t really know before until he mentioned it. He said that 
is why you should be taking warfarin. (Raj, Discontinued OAC) 
 
On a similar note, Katrina pointed out the influence the fear of strokes had on 
her in accepting warfarin. She was aware and knowledgeable on what a stroke 
was and what it can cause, but was not aware of the consequences of bleeds.  
 
K – Well they said there were a lot of risks if I didn’t take it. I may 
have had a stroke. So I didn’t have much of a choice didn’t I… I 
wasn’t happy taking it from day 1. 
R – So you’re more afraid of strokes than you are of bleeding 
K – Oh I wouldn’t want to have a stroke you know. It comes on 
suddenly doesn’t it? (Katrina, Discontinued OAC) 
 
4.2.2.2 What influenced the decision to refuse warfarin? 
Several factors influenced the patients to refuse warfarin as their OAC 
medication. These include the patients’ perception of the lack of education, 
communication skills and rapport building during the consultation, patient’s 
religious influence on treatment beliefs, and the challenges associated with a 
change in lifestyle brought about from need of blood monitoring, bruising and 
the fear of non-adherence to treatment based on past experiences.  
 
4.2.2.2.1 Perception of a lack of education during the consultation 
The lack of education as an influence in refusing warfarin was pointed out by 
several patients, as highlighted by Josephine’s excerpt below. 
 
I don’t think there was any discussion about it (use of warfarin to 
minimise the risk of stroke). They just said ‘would you like to go on 
it?’ and I said ‘no, no I don’t think so’. (Josephine, Refused OAC) 
 
On further prompting about the benefits of warfarin with Josephine, she points 
out that no one explored any educational information with her. In addition, 
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Josephine’s perceptions highlight the need for education for allied health 
professionals. Due to this Josephine had to obtain information herself from the 
internet. 
 
J - Nobody has ever mentioned these things that you are bringing 
up (warfarin better than aspirin in risk reduction of stroke) and I 
don’t have to come to the hospital anymore, so nobody really 
mentioned it. So erm I’ve never really thought about it. 
R – and also for example did they mention that with diabetes and 
AF you get a higher risk for stroke? Sorry (worried look on 
Josephine after researcher pointed out new information) I feel like 
I’m worrying you even more 
J – no no… to be honest, nobody has ever discussed diabetes. I 
mean I’ve got a wonderful GP, but I think he is so overworked at 
the moment that you tend to see the nurse and she is not good. 
She never really told me anything and what we found out, we did 
ourselves on the internet. (Josephine, Refused OAC) 
 
4.2.2.2.2 The perception of lack of rapport and a paternalistic attitude 
Greg’s AF was caused by his heavy drinking and he had refused to take 
warfarin as, like in Josephine’s experience, he felt he was not educated about 
the need for warfarin. However, in a second consultation, Greg was offered the 
chance to participate in a trial with NOAC tablets which were not affected by 
alcohol. However, Greg’s perception was that the physician was more 
concerned in enrolling him in that trial rather than treating him with care and 
respect. Since they were health professionals, Greg had expected the 
physicians to discuss with him the issue of binge drinking. In addition the fact 
that his physician asked another health professional to concur with his advice 
put Greg on a defensive attitude affecting his perception of the health care 
system. The perception of lack of empathy and respect during Greg’s 
consultation was a major influence for him to refuse OAC. 
 
G - They came and told me ‘since you’re a heavy drinker, we’ve 
got a new drug that you can try… if you’re prepared to try? Where 
you can drink… still drink’ and I still wasn’t happy about that. Then 
he called the other doctor, sort of to back him up and say ‘yeah 
you can sort of drink’ ‘you can be an alcoholic’ that’s the 
impression I got. That you can drink as much as you like but you 
take this one. The way I’ve seen it, they wanted me to take it. This 
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new drug, and not too concerned about… me. That was the 
impression I got. 
R – So correct me if I misunderstood you… the fact that as a 
doctor they didn’t tell you to stop the drinking, but they told you 
‘look we have another tablet that’s coming out that you can still 
keep drinking’ 
G – Definitely definitely, that’s the impression I’ve got. That they 
wanted me to have a go at this sort of… not that… it was a bit 
confusing, cause I was just told that the monitor, my heart had 
corrected. Then they’re telling me you have to have warfarin. I 
didn’t understand it and they never explained it. (Greg, Refused 
OAC) 
 
Similar to Greg’s perceptions, one of the experiences that influenced Will to 
refuse warfarin as his OAC medication was the perception that his consultant 
did not have his best interest in mind. Will believed that physicians are biased 
in prescribing more medications than what is needed. In addition, Will had been 
a participant in previous trials and he believed that consultants get 
remuneration for prescribing different drugs. 
 
W - I flatly refused (warfarin)… because… they told me about 
aspirin at first… you know 75mg. They said “Well you can have a 
stroke”… cause he’s a good cardiologist (named cardiologist) but I 
tend to think that the cardiologist (named cardiologist) likes a lot of 
medication… to take on a lot of medications. That’s my opinion 
anyway. That’s my honest opinion. You know, the guy gives you 
more medication than you need. They do a lot of tests, because 
they get paid for new drugs anyway. That’s why I was on a lot of 
drugs. (Will, Refused OAC) 
 
The influential paternalistic attitude of the physician was also felt by Josephine. 
During her consultation she felt that the physician was surprised that she 
refused the advice given by the expert. However Josephine later opposed her 
previous assertion by implying that she believed that a physician would be 
more assertive and paternalistic with vital drugs. This belief negatively 
influenced her perception on the importance of warfarin.  
 
J - He looked like a bit like ‘I’m your doctor, you should do what I 
tell you’…] [In my mind… if it (warfarin) was that important, he 
should have put me on it straight away when I was in the hospital. 
R – So if I understood you correctly, if a drug tablet is important, 
the doctor would just prescribe it to you rather than asking you 
‘would you like to go on warfarin’ 
J – Yes I think so. (Josephine, Refused OAC) 
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4.2.2.2.3 The perception of lack of communication skill in physicians 
In Greg’s second consultation he also misunderstood the physician in thinking 
that since he did not have AF symptoms at that time, he was in good health 
and he did not have a risk of stroke anymore. Greg’s experience was a clear 
indicator of the need for good communication skills and the importance of 
continuous education. 
 
G - And last time I came to the hospital, they told me that it has 
corrected itself, ‘you’re ok now’, so… that’s what the impression I 
got anyway… ‘you’re ok now, might happen again in the future’… 
and that’s why I don’t understand they were saying I should have 
warfarin. I still don’t understand why I should have had warfarin. 
(Greg, Refused OAC) 
 
Josephine also felt that since she did not have any symptoms, she did not 
understand the importance of warfarin. She perceived the importance of a 
medication based on how well it manages symptoms. Since warfarin was a 
medication that prevented symptoms, Josephine did not perceive it as 
important. On discussing this issue, Josephine also highlighted her cognitive 
dissonance as later she pointed out that it is difficult for a patient to change the 
status quo especially when the perception was that aspirin was working. . 
 
When somebody asks you to go on warfarin, you think ‘why? I’m 
better’, ‘I’m doing fine’, ‘I don’t need anything else’.] [I 
understand… (laughs) I think it’s bit… it’s denial that you think ‘oh I 
don’t need that, I’m better, I was going along fine with what I’ve 
got’ (Josephine, Refused OAC) 
 
Similar to Greg, Shona refused warfarin because she believed she was in good 
health. This could be due to the misinterpretation of the physician’s education 
as she considered blood pressure as a sickness but not AF. Furthermore she 
was also confused about the benefits and risks of warfarin. Shona did not 
perceive any benefits from taking warfarin but rather only perceived the risks.  
 
S – But erm… so I look into it and erm… I don’t have a sickness I 
only have blood pressure, so I told them no want it. And that is it… 
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and they wanted to give me the warfarin for the heart thing and I 
said I don’t want either one or the other. 
Friend – because she don’t feel ill at the moment, and since she 
don’t feel ill she don’t take it.  
R – So correct me if I’m wrong, just so I understand you better, 
since warfarin is not going to HEAL you, it’s not going to change 
things for you like they are right now… erm that’s why you didn’t 
want it? 
S – mhm (nods) I don’t want it. (Shona, Refused OAC) 
 
Shona later emphasised again that she believed that the tablet was not going 
to provide her with any benefits as she associated warfarin with death because 
it was a life-long medication and her friends were on warfarin when they 
passed away. In addition Shona’s perception of warfarin was that the bleeding 
could cause an untimely death, and thus it was going to interfere with God’s 
plans for her. This religious belief may also have influenced her decision in 
refusing OAC.    
 
R – And if I may ask, what was the reason for not wanting it? 
S – Because if I take it I’m going to die, and if I don’t take it I am 
going to die, alright? And I am not ready to die until god is ready 
for me. So I’d rather not try.][They (her friends) were on warfarin… 
and they passed away. I don’t think they really liked it that much. 
R – so kind of, the people you talked with had bad experiences 
with warfarin and they died while they were on warfarin.  
S – Yeah (elongated sigh) (Shona) (Shona, Refused OAC) 
 
4.2.2.2.4 Challenges associated with a change in lifestyle 
Some participants who refused warfarin as their OAC medication also 
commented that the challenges associated with a change in lifestyle had an 
influence. These challenges include the need for blood monitoring, the bleeding 
and bruising associated with warfarin and the fear of adherence to warfarin 
treatment regime. ‘A priori’ knowledge of blood monitoring could have an 
influence on the patient’s perceptions, as shown in Greg’s next quote. Greg 
pointed out that he got to know about blood monitoring from another patient. 
However from his friend’s experience it seemed that her INR was not stable 
and thus she divulged with Greg her negative experience. This influenced Greg 
to the point that he believed that his life would end up revolving around 
warfarin.  
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G – It is the monitoring thing that sort of put me off. I was talking to 
that girl I was on about. She said she has to come regular 
because they have… sometimes they give you more, sometimes 
they give you less. It seems to be taking over your life as well. 
(Greg, Refused OAC) 
 
Similarly Josephine who still worked at the time perceived the monitoring as a 
challenge to her lifestyle. Josephine was afraid that the responsibility of having 
to go for monitoring would clash with the responsibilities of her work. 
Additionally she hides her distress about this issue through jokes. 
 
Then you have to return to clinic every month or whatever, you 
know… to have your blood taken. I suppose you can… but when 
you work full time, where can I… I can’t have the time off to be 
doing all that. Erm… It seems to be doing alright, the drugs I’m 
on… I mean does anybody ever takes your blood and tells you ‘oh 
it’s lovely, it’s just the right consistency’ I don’t know (laugh) 
(Josephine, Refused OAC) 
 
Apart from blood monitoring, the risk of bleeding and bruising also posed a 
significant threat to the participants’ lifestyle. Since Josephine was still working 
at the time of the consultation and because of her social position at work she 
was very aware of bruises. She claimed that she was not careful of her 
surroundings and thus she was more prone to “bump” with the surroundings 
which she knew ‘a priori’ that it could increase the number of bruises when on 
warfarin. Knowledge from this past experience influenced her in becoming 
more aware of the social impact of visible bruises. 
 
J – I said (to the doctor after refusing warfarin) ‘well because, 
you’ll never get anybody more clumsy than me’, I’m walking and I 
bump myself. I thought… this is what you hear about warfarin you 
see. Covered in bruises and all that…][This having to mind 
yourself you know… you know with the bruising and that sort of 
thing because, erm… I am clumsy, I am very very clumsy. And I 
cut myself with the vegetable knife and it’s just the thought of all 
that. (Josephine, Refused OAC) 
 
Contrasting to Katrina’s experience with her fear of stroke and the subsequent 
influence in accepting OAC, Will discussed how his past experiences had led 
him to develop a fear towards bleeding to death. Will was so distressed when 
 149 
 
 
emphasising the issue of his blood not clotting that he almost started to panic 
and stutter. 
 
The other problem is that my blood doesn’t clot very good. I bleed 
a lot. You know and and and (stuttering)… they were so 
concerned with me heart, because if you into fast AF and you’re 
on the table with your kidney taken out, you’ll lose a lot of blood. 
And if they aren’t quick, they may not be able to stem the flow. I 
only just have to cut myself to bleed you know. (Will, Refused 
OAC) 
 
 
In addition to the above experiences, the fear of adherence was another factor 
that influenced the participants into refusing warfarin. Will expressed his 
concern towards his own adherence from his past experience with aspirin. 
However he did not perceive the non-adherence to aspirin as dangerous as if it 
would have been with warfarin. 
 
W – I don’t take the aspirin as well as I should do, I got to be 
honest. But it’s only 75mg. I wouldn’t take warfarin though.  
R – and why don’t you take the aspirin? 
W – mhm well I can’t really answer that. Maybe it’s because I 
forget them, but I shouldn’t… I don’t know. I’ve got to be truthfully 
honest. I do take them, but not every day. (Will, Refused OAC) 
 
Similarly, apart from Shona’s beliefs explored previously, she was aware of her 
problem with adherence. From her own experience with other medication she 
surmised that she would end up with similar practices with warfarin. 
 
S – Yeah I don’t think I can keep the timing. Sometimes I even 
forget the blood pressure tablets. So I couldn’t keep up the timing 
either. (Shona, Refused OAC) 
 
4.3 Life after the consultation  
The second over-arching theme (see Table 14) focuses on the patients’ 
experiences post diagnosis and the experiences that led some participants to 
discontinue their OAC treatment will also be explored. 
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Table 14: Main themes emerging from patients’ own experiences of AF and 
OAC 
Over-arching 
themes 
Themes Sub-themes 
Life after the 
consultation 
The challenges of 
living with OAC 
Food interactions 
Regular blood tests 
Support 
Experiences that 
lead to OAC 
discontinuation  
Balancing fear of stroke with negative 
experiences of OAC on QoL 
Being informed about patient rights 
 
4.3.1 The challenges of living with OAC 
Living with OAC sometimes proved to be challenging for the patients who 
accepted warfarin. This theme will discuss these challenges and how patients 
adapted to incorporate warfarin into their lifestyle and how they coped. 
 
4.3.1.1 Food interactions 
Since vitamin K found in certain foods can interact with warfarin affecting the 
patient’s INR control, patients had to be aware of the types of food in their diet. 
All of the patients who accepted warfarin mentioned that they were 
knowledgeable about the types food that could interact with warfarin. Although 
these interactions did not have a negative influence on the patients, there were 
misunderstandings on the dietary advice and that they could maintain their 
normal diet. Instead, patients like Fiona, in the quote below, mentioned that 
they stopped eating broccoli completely. In addition, participants like Fiona 
used humour, as seen below, as a way to cope with this challenge.  
 
F - There are things that you can’t eat, or have to be careful of with 
eating. Unfortunately that is something that I really love. (laughs) 
like cranberries (laughs) I used to love cranberry sauce with the 
turkey AND BROCCOLI… but that you can live without (laughs) 
(Fiona, Accepted OAC) 
 
A similar misunderstanding on dietary knowledge was raised by Raj’s wife. Raj 
and his wife pointed out that they stopped eating grapefruits. However, 
grapefruit, is a fruit which is usually recommended to be stopped when patients 
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are taking statins (drugs used to lower cholesterol), rather than warfarin. Thus 
although these participants commented that they had to stop eating certain 
fruits which were normally perceived as ‘healthy food’, patients had some 
misunderstandings on the dietary advice. 
 
R (Wife) – he couldn’t take cranberry… and he couldn’t have 
grapefruits, which 
R – I eat those every day 
R (Wife) – yeah he eats them every day. (Raj, Discontinued OAC) 
 
 
4.3.1.2 Regular blood tests 
Regular blood monitoring also proved a challenging experience for the patients. 
For Lionel, the regular blood tests had an impact on his QoL. He was the type 
of person who tried to keep his mind active, and for him the time was being 
wasted in the hospital while he could be doing something more interesting. In 
addition he discussed financial issues, related to hospital parking charges, that 
older patients who are on their pensions would find difficult to cope with. This 
prompts the need for raising awareness about possible GP practices who do 
blood monitoring that might be nearer to the patients. 
 
L – It’s a real inconvenience… getting here, by bus, I live 5 miles 
from here. I can’t get here by bus. In a car it’s 15 to 20 min. You 
can only get here by car or taxi. If you come by car, erm, you’ve 
got car parking charges. For what is exactly a 5 minute job. The 
longer they take to do it, the more money you have to pay them for 
the privilege of parking] [plus the fact that you have to come in 
regularly to be monitored. Plus the fact that there are car-parking 
charges. There’s no way that you can get in and out within 20 
minutes. So it’s going to cost you a couple of quid a time. Just to 
go in and have you finger pricked. One time it was chaos there, 
and you could get stuck for even an hour. (Lionel, Accepted OAC) 
 
Moreover the time consuming experience for Lionel was aggravated when 
warfarin had to be stopped for a few days because of other health procedures 
and then restarted. When warfarin is initiated, INR tests are done once a week 
until it is stabilised. Once INR is stabilised patients only need to go for blood 
tests every three to four weeks, so for Lionel every time he stopped warfarin 
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this meant that the blood tests had to be done more frequently until the INR 
was stabilised again. 
 
L – It does have an impact on my quality of life. This 
inconvenience is time consuming in coming to the hospital and 
taking part, having your INR checked. You have to be very careful 
if you’ve got a cut or a bruise. And erm… particularly at my age, 
everything you do… there is the dentist, any internal examinations 
at the hospital, you have to knock off warfarin.][Then you have to 
start the INR again and it’s all over the place. (Lionel, Accepted 
OAC) 
 
Conversely some patients commented that having their blood tested did not 
impinge on their daily lives. Jonas had good adherence to his medication. He 
pointed out that it was part of his character. In addition for patients like Jonas 
who lived alone, blood monitoring also served as a social activity. 
 
J – It didn’t bother me the monitoring. If I had to come here every 
week, if it had to be done, it had to be done. That is how I am. If 
you’re gonna go on, then you have to do it and I do have a good 
rapport with the nurse that does it, so it gives me a bit of a giggle 
when I go there. (Jonas, Accepted OAC) 
 
Similar to Jonas, Daniel complies with the expert’s advice, as explored in 
previous themes. However, Daniel also used his past experience with diabetes 
medication to justify the change in warfarin dosages. 
 
D - I was never bothered about the medication they used to 
prescribe. If I’m going to take it, I’ll take it. I have a check every so 
often and if they want to, they change it.][I just accept it, what I am 
told, I believe. As sometimes happens with the diabetes, when it 
goes high, they increase the dosage, it sounds like common sense 
to me. (Daniel, Accepted OAC) 
 
4.3.1.3 Support 
Patients talked at length about how the support they experienced from their 
relatives encouraged them to both to stay on warfarin or to discontinue it and 
also about the lack of support offered at work. On being prompted about this 
issue, Fiona jokes about how she broke news of the need of warfarin to prevent 
a stroke to her family. Interestingly, her children also used humour to cope with 
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the distressing news. She also pointed out the importance of assuring the 
family members through educational information. 
 
R – Did you tell your family about warfarin? 
F – Yes of course, and the general comment was, we always 
knew you were a rat… mum. (laugh) I think they joked about it 
because they didn’t know what to say to start with. I said it’s just to 
regulate things, to thin the blood down and prevent clotting and 
hopefully prevent any strokes and things like that. (Fiona, 
Accepted OAC) 
 
Fiona commented on how roles in her family got inverted, with her children 
taking on a protective role. Family support combined with humour was 
invaluable for Fiona and gave her a sense of pride towards her family.  
 
F – Sometimes they’ll tend to become a little bit overprotective 
shall we say. If they picked that I’ve got something planned that I 
shouldn’t be doing, that THEY think I shouldn’t be doing. They’ll 
mother me and I’ll be yes yes mhm mhm and do it (laughs) 
R – And how does this make you feel? 
F – It makes me realise that… even though they’ve not always 
said that they appreciate what I’ve tried to do to them. They show 
it to you through their actions. These actions. (Fiona, Accepted 
OAC) 
 
Lionel also disclosed how his friend provided constant emotional support 
throughout the years. In Lionel’s account he shows how they both find comfort 
and solace in sharing their concerns and support each other.  
 
R – In the beginning you told me that you lived with someone for 
40 years. Did you tell him about the AF? 
L – Oh yes yes. 
R – And what was his reaction? 
L – Well erm… I think it’s erm, acceptance of the inevitable really. 
He knew how I felt before this check-up. We talked about it and 
obviously he was concerned, erm… but at that time it wasn’t… we 
thought it wasn’t serious. It was just the start of something, so he’s 
just developed with it. He’s got his own problems… prostate 
cancer. He worries about me. Worries tremendously. When I got 
hepatitis back in 1980, I was very near to death’s door with 
hepatitis b and he nursed me back. (Lionel, Accepted OAC) 
 
Lack of knowledge on warfarin and its side effects, also had an influence on the 
type of support provided. In Katrina’s anecdote, she mentioned that her 
husband was already negative towards warfarin before she accepted it. 
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However, instead of supporting her during OAC, he encouraged her to stop 
warfarin because of his fears brought about from the visible side effects of 
warfarin. 
 
K – My husband was against me going on it, but I had to start it. 
Then when he saw the effects it was having on me he said you 
should get off the bloomin stuff. It’s not doing any good. I think he 
was worried when he started seeing me with the patches and the 
bruises. (Katrina, Discontinued OAC) 
 
On the contrary, since Katrina’s daughter was more knowledgeable on warfarin 
due to her work, she kept trying to educate her mother on the risks and benefits 
of OAC. 
 
K – My daughter, you know how nurses are, she said you are 
more at risk of a stroke, you should carry on it you know. (Katrina, 
Discontinued OAC) 
 
Robert, uncovered the lack of awareness of AF and INR testing in his 
workplace, leading to a lack of support from work.  
 
Rob – I cannot take time-off from work for monitoring. I can take 
time-off for other things, but not for this. It doesn’t work for them. 
They just don’t like it! (Robert, Discontinued OAC) 
 
Josephine also expressed her frustration from the lack of support shown at her 
workplace after she had a TIA.  
 
J - At work, no I wasn’t supported to be honest. (when she had the 
TIA) Erm they were like you’re back to work, get on with it. Not 
very supportive. Erm… the hospital’s been wonderful. Really really 
good. You can’t fault them. Every appointment has been bang on 
time. In the new treatment centre. At work no, but hospital yes. 
(Josephine, Refused OAC) 
 
4.3.2 Experiences that lead to OAC discontinuation 
The next theme discusses what experiences influenced patients to discontinue 
warfarin as their OAC medication. Participants argued about how they had to 
balance whether to live with the fear of stroke or live with the impact of the 
negative side-effects of warfarin on their QoL.  
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4.3.2.1 Balancing fear of stroke with negative experiences of OAC on QoL 
For some participants, however, the impact warfarin was having on their QoL 
was not bearable, especially when they could not perceive any benefit from 
taking warfarin, as Raj’s wife pointed out.  
 
R (wife) – He did take it for a little while, but it wasn’t doing 
anything to his blood and then he decided….Then they increased 
the dose to 4mg I think but it wasn’t changing anything (Raj, 
Discontinued OAC) 
 
Older patients also complained about the issue of polypharmacy (when patients 
take a myriad of medication). Raj believed that taking numerous tablets would 
prove more harmful than beneficial. He had explained how according to his 
perceptions, influenced by informal discussions with his friends who were 
physicians, most of the medications are actually placebo and that they were not 
as important as the health care system portrayed them to be. Raj used this 
logic to justify himself that warfarin was not an important medication. 
Interestingly however, he perceives hypertension as an important condition to 
monitor. 
 
R – Then I discovered I was taking tablets after tablets after 
tablets, erm for diabetes, high blood pressure tablets, aspirin and 
then warfarin erm… and I was just erm… any tablets you take do 
have a side-effect as well. And erm… I decided I’ll take the ones 
that I certainly DO NEED. Like the ones to keep my blood 
pressure controlled. (Raj, Discontinued) 
 
In addition to polypharmacy, Raj’s main reason that influenced his 
discontinuation of warfarin was the perception of loss of liberty from enjoying 
his retirement. Raj explained how when his children were younger he devoted 
his life to provide them with the best education. Since he had retired and his 
children are settled, he wanted to enjoy his retirement before he became less 
independent from ageing.  
 
R – I’ve worked as a financial advisor, I’m retired and I like erm to 
spend my time going on holidays. Whilst the children were young, 
we couldn’t afford to go away on holiday because of their 
education. They both went to University (named university) and 
they’re both dentists. Now we getting old and we want to try and 
make the most of it before it’s too late.] [While we have the 
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opportunity and good health we can do these things which we may 
not be able to do after, I guess. (Raj) 
 
Raj’s wife provided a rationale for what influenced this reasoning. She 
discussed how during one of their holidays, they had met an English gentleman 
who was also on warfarin. However he was bleeding from mosquito bites. As 
mentioned before, for Raj, travelling represented a very important aspect of his 
QoL. Raj’s observations of how warfarin had an impact on this English 
gentleman’s experience, clashed with his beliefs of what travelling represented 
and since he perceived himself as still in “good health” the risk of stroke was 
not as imposing as the impact warfarin would have on his QoL.  
 
R (Wife) – I’ll take you back to when we were in Goa, there was a 
gentleman there, an elderly man who was covered in bandages 
R – He was on holiday from England 
R (Wife) – yeah from England and we said, what’s happened to 
you and he said he’s on warfarin and he’s being picked by 
mosquitoes and it wouldn’t stop bleeding.  
Res – From the mosquito bites? 
R (Wife) – yes cause he was on warfarin and he had mosquito 
bites, and they inject something to stop the blood clotting, cause 
with his warfarin he started to bleed and the bleeding wouldn’t stop 
and he had to go to hospital because of that. 
R – We were all sitting there by the pool and nice and sunny 
(Smiles) and he was all bandaged from head to toe (laughs) 
R (wife) – and that was another thing that put him off continuing 
warfarin (Raj, Discontinued OAC) 
 
Raj disclosed that he was not against taking warfarin. However for him, being 
on warfarin influenced him in becoming more mindful of his situation. Thus, 
severely affecting his ability to enjoy his travels. Raj was aware of the risk of 
stroke when not on warfarin, thus he mentioned that he would “start it again” 
when it would not impinge on his travelling.  
 
R – I would go back to warfarin, but at the moment we’re trying to 
go away for holiday as much as we can. WHILST we can, this 
opportunity won’t stay forever. Erm… if I’m on warfarin I have to 
be very careful where we go. Basically it put me off for the time 
being. But when the time is right I would start it again. (Raj, 
Discontinued OAC) 
 
In rare occasions, patients might get an allergic reaction to warfarin, which 
would have a biopsychosocial impact on QoL. Robert developed such an 
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allergic reaction to warfarin. He described how the allergy to warfarin caused 
him great distress and covered most of his body. Robert’s wife further explains 
their long ordeal in trying to identify the cause of this rash (which was warfarin) 
and the distress this caused Robert until warfarin was discontinued. Apart from 
the physical itch that the rash gave him, Robert became so aware of it that he 
was too embarrassed to go out in public. Before warfarin was discontinued 
Robert ended up in a vicious circle, the more he became aware of the rash, the 
more he became distressed and isolated, which in turn made him more mindful 
of what was happening to him. 
 
 
Rob – The Rash was also on my face sometimes 
Rob (wife) – really bad blisters… they were like watery. They were 
terrible ones, and very itchy.  
Res – and that had an effect on your quality of life? 
Rob – OH YES OF COURSE!!! 
Rob (wife) – OH YES… the doc gave him ointments, tablets, 
nothing worked. 
Res – and how did that affect you when you go out? 
Rob – Of course I’d be embarrassed. We’re not posh or anything 
like that, we don’t go to fancy restaurants or thing like that, but 
even walking in the streets you feel embarrassed by people 
looking at you sideways (Robert, Discontined OAC) 
 
Conversely for the patients who discontinued warfarin, participants that were on 
warfarin decided to continue taking warfarin because of the fear of stroke. This 
fear was worse when the participant had direct experience of the disastrous 
impact of stroke on QoL. The fear of stroke was a critical factor in Lionel and 
Jonas’ experiences. Both of them had experienced caring for a relative who 
had a stroke. Although Lionel had accepted warfarin, he was not positive about 
the medication. However he was so distressed by the thought of having a 
stroke that he did not discontinue OAC. He preferred to wait for new OAC 
treatments to be licensed.  
 
L – I really can’t wait to get off digoxin, I really can’t wait to get off 
warfarin. I’m hoping that they had this alternative that they are 
testing, and that it works out. (Lionel, Accepted OAC) 
 
Lionel’s mother had experienced a stroke and this had left a traumatic 
experience on him. Lionel’s fear of stroke was not only related to the effects it 
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would have on his own QoL, but also he was afraid of the impact it would have 
on his friend’s QoL.  
 
L - That is my greatest fear is having a stroke, rather than dying 
outright, the greatest fear is having a stroke.  
R – Why is this? 
L – Erm cause it will affect other people. I can’t erm (forming tears 
in his eyes)… I can’t bear the thought (deep breaths) of 
somebody… I don’t want to label them or anything, but I can’t bear 
the thought of someone I love having to take care of a cabbage 
(cries) (Lionel, Accepted OAC) 
 
Similarly Jonas had taken care of his mother for 17 years after she had a 
stroke. Jonas was put on warfarin without his consent and when he was able to 
make an informed decision, through knowledge gained about AF and the 
knowledge gained from his experiences with stroke, he decided not to 
discontinue OAC. 
 
J – It was explained to me that I would’ve gotten a blood clot if I 
hadn’t been on warfarin. That is the reason I stayed on it. 
Obviously if the blood clot goes to the brain or the gets to the 
heart, you’ve got a problem. So that was why I stayed on the 
warfarin. 
R – So if I understood you correctly you stayed on warfarin 
because you were more afraid of the stroke then the bleeds. 
J – YEAH. My mother she had a stroke. I was with mum for 17 
years after she had a stroke. It’s something that I wouldn’t wish on 
anybody. Living it, with it or seeing it. She could do absolutely 
nothing. She could hardly speak, she got no control over any of 
her bodily functions. I wouldn’t like to end up like that. If that 
happened to me I would ask somebody to put a gun to my head. 
(laughs). (Jonas, Accepted OAC) 
 
4.3.2.2 Being informed about patient rights 
Similar to Lionel, Katrina had a negative perception towards warfarin. What 
encouraged Katrina to discontinue warfarin was when a health professional 
explained to her that it was her right as a patient to discontinue a medication 
that she did not like taking. Katrina had accepted warfarin because she felt that 
the physician gave her a “life or death” choice. In the below excerpt Katrina 
discussed how during one of her visits to the anticoagulation clinic, one of the 
nurses explained her rights as a patient.  
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K – The nurse told me ‘They can only offer the medication. (leaned 
forward) They can’t force you to take it. You shouldn’t take a 
medication if you’re not happy about it’ (Katrina, Discontinued 
OAC)  
 
Katrina’s perception of the decision making process was that of a paternalistic 
persuasion by the physician. Thus, on accepting warfarin, Katrina felt 
restrained for life with warfarin, and the knowledge gained from a health 
professional, gave her the ‘permission’ needed to stop warfarin. 
 
K - I was under the impression that you couldn’t come off it once 
you’d gone on it.  
R – So to summarise you were talking with the nurse about this 
issue and she went to check if you could stop it or not? 
K – Yes, she went to see the doctor I think. They tried to tell me 
again about the in’s and out’s about the risk, which I already knew. 
But she (the nurse) said ‘You know you got rights, they can’t make 
you have it against your will, it’s against the law’ 
R – Did you know about your right to come off it before? 
K – I didn’t think you could come off it you see. I thought it was a 
‘that’s it, once you’re on it, that’s it for life’. I wasn’t told I could 
come off it. (Katrina, Discontinued OAC) 
 
4.4 Patient’s experiential reflections 
The last over-arching theme revolves around the patient’s reflections on their 
experiences of OAC. These reflections were most often a result of their insights 
having thought and talked through their experiences during the interviews. Two 
themes emerged (see Table 14): (1) patient’s perceptions about warfarin and 
aspirin and (2) patient’s recommendations towards the changes needed to 
ameliorate the consultation and OAC experience for other patients and the 
need to raise awareness about OAC.  
 
 
 
 
Table 14: Main themes emerging from patients’ own experiences of AF and 
OAC 
Over-arching 
themes 
Themes Sub-themes 
 160 
 
 
Patients’ 
experiential 
reflections 
Perception of 
Warfarin vs. 
Aspirin 
Aspirin perceived as ‘old’ natural 
wonder-drug  
Warfarin perceived as dangerous/end-
of-life drug 
Patients’ 
recommendations 
Time & physicians’ communication 
skills in initial consultation 
On-going patient support 
Raising awareness about warfarin 
through the media 
4.4.1 Perception of Warfarin versus Aspirin 
Most patients in this study perceived aspirin as a natural ‘wonder-drug’ while 
warfarin was perceived as a dangerous drug usually given to people at the end 
of their life. Interestingly they perceived both drugs as ‘old’. However, for aspirin 
this had a positive association, with ‘old’ meant tried and tested and familiar, 
while for warfarin, ‘old’ meant “has been around for too long”. 
 
4.4.1.1 Aspirin perceived as an ‘old’ natural ‘wonder-drug’ 
Patients commented that aspirin was always perceived as a safe drug that was 
widely known to be helpful in everyday situations and for many medical 
conditions. Josephine aptly called it a ‘wonder drug’ and admitted that her 
family used to take it as prevention to other ailments. 
 
J - We’ve always taken aspirin, even before… 
Husband – 75mg a day 
J – Yeah we’ve always taken that. Cause it’s a wonder drug really. 
It’s aspirin. So we’ve always taken it. So when they said do you 
mind taking aspirin, I said no. I always do anyways (Josephine, 
Refused OAC) 
 
Josephine and her husband rationalised that they perceived aspirin as being a 
‘wonder drug’ because of the knowledge they gained through the media. They 
concluded that since it is made from a natural product, aspirin was safe. 
However, they did not know that even warfarin was derived from a natural 
product, highlighting the lack of knowledge and awareness about warfarin. 
Furthermore for Josephine, the perception of aspirin being ‘old’ meant that as a 
drug it is efficacious and safe because it had been around for a long time and 
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used widely by people for a variety of conditions. Conversely, Josephine did not 
perceive warfarin as an efficacious drug even she called ‘old’ like aspirin. 
 
R – Before… you called aspirin a wonder drug. How come you 
called it a wonder drug? 
J – Well it’s old isn’t it? It’s so… I mean… 
Husband – It’s from the bark of the willow. 
J – Yeah bark of the willow, sort of natural thing… and it’s… I’ve 
always known that…I’ve always taken it… (Josephine, Refused 
OAC) 
 
Greg commented that aspirin and warfarin had a similar function. He argued 
that patients perceive the two drugs in different ways. In addition, similar to 
Josephine, he added that patients do not think about whether they take aspirin 
or not, since it is perceived as safe. To Greg’s perception, aspirin has no 
negative connotations, unlike warfarin.  
 
R – did they he (his father’s friend) ever tell you that aspirin can 
cause bleeds too? 
G – yeah but not like that (warfarin). It does seem to be the same 
(as warfarin),strange… it’s the perception of it… I don’t know. 
R – so how do you perceive aspirin? 
G – I don’t perceive it as anything… you just take it. (Greg, 
Refused OAC) 
 
Moreover, since a patient does not need a prescription to buy aspirin, further 
intensifies the perception of aspirin as a safe drug. 
 
R – So if I understood you correctly aspirin is not like other 
medication, it’s more of a normal tablet 
W – No no, I mean yes yes…the other tablets are more important. 
I’ve had aspirin for quite a while, operation and after and all that.  
R – So aspirin is not that important of a drug, if I understood you 
correctly 
W – Yes yes that’s how I feel. 
R – So it’s like a normal over the counter thing 
W – Yes yes (Will, Refused OAC) 
 
4.4.1.2 Warfarin perceived as dangerous end-of-life drug 
Most patients in this study had a negative perception of warfarin. This was also 
influenced by the fact that it was used as rat poison in the past. Lionel 
comments that he was distressed the first time he became aware of this. 
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However he said this did not influence him to not take warfarin. Lionel was 
surprised by the way the word ‘poison’ influenced his perception of the drug, 
later arguing that what kills the rats was an over-dose of warfarin. In addition, 
the quote below highlights Lionel’s medicine perceptions. Lionel perceived all 
medications as being poisonous, probably from the belief that if a patient over-
doses from most medications it can lead to death. 
 
L – It was also used as rat poison 
R – And where did you hear that if you don’t mind me asking? 
L – Well it was YEARS ago that I heard that it was rat poison but 
also used on human beings, not to kill them but keep them alive. I 
was unhappy, knowing it was rat poison, but in a sense all 
medicines are a bit of a poison aren’t they.] [well it’s not really 
poison isn’t it, as it just makes them bleed, an internal bleeding. 
(Lionel, Accepted OAC) 
 
Like Lionel, Josephine pointed out the issue of rat poison. However she also 
labelled warfarin as an old-fashioned drug. Josephine had previously also 
categorised aspirin as an old drug, however by old-fashioned Josephine meant 
that she believed it needed to be changed. Josephine’s experience 
emphasised how she believes that people are more conscious of the negative 
information, probably because she is more risk averse. 
 
J - And it’s such an old fashioned drug as well. It’s been there for 
years and of course, when it first came out, everybody was ‘oh it’s 
rat poison’ cause that is what they used to kill the rats with you see 
(laugh). And that sticks in a lot of people’s mind. That it’s rat 
poison.] [Your dad was on it was he? (to husband) and he used to 
call it rat poison. (Josephine, Refused OAC) 
 
Interestingly, all patients mentioned that they became knowledgeable about 
warfarin being used as rat poison through informal communication. Josephine 
discussed how education from informal sources, such as relatives, only covers 
the negative perceptions associated with warfarin. In addition, Josephine 
pointed out that patients associated warfarin with a drug that is given near the 
end of life, as a last resort.  
 
J - This is what you hear about warfarin you see. Covered in 
bruises and all that… then you have to return to clinic every month 
or whatever, you know… to have your blood taken] [I think that 
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comes into it a bit that… that you ‘oh no warfarin… that will end 
you up dead’]  
[R – so what you said before, if I understood you correctly, you 
meant that warfarin is associated with end of life? 
J – Yes that’s right, I think it is, isn’t it? Cause you have to have 
something major with your heart… erm for them to put you on 
warfarin. (Josephine, Refused OAC)  
 
This was an interpretation shared by Lionel as well. Since warfarin was similar 
to a stronger version of aspirin, being on warfarin meant that a harsher 
treatment was needed for a more severe condition. 
 
L – yeah aspirin it’s a fixed dose. Warfarin is different; it’s like… 
erm… It’s stronger so in a sense it feels like a warning sign, that 
things are deteriorating rapidly (Lionel, Accepted OAC) 
 
However not all patients had negative associations to warfarin. Robert uses an 
analogy that his cardiologist had told him to describe warfarin, comparing OAC 
to a luxury car. 
 
Rob – They call it like the Rolls Royce of the treatment you know, 
warfarin… (Robert, Discontinued OAC)  
 
4.4.2 Patients’ recommendations 
Throughout the interviews patients provided several recommendations, based 
on their experiences, emphasising the need for better consultations, on-going 
support, and the importance of raising awareness of AF and the need for 
warfarin. 
4.4.2.1 Time & physician communication skills in the initial consultation 
A common argument brought about by patients throughout the study was the 
need for an increase of available quality time with patients during the initial 
consultation. Most of the patients talked about the paternalistic attitude taken 
by the health professionals during the most crucial consultations. Patients 
should be given time to assess the situation especially after receiving 
distressing news. 
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L - But you don’t think of what to say during the consultation, if 
you’ve had some bad news. You don’t know what to think. (Lionel, 
Accepted OAC) 
 
On a similar note, Greg pointed out that from his experience a longer first 
consultation is imperative for the patients. The extra time is critical in providing 
adequate educational information.  
 
R – We mentioned kind of time before and how much time they 
spent with you… from your experience, what do you think of the 
length of the consultation? 
 G – Yeah I think a longer one would be better so… especially to 
take in all of this, cause it was sort of new to me.  
R – So new consultations should be allocated more time 
G – Definitely… the first initial one. The nurse in the ward told me 
a little about it… but when you go and see a surgeon or a doctor… 
it’s more serious… it’s the FACTS of what it is. (Greg) 
 
According to the participants, quality time and communication skills were both 
crucial in improving education to patients. They highlighted that a patient needs 
to know exactly why the need for a particular medication.  
 
J (Husband) – you need to know what is wrong with you, why 
you’re giving me those tablets… once you know… it’s not just a 
case of taking the tablet. It’s a case of taking a tablet knowing why 
you are taking it. 
J – Yeah yeah definitely. You just need to know (Josephine, 
Refused OAC) 
 
The time spent during the interviews to discuss Josephine’s experiences, 
helped Josephine to change her negative perceptions of warfarin. She had 
failed to weigh the risk of bleeding with the risk of an eventual stroke and 
through these discussions, she argued that warfarin would actually benefit her 
more since she already had a previous TIA. 
 
R - so thinking a bit about the side-effects of warfarin vs stroke, 
which would you weigh the most important to 
J – (laughs) well you would have to go with the fewer side-effects 
wouldn’t you (laughs) Better just a few bumps than that yeah. 
R – so you’re more worried about the bleeding? 
J – oh no no… I am more worried about the stroke 
R – oh sorry I misunderstood you. 
J – no no, sorry… for a few tablets it’s worth it isn’t it… but it’s the 
erm… it’s just the thought of having to attend a clinic you know. 
But I suppose it won’t be that often. But if it’s gotta be done, it’s 
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gotta be done. It will get me out of the office for a bit wouldn’t it 
(laughs). (Josephine, Refused OAC) 
 
Communication skills were also an asset that patients thought was lacking in 
consultations. Fiona had two differing experiences from different clinics, so she 
was in a position to comment on what were the ingredients of a good 
consultation. She highlighted the need for health professionals to be more 
aware of their communication skills, particularly listening.  
 
R – if you had to point out differences between a good 
consultation you had and a less good one from the clinics you 
went through for AF, what would those differences be? 
F – I felt when I came out of it that he (the first clinic where she 
didn’t experience a good consultation) treated me as though I was 
wasting his time. You know.] [LISTENING. You know, I mean… if 
in the consultations questions are asked… you don’t want to feel 
that (when) you(are) answering somebody is just like (doing them 
a favour)… you know what I’m saying? It erm… as I told you 
before, I’m not an attention seeker, but if somebody is asking me 
questions and wanting to know about myself I do expect them to 
listen. (Fiona, Accepted warfarin) 
 
Others commented that there was a lack of empathy from the specialists, 
contrary to the relief some of the patient experienced. From his experience, 
Lionel concluded that there was a lack of patient-physician bonding. In the 
following quote he points out how the lack of empathy towards his feelings and 
the lack of interaction, between the patient and physician, he experienced has 
altered his perceptions of NHS health professionals.  
 
Consultations aren’t consultations. It is the wrong expression for 
what is happening. You’re just told what… this is the medicine and 
this should be your dose. So I see you in 6 months’ time. It’s not a 
consultation; there is no interplay of patient’s feelings or thoughts.] 
[This doesn’t do anything to improve my opinion about NHS 
consultants. (Lionel, Accepted OAC) 
 
A similar account was experienced by Fiona. She commented on the lack of 
empathy and communication skills shown by the consultant who was visiting 
her. Furthermore, Fiona mentioned that the consultant was telling her about 
“this and that”. However because of his communication skills, she did not 
perceive it as adequate education. In addition similar to Lionel, Fiona 
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commented that she perceived that her feelings were not being taken seriously. 
Thus she perceived that the consultant took a paternalistic approach. 
 
I was told that they thought I had atrial fibrillation, sent to (hospital) 
he went through all the jargon, he did the bits and bobs… he said 
yes it was definitely an irregular heartbeat.][Don’t get me wrong… 
I’m not a hypochondriac and I’m not an attention seeker. But I 
didn’t feel that I was being taken seriously and it proved correct, 
cause I didn’t go back to that other hospital. He (the consultant) 
didn’t seem… he seemed non-plus. He didn’t care. He was just 
there asking questions, just doing erm… so and so and so, and 
you have to do this and that and the ECG… and I was just sitting 
there and trying to understand what he was on about. (Fiona, 
Accepted OAC) 
 
After this experience, Fiona and her husband decided to go to a different 
hospital. In the quote below, Fiona recounts how a different attitude adopted by 
the health professionals changed her perception of the consultation. 
 
F - My husband took me to )[another hospital] and compared to 
the first it was totally different. They said it was irregular heart beat 
and explained it a bit and said that it needed attention as we were 
away from home and gave me a letter for my doctor.][then my 
doctor sent me to [the] clinic in the hospital and erm… 
R – and how was the consultation? 
F – they were explaining things and what it meant… (Fiona, 
Accepted OAC) 
 
Daniel, although he was the type of patient that would accept a medication if 
advised by the expert, also stressed the need to include patients in the 
discussions, and to use terms that the patient is able to understand. 
 
But when they were consulting with each other while looking at my 
notes, they were consulting in their own language. I thought well 
that really is not right. They should be talking in a way that I would 
understand what they are saying. (Daniel, Accepted warfarin) 
 
Greg also suggested that presenting patients with probabilities could help them 
understand the risk to benefit ratio. 
 
G - They need to tell you WHY you need it] [give you some odds 
like 70% this or that, to weigh it up. Give me a reason why… no 
one ever told me that. (Greg, Refused OAC) 
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4.4.2.2 On-going patient support 
On-going emotional and financial support from the healthcare professional was 
cited by several patients as a crucial function a good health care system should 
adopt to ameliorate patient-physician relationships. Emotional support and 
empathy from health professionals helped lessen the feeling of paternal 
attitude. Fiona explains how she asked to be transferred back to a clinic where 
she felt respected as a patient. Having a positive attitude towards her health 
professionals helped her cope with some of the challenges of warfarin, 
especially blood monitoring, where she felt she was visiting friends rather than 
a hospital setting. 
 
F – I was transferred to a different clinic. But I asked to be 
transferred back to this one. I mean it’s true it’s a bit further away 
but come on, this feels like a family. They make you feel at ease. 
That is what you need. If you have a problem health-wise, I think 
that if you can be put at ease by the people who are dealing with it 
and your health and help you get through it. If you can be brought 
in as a member of a group… build a relationship, it helps.  You 
don’t feel as though you’re wasting anybody’s time. You don’t feel 
as though you’re another number on a piece of paper. You’re part 
of things. People ARE taking notice and you feel like you’re being 
cared for. (Fiona, Accepted OAC) 
 
Likewise, Josephine’s husband recalled an episode in their life where a 
consultant they just met once, called them on their mobile to check on her after 
the TIA. Such empathic gestures helped patients to open themselves to 
discuss issues with their physicians. 
 
Husband – that weekend (after Josephine came out of the hospital 
from her TIA, they went straight to their caravan) we received a 
call and it was the doctor from the hospital here, checking… to 
make sure that she was ok 
J – I thought that was wonderful. I couldn’t believe they bothered 
to do that. 
Husband – no no (Josephine, Refused OAC) 
 
Apart from emotional support, patients also commented on the need for 
financial aid to patients who are pensioners. Robert suggested that parking 
fees in hospitals would have a significant impact on older patients who were not 
working and are living on only their pensions. In the beginning INR testing is 
more frequent until the INR becomes stable and patients may need to go to 
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hospital once a week. In addition, although INR testing does not take long, 
patients may still end up waiting in queues for a long time because of multiple 
appointments. 
 
Rob – It’s a little thing but over time the expenses will go up very 
high. Especially for pensioners or disabled people. Parking should 
be free, for disabled people it should be free you know. Average 
price it’s almost £3 every time. (Robert, Discontinued OAC) 
 
4.4.2.3 Raising warfarin awareness through the media 
Patients commented that knowledge about warfarin was more easily acquired 
from diverse media sources. Participants emphasised the need to raise public 
awareness about the need and risks of warfarin for stroke prevention in AF 
patients. Furthermore Robert added that media could help augment such 
awareness by providing appropriate education. 
 
Rob - People should know that warfarin is the best there is, but it 
has its dangers. They should carry a card on them, you know in 
case of an accident. So the ambulance would know what they’re 
on and also people should be careful about cuts. Maybe an advert 
on the media showing that you can get a cut and it will take longer 
to stop but it’s not a big bleed that you should risk a stroke. 
(Robert, Discontinued OAC) 
 
However educational material available publically in the media is not always 
appropriate and Raj explored this issue in the quote below. Raj pointed out the 
lack of awareness about warfarin amongst patients. This lack of knowledge 
would impinge on the patient’s ability to follow the discussion during the 
consultation. In addition Raj commented that patients end up accepting 
information they deem is coming from reliable sources, such as newspapers. 
 
R – You need to reason things rather than just accepting things for 
the sake of it. A lot of people who have very little knowledge don’t 
even know what the physician is saying. Not only that, even the 
gardener says take aspirin as I read in the paper… so he starts 
taking aspirin. 
R (wife) – well on the newspaper there was written that 75mg daily 
aspirin can prevent bowel cancer. 
R – And because of this a lot of people start taking aspirin for no 
reason. Whether the people need it or not, just because the 
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newspaper media says so, they start taking the tablet. (Raj, 
Discontinued OAC) 
 
Other patients like Josephine commented on the negative connotations that are 
associated with the brand name warfarin and that rebranding might help alter 
patients’ perceptions. She suggested this change because patients associate 
warfarin with rat poison and although the fact that it was used as rat poison did 
not appear to bother the participants, the association of warfarin with the word 
poison did. 
 
Really I think they should just change the name (laughs), ‘This is a 
new drug we’ve got here’ People would have it more easily 
(Laughs)] [It’s warfarin isn’t it, it’s the name. Change the name. 
(Josephine, Refused OAC) 
4.5 Conclusion 
The aim of this study was to explore the experiences which motivate patients to 
accept/decline/discontinue warfarin as their OAC medication. Patients explored 
their experiences during their initial consultations about AF. Most of the 
patients, except Daniel, vividly reminisced about their first experiences with AF 
and their initial consultation where they got to know that they suffered from AF. 
Patients’ felt that in their consultations, there was a lack of take home material. 
Since most of them did not cope well with the education that was given to them, 
educative material that could be taken home could have been of benefit to 
increase their knowledge. 
 
After being diagnosed with AF, patients recounted what experiences influenced 
them in accepting or refusing warfarin. These include how the paternalistic 
approach forced some to accept OAC, while in others a paternalistic attitude 
demotivated them and ended up refusing OAC. Other patients commented that 
a shared-decision making process, mainly the imparting of information from the 
physician played a key role in helping them accept the medication. 
 
Patients also explored their lived experience while on OAC and how these 
experiences influenced some participants to discontinue their OAC treatment. 
Being mindful to food interactions, blood monitoring and support where the 
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emergent sub-themes. Some patients commented that blood monitoring was a 
challenging issue on their life, especially having to take time off and the 
financial drawbacks they incur from parking charges in the hospital. However, 
some patients like Jonas and Daniel did not mind the monitoring as it gave 
them an opportunity to socialise. This was especially prominent for Jonas since 
he lived alone. Patients also explored the issue of how support was given from 
different sources. Some patients mentioned that their family were supportive, 
while others commented how their family members were fearful for them as the 
side-effects started to show. Participants also argued how the side-effects of 
warfarin had a negative impact on their QoL.  
 
The last over-arching theme explored the patients’ own introspections on OAC. 
Patients discussed their different perceptions of warfarin and aspirin and also 
provided some recommendations that could ameliorate OAC management in 
AF and the healthcare system. These include an emphasis on  the need of 
raising awareness, better consultations and on-going support.  
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Chapter 5: Physicians’ experiences of AF and OAC 
prescription 
5.1 Introduction 
This chapter includes the interpretation of the lived experiences of physicians 
during their consultations with patients who were diagnosed with AF and their 
experiences with OAC prescription. Data was collected from four sub-groups of 
physicians in different specialties (cardiology, general medicine, and general 
practice) and at different levels (registrar and consultant); consultant 
cardiologists, consultant general physicians, general practitioners and 
cardiology registrars. The study attempts to answer the following research 
question: What are the experiences, beliefs and attitudes that influence 
warfarin prescription by physicians? 
 
The participants spoke of the consultation with the patients, the issues with AF 
and warfarin and how they approached decision-making. They also talked 
about how they discussed information relating to AF and OAC with patients, 
and how they tried to help patients understand what is happening during the 
time available in the consultation. In addition they discussed how decisions 
were taken during their consultation. During the interviews, they all indicated 
that they keep themselves updated with current research in their field and 
although they have gained a lot of experience on how to tackle patients’ 
concerns during the years, they still discussed some challenges that they face 
when prescribing warfarin. These challenges could be categorised as their 
interpretations of patient related concerns, and the challenges that they, as 
professionals face. 
 
Analysis of the data lead to the development of two over-arching themes (see 
Table 13): (1) Communicating information – a shifting paradigm and (2) 
Challenges within OAC prescription for AF.  Within each of these overarching 
sub-themes were two themes and a number of sub-themes, as illustrated in 
Table 15. 
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Table 15: Overarching themes, themes and sub-themes elicited from 
physician’s experiences of AF and OAC prescription 
 
Over-arching 
themes 
Themes Sub-themes 
Communicating 
information – A 
shifting paradigm 
Patient focused 
information – 
Aspiring for 
adherence 
Reassuring the patient 
Knowledge of warfarin as ‘rat poison’ 
Pictorial reference 
Use of analogies 
Use of statistics 
Motivating the patient 
Physician focused 
decision making – 
Focusing on 
compliance 
Paternalistic approach & issue of patient trust 
Exploiting the fear of stroke - Highlighting 
benefits and minimising risks of warfarin 
Passing on the decision about OAC treatment 
to secondary care 
Hope from new drugs 
Challenges with 
OAC prescription 
for AF 
Challenges that 
physicians face as 
health professionals 
Lack of Time  
Language and cultural barriers 
Guideline adherence 
Information overload for the patient 
Physicians’ 
interpretation of 
patient related 
challenges 
Impact of blood test monitoring 
Side-effects and interactions of OAC therapy 
Differences between symptomatic & 
asymptomatic patients 
Physicians’ perceptions of the patient’s 
experiential knowledge 
 
Each of the over-arching themes, their themes and sub-themes are discussed 
in more detail in the forthcoming sections. Verbatim extracts and their 
meanings are included in the text to highlight the physicians’ experiences. 
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5.2 Communicating information - a shifting paradigm 
Good and effective communication skills were imperative during the 
participants’ medical consultation. This over-arching theme focused on how 
different physicians in different specialties (cardiology, general practice, general 
medicine) and at different levels (consultant and registrar) communicated 
information on AF and OAC to their patients. The medical consultation with 
regards to AF and OAC took the form of a shifting paradigm, where the model 
of patient inclusion changes during the consultation. The beginning of the 
consultation adopted a patient-focused communication style where physicians 
aspired for patient adherence. When the consultation shifted to the decision 
making, it adopted a physician focused communication style were physicians 
took the decisions and focused on maximising compliance. These two 
opposing communication styles were the main themes that structure this over-
arching theme. 
 
5.2.1 Patient focused information – Aspiring for adherence 
In this theme, participants explored how they initiated their consultation by 
focusing on diagnosing and imparting information about AF and OAC to the 
patient. The initial part of the consultation took a patient focused style, were the 
emphasis lay in patient education and reassurance. The physicians’ focus was 
to increase patient knowledge about AF and OAC through the use of several 
communication aids, as a preparation to decision making. These 
communication aids and how these were used by the various physicians are 
discussed in following section. 
 
5.2.1.1 Reassuring the patient through a structured consultation and the use of 
everyday language 
All of the physicians discussed how they provided a structure to their 
consultation. Irrespective of specialty or level, generally all physicians 
structured their consultation in a similar generic way however, some also 
commented that they individualised it. They began with the diagnosis of AF, 
talking about the likely cause of the individual patient’s development of AF and 
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possible recommendations for rate and/or rhythm control as well as OAC 
therapy. However, consultant cardiologists and registrar-level cardiologists 
went into more detail regarding possible treatments for AF, such as 
cardioversion (electrical or drug therapy) and rate or rhythm control 
(medications to control the heart rate) (rate-control) or to try to return the heart 
rhythm to ‘normal’ sinus rhythm (rhythm control), than consultant level 
physicians and general practitioners. In addition, all physicians discussed the 
increased risk of stroke associated with AF and how it can be subsequently 
reduced with OAC therapy, most commonly with warfarin. Thus by providing a 
structure to the consultation, physicians’ perceptions were that patients would 
be in a better position to follow the ongoing discussion. The following extract 
from consultant cardiologist Sean, provides an example of the generic structure 
and the crucial issues that need to be covered by physicians for an AF 
consultation. The consultation is split into two main issues, how AF leads to a 
speeding up of the heart rate and how clots formed from the irregular 
irregularity of AF.  
 
The issues that we need to convey to the patients are two-fold. 
Firstly they have a heart rhythm disturbance which results in two 
main problems. Firstly it can cause the heart rate to speed up, the 
second thing is it causes clots to develop within the heart and both 
of those are associated with problems.] [The SECOND issue 
which is probably the more important issue is that of 
thromboembolic events, meaning the risk of them having a stroke. 
(Sean, Cardiologist) 
 
On the other hand, Cardiology registrar Jeffrey argued that there cannot be a 
single simple structure to follow as a consultation should be individualised to 
the educational background of the patient. 
 
I think you have to… you have to describe it in terms that the 
individual patient can understand. So obviously people come from 
different backgrounds, different educational levels. But I just try 
and start off in a simple way and explain it… some patients almost 
don’t want to know too much. But some people are really 
interested. You have to pitch it in the right way. (Jeffrey, Registrar) 
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Furthermore, physicians pointed out the importance of communicating 
information that is easily understood by the patient as they do not have an 
understanding of medical terminology. In addition to using everyday language, 
physicians emphasised the need for reassurance. Consultant cardiologist John 
highlighted this need in the following extract.  
 
Many people have had relatives with atrial fibrillation who have not 
done well and partly because it happens in mostly in older people 
and older people get things… and it is important for us to reassure 
them… they can live for many years with atrial fibrillation although 
you and I know that the prognosis is not as good as if they did not 
have atrial fibrillation… and we can reduce the risks and 
complications via medications, mostly via anticoagulation… (John, 
Cardiologist) 
 
Consultant cardiologist Melanie, apart from using every day language to 
describe an irregular rhythm (shown in the phrase ‘the rhythm has gone a bit 
wonky’) she believed she reassured her patients by normalising AF as part of 
the ageing process.  
 
As I told you before most of my patients are in their 70s and 80s 
and I describe atrial fibrillation as an ageing process of the heart. 
Nearly most of the people… it’s just of those things that happens. 
Some people will get it earlier than others and it doesn’t 
necessarily mean that there is something wrong with your heart… 
it just means that the rhythm has gone a bit wonky (Melanie, 
Cardiologist) 
 
Similar to cardiologist Melanie, registrar Jeffrey also reassured his patients by 
normalising AF (i.e. telling patients that it is a common condition). From the 
following excerpt, Jeffrey was showing that most of his patients were very 
anxious when they came to medical consultation. Thus reassurance was a 
critical communication skill. 
 
So I think the first thing to do is that I try to reassure them that it’s 
erm a very common problem and it’s something that we can do 
something about and… they are not going to come to any 
immediate harm. Just to try to reassure them, because often they 
think that they have some kind of time-bomb ticking that is going to 
explode and that something badly wrong is going to happen. 
(Jeffrey, Registrar) 
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From his experiences, cardiology registrar Ted showed that patients that were 
referred to secondary care always expected the worst outcome. Furthermore 
he emphasised the role reassurance played when explaining that AF is a 
condition that is more common with age and that normally it is not a result of 
the patient’s lifestyle as shown through the phrase ‘probably nothing that 
they’ve done’. 
 
I think what they want to know is, is there heart going to stop? Is it 
a heart attack?… or a sign of heart failure or something they’ve 
done wrong in life?… you know could it have been their excess 
alcohol?… where it could be?… and you have to educate that. Is it 
the fact that they’re a bit overweight… well probably not… so just 
trying to reassure them that it’s probably nothing that they’ve 
done… it’s a condition that becomes more common as you get 
older. (Ted, Registrar) 
 
Likewise, general physicians, such as Nilan reassured the patients that AF is a 
common disturbance. This alleviates the initial anxiety of the patient when 
receiving medical news on his heart. Furthermore, in his experiences, he 
informed his patients about both the actual name of the disturbance and a more 
common name that more easily describes the condition. 
 
I mean generally I say, you have an abnormal heart rhythm. In a 
normal person, the heart is beating at regular intervals. In you the 
heart is not beating at regular intervals, so that’s why your heart 
beat has become irregular and it’s not an uncommon rhythm 
disturbance. It’s very common as people grow older. Erm there is 
a medical term for this, what we call as atrial fibrillation or in simple 
lay terms, irregular heart rhythm. (Nilan, General physician) 
 
Tom also focused his consultation on patient reassurance. At every stage 
where he gave information which could have caused anxiety to the patient, he 
balanced it out by normalising the issue of the irregularity of the heartbeat. 
Furthermore, he assured the patients that both the AF and the clotting of the 
blood can be controlled. 
 
The heart is beating irregularly, it’s not a regular pattern. And 
that’s fine. It could have been doing that for years, but there are 
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problems with that. Sometimes it goes too fast in that pattern, so 
we have to slow it down a bit so we may use tablets for that. The 
other problem is, while it’s being irregular, it can slightly increase 
your chance of getting clots. Not necessarily happen… most 
people don’t but it slightly increases your chance and we think you 
would need blood thinning (medication) included. That’s the simple 
way I describe it. (Tom, General physician) 
 
On being prompted, he provided further rationale for why reassurance was an 
integral part of any consultation. He argued that providing only information 
without reassurance on the safety of treatment, may lead to stress and anxiety 
on the patient.  
 
R – So kind of… from what you told me before, it’s like trying to 
keep the situation calm, reassuring the patient on the treatment? 
T – Yes… I don’t want them to go away thinking that they’re 
certain to have a clot and a stroke. Certainly, the warfarin keeps 
away. You know I say there is a risk, but it’s not a definite thing. 
(Tom, General physician) 
 
On a similar note, general practitioners also focused their communication style 
to the patient’s “level”. Through this excerpt, one can note that Matthew 
reassured the patient by focusing on their concerns. Periodically questioning 
the patient helped Matthew to recognise the amount of information to be 
conveyed. 
 
The heart is basically beating irregularly and you are sending them 
for an ECG. You bring them back and they’re a little bit 
apprehensive in terms of the results. So you need to pitch your 
consultation based on their level, so I always… particularly if 
they’re elderly and particularly if English isn’t their first language. I 
always tend to take it a little bit slower and explain to them at their 
level. So the heart isn’t beating regularly, what does that mean, 
trying to get their understanding a bit, what the implications for that 
is, and part of that consultation is offering them the option to be 
seen at the specialist clinic at the hospital or being referred to… 
‘cause obviously we have our own specialist here, being referred 
to one of our specialists for further consultations based on that. 
(Matthew, General practitioner) 
 
One major skill difference that was mentioned in the communication style used 
between the hospital physicians (cardiologist, general physicians, and 
 178 
 
 
cardiology registrars) and general practitioners was probing patients’ concerns 
and understanding of the condition. According to the general practitioners’ 
accounts, probing the patient at certain stages of the consultation helped in 
exploring the patient concerns and through reassurance, alleviated the stress 
and anxiety built from inaccurate associations through ‘a priori’ knowledge. 
General practitioner George discussed the importance of exploring the patients’ 
concerns through the use of probing questions. Similar to hospital physicians, 
George also commented that his patients got anxious about the ‘worst case 
scenario’.  
 
When the people have chest pains, their main concern is, are they 
having a heart attack. That’s the worst case scenario as far as 
they are concerned. So when you start doing heart traces on 
people, they are thinking straight away… he thinks I’m having a 
heart attack. So… and actually addressing that is important. You 
should ask them, what are you worried about today? (George, 
General practitioner) 
 
General practitioner George adopted this probing style throughout his whole 
consultation, constantly exploring the patient’s existing knowledge about AF 
and the treatment options to reduce the chance of a stroke and building upon it, 
as one can see in the next quote.  
 
To treat AF, we got this stuff to control the random electricity 
around the heart, and we got stuff that lessens the risk of getting a 
stroke and these are drugs that thin the blood. So the drugs that 
we use are usually two. One is aspirin and one is warfarin. Erm 
and there are advances and disadvantages to both, erm… to me 
then I would talk about warfarin and not necessarily about aspirin. 
So I would say, do you know anybody on warfarin? Do you know 
anybody with a yellow book? And see what their perception of that 
is. Usually you can pick up something. Most people usually know 
somebody on warfarin and what that means. You can say that the 
downside of warfarin is that the dose that I need to give you, I 
don’t what it is exactly. So the only way we can get to know is by 
doing regular blood tests. So the problem with warfarin is that we 
have to have regular blood tests. And we do have to change the 
dose around depending on the results of the monitoring. And then 
I ask them what you think about that (George, General 
practitioner) 
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Furthermore, when he was about to discuss warfarin, rather than explaining 
warfarin itself, he explored whether the patient was already familiar with the 
treatment. This probing style made the consultation more interactive, helped to 
reduce the patients’ anxiety by addressing their concerns and also aided in 
building a rapport between the physician and the patient. In the above excerpt, 
George first provided some information about possible treatments and then 
probed the patient on his ‘a priori’ knowledge. In this way, George gauged the 
level of knowledge the patient had on AF, whether the information that was 
provided was understood and addressed the patients concerns directly. In 
addition, all physicians used humour such as laughter or smiling within their 
experiential accounts of their consultation, as they believed it lessened the 
patient’s anxiety level, enhance rapport and trust during the consultation. This 
was portrayed in consultant cardiologist Melanie’s next quote. She sometimes 
introduced humour during the consultation as a way to minimize a stressful or 
difficult situation. While trying to explain a difficult concept, such as statistics, 
she laughed with the patients at her own statements, as seen in the latter part 
of the following quote. 
 
I say that if there are a hundred of you without AF, 1 of you will 
have a stroke over the year. If you’ve got this irregular heartbeat, 
then 4 people will have a stroke. I use the figures so I can make 
you like everybody else. Rather than you be 4, you’ll be 1, and 
that’s it. It doesn’t mean of course that 96 people won’t have one 
but I am not clever enough to know whether you are the 1 or 1 of 
the other 96. That’s what I explain to them and we laugh (smiles) 
(Melanie, Cardiologist) 
 
Humour was especially used by physicians, particularly by general physicians 
and some registrars, when discussing the concerns of warfarin being used as 
rat poison. General physicians and registrars illustrated how they are friendly 
within their consultation through the use of humour, such as Nilan’s or Chan’s 
quotes below by smiling or keeping the discussion light hearted, to assure 
patients that even though it was used as rat poison, warfarin was a modified 
version of it, so they are not going to be poisoned.  
 
Well generally I tell them ‘look I am going to start this new drug, 
which is called warfarin, in the past it was used as rat poison. But 
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we are not going to poison you with that (smiles). (Nilan, General 
physician) 
 
Well sometimes, just to break the ice… erm… a lot of patient 
would have heard as well. I tell them, (leans forward) I know that 
you probably heard from somewhere else that warfarin is used as 
rat poison. So you start with that and then they start laughing and 
they go yeah fine whatever. (Chan, Registrar) 
 
5.2.1.2 Knowledge of warfarin as rat poison 
There were mixed experiences between physician groups with regards to their 
perceptions of patients’ knowledge on warfarin being used as rat poison. 
Cardiologists argued that patients were very knowledgeable and anxious about 
warfarin previously being used as rat poison. In the excerpt below by consultant 
cardiologist John, he argued that according to his experiences, the knowledge 
that rat poison works by causing fatal bleeding in rats was well known among 
patients and therefore he believes that this lead to an increase in bleeding 
concerns in the patients. 
 
They [patients] worry about warfarin itself… erm everybody knows 
that initially warfarin was used as rat poison] [and they worry about 
the bleeding complications as everyone knows how rat poison 
works. (John, Cardiologist) 
 
Cardiology registrars in this study had similar experiences as those of 
consultant cardiologists. Their patients were anxious about the fact that 
warfarin was used as rat poison. In the quote below, registrar Ted argued that it 
was the meaning that patients attached to the word poison that gives rise to 
this negative perception of warfarin.  
 
I think especially with the older generation… a lot of them, as soon 
as you mention warfarin, they will say rat poison. So many patients 
say that… because it was used as rat poison… I’m not sure if it is 
still used as the poison. But this is what they automatically say 
so… erm… That is automatically a negative perception on 
warfarin. (Ted, Registrar) 
 
Registrar Dheepak and Registrar Jeffrey argued that they preferred bringing up 
this subject themselves as they believe that patients would not make the 
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connection between warfarin and rat poison unless raised by themselves. 
Dheepak pointed out that older people were more aware of this fact, prompting 
the question that this could be a generational issue. Older patients may 
remember the time when warfarin was still the main ingredient in rat poison. 
Dheepak educated the patients by telling them that it was a poison for rats not 
for humans. 
 
Sometimes I do tell them it was used as rat poison. Some people 
would remember using it… and would ask me whether they should 
be taking it or not.] [older people are more aware of these things 
than younger people. I tell them that it was used as rat poison, but 
you are not a rat. That tends to avoid any further questions about 
it. (Dheepak, Registrar) 
 
Likewise, general physicians’ and general practitioners’ experiences conform to 
those of cardiologist and cardiology registrars where they agreed that 
knowledge of warfarin being used as rat poison is wide-spread among patients. 
However, in contrast to cardiologists, they also commented that rat poison was 
not a major patient concern in their experience. On being prompted, general 
practitioner Nick pointed out that his patients are not concerned about the fact 
that warfarin was used as rat poison. However he did not say that they did not 
know about it.  
 
R - Do you get patients that ask you about some daily concerns on 
warfarin… like the issue of rat poison for example? 
N – No no they are not concerned about that (Nick, General 
practitioner) 
 
In addition, general practitioners did not try to change patient perceptions on 
warfarin being used as ‘rat poison’. General practitioner George, rather than 
trying to change the patient’s perception of warfarin, he just stated that even 
though it is used as rat poison that is not a good reason to decline it. 
 
R – And do you get patients that tell you about rat poison? 
G – yeah 
R – And for example, how would you react to that? 
G – I say it’s true, that’s what it is, but that doesn’t mean that it’s 
not worth taking. (George, General practitioner) 
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Differing from other specialties, general physicians such as Nilan commented 
that they take advantage of the patients’ experiential knowledge of rat poison to 
explain what warfarin was and how it worked. Nilan explained that his rationale 
in linking to the patients’ knowledge about rat poison was to lessen their anxiety 
about starting a new drug.  
 
What I explain to them is that it is a blood thinning tablet, erm… 
and the way it works is erm… it’s like the old rat poison, but of 
course this is a modified version of it] [If you tell them warfarin or a 
blood thinner, majority of people don’t know, but once you tell 
them about the rat poison. They all know about it, they [click] 
(Nilan, General physician) 
 
Similar to the other general physicians, Manpal argued that mentioning rat 
poison aids in lessening the burden of explaining the mechanism of warfarin. 
However, he also assured the patients on the safety of warfarin by telling them 
that it is a “modified version”.  
 
R – And erm… can you tell me… how you would explain warfarin 
to the patient? 
M – What I explain to them is that it is a blood thinning tablet, 
erm… and the way it works is erm… it’s like the old rat poison, but 
of course this is a modified version of it (Manpal, General 
physician) 
 
 
 
5.2.1.3 Pictorial reference 
Drawing the heart to explain how the heart beats normally, how AF affects the 
heart’s natural pacemaker causing it to beat faster and irregularly, how the 
irregular beating of the heart increases the likelihood of a blood clot forming, 
and the consequences of such a clot, was a technique used by most of the 
physicians interviewed, with the exception of the consultant general physicians. 
 
Consultant cardiologist Sean shows that pictorial aids during an AF 
consultation helped him in explaining procedures in non-medical terms and 
improved time-management. Furthermore, according to the physician’s 
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experiences, the patient needed to have good understanding of the link 
between AF and stroke (which was the responsibility of the physician to impart) 
in order to understand the necessity and importance of OAC. 
 
We speak in very basic terminology. Now obviously they don’t 
know what arrhythmias is so we say there is a heart rhythm 
disturbance within the heart and erm and usually I do it on the 
basis of drawing pictures (Sean, Cardiologist) 
 
In addition, these pictorial aids would help the patient in understanding the 
rationale of the physician when advising the appropriate medical treatment, as 
can be seen in the next quote by consultant cardiologist John. 
 
J - Sure I draw a heart and I draw the normal ECG and then I 
explain what happens in atrial fibrillation… how the back chambers 
stretch and how the front chambers are more like a tyre and don’t 
tend to stretch… the back chambers and that’s what we think 
causes in majority of patients and they understand that as it’s a 
simple concept. 
R – So you use a visual impact kind of 
J – Absolutely 
R – And that helps [to] 
J – [Yes] cause they understand why it’s happening and why for 
instance… why they will be suitable for either ablation or 
cardioversion (John, Cardiologist) 
 
Cardiology registrars also used pictorial aids within their consultation. This 
could be linked with cardiology registrar Dheepak’s argument with regards 
consultation structure. He argued that the way a physician structures his 
consultation is partly based on experience. Dheepak believed that through 
medical practice, he realised that patients have poor knowledge of the heart’s 
anatomy and that a picture can aid explanation of AF. Cardiology registrar Ted 
observed how patients may lack anatomical knowledge of the heart, thus by 
drawing a picture of the heart he helped the patient identify the origin of the 
problem, included them in the discussion and focused the discussion on the 
issue, thus saving time. 
 
A very simple picture of what a heart is. Cause some patients 
won’t know where are the atria in the heart, where the clots are 
going to be building up. So I just draw a left atrium appendage… 
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Just to show them that the blood doesn’t circulate very well… 
because of the fibrillation.] [That is how I usually talk to them about 
stroke… sometimes I show them the ECG… just to show them the 
irregularity…it’s easy to do a quick diagram (Ted, Registrar) 
 
Pictorial aids during the consultation were also used as a way to reassure the 
patient. General practitioner George used pictures of the heart to emphasise to 
the patient that if the condition was controlled, the heart would still operate 
normally.  
 
If I have got to describe it, I would draw a picture of the heart really 
quickly and show the two top chambers and the bottom chambers. 
Now electrically the rhythm of the opposite chambers, top and 
bottom, can go wrong. The heart muscle on the top can decide it 
wants to fire on its own way and what then happens is you get an 
incoordination between the two. Now the heart works still, there 
are no problems with the heart, but provided it stays well 
controlled. (George, General practitioner) 
 
Contrary to other physicians, all general physicians showed confidence in their 
ability to impart information to patients and commented that they do not make 
use of any visual aids within their consultations. On being prompted about this 
issue, general physicians Balu and Manpal mentioned that they do not using 
drawings in their consultations. Furthermore Manpal also gave the impression 
that he dismissed AF as a simple disturbance that according to his 
interpretation, patients understood easily as he argued that for other conditions 
he may adopt pictorial reference. 
 
R – Do you kind of use any… any other things to help your 
explanations? Like do you do drawings or stuff like that? 
M – For AF probably not, for other conditions maybe… if they 
didn’t know what it is. But for AF, no (Manpal, General physician) 
 
Conversely, apart from drawings, general practitioners were more prone to use 
or print off educational material to help them explain AF rather than using their 
own drawings. Both general practitioners Matthew and Nick described using 
educational materials printed off from their own computers.  
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N - that is part of our practice. I haven’t mentioned it… but I’ll 
always try and print off some materials 
R – so you give information to the patient 
N – yeah I try to print off on some occasions from my computer, 
information about AF (Nick, General practitioner) 
 
Moreover, general practitioner Matthew argues that by providing these 
educational materials, he felt more at ease than if new patients had to read 
information from a random website which was not approved by a health 
professional as shown in some patients’ experiences in this study where they 
mentioned that they printed off material from internet. Such a procedure also 
helped the consultation to adopt a patient centred approach as it facilitated 
discussion.  
 
I would say most of my consultations… certainly every NEW 
patient that I see with a particular diagnosis, I generally will always 
print something off. And it gives them an opportunity to just read 
something that erm… is kind of vetted by a medical professional 
as it were. As opposed to just going on the internet and trying to 
log on to some random website. And it gives them to opportunity 
to sort of read that, digest that, or get it read to them if they don’t 
read English… and then come back with questions. I tend to do 
that rather than draw myself (Matthew, General practitioner) 
 
5.2.1.4 Use of Analogies 
Analogies were also something that physicians used in their experiences as a 
way to explain information in non-medical terms. The following three excerpts 
illustrate how physicians used analogies to explain what AF is, how OAC 
medications work and differences between warfarin and one of the new OACs, 
and how much risk reduction a patient might gain from OAC treatment. General 
practitioner Nick commented on his use of analogies to explain AF to a patient. 
He compared AF to wiring in the house, and similar to the wear and tear 
brought about through time in these wirings, he explained to the patient that AF 
was an illness most commonly brought about by the ageing process. However, 
such an analogy is mechanistic and portrays the body as a machine. As seen 
by the analogies used by patients, such as Jonas, where he describes how you 
go to the mechanic to fix your car engine, such mechanistic analogies might not 
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be good definitions. For example in Nick’s quote, a patient might see Nick as 
the ‘expert electrician’ that has to decide on what needs to be done to 
ameliorate the ‘wiring of the old house’. 
 
I would explain to them that they have an irregular heart and their 
heart is going irregularly, irregularly and I usually sort of tap it out 
for them as to what is happening. I tell them that the electrical 
wiring of the heart is erm still there and fine but like any wiring in 
an old house. You know the insulation is just got a bit worn. So the 
currents tend to short-circuit and not connect up. That is a sort of 
analogy for the patients. And erm… that erm in the short term they 
are not in any risk but we need to get it sorted out. (Nick, General 
practitioner) 
 
In the following excerpt, consultant cardiologist John portrayed how such 
analogies were used in his consultation. He also mentioned a new upcoming 
OAC drug, dabigatran, to patients and compared the two through the same 
analogy. Also it was interesting to note the imagery used in these analogies. 
However, similar to Nick’s analogy, it objectifies the human body, taking out of 
the equation the control and behaviour of the patient. 
 
Well I tend to explain to them that it’s a bit like target bombing and 
we basically stop one of the vitamins, vitamin K, working but that 
effects a more different bunch of pathways which is why it has all 
these reactions with alcohol, foods, medicines. Erm… whereas to 
some extent, the new drugs that are coming, dabigatran in 
particular because it is coming so soon… is more like cruise 
missile. It specifically targets, the thing that causes clots in the 
blood, and they understand that. Most people get the idea of target 
bombing and cruise missiles (smiles) (John, Cardiologist) 
 
An interesting analogy was also presented by cardiology registrar Jeffrey. 
Through his experiences he argued that when describing stroke risk reduction, 
patients might not understand percentages correctly and a 10% stroke risk 
reduction when on warfarin might not seem as a viable option for them. 
However he used an analogy to explain what 10% means through a real-life 
scenario. By using the lottery as a real-life scenario patients can compare 
experiential knowledge with their ‘a priori’ knowledge, thus Jeffrey “put things in 
perspective” for the patient. However Jeffrey did not mention if patients do 
understand his statistical analogy. 
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J - If you had a 10% chance of winning the lottery, you’d buy a 
lottery ticket. You have to kind of put into 
R – Perspective 
J – Exactly… (Jeffrey, Registrar) 
 
5.2.1.5 Use of statistics 
Almost all of the consultant cardiologist and cardiology registrars mentioned 
that they discussed statistical figures or probabilities, during their consultation. 
General physicians and general practitioners did not mention the use of specific 
statistics or probabilities in their consultations to explain risk to the patients. 
Similar to cardiology registrar Jeffrey, consultant cardiologist Peter brought 
about the notion of probability and “odds” of playing the lottery to justify the use 
of statistical figures during his consultation. He argued that since patients know 
and play the lottery, they could have an understanding of odds in reducing the 
risk of stroke.  
 
I think giving patients and figures, maybe it’s a bit too much, I don’t 
know, but if you do… patients do sort of enter the lottery and 
presumably have some appreciation of odds and things, and they 
know how to do betting things… if you say that you are reducing 
the risk of stroke by 7% in absolute terms per year then that’s… 
that’s a really, it sounds quite substantial I think… it’s similar to a 
lottery (Peter, Cardiologist) 
 
In addition, some cardiologists, such as Melanie, did not mention percentages 
directly, but used numbers of people as figures of speech in an attempt to 
make probabilities easier to understand. However, she herself noted that she 
did not know if patients actually understood these statistical odds.   
 
Conversely cardiology registrar Chan used statistical data to reassure the 
patient on warfarin. The focus in registrar Chan’s quote below was not in the 
percentages, but rather the emphasis lay in the phrases exactly after talking 
about the percentages (shown in italics). After Chan mentions percentages he 
mentions if this percentage is actually high or not according to medicine, thus 
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linking percentages to an everyday concept, making the rationale for 
recommending warfarin more apparent.  
 
Your risk of getting a stroke based on what we know… is going to 
be 7-8%. If I put you on aspirin I’ll bring you down to 4-5%... which 
is still quite high, higher than the average population. But if you 
start warfarin, you bring it down to 2-3% which is only slightly 
higher than someone at the same age. (Chan, Registrar) 
 
5.2.1.6 Motivating the patient 
Physicians in this study, except for consultant cardiologists who did not mention 
the issue of motivation, pointed out that since warfarin was a potentially 
dangerous drug, patients needed to be motivated to adhere to treatment. In this 
respect, registrars also argued that a consultation should adopt a shared 
decision making process rather than the physician adopting a paternalistic 
approach and taking all the responsibility. Although physicians contended that 
patients should be motivated to be responsible for adhering to their treatment, 
no one suggested who should take the responsibility to motivate the patient or 
what needs to be done to motivate the patient. The importance of motivation 
was clearly seen in registrar Chan’s quote below.  
 
So with warfarin it is something that you need to have a shared 
responsibility. Cause you cannot go chasing the patient… you 
need your INR checked today. The patient needs to have some 
motivation. (Chan, Registrar) 
 
Similarly, general practitioner George also emphasised the notion of motivation 
within his consultation. He argued that during his consultation he pointed out to 
the patient why decision making should also entail some patient responsibility 
as ultimately it was the patient that has to maintain optimal blood control. 
 
I can’t make the decision for you, I can give you a 
recommendation, you’re the one that has to go to have the blood 
tests. You’re the one that comes here and you’re the one that is 
going to take the medication, not me. So it’s still going to have to 
be their decision. (George, General practitioner) 
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General physician Nilan emphasised the issue that the patients and not 
physicians were responsible for their own safety with regards warfarin 
interactions with alcohol and other medications. Rather than focusing on side-
effects, Nilan seemed to shift his communication style to how the patients 
should be responsible for their own safety. 
 
Again I tell them that there are a few precautions that you need to 
take, like if you cut yourself, to apply pressure for 5 minutes, 
secondly don’t buy any pain killers from the counter and take 
them. If you need any pain killers, go to your physician. If you are 
going out for a party, don’t indulge in binge drinking. (Nilan, 
General physician) 
 
According to Nilan, the patient was responsible for his care and to keep within 
the therapeutic range of warfarin. He stressed the precautions that the patients 
needed to keep in mind when on warfarin, especially when alcohol was 
involved. 
 
That is why there is the need for all these precautions you know… 
that you don’t take any tablets or pills which you get over the 
counter which can react with it. Again it’s very important that you 
have the blood tests regularly because that is what we use to 
monitor and again like I said to you, not to indulge in bad binge 
drinking, because that can make your INR to go all over the place. 
(Nilan, General physician) 
 
When general physician Balu was informing the patient on the side-effects of 
warfarin, one can note the use of the word “efficiency”. Rather than arguing on 
the side-effects that can be caused from warfarin, he shifted the responsibility 
of care to the patient by pointing out that if the patient does not adhere to the 
treatment, warfarin will lose its efficiency, thus increasing the possibility of 
having the side-effects. 
 
The two sides of the equation with warfarin; if drugs interact with it, 
you can lose efficiency or the drug can be over-efficient and cause 
bleeding. So you need to be aware of certain antibiotics so when 
you are prescribed by the GP, make sure to let the GP know that I 
am on warfarin. So that drug interaction is very important. They 
need to know! Then again you stress to them the importance of 
keeping the INR between 2 and 2.5 so when they are ill, when 
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they are on antibiotics they need to take a bit more, there are 
certain drugs that when they are taking it, they will need to take in 
a little less. (Balu, General physician) 
 
Likewise general physician Tom argued about the importance of adherence to 
OAC treatment. He argued that if patients were not responsible with their 
treatment, safety was not assured. Thus Tom believes that if his patients do not 
show an interest during the consultation, he might be influenced in not 
prescribing warfarin as OAC therapy. This is a crucial factor when considering 
that some patients, like Daniel and Jonas, might prefer a paternalistic 
consultation where they trust physician as the expert to take the decision for 
treatment.  
 
If he’s not very committed to it, it’s not going to work anyways isn’t 
it? They won’t be taking it, they won’t be going to their 
appointments. You want to erm… make sure they are on board. 
(Tom, General physician) 
 
Concurring with Tom, general practitioner Nick highlights that according to 
normal practice, patients were responsible for adhering to treatment and that 
motivating patients to be responsible had an impact on their level of adherence. 
However Nick did not specify who has the responsibility to motivate the patient.  
 
And in this case we are talking about the risk of embolus, it’s 
significant and that they need to take the situation seriously. Well 
it’s standard general practice that patients should take personal 
responsibility for their condition. They should be motivated to 
manage it responsibly (Nick, General practitioner) 
 
Similar to Nick, registrar Ted also noted the need for the patient to be motivated 
towards adherence to OAC, i.e. taking the pills regularly and being aware of the 
interactions with warfarin. In addition, like Nick, he also does not explore who 
should shoulder the responsibility to motivate the patient. From the following 
quote Ted is also pointing out a drawback of a paternalistic approach in 
decision making. He believes that if a patient is not educated and involved in 
the discussion about AF and the risks of OAC, the patient would not be 
knowledgeable of his role in adherence. Furthermore, Ted was assuming that 
education is enough to motivate patients. 
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Not enough is done to make the patients think. So motivation is 
important. (Ted, Registrar) 
 
5.2.2 Physician focused decision making – Focusing on compliance 
This theme explored how communication during the decision making process 
adopted a paternalistic approach rather than a shared decision-making style 
between the physician and patient. Physicians in different specialties used 
various methods to influence the patient into complying with their choice for 
treatment. These included the hope from new forthcoming OAC drugs, 
highlighting the benefits of, and minimising the risks of, warfarin, and taking 
decisions in a paternalistic way. In case of general practitioners’ experiences, 
although they comment that in some practices they started warfarin 
themselves, the decision to initiate warfarin was usually passed onto secondary 
care. 
 
 
 
5.2.2.1 Paternalistic approach 
Physicians often talked about how their patients asked their advice on what 
medication they should take as the patient viewed the physician as the expert. 
Cardiologist Melanie commented that this was a common practice. She tried to 
build rapport with the patient by taking a familial approach, stating that she 
would advise the patient as if they were her relatives. Melanie perceived herself 
as not being “paternalistic or maternalistic”. However, she later argued that her 
job is to provide the expertise needed by the patients and that it is important 
that patients pay attention to the expert’s advice. This brings to the forefront the 
issue of an unavoidable paternalistic attitude, as Melanie is trying not to take a 
paternalistic role, however it is a role that she feels she has to take. In addition, 
Melanie highlights the problem of using mechanistic analogies which takes 
away the proactive role that a patient plays during a shared decision making 
process. 
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M – well I often say to the patient… if they are not sure, I say look. 
If you were my mum, I would really like you to go on this 
medication. Okay? But I can only do that to people that I know 
obviously. And the other thing is they (the patient) say…erm… well 
what would you do physician… and I say well if I am this or the 
other I would do this. Because it’s a bit like if somebody asked me 
about my car. Oh madam should we fix that… if it was your car, 
would you fix it. It’s like… I’m not paternalistic OR maternalistic 
towards my patients but I hope that they listen to the degree of 
guidance that we offer as physicians. That is our job. So I 
sometimes use that car experience to them, cause they… 
sometimes they throw back at me 
R – I see you use it as an analogy 
M – They usually say I work in business and I wouldn’t expect you 
to tell me about my… I have come to ask you… and my opinion, 
this is what it is… and allow me to use the granny test. If you were 
my grandmother or grandfather, what would you do? (Melanie, 
Cardiologist)  
 
Conversely cardiologist John, in the quote below, actively tried to persuade the 
patient to conform to his preference for treatment by telling him ‘if I were you’.  
 
So yeah most people say that they want to go with aspirin rather 
than with warfarin… erm again that’s a common thing and you 
have to persuade them of the pros and cons and you have to tell 
them the truth which is, if I were you I would be taking warfarin at 
this stage. (John, Cardiologist) 
 
However not all cardiologists were of a similar opinion. Cardiologist Sean 
stated that power used to be in the physician’s hands. However he emphasised 
that there was a need to empower patients to be able to make the right 
decisions because according to him this influenced the patients’ level of 
adherence. His reflection meant that patients should show a degree of 
responsibility when agreeing to take on warfarin as they have to manage the 
treatment. He argued that the only way to empower patients is by providing 
them with appropriate information. At the end of this excerpt, however, he 
stated that the majority of his patients ultimately left the decision to him. Thus, 
in Sean’s experience the patients preferred to abdicate responsibility of 
decision regarding OAC treatment to the expert out of trust, a patriarchal 
solution where the expert’s decision was dominant. As mentioned before, such 
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an experience would place the physician in an unavoidable paternalistic 
position where the physician has to take the final decision. 
 
R – so you took the initiative to learn, to learn the language? 
S – yeah yeah. Because it’s something that you do not understand 
the importance of when you are young. But when you are older, 
you suddenly realise how important it all is. 
R – So you did it (learning other languages), to help you build a 
better erm 
S – I think so, it is important erm… because the olden day 
relationship, the physician was in a superior position and the 
patient was in a passive erm… inferior position. This no longer 
applies and if you empower the patient to make decisions erm and 
erm… the only way you can empower the patient to make 
decisions is to provide the information that they require to make 
that decision. AND if you don’t then they make the decision on the 
basis on inaccurate or inadequate information and they often 
come to the wrong conclusion. Erm whereas if you provide them 
with a balanced argument, it erm… essentially you give your best 
advice to the patient and then it’s their decision to make, but it’s 
important for you to provide them with that information. But often 
time the majority of my patients leave it to me to decide okay. I still 
give them information so that they understand the decision making 
that I am erm… erm I’m making but erm the majority just allows 
me to choose what’s best for them. (Sean, Cardiologist) 
 
Registrar Dheepak echoed the sentiments of Sean and also tried to adopt a 
shared-decision making style during his consultation. However, as with Sean, 
the patients themselves led him to take a paternalistic approach and asked him 
to decide for them. In addition, because of the potentially harmful side-effects of 
warfarin, neither the physician nor the patient may want to take responsibility 
for the final treatment decision, as illustrated in the next excerpt: 
 
Well I always give them the choice. I will ask them what they 
would want, because particularly with warfarin… it can have 
harmful side-effects. So I think the patient should take a role in the 
decision making. He has to be sure on going on to it. That is the 
ideal way, however most of the times… the patient may say you’re 
the physician, you tell me. (Dheepak, Registrar) 
 
Registrar Chan drew a similar argument as the one proposed by registrar 
Dheepak and Sean. He pointed out that since warfarin management was the 
responsibility of the patient, decision making should also include the patient’s 
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choices. Further, he stated that rather calling it a shared decision, it should be a 
shared responsibility. 
 
I don’t like to take the paternalistic approach where I tell the 
patient what to do. They need to understand the disease] [I prefer 
a shared decision, cause if you take… especially with warfarin… 
there is a lot of responsibility lies with the patients. You need to 
know when they need to be tested, not to miss them. They need to 
be sure why they’re doing it. As taking a higher dose or lower 
those would be not only ineffective but it is dangerous. So with 
warfarin it is something that you need to have a shared 
responsibility (Chan, Registrar) 
 
The issue of responsibility was further explored by registrar Jeffrey. He 
suggested that a physician’s responsibility and moral duty was to educate the 
patient on the best treatment available. In the following quote Jeffrey 
emphasised through repetition the importance of patient education during 
decision making. In addition Jeffrey believes that patients should not make rash 
decision based on an emotional response to warfarin being rat poison, but 
rather make an informed logical decision which is the need to take warfarin to 
reduce the risk of stroke. 
 
Well I think that you’re not really doing your job properly unless 
you’ve had really kind of… full front discussion. If one wants to 
take warfarin, it’s straight forward. But if someone doesn’t want 
to… I think you really got to talk to them for quite a long time to try 
to… erm erm… erm… educate them… put them in the whole 
picture so they do reach a rational conclusion.] [I think you have to 
make an effort to go through it with enough time and enough detail 
for them to reach that rational conclusion. Which is very difficult 
sometimes when you got kind of 10 minutes to see someone in a 
busy outpatient. It’s very easy to say… ok you don’t want to be on 
warfarin, that is fine. Then you write in your notes, warfarin 
discussed, patient declined. Job done. (Jeffrey, Registrar) 
 
As showed in previous experiences with regards the unavoidable paternalistic 
attitude, Jeffrey also points out how difficult and stressful it is for physicians to 
balance the patients’ needs during the consultation which might lead them into 
taking the easy way out. However, Jeffrey later commented that because of 
warfarin’s mode of action, patients had to trust physicians that it was the best 
treatment. 
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Yeah they have to kind of trust you… because you’re asking them 
to take a drug that is not going to make them feel any better. For 
the majority of the patients it won’t do them any good, as the 
majority of the patient don’t have a stroke. So they do have to…. 
They do have to put some kind of faith in you, to take a drug that 
isn’t going to make them feel any better. (Jeffrey, Registrar) 
 
 
Conforming to the registrar’s point of view, general physician Nilan explained 
that, through education patients were empowered to take informed decisions. 
However, immediately after, he contradicted himself and agreed with the 
cardiologists, that when patients put him on the spot and asked his expert 
advice directly, he took a paternalistic approach in conveying the message. 
Using a similar method as that used by cardiologists, ‘If I were you I would’.  
 
So YOU are EMPOWERING them rather than you are taking 
decisions on their behalf. That’s what I tend to do. So I say ‘let’s 
look at this’ and then ‘If I were you’ I mean generally people ask 
you, ‘what would you do in my place’ then I say ‘if I were you I 
would take this’ and they ‘okay then, it’s fine’ (Nilan, General 
physician) 
 
Similar to other the other specialty groups, general practitioner George argued 
that patient education was imperative in a consultation for a patient to be able 
to take a decision. However, George further pointed out that a physician should 
not fall into the unavoidable paternalistic approach and just abide by the 
patient’s trust. George outlined the importance of adapting the consultation to 
the individual patient within the medical consultation, arguing that patients 
should be involved, and through discussion empowered with the knowledge of 
risks and benefits.  
 
You have to give information so that the patient can base his 
decision on something. When the patient says ‘okay, whatever you 
want doc’, that is not a good way how to decide on things. So you 
have to adapt to the patient, but there is always a certain way. 
Good medical practice says that there are ways that you should 
prescribe drugs, and that is involving people and helping them 
understand the risks and benefits. (George, General practitioner) 
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General practitioner George also explored the issue of his interpretation of the 
patient’s perception of trust. He argued that since physicians are trusted so 
much, they should be more responsible. At the end of the following quote he 
pointed out that patients expected physicians to take decisions ‘on behalf of 
them’. Thus George’s experience is that a paternalistic approach was also 
ingrained within the patient’s attitude during the consultation. 
 
There is an absolute evidence that the most trusted bunch of 
people that we have as far as the population goes, are doctors. 
And so I think having such a responsibility means that you are 
trusted, erm… you are trusted to do decisions on behalf of your 
patients, with your patients, but on behalf of them as well. 
(George, General practitioner) 
 
He went on to argue that patient’s illness perceptions are an important facet in 
a consultation with a general practitioner. A patient presented the general 
practitioner with their interpretation of their symptoms, where in turn they 
trusted the general practitioner to interpret their interpretation.  
 
If you’re gonna see a GP, what you’re coming with when you see 
a GP, you’re presenting with an illness, but you’re also presenting 
perceptions of an illness as well. (George, General practitioner) 
 
George’s accounts highlight the need for physicians to understand the 
individual patient’s illness perceptions and beliefs. He believes that this can 
lead to a better involvement of the patients during the consultation and decision 
making process, however as other physicians showed, there are historical and 
power-related challenges that need to be overcome.  
 
5.2.2.2 Exploiting the fear of stroke - Highlighting benefits and minimising the 
risks of warfarin 
When discussing warfarin during their consultation, physicians often used two 
opposing strategies in discussing warfarin with patients. The two strategies 
were highlighting the benefits of warfarin in terms of stroke risk reduction and 
minimising discussions on the risks involved, predominantly from bleeding, in a 
bid to obtain medication compliance from patients. Conforming to the first 
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strategy, consultant cardiologist Peter argued that in his experience, patients 
were afraid of the disabling effects of stroke. This was corroborated by the 
experiences put forward by the patients in the previous study. Patients 
commented about their knowledge of what stroke can cause, especially in 
patients like Jonas where he took care of his mother for almost two decades 
after she suffered a stroke. In lieu of this, he emphasised this part of the 
consultation on the negative aspects of strokes, the risk of losing their 
independence and having to go into nursing homes. By doing this he believed 
that patients were more receptive to the OAC treatment proposed.  
 
If you ask patients what you think about having a stroke and 
becoming disabled, I think that obviously they fear THAT as well 
and you know if you go into WHY you want to anticoagulate them, 
strokes can be very disabling and end up in a nursing home and 
locked in and that sort of thing. ERM… risk of strokes can be 
reduced by two-thirds by the anticoagulation and then… erm then 
they might be more receptive (Peter, Cardiologist)  
 
Likewise, general physician Nilan pointed out that patients were apprehensive 
of the effects of stroke. According to his experience, the fear of the loss of 
independence from stroke, was one of the reasons patients complied to 
treatment. In addition, Nilan commented that adherence to treatment was 
ameliorated by assuring the patients of the safety provided through treatment. 
 
I mean generally, if you tell them it’s a stroke, they get worried 
about it and generally as you know, when people think of stroke. 
They think ‘oh my god, I’ll become bed bound, very disabled, I 
wouldn’t be able to do it’. So they start to take it very seriously that 
AF is not as benign as they expected it. (Nilan, General physician) 
 
Furthermore, general physician Manpal argued that the fear of stroke increased 
compliance to warfarin prescription, using the word ‘promote’. However Manpal 
said that “If they can understand”, eliciting the idea that if patient education was 
not done appropriately, patients would not understand the benefits of warfarin. 
 
If they can understand the risk of stroke from AF, that will help to 
promote warfarin as a much better medication (Manpal, General 
physician) 
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The second strategy involved minimising the patient’s perceptions  associated 
with warfarin  causing bleeds. As one can note from consultant cardiologist 
Melanie’s following excerpt, when patients asked about the side effects of 
warfarin, she transferred the focus from the side-effects to the action of the 
drug. She then only mentioned the smaller risks involved, like bleeding from 
“small things like shaving”. She also used certain words that would highlight the 
benefit of warfarin over the risks involved, such as the word “protect”.  
 
They also ask about side effects and I say, there aren’t very many 
because it really is just a drug that stops your blood being sticky or 
thinner. And then I warn them about the small things like shaving 
or whatever happens to be, about the little bleeds. I don’t usually 
warn them about brain haemorrhage… perhaps I should. But I 
don’t] [I explain what is happening as part of the explanation as I 
start to tell him about the blood clots. To say although I know you 
are well, I do want you to think about this treatment because it will 
protect you against stroke and I use the word protect. (Melanie, 
Cardiologist) 
 
In justification of this, consultant cardiologist Sean argued that from his 
experiences, patients’ did not perceive a haemorrhagic bleed in the brain as a 
stroke. In his consultation, Sean focused his discussion on an embolic stroke 
(from a clot), opting to leave out haemorrhagic stroke (from a bleed). By leaving 
out such a discussion on possible haemorrhage, Sean might have influenced 
the patients towards the more beneficial aspects of warfarin. Interestingly it is 
important to note the disjuncture between physicians’ accounts that 
emphasised the need for education in the previous theme and the strategies 
employed in this theme where the physicians explored partial truths and 
actively left out information that might scare patients. 
 
R – Do they associate bleeding in the brain with stroke? 
S – erm… no… usually they perceive what they have seen and 
usually it means bleeding from somewhere that they can see. Like 
bleeding from the vomit or bleeding from the back passage. Erm… 
spontaneous cerebral haemorrhage isn’t something that they 
consider and usually stroke… I don’t think they conceptualise 
embolic or haemorrhagic stroke… erm 
R – but more the symptoms of the stroke 
S – yeah… but when we counsel them the thing that we try to stop 
is a clot type stroke. Erm and when they conceptualise when I 
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draw the diagram of the heart and I put little dots meaning these 
are bits of debris and if they break off they’ll go to the brain 
causing a stroke, then I think they conceptualise that is an embolic 
episode. Although I don’t use the term embolic. (Sean, 
Cardiologist) 
 
Registrars pointed out that their patients knew that bleeding in the brain was 
also a type of stroke. Registrar Chan took advantage of this patient knowledge 
to further strengthen his rationale for recommending warfarin.  
 
They [patients] do [associate bleeding in the brain with strokes]… 
erm… but then I tell them that if they’re not on warfarin, then they 
also… they are at a MUCH higher risk of having a stroke. Less 
likely to be haemorrhagic but the effects could just be as 
devastating. (Chan, Registrar) 
 
Equally, registrar Jeffrey used a different strategy than that of the cardiologists. 
Like Chan, he explained both the pros and the cons of taking warfarin, and 
opted to divulge to the patient that bleedings could pose a threat as well.  
 
You say warfarin is good because it would reduce your risk of 
having a stroke, but it does thin your blood and that can give you 
bruising and bleeding and most bleeding is just annoying bleeding, 
like shaving or nose bleeds. But you can get nasty bleedings 
within the bowels or the brain. (Jeffrey, Registrar) 
 
5.2.2.3 Passing on the decision about OAC treatment to secondary care 
Although general practitioners had experience in prescribing warfarin, they 
commented that usually patients were referred to secondary care so the 
decision to initially prescribe warfarin was taken by the cardiologist. One of the 
reasons, as shown in the below excerpt, was that to diagnose AF, patients still 
had to be referred to secondary care to undertake an echocardiogram as 
suggested by the NICE guidelines.  
 
N – Well funnily enough I think that I on the whole don’t do that. 
Because usually most of the cases, one refers down to hospital… 
for an echocardiogram… and the cardiologist having done the 
basic work-up of AF, excluded the obvious causes. One then 
refers them to the secondary sector, and only after having the 
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echocardiogram, they are… the severity of AF is graded and 
erm… and andand a decision is taken about warfarin in the 
secondary sector. (Nick, General practitioner) 
 
General practitioner Nick further provided a rationale for the benefits of 
referring patients to secondary care. He argued that a patient was often 
assured by seeing a cardiologist as he believes that patients see a cardiologist 
as the expert on the heart. This also pointed out that through Nick’s 
experiences, although general practitioners had a strong relationship with their 
patients (which was also agreed by patients in the previous study), he believes 
that patients do not perceive them an authoritative figure on AF, as hospital 
physicians (cardiologists or general physicians). 
 
Unless the GP is known to have a specific expertise in the world of 
cardiology… which there are some. Erm… I would think the 
patients are reassured by the fact that they have seen a 
cardiologist. (Nick, General practitioner) 
 
Likewise general practitioner George argued that it was not the GP’s role to 
make the decision with regards warfarin. He believes that this gives the general 
practitioner a way out of the responsibility of dealing with this issue as seen in 
the final part of the quote below.  
 
I think because GPs can still stand back and say… erm… to 
prescribe warfarin or not in a patient is a specialist decision rather 
than a GP decision. So it’s easy to say well… if the specialist told 
me to do, I’ll do it, but they haven’t. (George, General practitioner) 
 
5.2.2.4 Hope from new forthcoming OAC drugs 
Consultant cardiologists and cardiology registrars in this study were more 
informed about current research in relation to AF and stroke prevention than 
physicians in other specialties, and had greater awareness and knowledge of 
new OAC drugs for stroke prevention in AF patients that were currently under 
investigation in clinical trials. Cardiologists used this information as a way to 
reassure patients that they were not going to stay on warfarin for their whole 
life, but only as a temporary solution until the “better drug” got a license. During 
the interview, consultant cardiologist John mentioned that he took an evidence-
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based approach and illustrated the pros and cons of warfarin by quoting 
studies. Later, he motivated patients to initiate warfarin by informing them about 
new OAC which did not need blood monitoring, implying that in the future they 
could change their therapy from warfarin to the new drug. He likened the race 
between warfarin and the NOACs to that of horse races. He explained that 
warfarin is the ‘favourite horse’ as it is tried and tested and it is known to work, 
however sometimes ‘the outsider’, which are the NOACs, are ‘win’ over the 
‘favourite horse’.  
 
I tend to be very evidence based. I go through the evidence and I 
show the studies… and I show them the pros and cons and you 
tell them that erm… that it is a double edged sword and you tell 
them that dabigatran is just round the corner and erm… so, but 
yeah there are no… there are you know… you back the favourite 
in a horse race you don’t back the outsider, but sometimes the 
outsider wins, so you have to work on probabilities (John, 
Cardiologist) 
 
Likewise, when Melanie’s patients did not want to start warfarin because of the 
constant monitoring involved, she sometimes used John’s same strategy. 
 
I keep telling my patients that we are looking forward for the next 
drug where they won’t have to have their blood tests] [Once we 
get around that, then we have to make your blood less sticky, or 
thinner and to do that we need to thin your blood or we may use 
something called warfarin. They all stop me there, they ALL know 
about warfarin… I don’t wanna be on that, oh my mum was on it or 
whatever and then you have to… erm you have to explain that yes 
it is a bit of a nuisance having a blood tests but I tell them it won’t 
be for very long because we have got a new drug that is going to 
be along very soon. (Melanie, Cardiologist) 
 
However she went on to say that she did not discuss this issue with all the 
patients, but mostly with younger patients with whom she envisioned a longer 
lifetime on OAC. 
 
Yes, it depends on the age mostly, for example, if a patient of 65 
comes in I tell him that we’ll start this drug but it’s not going to be 
lifelong as there are new drugs round the corner… I used to say 
that for ximegalatran and then it didn’t get its licence (laughs) 
(Melanie, Cardiologist) 
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In contrast, cardiology registrar Ted argued against such a method as even 
though it might reassure the patient during the consultation, because it might 
give false hopes on a longer term, especially if they are not commenced on the 
new NOACs such as patients with renal problems.  
 
Now you have much more research coming out about these new 
factor 10a inhibitors, thrombin inhibitors… you know, relegation of 
warfarin so… patients who see that, they tell you, I don’t want 
warfarin… I want to take this, but you have to tell them… it’s not 
licensed yet… sometimes it gives false hopes. (Ted, Registrar) 
 
5.3 Challenges with OAC prescription for AF 
This over-arching theme focuses on the challenges that the physicians in 
different specialties and levels of clinical experience, face when prescribing 
OAC for AF. This over-arching theme was split into two different sub-themes 
(see Table 13 on the next page); The challenges that physicians faced 
themselves as health professionals and physician’s interpretation of patient-
related challenges with OAC treatment. 
 
5.3.1 Challenges that physicians face as health professionals 
This theme will explore what experiences physicians find challenging when 
prescribing OAC to AF patients. Within this sub-theme, four themes emerged 
relating to the time available for each consultation within the various health care 
settings and how this had a major impact on content, structure and delivery of 
patient education, the physician-patient relationship and patient satisfaction. 
Physicians also discussed issues regarding language use. Furthermore, 
general physicians and general practitioners pointed out the problems they face 
with regards to adhering to AF clinical guidelines. In addition, information 
overload for the patients during initial consultation was also a concern that 
influenced physicians in how much educational information they gave to 
patients regarding their condition and its treatment. 
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Table 15: Overarching themes, themes and sub-themes elicited from 
physician’s experiences of AF and OAC prescription 
Over-arching 
themes 
Themes Sub-themes 
Challenges with 
OAC prescription 
for AF 
Challenges that 
physicians face as 
health professionals 
Time 
Language and cultural barriers 
Guideline adherence 
Information overload for the patient 
Physicians’ 
interpretation of 
patient related 
challenges 
Impact of blood test monitoring 
Side-effects and interactions of OAC therapy 
Differences between symptomatic & 
asymptomatic patients 
Physicians’ perceptions of the patient’s 
experiential knowledge 
 
 
5.3.1.1 Time 
Time as a barrier within the health care system was a challenging experience 
commented on by all the physicians in this study, irrespective of specialty or 
level. This barrier was even more noticeable when physicians had to conduct 
the initial consultations with the patient and this was corroborated by the 
patients in the previous study, who perceived that was a lack of time during 
their initial consultation (see Section 4.4.2.1). Physicians had to diagnose the 
patients, convey appropriate educational information and negotiate the 
treatment with the patient in a short amount of time; thus leading to concern in 
physicians in trying to allocate appropriate time to each patient.  
 
5.3.1.1.1 Lack of time  
Consultant cardiologist Sean balanced his consultations by allocating time 
according to the patient’s needs (i.e. he spends more time with initial 
consultations and less time during follow-ups). Furthermore, Sean talked about 
a dichotomy of patient types, those who accepted a paternalistic consultation 
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and do not give any input and those with whom the consultation is a shared 
discussion.  
 
You will always be (constrained with time) because… it’s a bit like 
being a general practitioner. You can’t tell what’s going to come 
through the door. And you have designated slots for… for that 
patient. And sometimes you get very simple patients who you 
finish in 5 to 10 min and other times you get patients who take 
much longer because they are more complicated. And also there 
is less time to answer any questions that they may have and 
erm… it depends on the intelligence level of the patients. 
Sometimes people are very amenable to whatever you give them, 
that’s fine. Other times they are more questioning and they want to 
know all the ins and outs of a particular therapy. But there is 
always constraints for time. That is the nature of medicine really. 
(Sean, Cardiologist) 
 
In addition, cardiologist Sean argued that because of this time barrier, 
cardiologists are tempted or sometimes forced to adopt a paternalistic attitude 
and Sean advocated against it. He pointed out that warfarin was a potentially 
dangerous drug and for patients to adhere to treatment they needed to be 
educated about the risks and benefits involved.  
 
There is a tendency especially in cardiology clinics because of 
pressure for time… just for somebody to come and you say, 
you’ve got atrial fibrillation and you need to go on this pill and this 
pill, thank you very much and see you in 6 months’ time. Nobody 
is going to take medication on that basis. So it’s important to 
explain things in detail so that they understand that you are giving 
them drugs which are potentially dangerous and warfarin can be 
potentially dangerous (Sean, Cardiologist) 
 
Registrar Chan admitted that patient education was limited in his practice 
mainly because of these time constraints. Physicians were aware of the areas 
of knowledge they needed to educate the patient on, but lacked guidance on 
how much education a patient needed.  
 
Patient education is very important, but it is one that we do badly, 
because there isn’t enough time. In general I see about 15 to 16 
patients in 3 hours… so there is not enough time to talk about AF, 
talk about what you’re gonna do… and start talking about warfarin 
and then educate patients as well. (Chan, Registrar) 
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In contrast, registrar Dheepak perceived that enough time was allocated for the 
diagnosis, patient education and to reach a decision on treatment. However, at 
the end of his interview, when he realised that he spent an hour and a half 
discussing issues on the consultation, he emphasised that perceived time 
spent with the patient may be actually shorter than the actual time spent. 
 
From doing this interview you realise how much time is actually 
needed to explore all the educational information with the patient 
when putting him on warfarin and in 10min you can’t really explore 
all of it. So I guess what we talked about (the whole interview) 
would probably be the ideal consultation, but we try to make it as 
close to that as possible (Dheepak, Registrar) 
 
General physicians’ experiences agreed with those of cardiologists and 
registrars. General physician Tom pointed out that in his experience, time 
available for his consultation with the patient was further limited because of 
ward rounds. He admitted that decisions were taken in a brief amount of time, 
so a paternalistic approach was most probably used. The patients in these 
cases ended up not receiving adequate information.  
 
It’s a brief… I’m doing a ward round, late at night or 7 in the 
morning. Making quick decisions on whether sending them to the 
right wards or home and that’s quite a brief discussion. It’s not 
long enough really (Tom, General physician) 
 
Similar to cardiologist Sean, general practitioner Matthew commented on how 
time in his practice was usually balanced out between patients that needed a 
long discussion and those that did not. However he also pointed out that in his 
general practice it was normal to go beyond working hours, which shows that 
although the system is flexible, it is not adequate and GPs are required to 
extend their time with patients. 
 
The way we run it is we have 3 hour surgeries and erm… some 
patients would take 20min others would take just 5… the course of 
the 3 hours, overall it balances itself out… usually running maybe 
20-30min behind at the end. So some of these patients who are 
sometimes a bit more difficult, absolutely if you need to spend 
more time… you spend that time. Cause it’s important that 
patients need to be told at their level of understanding. Most of 
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them don’t and you need to follow them up. (Matthew, General 
practitioner) 
 
General practitioner George also discussed the issue of time in the excerpt 
below. He posits an argument were he differentiates between enough time for 
legal consent (where enough information is given to the patient as required by 
law) and time for proper patient education. According to George, the current 
amount of time given to physicians to spend with the patient was enough to 
comply with the former of the two. However, as a general practitioner, he was 
in a position to give the patient time to think, by offering multiple follow-up 
sessions. This helped George to form longer-lasting relationships with the 
patients.  
 
Time…you don’t have as much time with the patient as you would 
like… I think you can. What’s enough time mean? Is it enough to 
get consent to do it legally? Then yes. Is it as much as patient 
seem to want most of the time?... Probably if I had more, would I 
use it? Definitely. Would the patients like it if I had more? 
Definitely. In general practice at least I could tell them we don’t 
have much time right now, but we can meet again next week and 
chat about it in more detail, so the follow-up time is much shorter 
then with hospital. I could see the same patient every day if I 
wanted to. (George, General practitioner) 
 
5.3.1.1.2 Psychological impact of lack of time on physicians 
Consultant cardiologist Melanie comments on the difficulty she faces at the 
thought of having to do a first consultation with a new patient as it would take 
her at least 20min, expressing her emotions by saying, ‘my heart almost sinks’. 
 
For some reason, as doctors we never got it right, but I have been 
in medicine 20 years and it still doesn’t feel. I think it’s partly a time 
issue, erm… the other thing about warfarin is the discussion is so 
time consuming and to be fair to a general practitioner he does not 
have a lot of time to do it] [oh I’m very slow… I give the patient the 
time they need, which is not long clearly (laughs)… but… so if I 
see someone that I need to start on warfarin… my heart almost 
sinks… as its going to take 20 minutes. ATLEAST to get through it 
all. (Melanie) 
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Further, Melanie stated that because of the lack of time, patient education 
would be limited by the amount of information they can absorb. To counteract 
this, she suggested the use of literature within the clinics or the use of specialist 
nurses; however she re-iterated that the lack of time was a barrier that every 
health professional faced. Prompting the notion of whether it was more an 
issue of lack of staff rather than available time. 
 
Well since it’s new news… I don’t think they take in half of what I 
have said. Erm… but then again in the old days, he’ll go to the 
anticoagulation clinic and he’ll get the message repeated AGAIN… 
and that would’ve helped and then they get the booklet. So there 
is a lot of backup. Maybe we need to think about having some 
form of literature in the clinic and we try to persuade our specialist 
nurses to be more involved with this… but everyone is so busy 
already… its quite difficult. (Melanie, Cardiologist) 
 
Consultant cardiologist Peter also experienced this issue. Peter added the fact 
that apart from the burden of workload, even if he managed to find the extra 
time to spend with a first consultation, he was still concerned by the pressure 
from the patients waiting outside. This was due to a ‘conveyor belt’ effect where  
he believed that the patients perceived that they were just another number 
waiting in line and thus vented their frustration through complaints to the 
system, which in turn placed more distress on the physician.  
 
I think that one of the things is the national patient safety agencies 
are just… it requires extensive education about warfarin… erm… I 
think that if I actually write to my haematology colleagues… and 
say ‘Can you initiate warfarin?’ they would tend to go over the 
yellow book with the patient and you know… if physicians have to 
do that, erm… then again it might sort of tip the balance, you 
know… you need 10 to 15 minutes running over this with the 
patient, which of course if it’s an important thing in the patient’s 
lives… it’s not unreasonable in general terms… but the way ward 
rounds and clinic works in the NHS, it is difficult to find that extra 
10 or 15 minutes, when there is a queue of patients outside the 
door, getting a bit irate (smiles) (Peter, Cardiologist) 
 
5.3.1.1.3 The importance of continuity 
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Since follow-ups were easier to conduct with general practitioners, they had 
more time to spend with patients. Furthermore, because they knew patients for 
a longer time general physicians were in a better position than other hospital 
physicians when it came to familiarity with the patients. Consultant cardiologist 
Melanie commented that one of the main challenges she faced was her limited 
knowledge about the patient’s life. Thus, Melanie was influenced, by this lack of 
knowledge on the patient, not to prescribe warfarin if she was not sure about 
the patient’s background, especially as she did not want to cause more harm 
by prescribing warfarin to a patient who might end up not adhering to treatment 
and cause bleeding. 
 
I will always err on the side of not giving warfarin if there are falls. 
As I see too many people with head injuries and intracranial 
bleeds] [their GP… I think via the GP… not much helpful is the 
wrong word, but I am not sure how much, how much they feel they 
have input in these decisions.] [Yes I think they should do. I think 
GPs should… they know the patients better than I do, they know 
whether they take the pills, they know what the family 
circumstances are. I don’t what worries me is also patients who 
have a habit of taking over the counter medications] [it is a 
decision that is better made by somebody who knows the patient. 
That’s a barrier to me prescribing it. I would probably not prescribe 
it and erm… I would always err on the side of not prescribing… 
maybe other people don’t, on the basis of first do no harm. But if I 
knew the patient, I may well be able to make that step… (Melanie, 
Cardiologist) 
 
In addition, registrars also commented about the lack of knowledge on their 
patients, especially because of the lack of continuity. Registrar Jeffrey 
interlinked the issue of continuity and time pressures in secondary care, 
forming a vicious circle. 
 
I think maybe this highlights that continuity is important. I think that 
is one of the problems in the health services especially in the 
hospital setting. Each time a patient comes to the hospital, they 
don’t see the same person. I think that is the difficulty. Cause it is 
going back to TIME pressures. (Jeffrey, Registrar) 
 
Registrar Chan’s view on the subject agreed with that of Jeffrey. He argued that 
for hospital physicians it was difficult to build rapport because of the lack of 
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continuity. This in turn had an effect on the shared discussion that the hospital 
physicians needed to conduct with the patient. 
 
I think it is important to develop a relation but unfortunately we 
don’t get as much follow ups to build such a relation. With the new 
system it’s being lost more and more. Because most of the 
patients just go and see the GP. We only see them once or twice. 
(Chan, Registrar) 
 
Registrar Ted further discussed how the lack of rapport had an impact on the 
discussion with the patient. He commented how his patients preferred to 
consult with a GP ‘who’s known me for 20 years’, showing the difference 
between the patient physician bond in primary and secondary care. This was 
similar to what some patients, like Josephine mentioned, where they mentioned 
that they had a strong rapport with their GP. However, what Ted proposed was 
against what general practitioners mentioned that patients perceive the hospital 
physicians as the experts. 
 
Sometimes patients don’t want to commit to you, to take warfarin. 
They say I hear what you are saying… but I’d rather talk this 
through with my GP who’s known me for 20 years. And that’s 
absolutely fine. (Ted, Registrar) 
 
Similar to the other general physicians, Tom also pointed out that other health 
professionals were an unexploited asset in patient care. He commented how 
his responsibility towards the patient ended with the consultation as he did not 
do follow-ups. However since GPs follow the patients more often, he argued 
that they should be “responsible long term” for their treatment. 
 
R – erm… you think other health professionals could have a role in 
warfarin management or education? 
T – Yes… they probably disagree but GPs or pharmacist, have 
more time to do things. For example I only have a couple of 
minutes in the ward round. I’m sure they have more. Plus this is a 
fluid decision. This could be reviewed every time they see them. 
One might think it is safe now, in two years’ time, they may reach 
a point where it’s not safe. And they [GPs] are the ones who 
review this and say ‘now I think we should get you off the warfarin’ 
or ‘now it’s time we should start you on warfarin again’. So yes 
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they should. They should be responsible long term. We may never 
see them again. (Tom, General physician) 
 
Similar to other General physicians, Manpal pointed out the role GPs could 
have in influencing warfarin prescription.  
 
GPs should have a huge responsibility about these kind of things 
as they would know the patient for a number of years, so they 
would know more. Erm whereas we see them once, twice, maybe 
three times. That’s it, we might not see them again. Or we might 
see them for another medical condition… so GPs are central to 
this and they need to help us when deciding whether to put them 
on warfarin or not. (Manpal, General physician) 
 
5.3.1.1.4 General practitioner’s perceptions of their own role 
Conforming to the perception put forward by the cardiologist, registrars and 
general physicians, all of the general practitioners mentioned that they felt they 
had more concrete knowledge of the patient’s background and stronger 
relationships with their patients than hospital physicians. General practitioner 
Samir argued that since the patients can see the same practitioner, this 
ameliorated the rapport between them. According to Samir’s experiences a 
general practitioner would also be knowledgeable about the patient’s social 
history and support systems and how these could influence adherence to 
medication. 
 
S - In our chronic disease clinics… the people with AF on warfarin 
will see the same practitioner. 
R – yes and would that have an effect on their relationship? 
S – yes exactly it’s a very good system… helps build a very good 
relationship] [I know how they live, where they live, their family 
members, what support system they have got. As well as the 
medical history I know their social history. (Samir, General 
practitioner) 
 
Likewise, general practitioner Matthew argued that knowing the patient’s 
background would influence him in deciding against warfarin if social factors 
demanded so. Matthew pointed out that the knowledge that general 
practitioners possess about the patient was different than that of hospital 
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physicians, thus it provided him with a better judgement on the patient’s ability 
to adhere to treatment. 
 
If they’ve got co-morbidities or a little bit older that might sway you 
a bit more towards… I’m worried a bit about compliance here, I’m 
a little bit worried about are they going to get their blues and brown 
tablets mixed up. So that is probably my… physician-patient 
knowledge about the particular individual which is probably 
different to someone at the hospital who doesn’t know that 
background. (Matthew, General practitioner) 
 
In the following excerpt, general practitioner George agreed with the rest of his 
group when talking about his knowledge of patients. However, George also 
pointed out that even though general practitioners were more familiar with the 
patient than hospital physicians, they were not comfortable in conducting a 
warfarin risk versus benefit assessment.  
 
[I think] GPs are more likely to know the patient’s social 
background or the way that the patient’s health seeking behaviour 
generally and I think GPs are in a better situation, NOT ALL THE 
TIME, most of the time… GPs are not as used to working the 
benefit versus risk in patients. (George, General practitioner) 
 
5.3.1.2 Language and cultural barriers 
Since Birmingham is a multi-cultural city in the UK, the majority of the 
physicians mentioned that they faced several language and cultural barriers 
when it came to communicating information to patients from minority-ethnic 
groups as often they were not able to communicate directly with the patient but 
through an interpreter. Furthermore, when interpreters were used, the 
physicians felt that, the message was lost in translation. This was evident in 
what cardiologist Melanie stated in the quote below. Melanie seems to be 
saying that she felt a higher cultural affinity with white people than other 
ethnicities because of the common ethnicity and language.  
 
In our populations that is a bit tricky. And of course we haven’t 
even started to mention, but I can’t communicate in this way with 
half my patients, so you sometimes need an interpreter, which is, I 
find it really hard, because you can’t get the patient’s real feelings 
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for it] [if I had an elderly Caucasian man in front of me, I would pick 
up a lot of non-verbal cues as to what why he doesn’t want 
warfarin, what he’s thinking and how to get around. Yes… but I 
wouldn’t necessarily know all the cues, or interpret them 
appropriately (with other ethnicities). (Melanie, Cardiologist) 
 
Later Melanie also talks about her connection with her Asian patients. Melanie 
points out that she does not have the same language and cultural link with 
Asian patients as she has with her own ethnicity. She emphasises the obvious 
language issues which can be overcome with an interpreter. However it is 
through repeated clinical practice with ethnic patients that she is able to 
understand some of the cultural nuances.  
 
You really need to be able to switch on who they are and where 
they are coming from to get them to understand it. And erm… and 
mostly our population are usually erm… the older patients are 
generally English Caucasian, so whereas now we are getting a 
bigger cohort… And I find that families… in the Asian cultures for 
example… the older members of the family, won’t do a thing 
without the younger members saying that’s the right thing to do… 
(Melanie, Cardiologist) 
 
Cardiologist Sean went on to add that during his medical training years, when 
he used interpreters or family members to translate what he was trying to say, 
the message was also being lost. Sean’s anecdote also highlights the need for 
additional time when using an interpreter. In addition, there is an issue of trust 
between Sean and the interpreter as Sean cannot understand first-hand the 
patient replies. He has to trust the interpreter to be translating ‘properly’ which 
would be impossible to judge if he does not know the language. Sean later 
stated that after learning some of the Asian dialects aided him both during the 
diagnosis and in having a compliant patient, thus implying that the consultation 
could adopt a more negotiated style rather than a paternalistic approach. 
However in the last sentence of this quote, Sean still used phrases such as 
‘take the medication that you need them to take’ referring to a paternalistic 
approach to decision making.  
 
S - What I found is that even if you use the relative as for 
translation or even trained translators, the message is lost. Initially 
when I first became a physician I used to use translators or 
relatives. And I found that what they… erm my explaining to the 
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patient relative then the patient’s relative to the patient and then 
the patient back to the relative and then the relative back to me… 
there was so much loss of the message that it became pointless. 
And you can well understand that if you do not understand 
somebody’s language… we have a lot of eastern European 
patients here as well and I don’t understand for example, Polish. 
And therefore I have the same difficulty in that context. But the 
majority of patients are either Afro Caribbean, and I grew up in an 
area where there was lots of Afro-Caribbeans so I understand the 
dialect. Erm… and most Asian languages I speak as well… so it 
transforms the consultation, firstly it takes less time. Because you 
are not going through a… 
R – yeah a bridge 
S – but also you can explain things in a much more detail and if 
the patient understands that you understand, then they are more 
amenable to take the medication that you need them to take. 
(Sean, Cardiologist) 
 
Registrars’ accounts also highlight the mistrust in interpreters’ abilities to 
convey their message. Dheepak argues that an interpreter may not be as 
committed as the physician in putting the same emphasis on the important risks 
involved with AF or the treatment involved. 
 
I think the emphasis you give on certain things, may not be 
appropriately conveyed to the patient. Particularly in the necessity 
of stroke prevention. I feel that the interpreter is not putting as 
much emphasis I would want to try to pass on to the patient. 
(Dheepak, Registrar) 
 
However, registrar Chan pointed out that in his experience, using a 
professional translator was better than using a family member. He emphasised 
the importance of translating correctly the medical terms, something which a 
family member might not be knowledgeable of. The mistrust in the interpreter’s 
ability to transmit the discussion to the patient was also shown in general 
physicians. Some physicians were advantaged when speaking with Asian 
patients as they knew some of the dialects. Manpal argued that it if he knew 
parts of the language, it was preferable for him to talk to the patient rather than 
involve an interpreter. 
 
That’s where the difficulty comes in (patients with different dialects 
of Urdu). If that does happen, you either get a family member 
involved or you get a translator there, to help you.] [Always a risk. 
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Stuff can get lost with translation, so that’s why I prefer to talk 
myself rather than getting a translator. If I know the language or 
some parts of it (Manpal, General physician) 
 
The experiences of the physicians show that communication during the 
consultation was more than just the use of different languages. Physicians are 
showing that because of the cultural difference, communication during the 
consultation had to change with the addition of an interpreter as the rules of 
reciprocity in normal conversations, the direct eye contact, metaphors, and 
analogies used naturally in conversation between the physician and patient get 
pushed aside. This has an impact on the relationship with the patients because 
these restrictions weaken the normal interactions. In the long excerpt portrayed 
below by general practitioner Matthew, similar language challenges were 
experienced, emphasising the multi-cultural side of Birmingham. However, on 
being prompted on the effect of this barrier on the patient-physician 
relationship, Matthew stressed that an interpreter during the consultation is an 
issue of concern for him as he feels uncomfortable exploring certain issues 
which he believes would be distressing for the patient.  
 
M – I am lucky that I know several languages of this area and that 
stroke is stroke no matter which language it is… but lately we’ve 
been getting a lot of Eastern-Europeans and Somalians which I 
don’t know the language. In that case you have to use an 
interpreter and things get lost during translation and you worry if 
what you told the interpreter is being told the same way to the 
patient. 
R – And you also mentioned the relationship built between you 
and the patient several times as well… does the fact that you have 
to talk through an interpreter affect that relationship? 
M – always… forget about AF, put that to one side… generally 
speaking when you are trying to have a consultation with a third 
person there, there are disadvantages, the whole conversation 
gets a bit uncomfortable. It’s not the ideal scenario. And 
sometimes you also avoid asking intimate questions that could be 
relevant because of another person being there. So a good 
example of that would be erm… erm… get a lot of patients with 
blood pressure…and you want to talk about impotence for 
example… as a side effect and you can’t because of the third 
person. The patient may not feel comfortable talking about these 
sort of things. (Matthew, General practitioner) 
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Like cardiologist Sean, general physician Tom argued that language barriers 
could also influence the physician to take a similar paternalistic approach. 
Rather than going through the “hassle” of checking if the patient understood 
him, Tom took a more direct approach in decision making, opting for a 
paternalistic at the detriment to the patient’s right for education. 
 
 
 
T – Oh that would mean the use of an interpreter. This isn’t just to 
do with AF, this has to do with everything. It’s not as good. It’s not 
the same conversation. All you could do is say a few statements, 
they are interpreted, and you don’t get much back. This is not as 
easy.  
R – So meaning gets lost in the translation 
T – Yes… definitely. And then in that case, we end up doing the 
decision. We try to involve the patient but when you are using an 
interpreter, you end up saying ‘so we are going to do this, do you 
have any questions’ and that’s it (Tom, General physician) 
 
In addition, this impact on the approach taken by the physician was something 
experienced by primary care as well. Conforming to the challenges lived by the 
cardiologists and general physicians, general practitioner Samir also pointed 
out the inevitable use of a paternalistic approach to decision making with 
patients who speak other languages. 
 
R – Erm… do you get patients that speak languages that you don’t 
know? 
S – Yeah, Chinese, some of the Arab languages, there we rely on 
the family members or translators. And it is much more difficult.  
R – And what do you feel? 
S – I don’t think the message always gets through.  
R – So patients with other languages get less information? 
S – yesyes inevitably… 
R – with regards to decision making 
S – it will be very difficult to get what they are thinking, most of the 
times you end up deciding for them (Samir, General practitioner) 
 
5.3.1.3 Adhering to guidelines 
Physicians commented on how they are usually influenced by evidence-based 
medicine rather than their own opinion or hunches. Most of the cardiologists 
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mentioned that they either followed the NICE guidelines in deciding whether 
warfarin therapy is recommended or stroke risk scoring systems such as the 
CHADS2 score. Sean’s interview was later than the other cardiologists and in 
that time a new acronym was developed. It was interesting to note that after 
only two weeks that the acronym was published; Sean had already started 
implementing it in his consultations. This quick uptake of the new scoring 
system was probably influenced by the fact that he works closely with one of 
the authors of this new stroke risk score. 
 
R – [yeah]… and erm… now you mentioned and even before you 
mentioned it. The CHA2DS2-VASc… and that before there was the 
CHADS and now it’s updated… erm how come you started using 
the CHA2DS2-VASc rather than the CHADS 
S – erm because as times go on, things get refined. So it was the 
CHADS2 score, then it was the CHADS2 score, than it’s been 
refined even further] [this is why the CHA2DS2-VAScscore has 
increasingly put emphasis on people ending up on warfarin which 
basically… if you have any risk factor, you will end up on warfarin.] 
[I think you have to (be influenced by evidence) because 
otherwise, if for example you manage somebody based on your 
opinion and there is a problem, then people can argue. Because 
the opinion is yours… it belongs to you. It’s your entity. Somebody 
else’s opinion may be different to yours. But if you base your 
opinion, based on, on the evidence base. Then it's not your 
opinion any more. It’s the opinion of experts or peers in the field. 
Erm and therefore if somebody argues you can say… look 
according to such and such and such society guidelines or 
according to such and such erm research study… we elected to 
manage you in a particular way but it’s based on this evidence. 
Therefore it’s a much more difficult for them to challenge your 
decision making. (Sean, Cardiologist) 
 
At the end of this excerpt cardiologist Sean rationalised that the diagnosis 
needs to be evidence-based rather than on opinions because of the need for 
physicians to demonstrate they’re up to date and practising within the 
guidelines especially when their decision is questioned. In contrast, cardiologist 
John pointed out that evidence-based medicine was only part of the physician’s 
diagnosis. One also has to take into consideration the patient’s lifestyle and 
how the system works. He argued, for example, that because there was the 
need of monitoring, warfarin would not be suitable for patients who are 
housebound and cannot regularly go to have their INR tested. John 
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emphasised the importance that a medical consultation should be a 
combination of evidence and experience aimed at the care of the individual. 
 
J – sure… erm at the moment I use the CHADS2 score that was 
invented by my esteemed colleague and erm…but I also am 
significantly influenced by erm… co-pathologies, structural 
abnormalities within the heart, any mitral stenosis would probably 
go for warfarin… so yeah it is a balance to be had but the CHADS2 
score is straightforward and allows us to choose. It’s going to be a 
bit more difficult when dabigatran is available because it doesn’t 
quite use the CHADS2 score and erm… but that’s the basic 
evidence that we use at the moment...] [Clinical practice, clinical 
experience is a combination of evidence and past experience so 
for sure yeah ABSOLUTELY… and knowing how the system 
works and doesn’t work, there is no point in putting someone on 
warfarin if he cannot get out for blood testing for instance.] [well 
the evidence is one side of things, but you also have to put in the 
patient scenario, which does not always fit into the CHADS2 
score. Every individual is an individual by definition… (John, 
Cardiologist) 
 
Unlike cardiologists, general physicians like Nilan, argued that since they have 
to be knowledgeable on a myriad of conditions and not just heart related, it was 
more difficult to remember and adhere to specific guidelines. Thus Nilan 
commented that in his experience it was easier to remember a short acronym 
like the CHADS2 score rather than the complex and ambiguous table of the 
NICE guidelines.  
 
I mean generally, to me, looking at NICE guidelines, I mean I find 
it very difficult, especially if you do not have it, it is very difficult to 
remember and then see what it is. What I tend to use is the 
CHADS2 score, which is much more simpler (Nilan, General 
physician) 
 
Similarly, general physician Balu voiced his dissatisfaction with the AF 
guidelines several times in his interview. However one can note, that initially he 
showed agreeableness towards the use of guidelines, but went on to 
emphasise the benefits other health professionals would reap from a simpler 
version. He argued that guidelines should be specific to the specialty of the 
physician. 
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To most people, they are confusing. Because there are so many 
cut offs, it’s not simple. The defined asymptomatic and 
symptomatic patients, then you’ve got the paroxysmal, permanent, 
lone atrial fibrillation, to a lot of health professionals, particularly 
GPs, a. they don’t have the time and b. it’s too confusing, because 
it’s not very simple to follow. That’s my personal view. 
R – So you think that simplifying or shortening the guidelines could 
be an easier way to put them? Or focusing the guidelines to the 
type of health professionals 
B – That would be very useful. To cardiologists, you can make it 
as difficult or as complex as it is. But to general physician you can 
perhaps divide it into risk categories. But to a general practitioner, 
again it’s a bit difficult. (Balu, General physician) 
 
Further on during the interview, Balu reflected on this issue again, where he 
commented that in guidelines, a single cut-off which in this case is age, is 
difficult to apply to the individual patient. He pointed out the need to educate 
health professionals through the use of guidelines that are specific to each 
specialty.  
 
Well it’s by education, by making guidelines simpler and easy to 
use and by stratifying the guidelines, there should be 1 A4 page 
for an emergency department medical assessment unit, a different 
A4 for cardiology clinics, different A4 for general practice, and 
different one for general physicians. All probably saying the same 
thing, but the way it is being put across, the simplicity is the 
important point. (Balu, General physician) 
 
The need for health professionals to be educated on how to adhere to 
guidelines was also picked upon by general practitioners. GP Matthew 
specified the need for health professionals’ education with regards AF 
guidelines. In contrast, when general practitioner Samir was prompted on this 
issue, he argued that education should not be relocated to just general 
practitioners but also to secondary care. He felt that an important aspect that 
influenced patients’ adherence to treatment is common knowledge between 
health professionals in different specialties. However at a later stage of the 
interview he also suggested ways in which this educational system may be 
broken down, wherein the guidelines would specifically suggest when to refer 
patients to secondary care.  
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R – Erm… and what do you think about the current guidelines? 
S – I think the most important thing is that we have a responsibility 
that they agree across both primary and secondary care. So we 
can’t have a disagreement. Otherwise the patient will think, who 
will I rather believe? So we all need to do the same thing. As long 
as we are doing the same thing… I don’t mind.] [The beginning bit 
should be the same for both, the last bits should be different. So 
for example when there is a complicated consultation, for GPs it 
should say that at that point, refer to the specialist and then in the 
specialist bit it would include more detail. (Samir, General 
practitioner) 
 
Cardiologist registrar Ted also commented about the ambiguity in AF 
guidelines. Ted pointed out that guidelines only took into consideration the 
biological aspect of treatment, while during diagnosis Ted suggested that other 
individual factors should be given equal importance, for example the 
individual’s likelihood of falling.  
 
Then the present NICE guidelines as you know are a little bit 
ambiguous and say that you can either go down the warfarin or 
the aspirin route. Sometimes you’ve got to take into account the 
other side of things. Like if they are very elderly, they are prone to 
falling… (Ted, Registrar) 
 
Likewise general physician Manpal pointed out the difficulty in adhering to the 
guidelines and making decisions on an individual setting. 
 
R – And erm… what do you think about the current guidelines of 
AF? 
M – erm… you want my honest opinion (laughs) yeah you would] 
[M – (Laughs) yeah yeah… it’s just a national thing you know, 
that’s why. I think AF is still a complex disease, still no one knows 
the perfect way of treating it. There are some guidelines out there. 
People still do their own thing sometimes. There is no right or 
wrong. I think and as you mentioned with the cases, every case is 
different. You have to risk assess them separately. And even 
within the cardiologists themselves they all disagree with each 
other as well sometimes. (laughs) so I don’t think there is an actual 
perfect way (Manpal, General physician) 
 
Later on, Manpal reinforced his argument by discussing how guidelines give a 
general solution which is difficult to apply to the individual, highlighting the issue 
that during the consultation, the individual patient might be different than the 
patient whose average characteristic are portrayed in the guidelines.  
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M – I don’t think there is an easy answer, because there have 
been so many studies, so many different groups of patients have 
been studied. Do your patients fit into that group or not? That’s 
always the difficult thing. Erm so I don’t think there will be a clear 
cut answer for it. It’s just gonna get more and more harder 
because more and more studies are coming out. Some conflicts, 
some support what previous ones have found out. (Manpal, 
General physician) 
 
5.3.1.4 Information overload for the patient 
According to physicians, educational information given during the consultation 
was critical to ensure that the patient was able to participate in a shared 
decision making process and to enhance adherence to treatment. However, 
physicians in this study, mainly general physicians and general practitioners, 
commented on the risk of providing too much information to the patients and 
how much of this information patients would be able to recollect. Interestingly 
patients in the previous study commented that they did not receive education 
on AF and OAC. It could be possible that although some patients were given 
education, they did not remember it due to information overload as suggested 
in this sub-theme. Concurring with cardiologist Melanie, where she commented 
that she is unsure whether patients remember all the information they are 
given, general physician Manpal, also discussed his awareness of evidence 
that had shown patients’ limited ability to retain knowledge after the 
consultation, and questioned the usefulness of bombarding the patient with 
information.  
 
Yeah usually I do make an effort to tell them all these things. The 
problem is how much they are going to retain. Studies have been 
done to show that patients probably only remember 20% of 
whatever you tell them (Manpal, General physician) 
 
Similarly general practitioner Matthew pointed out that according to his 
experiences, in an initial consultation, the information that a patient would 
remember most was the name of their condition. He argued that since the 
patient was receiving important news they might be too distressed to remember 
what was said with regards risks and benefits to treatment. 
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I’m sure that if they walk out the door and see someone else and 
asks them, so what did the physician say, they would say, my 
heart is beating irregularly, I don’t remember anything else. So you 
again, you telling them some profound news which they may or 
may not be expecting. (Matthew, General practitioner) 
 
Following the model of concordance, where patients are given the needed time 
to reflect and discuss with significant others the information provided before 
taking a decision, general practitioner Matthew, remarked that patients needed 
time to understand medical information. Thus he used follow-ups as an 
advantage to give patients time to reflect and then discuss treatment later. 
However one must note that during the wait for this follow-up patients were still 
at high risk of developing a stroke if not commenced on warfarin. 
 
Lots of patients need that time to digest it (information). That’s why 
I always do that. Give them a leaflet] [you have to give them the 
opportunities to digest that information at their own pace and come 
back to you before you sort of… yes I’ve decided, you’re going on 
warfarin. It’s not like that. (Matthew, General practitioner) 
 
5.3.2 Physicians’ interpretation of patient related challenges 
The second theme under the over-arching theme of challenges with OAC 
prescription for AF, explored the physicians’ interpretations of their experiences 
of concerns relating to OAC treatment that were raised by their patients. 
Physicians reported what they believed were experiences that proved 
challenging to the patient, including the impact of blood monitoring, concerns 
about the side-effects and interactions of warfarin, how the patients’ 
experiential knowledge had an influence on the consultation and the concerns 
raised by symptomatic and asymptomatic patients. 
5.3.2.1 Impact of blood monitoring 
Some patients in the previous study raised concerns about the regular blood 
tests required to check their INR as part of OAC treatment. Similarly almost all 
of the hospital physicians, particularly the cardiologists, commented that they 
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felt that patients were concerned about having to have regular blood tests, 
illustrated by the quote from cardiologist Melanie.  
 
M - … I think it’s the blood tests that mostly puts them off 
R – Do you think that is a barrier? 
M – I think that is a huge barrier for most 
R – The fact that they have to come in for the 
M – Yeah they have to do the blood tests (Melanie, Cardiologist) 
 
Registrar Ted agreed with cardiologist Melanie when he stated his assumption 
that one of the downsides of warfarin from the patients’ views was the 
inconvenient frequent blood monitoring in the early stages of the treatment. 
 
It’s (blood monitoring) however inconvenient for the patient… 
having to have it monitored… initially quite frequently eventually, 
probably and hopefully about 6 to 8 weeks. (Chan, Registrar) 
 
Cardiologist Sean also added that this was not only a hassle to the patients 
(which some the patients agreed with) but also had a significant financial 
impact on the health care system, where a specific service had to be employed 
to cater for the anticoagulation service. 
 
The main downside of warfarin is the hassle of having to have it 
monitored. Erm… it’s a hassle for the patient because they have to 
come to the anticoagulation clinic and it’s erm… it has financial 
constraints, because you have to employ a service to look after 
anticoagulation and hence that’s the downside to warfarin. (Sean, 
Cardiologist) 
 
Like Sean, cardiologist Peter also pointed out that he perceived that the health 
care system was experiencing similar financial stressors. He stated that not all 
patients are mobile or have transport available to them, and thus ambulances 
had to be utilised, adding to the financial impact on the health care system. 
 
Even now, patients in a lot of visits, although people say it only 
costs 300 pounds a year. Some of the patients need ambulances 
to get to the hospital to have the INR checks. I think domiciliary 
anticoagulation must be considerably more expensive. (Pete, 
Cardiologist) 
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General physicians like Nilan also experienced similar concerns. Patients, 
according to Nilan, would be more willing to accept warfarin if monitoring is 
done in their homes as it would remove the financial impact on the patient 
brought about by the increase in parking fees and public transport fares. The 
financial impact was also highlighted by patients in the first study, particularly 
by Lionel, when he commented on the increase of hospital parking fees. 
 
Registrar Chan further added that he had experience with reassuring anxious 
patients concerned with travelling overseas when on warfarin. This argument 
was also brought up by one of the patients, Raj, who discontinued warfarin. 
One of the factors that influenced Raj to discontinue warfarin was that he 
believed he could not travel while on warfarin (see Section 4.3.2). 
 
I’ve been asked are whether travelling is still possible. I tell them 
that INR management is standardised now… so it won’t make a 
difference between a level 2 here and a level 2 in Spain or 
Portugal… so if anytime you’re not sure and you need to check… 
then someone is going to be able to check it for you. (Chan, 
Registrar) 
 
Registrar Ted comments that in his experience, patients might be concerned 
that blood monitoring would have an impact on their QoL by limiting their 
available free time. This was also commented on by patients in the previous 
study. Patients like Lionel commented how time was lost waiting in long queues 
at the clinic (see Section 4.3.1). However, Ted also pointed out that although in 
his experiences he perceived patients as being inconvenienced by monitoring, 
other patients found solace in knowing that they are within the therapeutic 
range of warfarin.  
 
Some of them they tell you that they are going on a holiday and 
the blood monitoring would disrupt travelling, others would tell you 
that they are already having a number of blood tests for diabetes 
or kidneys or whatever… or going every 4 days to the GP because 
their INR is all over the place. On the other hand… you find some 
people that like to go to the GP often, because they get 
reassurance that their warfarin level is ok. So for some monitoring 
is a pro because of the reassurance they get. (Ted, Registrar) 
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Registrar Jeffrey also experienced similar time concerns as those pointed out 
by Ted. Jeffrey emphasised the issue that since most AF patients were older 
people they probably had other comorbidities that had similar monitoring 
issues. So when a physician prescribed a medication that needed monitoring, 
such as warfarin, Jeffrey believed that the patient perceived it as an extra 
encumbrance. Furthermore, Jeffrey’s perception was that the older person 
found the constant travelling to and fro hospital as a major inconvenience. 
 
I think the older ones… erm are worried about the blood test that 
they need. Because a lot of them go to different outpatient clinics 
for different things and they spend half their life going to clinics 
and to the GPs. Some of them see it just as an extra thing. It is a 
big deal for them. If you tell them you need to go see the 
anticoagulation clinic, you know… ultimately maybe only once a 
month… but it’s still a big ordeal for an old person. It’s a big ordeal 
for them to go to the hospital, get the bus, park, wait around… 
there are always delays… it is a big deal for them. I think a lot of 
people think that having a lot of blood tests is just too much. 
(Jeffrey, Registrar) 
 
In contrast to hospital physicians’ (cardiologists, cardiology registrars and 
general physicians) interpretations of their patients’ experiences, general 
practitioners commented that their patients did not appear to them to be 
concerned by blood monitoring. General practitioner Matthew commented that 
regular monitoring was a normal routine for older patients. 
 
Many of these patients are used to coming, cause of the co-
morbidities, they are used to having blood tests and used to being 
monitored on a regular basis for certain things on a regular basis. 
So it’s not a big thing from that point of view. (Matthew, General 
practitioner) 
 
In the following quote, General practitioner Nick, added that concerns around 
routine blood monitoring dissolved once they had an actual experience of the 
anticoagulation clinic. Thus, pointing towards the notion that general 
practitioners’ patients changed their perceptions and concerns of blood 
monitoring once they had experienced the clinic first hand.  
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Most of them, by the time they’ve seen the cardiologist and been 
to the anticoagulant clinic… erm I would say most people feel 
comfortable about it… well it is slightly an unnerving experience 
starting life on warfarin. But I think they feel reassured by the 
monitoring (Nick, General practitioner) 
 
General practitioner Samir argued that since monitoring of OAC treatment had 
started in his general practice, patients did not have negative associations. 
Samir pointed out that patients associated monitoring in the hospital with long 
waiting queues (as pointed out by some patients in the previous study as well), 
which could explain the cardiologists’ interpretations. Patients might feel like on 
a ‘conveyor belt’ in a hospital environment, while at the general practice Samir 
explained that the experience was different.  
 
It is interesting now that more and more now, as we offer it locally, 
more of them are happier to come here then to go to hospital. I 
think the bad thing they hear is the long waiting queue in hospital 
and in clinic and they get results on books and have to come back 
you know. Whereas at the surgery the experience is different. 
There are set appointments, they come in, give them the results 
and that’s it. (Samir, General practitioner) 
 
5.3.2.2 Side-effects and interactions of OAC therapy 
Physicians in this study commented on their interpretations of what they 
perceived as patients concerns with regards to side-effects and interactions of 
warfarin. One of the side-effects of warfarin that physicians believe is 
commonly raised as a concern during the consultation was the risk of bleeding 
and bruising because of the thinning of the blood. Registrars pointed out they 
believe that bleeding was one of their patients’ main concerns as can be seen 
in registrar Chan and registrar Jeffrey’s quotes below. 
 
They generally worry about the risk of bleeding. Erm… that’s the 
main one. (Chan, Registrar) 
 
People do worry about bleeding. I think that is a significant 
concern for a lot of people. (Jeffrey, Registrar) 
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Cardiologist Melanie said that gentlemen in her practice complained of bleeding 
from cuts when they are shaving, showing the impact warfarin have on these 
patients even in minor everyday life situations. Furthermore, Melanie added 
that female patients often complained about age spots and rusty coloration of 
the legs. This meant that according to her, even minor bleeds and bruises in 
visible areas could be having an impact on the patients’ perceptions of warfarin.  
 
 [It’s the bleeding]… they also don’t like, particularly the 
gentleman, they don’t like I when they are trying to shave… they 
get… they get cuts. And the women don’t like… the age spots get 
worse. They say… they come and say I got this rash which is 
getting worse and I also do think that the other red… the sort of 
rusty coloration of the legs with patient’s high venous pressures, I 
think that does get worse with warfarin. And that makes sense 
because that is due to capillary rupture and the leaving of haem in 
the cell. And that would make sense because they are more likely 
to rupture… well rupture, but ooze. So that makes it worse] [yeah, 
a lot of patients, they… look for any reason to come off it. They 
have gone on it reluctantly and you know they are gonna come to 
you to take them off. (Melanie, Cardiologist) 
 
However, although she found a medical explanation for the possible colouration 
and hair loss in patients, she often dismissed the patients’ concerns as excuses 
that patients found in an attempt to stop taking warfarin. Similarly, in the quote 
below from cardiologist Sean, rather than attributing bleeds to warfarin, Sean 
attributed the causes of bleeds to other external factors which are in the 
patients’ control. 
 
Erm it (warfarin) doesn’t cause bleeding by itself but if they were to 
bleed for another reason, then any bleed that would occur would 
be heavier. (Sean, Cardiologist) 
 
In contrast general physicians and general practitioners did not explore 
bleeding as a major concern like the cardiologists and registrars did. Other 
challenges presented by patients, as perceived by the physicians, that 
influenced warfarin prescription with regards side-effects of warfarin were the 
numerous interactions warfarin had with various other substances. These 
included vitamin K, which was found in green leafy vegetables as well in food 
supplements, alcohol and other drugs. The interaction of OAC with food and 
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alcohol was also commented on by some patients in the previous study; 
however it was only expressed as a minor concern. In the following extract, 
cardiologist John highlighted a misconception with regards to warfarin and 
vitamin K consumption. He said that in anticoagulation clinics patients are told 
that there are certain foods they shouldn’t eat, which confused the patients 
especially since the same foods that are being stopped are the foods the NHS 
was promoting as “super-foods” in the “five-a-day” campaign.  
 
J –In the warfarin clinic they tell them that there are certain foods 
that they don’t like them having. So they also complain that they 
can no longer have broccoli and other things that they very much 
enjoy. And these are of course foods, super foods that we are 
pushing as health foods 
R – yeah and with the five, five 
J – five a day yeah exactly… so a lot of them don’t like that. (John, 
Cardiologist) 
 
This was also similar in cardiologists Melanie’s experience. She commented 
that her patients were accustomed to buying several over the counter 
medications and vitamin supplements. Thus during her consultation she needs 
to take extra care when discussing warfarin treatment. 
 
So I get some ladies that come in and I say what tablets are you 
taking, and I say well that’s ok… they come with a bag full of 
tablets and I say… show me and they start emptying them, and I 
say no no, you can empty the bag on the desk… and I say what 
are all these, and they say oh yeah, that’s my vitamin, and so you 
have got to be really careful. (Melanie, Cardiologist)  
 
Cardiologist Sean explored the issue of alcohol consumption. He argued that in 
the current society, excessive consumption of alcohol was fairly common and 
this could interact with the chemical pathways of warfarin, possibly making the 
blood thinner and increasing the risk of bleeding. Later, he divulged that with 
patients who did not agree in lowering their consumption of alcohol, he did not 
recommend the use of warfarin as it would cause them more harm than benefit.  
 
I had patients who have been drinking excessive amounts of 
alcohol and you say look. It would be difficult for you… for 
example I had a gentleman who drank nothing during the week 
and on a weekend consumed maybe 30 or 40points of alcohol. 
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Now that fluctuating level of alcohol does cause serious fluctuation 
in anticoagulation. So I explained to him that this kind of drinking 
pattern firstly wasn’t good for him anyways and particularly 
wouldn’t be good if he was on warfarin and therefore he elected to 
not go on warfarin (Sean, Cardiologist) 
 
The above anecdote brings to the forefront the experiences from one of the 
patients in the previous study. Greg, whose AF was caused by excessive 
alcohol (which he later stopped) commented on his perception of the 
cardiologist’s behaviour in his consultation. Greg mentioned that according to 
him, his cardiologist was less empathic of his feelings and his problem with 
alcohol, and more interested on starting him on a clinical trial with a NOAC. On 
the other hand Sean had a similar experience with a different patient. However 
in Sean’s anecdote, as the final italic part of the above quote, firstly addressed 
the patient’s problem with the alcohol and then addressed the influence of 
alcohol on warfarin.  
 
Registrars also underlined that alcohol, apart from being perceived as a patient 
related challenge; they also perceived it as a patient concern. Registrar 
Dheepak commented that his patients were concerned by the fact that alcohol 
can cause interactions with warfarin. Thus he emphasised the need for 
appropriate patient education on alcohol interaction during the consultation.  
 
For some reason they are always concerned about the alcohol. 
Because they are aware that it would cause trouble. (Dheepak, 
Registrar) 
 
As mentioned previously, unlike the physicians’ perceptions, although patients 
in the previous study expressed only minor concern with regards to food and 
alcohol, it was not an issue that influenced them in accepting or refusing 
warfarin. 
5.3.2.3 Asymptomatic vs. symptomatic patients 
Most of the participants discussed the differences in recommending warfarin to 
symptomatic and asymptomatic patients. Physicians know that OAC treatment 
will not have any effect on AF symptoms and it is recommended whether the 
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patient is symptomatic or asymptomatic because stroke risk is not dependent 
on the presence or absence of symptoms of AF. However since asymptomatic 
patients did not feel any symptoms from the AF (such as the irregular beating 
of the heart, palpitations, breathlessness, fatigue), physicians believe that 
patients often find it difficult to accept a life-long medication with potentially 
serious side-effects, for a condition that according to them, they would not see 
any tangible benefits. Cardiologist John went on to state that prevention was 
difficult to explain to patients when there was no link. In the below quote, John 
also pointed out that with asymptomatic patients, education on the risk 
reduction with warfarin was critical in increasing adherence to treatment. 
 
J – erm most of the patients surprisingly are asymptomatic and 
erm… yeah you know when you say you are going for a drug for a 
long time if not forever, and these are the reasons why, it’s quite 
an undertaking to put someone particularly on warfarin erm who… 
is entirely asymptomatic, who now is gotta have to come to the 
hospital every 4 to 6 weeks forevermore or at least until dabigatran 
comes. So for them it’s a big undertaking. So they have to realise 
the reasons why they are doing it, the stroke risk and the reduction 
of stroke risk with warfarin therapy. It’s quite a big undertaking 
R – Cause they don’t associate kind of the medicine with 
something they can feel 
J – Prevention is much harder to convince patients to erm… than 
link… once they had the mini stroke or the stroke, erm it’s much 
easier to convince them to take warfarin. But if they do not have 
any symptoms, it’s very hard to convince them. (John, 
Cardiologist) 
 
Likewise Cardiologist Sean stated that when asymptomatic patients received 
their medication, they only perceived the disadvantages of the medication 
rather than the benefits. This was something that physicians were aware of and 
concerned about when communicating the need of warfarin to patients. 
 
Somebody who is asymptomatic and therefore you give them the 
medication and the medication gives them side effects, they only 
perceive a disadvantage to being on medication and therefore 
compliance might be an issue. (Sean, Cardiologist) 
 
Similarly, general physician Manpal discussed the issue of warfarin acceptance 
by asymptomatic patients. One can note Manpal’s concern and frustration from 
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discussing appropriate treatment with the patient, when he used the phrase “a 
bit harder to convince”. 
 
M – Yeah I think, the symptomatic ones are probably more 
amenable to have treatment, because they have symptoms. 
Asymptomatic patients ‘why should I have warfarin with the risk of 
bleeding and all the other complications, and have to have lifestyle 
changes’ so a bit more harder to convince the asymptomatic group 
as compared to the symptomatic group. 
R – Since they never had experiences of symptoms? 
M – Absolutely, since it doesn’t bother you, why should you take 
medication. It’s all about primary prevention. (Manpal, General 
physician) 
 
In agreement with general physician Manpal, general practitioner Matthew 
compared the discussion he conducted with asymptomatic AF patients to other 
asymptomatic conditions such as hypertension. Matthew was pointing towards 
the crucial role that education and communication skills play in explaining the 
benefits of warfarin.  
 
Blood pressure is another example… where patients are 
asymptomatic. They don’t feel any problems. It’s the same with 
some of our AF patients. They feel fine. You pick it up on an 
incidental ECG or what have you or check the pulse. And erm, the 
concept is slightly different in trying to erm go through the benefits 
long term benefits. Erm… potentially giving them drugs that will 
make them feel unwell and require a lot of monitoring in particular 
and lot of input from us. And what the benefits for them as an 
individual are. The blood pressure is slightly easier, because you 
can sort of say, you’re going to have a heart attack, and you 
know… you’re reducing the risk of that. With AF, it’s a little bit 
more grey area. Because of the side effects of warfarin and they 
are much greater, and the risks are much greater. (Matthew, 
General practitioner) 
 
Cardiology registrars, like Chan in the excerpt below, commented on the 
difficulty of diagnosing asymptomatic patients and the distress this causes to 
the older patients because of the repeated tests.  
 
Problem with asymptomatic patients is you can’t tell when AF 
started.] [Asymptomatic ones are very difficult. Sometimes you 
end up doing a number of 24hr tapes just to make sure that there 
isn’t any other paroxysms of AF. (Chan, Registrar) 
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Similar to registrars, general physician Nilan highlighted the anxiety 
asymptomatic patients go through during their consultation. Since they did not 
feel symptoms, discussing risks brought about by AF caused anxiety in the 
patients because of the unexpected severity of the situation. Furthermore, while 
other patients were assured that warfarin can lower the stroke risk, 
asymptomatic patients get more anxious as they perceived only the bleeding 
risks associated with warfarin. 
 
Some of these patients, you know, you see them in the TIA 
(transient ischemic attack) clinic or in the clinic, they had it… they 
just started or its new and they are rate controlled. So they are not 
symptomatic from it. So that’s why when you try to tell them that 
there is a risk that you can get a stroke. THEN they get worried 
about it, and then you say yes you can get a stroke. Therefore you 
should be getting warfarin. THEN they get more worried about it. 
(Nilan, General physician) 
 
General practitioner Nick further emphasised the importance of reassurance 
with asymptomatic patients in the initial stages of the consultation. 
Furthermore, Nick was showing that asymptomatic patients might be more 
anxious than symptomatic patients in these initial stages of the consultation.  
 
I suspect that its patients who are asymptomatic, and the lone 
fibrillators and so on, who are gaily going through life and then 
suddenly something is found, may be a little bit more disconcerted 
and need a little bit more convincing on the significance of their 
illness (Nick, General practitioner) 
 
5.3.2.4 Physicians’ perceptions of patient’s experiential knowledge 
Since AF is a heart condition that is most common in older people, and given 
that warfarin had been around for the past 60 years, most of the physicians’ 
patients had family members or neighbours or friends who were taking or had 
taken warfarin. Physicians believed that the experience of these family 
members or friends often influenced the patient’s perceptions. This was 
something that was experienced by most physicians in this study. They talked 
about the difficulty in prescribing warfarin to such patients who already had ‘a 
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priori’ knowledge of the possible course of the treatment. Cardiologist Melanie 
argued that she found it hard to persuade these patients to take warfarin. So, 
like the general practitioners, she preferred to give the patients time to think 
about their treatment decision and discuss the issue again during a follow-up. 
She argued that patients had all these misconceptions because warfarin is a 
well-known drug and compared it to digoxin which was usually given alongside 
warfarin. She believed that her patients did not complain in the same way about 
digoxin, as it was not a well-known drug like warfarin. 
 
Well some of them say I’m not having it. My friend has it and it was 
not good for her or whatever. And you cannot persuade them. But 
then you can say that despite explanation… I usually tell them, 
have a think about it, and we’ll talk about it next time you come 
and you know, just leave it like that. Erm cause quite a lot of older 
people don’t want to come on it] [lay people do know about it, 
cause so many of their friends are on it. And therefore the sort of 
whispers about what happens in medicines… so sometimes they 
need a long time to think about it. You don’t get the same problem 
with digoxin, which is used alongside it, cause they don’t 
PERCEIVE THAT as a drug with problems because they don’t 
know what it is. (Melanie, Cardiologist) 
 
Similarly the patient Josephine commented that because warfarin was well-
known, patients might already have formed their own perceptions about it 
before the discussion with the physician. Conversely, cardiologist Peter blamed 
the negativity of patients on the lay press and other health professionals who 
exaggerated the risks involved with taking warfarin. The patient Raj, from the 
previous study, took a similar stance. He argued that patients should not 
believe everything they read but rather question the information they are 
presented with. Cardiologist Peter also mentioned the possible lack of 
knowledge that non-specialist physicians have.  
 
Patients will vary in perception. As patients do frequently look at 
individual experience and you know, if a relative or a friend has 
had a certain treatment and it went well. They say oh yes of 
course my neighbour had an angioplasty and if they happen to 
know about somebody who has had a bad experience for example 
a patient went to have a bypass graft, had complications and died. 
The same applies to warfarin. People have heard of friends or 
relatives on, and some patients are positive about it, but there is 
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quite a lot of negative vibes about it going on] [I think that doctors 
and as well as the lay press may again exaggerate the risk of 
warfarin so some patients are negative] [Another problem is that 
sometimes it’s not even clear to the doctors… people do think that 
aspirin is a suitable alternative to warfarin… I don’t think it is but, 
there is a wide spread perception, including amongst some non-
specialist doctors that it is a suitable alternative… (Peter, 
Cardiologist) 
 
In addition, registrar Chan commented that when the patient had ‘a priori’ 
knowledge of bleeding in relevant others, the patient formed a strong negative 
association to warfarin.  
 
Sometimes patients tell you my wife or my relative died because 
she or he was on warfarin and bled to death. I’m not going to have 
the warfarin at all (Chan, Registrar) 
 
Conversely to the above statements, cardiologists, such as Melanie’s excerpt 
below, also stated that ‘a priori’ knowledge could even work in favour of the 
consultation.  
 
Well the positive side is that sometimes you get patients who had 
a positive experience, oh yes my dad was on that and it was fine, 
or my husband took that for years before he died. There is a 
familiarity with it… it can be a good thing, not necessarily a bad 
thing (Melanie)  
 
Like cardiologist Melanie’s experience, registrar Ted also pointed out that 
perceptions based on ‘a priori’ knowledge varied according to the experiences 
of the patients. These perceptions in turn influenced the discussion on warfarin 
and therefore the readiness for concordance with the physician’s suggestion. 
 
I suppose it depends on if they know friends, relatives who have 
been on it who had a good experience. Then they’ll already… be 
erm more willing to take it.] [you often have patients who say that 
my grandma was on warfarin, didn’t get on with it at all, had lots of 
side effects, so I’m not taking it… so you definitely do come across 
patients like that. (Ted, Registrar) 
 
Conforming to Ted’s arguments, as shown in the previous patient study, past 
experiences with stroke or bleeding had an influence on the patient perception 
of warfarin. Registrar Dheepak also believed that patients’ perceptions of 
 234 
 
 
warfarin were not always negative but influenced by other’s experiences. 
Dheepak pointed out that the experiences of new patients with warfarin, 
influenced the experiences of the possible future generations. Suggesting that 
raising awareness of warfarin could help in alleviating the negative perceptions. 
Raising awareness of warfarin was also something suggested for the same 
reasons by patients in the previous study. 
 
D – I think it’s when they have heard about it…  sometimes it’s 
bad, sometimes it’s good news… it’s about 50/50 I think. 
R – Cause you get some patients that heard kind of positively 
about warfarin? 
D – Yeah exactly… so erm… people who had bad experiences, 
have pre-fixed ideas. This in turn influences on people who they 
talk to. Especially if they are family members or close relatives. 
(Dheepak, Registrar) 
 
General physician Nilan added that he encouraged relatives to come to his 
consultation with the older person. He argued that sometimes the relatives 
accompanying the older person had researched the condition on the internet. 
Nilan found that according to his experiences this ameliorated the discussion 
for the choice of treatment, and helped understand the rationale for need 
warfarin.  
 
Some of the patients are older patients, and they come with 
relatives. The advantage of that is… you find that the majority of 
the relatives have been to Google and they know more than what 
you are expected to know. So in a way it makes your task slightly 
easier, they go ‘oh yes yes’. So when you tell them it’s irregular, 
they say ‘yes yes I read it, it’s atrial fibrillation’ and then you say 
there is a scoring for it to find out how… CHADS2 score to find out 
what your risk of stroke, ‘oh yes I looked at that and I scored 
myself as two’ and then I say ok look, there are these drugs that 
we can give to you and there is the risk so… In some ways it 
makes an advantage, but certain times, they ask ‘yes I have read’ 
or ‘I’ve seen on the internet, you know, that you can give (Nilan, 
General physician) 
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5.4 Conclusion 
The lived experiences of physicians (consultant cardiologists, consultant 
general physicians, general practitioners and cardiology registrars) during their 
consultations with patients who were diagnosed with AF and the physicians’ 
experiences with OAC prescription were explored. The medical consultation 
model that seemed to transpire from the interviews with the physicians, was 
similar to a shifting paradigm. The initial section the consultation focuses on a 
patient-oriented communication style where physicians aspired for patient 
adherence. Good and effective communication skills were imperative during 
this part of the medical consultation. Assurance and patient education was also 
critical; this was enhanced with communication aides such as drawings of the 
heart and the use of metaphors. However, the use of drawings or the use of 
statistical figures was an individual preference in physicians, with general 
physicians opting not to use drawings to explain AF (however they pointed out 
that they do use pictorial aids for other conditions) and cardiologists and 
registrars mostly mentioning percentages to patient. General practitioners were 
especially adept in assuring patients, mostly due to the fact that they might 
know the patient from before and thus may have a stronger or more familiar 
patient-physician relationship. 
 
In line with a shifting-paradigm model, the second part of the consultation 
revolved around decision making. During this part, the consultation, adopted a 
physician focused communication style where physicians took the decisions, 
focused on maximising compliance and used a paternal style where patient 
wouldn't adhere, also to expedite consultation; even though all the physicians 
commented that they try to have a shared decision making process. Physicians 
in different specialties used various methods to influence the patient into 
agreeing with their choice for treatment, such as when some cardiologists used 
the hope from new drugs. Physicians also highlighted the benefits and 
minimised the risk of warfarin. Some of them also admitted that they sometimes 
end up taking the paternal route either because of patient trust or because the 
physician feels the patient would not adhere to medication. In addition even 
though general practitioners interviewed commented that in their practices they 
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offer blood monitoring services, all of the general practitioners mentioned that 
they refer patients to secondary care rather than taking the decision to 
commence OAC.  
 
During the interviews, the cardiologists and registrars indicated that they keep 
themselves updated with current research in their field. General physicians 
although knowledgeable about risk scores, such as the CHADS2 score, 
commented that they also need to be knowledgeable about other non-
cardiology related issues which makes it harder for them to be aware of new 
guides. Similarly general practitioners expressed their lack of knowledge on AF 
and OAC, highlighting their concern in trying to adhere to AF guidelines. 
 
Although physicians in this study have gained a lot of experience on how to 
tackle patient concerns during the years, they still discussed some challenges 
that they face when prescribing warfarin. These challenges could be 
categorised as their interpretations of patient related concerns, and the 
challenges that they, as professionals face. All physicians from different 
specialties commented that the major challenge they experience, especially 
with a first time patient where they need to be educated on AF and OAC, was 
time. They commented this was a challenge not only with regards to AF and 
OAC but also transferable to the healthcare system as a whole. Physicians also 
discussed language barriers and how the use of a translator impinged on the 
transfer of knowledge and shared decision making.  
 
Physicians also interpreted the challenges and concerns that from their 
experience, patients routinely faced. All physicians mentioned that they believe 
their patients were concerned about the monitoring, the side-effects and the 
interactions of warfarin. In addition they explained how patients’ experiential 
knowledge (knowledge gained through their own experiences) or ‘a priori’ 
knowledge (knowledge gained before from other sources) of strokes and 
bleeds influenced their decision to accept or refuse warfarin. 
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Chapter 6: Discussion and Conclusion 
6.1 Introduction 
This study explored the patients’ and physicians’ experiences of AF and OAC. 
To reach these aims, the programme of work was divided into two interlinked 
studies. One study focusing on the patients’ experiences and another study 
focusing on the physicians’ experiences. This chapter intends to draw the 
findings of the two studies together and compare them to the literature (see 
Chapter 1) and the findings from the meta-synthesis (see Chapter 2). In 
addition, the strengths and limitations of the study will be discussed. Reflexivity 
during data collection and data analysis will also be outlined followed by future 
research and practical recommendations based on the findings of this 
programme of work. 
 
6.2 Summary of the key findings from the patients’ and physicians’ 
experiences 
6.2.1 Communication within the consultation 
The experience of the initial consultation was explored with both patients and 
physicians. Some symptomatic patients expressed concern when they first felt 
the AF symptoms, as they thought it was a heart attack. However they all 
experienced relief during their initial consultation where they said that their 
physicians told them it was not a heart attack. This finding was confirmed 
through the physicians’ experiences as they also pointed out that they believed 
their patients were initially worried that they were going to have a heart attack. 
In addition physicians commented that a critical component of the AF 
consultation was to provide assurance to the patient that it was not a heart 
attack and that the condition could be managed. The continuous relief resulting 
from the physician assurance and reassurance during the consultation was 
similarly confirmed in patients’ accounts.  
 
All physicians explored the importance of patient education during the 
consultation. However, this was an issue that patients still felt was lacking in 
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the AF consultation, especially the absence of take home educational 
materials. Another key difference in experience between the patients and 
physicians was the perception of the approach taken during the decision 
making process. Most patients commented that they perceived the approach 
taken by the physician during the AF consultation as a paternalistic approach to 
decision making, where they believe the physician took all the decisions without 
involving them, sometimes without giving them any alternative. Their perception 
of the paternalistic approach was the most influential reason why patients both 
accepted and refused OAC treatment for AF. Some patients also commented 
that they preferred the physician to take the decision as he/she was the expert. 
These patients also pointed out that they made sure to let the physicians know 
their opinions if they did not agree. Physicians explained how they tried to take 
a shared approach to decision making, however they admitted that because of 
external factors, such as available time, language barriers or patient trust in 
them as the expert, physicians ended up taking a paternalistic approach. 
Physicians’ continuous use of the word compliance during this study, denoted a 
lack of awareness of the connotation of the word and its association with a 
paternalistic approach to the consultation.  
 
6.2.2 Emerging challenges from the patients’ and physicians’ experiences 
A crucial challenge that was reported by both patients and physicians was the 
perception of time within the consultation. Some patients reported that they 
were dissatisfied with the way their consultation was managed and felt that 
more time was needed with the physician so that they could be more 
adequately informed about their condition. In contrast patients who were 
satisfied with their consultation did not perceive the need for extra time. Some 
physicians also pointed out that the lack of time available with the patient was a 
challenge to their practice. They argued that in secondary care there is limited 
amount of available time that can be spent with a patient. This lack of time also 
had an impact on the amount of education imparted to the patients and the 
choice of approach taken to decision making. General practitioners also 
reported that time constraints were a challenge however in primary care they 
had an advantage over secondary care as general practitioners said they were 
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in a better position to have follow-up appointments with patients, albeit at the 
patient's request. Through these follow-ups, they argued that patients were 
given more time to reflect on their discussions and come back with concerns. In 
addition, follow-ups increased continuity which in turn were perceived as critical 
in increasing the physicians’ knowledge of the patient and in ameliorating the 
relationship with their patient. Some patients also commented that they had a 
better relationship with their general practitioner and the health professionals in 
the INR clinics. Physicians in secondary care (cardiologists, registrars and 
general physicians) commented that this continuity of care was often lacking in 
their practice. General physicians and general practitioners also pointed out the 
challenges in following clinical guidelines. They commented that there was a 
need to educate non-specialist physicians through simpler guidelines that 
highlight what steps physicians in different specialties should take.  
 
Patients in this programme of work also commented on how OAC influenced 
their QoL. Similarly, physicians presented their beliefs of what influences 
patients’ QoL. A common influence reported by physicians and confirmed in 
patients’ experiential accounts was the influence of repeated INR testing on 
QoL. Some patients commented that they perceived INR tests as an 
inconvenience. Some patients even added that because monitoring was going 
to affect their overseas travel plans, they decided to discontinue OAC. In 
addition, patients felt that INR monitoring incurred a financial burden to them 
through the increase of hospital parking charges. However, other patients, 
especially patients who lived alone or were satisfied with their treatment, 
commented that they enjoyed the INR clinic because they perceived it as a 
social activity. Another aspect of OAC’s influence on QoL that both patients and 
physicians mentioned was the interaction warfarin has with certain foods and 
drugs. However while physicians believed this was a major issue for patients, 
patients suggested that they were not concerned by food interactions. The 
other impact OAC had on patients was bleeding and bruising. Physicians 
believed that patients were concerned about the increased bruising and 
bleeding risk incurred from taking warfarin. Some patients pointed out their 
concerns about bruising and others even mentioned that this could have had 
an impact on their social life since they were still working. Patients, who had 
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past experiences with bleeds, either when a significant other had a bleeding 
episode or during travelling, commented how this negatively influenced their 
perception on warfarin. Patients' understanding of warfarin and aspirin varied 
considerably. Warfarin was described by patients as an old (therefore unsafe) 
drug which is usually prescribed when a person is near the end of life, while 
aspirin was described as an old (therefore safe because it is tried and tested) 
natural drug. This clearly demonstrated that other significant factors, like past 
experience and influence from the media, played a role in patients' beliefs 
about two similarly old medications. 
 
6.3 Communication within the consultation 
6.3.1 Physicians’ and patients' experience of reassurance   
Both patients and physicians commented about the importance of assurance 
and reassurance during the AF consultation. Physicians from all groups in this 
study commented that patients needed to be reassured through appropriate 
communication to minimise the initial anxiety of the patients. This study further 
confirmed the findings of McCabe et al. (2011b) where symptomatic patients 
commented on their relief on being diagnosed with AF. Building rapport with the 
patient and adopting a patient-centred communication style was a useful 
method for physicians in this study to alleviate illness concerns and increase 
reassurance (Kessel, 1979). Physicians believed that this was achieved by 
ensuring that the patients' thoughts and fears had been adequately addressed, 
thereby conveying to the patient that they had been heard and understood.  
 
However, even though assurance may appear successful during the medical 
consultation, once the patient leaves the medical environment they may be 
influenced by a number of social factors that present obstacles to reassurance 
(McDonald, Daly, Jelinek, Panetta, & Gutman, 1996). Media stories concerning 
health threats have become commonplace, especially with regards warfarin 
and its previous use as rat poison. This can have the effect of undermining 
individuals’ perception of their own health, heightening vigilance for symptoms 
and increasing the likelihood that symptoms will be interpreted negatively 
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(Barsky & Borus, 1995). The influence of media on OAC treatment perceptions 
will be discussed later in this chapter. 
6.3.2 Education within the consultation 
All physicians in this study reported that they tried to engage patients in an 
educational approach to help them understand AF and OAC. Confirming 
previous studies and the findings of the meta-synthesis, the majority of patients 
in this study wanted more education about AF and OAC than they were 
typically provided with (Audit commission for local authorities and NHS, 1993; 
Benbassat, Pilpel, & Tidharet, 1998; see Chapter 2). Furthermore, although 
knowledge was acquired, it was not necessarily understood. Similarly some 
physicians in this study showed concern about how much patients actually 
remembered from the information given to them during the consultation. 
Likewise, the patients often perceived the consultation as lacking an adequate 
educational component. This was highlighted in Ley's (1992) work, that patients 
have gaps in understanding and recall following face-to-face consultations. 
Knowledge acquisition does not necessarily transpose to understanding. The 
acquisition of knowledge is multi-layered and may not be attained by one 
educational session (Ley, 1992), a finding which is supported by the present 
study. One example is where general practitioners pointed out that they could 
have an advantage over secondary care. Time could also be a measureable 
denominator to ascertain whether the knowledge had been acquired (Mazor, 
Baril, Dugan, Spencer, Burwinkle, & Gurwitz, 2007). The effects of time will be 
discussed in a separate section. 
 
Doctors in this study, like Melanie, commented on the patient’s ability to recall 
information after the consultation. Doctors in secondary care argued that since 
they have limited availability for follow-ups, patients receive large amounts of 
new information and medical advice at a single consultation. In order for 
patients to adhere to this advice, they must be able to recall it afterwards; 
however, similar to several studies, doctors in this study have shown that most 
patients do not fully understand or memorize it. Lack of understanding and 
recollection reduces patient satisfaction and commitment to treatment (Kessels, 
2003; Watson & McKinstry, 2009). Recall is also affected by the use of medical 
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terminology (which is sometimes difficult to understand), the form of the given 
information (oral or written), and patients' expectations and level of education 
(Jansen, Butow, van Weert, van Dulmen, Devine, & Heeren, et al. 2008; 
Watson & McKinstry, 2009).  
 
Recollection of information also declines with age (Kessels, 2003), with older 
people being less able to recall information successfully (Watson & McKinstry, 
2009). The association between intelligence and recall has not been shown to 
be significant, but a higher level of medical knowledge was associated with 
better recollection (Kessels, 2003; Safeer & Keenan, 2005). Memory and 
anxiety levels are connected to recollection in an inverse U curve: there is 
significantly better recollection at a moderate level of anxiety than at low or high 
levels of anxiety (Kessels, 2003; Jansen et al., 2008; Safeer & Keenan, 2005). 
There also seems to be an association between the amount of information 
given and how much is recalled; the more information is provided, the more is 
lost (Safeer & Keenan, 2005).  
 
The effectiveness of different ways of introducing information (i.e. written, oral, 
pictorial) has also been studied. Some studies have shown that the use of 
pictorial instructions is beneficial (Jansen et al., 2008; Watson & McKinstry, 
2009), although this has not been supported by others (Kessels, 2003; Watson 
& McKinstry, 2009). The combination of oral and written advice appears to be 
the most effective (Jansen et al., 2008; Watson & McKinstry, 2009). Written 
information was more commonly reported to have been used by general 
practitioners in this study, which could play an important role in knowledge 
acquisition, to serve as a reminder of what has been discussed or to provide 
more detailed information. In addition, findings in this study confirm Mazor et al. 
(2007) that on-going educational support sessions are required, however, 
according to participants in this study, this does not occur in clinical practice. 
Research also indicates that patients are more passive in consultations than 
they intend to be (Harrington, Noble, & Newman, 2004). This was sometimes 
found to be the case in the experiences of patients in this study. For example 
although Lionel had concerns about warfarin, he did not voice these concerns, 
similarly Daniel took on a passive attitude during the consultation as he 
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believed in the expertise of the physician. Improving patient participation in 
consultations was shown to improve outcomes (Harrington et al., 2004).  
 
Similar to previous qualitative studies (see Chapter 2), patients highlighted the 
need for educational material. However provision and production of educational 
material were not without limitations (Audit commission for local authorities and 
NHS, 1993; Eysenbach, Powell, Kuss, & Sa, 2002). Patient focus groups have 
reported a number of problems with written information, such as omission of 
topics of importance to them, over-optimism, and avoidance of uncertainty and 
lack of detail (Coulter, Entwhistle, & Gilbert, 1999). Feedback from patients is 
not commonly sought when written materials are being prepared, despite the 
use of techniques such as lists of ‘frequently asked questions’.  
 
The literature on patient leaflets was examined by Dixon-Woods (2001), who 
identified two discourses: a ‘patient education’ theme, where patients are 
perceived as passive recipients of information and healthcare in general; and a 
‘patient empowerment’ theme, which takes into account patients’ priorities and 
promotes active participation in decision-making. Physicians’ accounts shown 
in this study are more congruent with the former discourse, where patients 
were believed to passively absorb information given to them (Dixon-Woods, 
2001). General practitioners however commented on the importance of making 
sure that patients understood what is being given to them, which conforms 
more to the latter of the discourses found by Dixon-Woods (2001). Dixon-
Woods (2001) argued that the majority of patient leaflets serve a biomedical 
agenda, by aiming to save time in the consultation, increase staff’s motivation 
towards patient interaction and promote behaviour changes desired by 
professionals, such as compliance. Other investigators have concluded that 
written materials may serve professional or commercial agendas, such as 
encouraging an uncritical approach to treatment (Kenny, Wilson, Purves, Clark, 
Newton, Newton, et al., 1998). However, Coulter et al. (1999) made a series of 
recommendations for the preparation of written materials, which included 
involving patients throughout the process, being honest about uncertainty and 
risks, and educating clinicians about techniques to promote shared decision-
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making, such as using educational leaflets in aiding physicians to elicit 
questions from patients regarding treatment (Ehrenberger, 2001). 
 
6.3.3 Communicating risk  
Cardiologists and registrars in this study commented on the use of numerical 
information within their consultation.  Much discussion of risk communication 
has centred on how numerical probability information should be presented 
(Calman & Royston, 1997; Edwards, Elwyn, Mathews & Pill, 2001; Edwards, 
Elwyn, & Mulley, 2002; Edwards, Unigwe, Elwyn, & Hood, 2003; Paling, 2003). 
However, there are differences between estimates of actual risks, as calculated 
from mortality statistics and how patients perceive these statistics (Lichtenstein, 
Slovic, Fischhoff, Layman, & Combs, 1978). These include a tendency to 
under-estimate the frequency of large risks and over-estimate small risks, 
especially when there is a lack of knowledge on the subject, for example the 
overestimation of the associated risks of bleeding and underestimation of the 
stroke risk during clinical practice in OAC for AF (Boulanger, et al., 2006; Lane 
& Lip, 2008a; Pugh et al., 2011; Taggar & Lip, 2008; Tay et al., 2009).  
 
Providing information about the probability of health risks alone only has a 
small influence on how people think about those risks and on their risk-related 
behaviour. Rothman and Kiviniemi (1999) argue that that people find difficulty 
in understanding and interpreting numerical probability statistics. However, 
some physicians in this study commented that there might be an association 
between how patients perceive medical risk and how they perceive lottery 
probabilities. Meta-analyses of studies investigating the effects of fear-rousing 
communications show that perceptions of vulnerability have on average a small 
effect on intentions to change behaviour and on concurrent and subsequent 
behaviour (Floyd, Prentice-Dunn, & Rogers, 2000; Milne, Sheeran, & Orbell, 
2000; Witte & Allen, 2000). Reasons for the lack of influence on patients might 
include difficulty following the logical sequence of probabilities during a 
consultation and in evaluating risk without supplementary information.  
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When people receive probabilistic risk information, it can be difficult to evaluate 
this, if they have nothing against which to compare it (Roth, Morgan, Fischhoff, 
Lave, & Bostrom, 1990). People need additional information to clarify the 
implications of absolute risk information. This includes the risk that others 
similar to them have, or their own risk if they were to adhere to recommended 
medical advice (Roth et al., 1990). Thus, when asked what information they 
want in order to understand a health risk, people typically ask for comparative 
information about the probability of other risks (Roth et al., 1990). Presenting 
information about relative risks generally has more impact on perceptions of 
likelihood, emotion and decision-making, than information about absolute risks 
(Edwards et al., 2001; Nexoe, Gyrd-Hansen, Kragstrup, Kristiansen, & Nielsen, 
2002).  
 
Changes both within and outside of healthcare have resulted in an increasing 
emphasis upon providing services in ways to facilitate patients making informed 
choices. Core elements of definitions of informed choice are an understanding 
of the different options and their likelihoods (Bekker, Thornton, Airey, Connelly, 
Hewison, Robinson et al., 1999; Marteau, Dormandy, & Michie, 2001). Despite 
understanding being a central outcome to risk communication, there have been 
few attempts to define what it means to understand a risk (Weinstein, 1999). In 
addition, although studies have shown that fewer patients opt for OAC when 
presented with statistical information in decision aids (Fuller et al., 2004; 
Holbrook et al., 2007; Howitt & Armstrong, 1999; Man-Son-Hing et al., 1999; 
Protheroe et al., 2000; Thomson et al., 2000) (see Section 1.4.1.4.1), there is 
no persuasive evidence that patients understand risk in OAC for AF.   
 
A general framework for selecting the appropriate strategy for communicating 
risk information and supporting decisions has been developed (O’Connor, et 
al., 2003). According to this framework, the most appropriate risk 
communication strategies depend upon whether patients are faced with 
decisions concerning either ‘effective’ health services, where there is firm 
evidence of benefits that greatly outweigh limited harms (e.g. in OAC where the 
reduced risk of stroke outweighs the increased risk of bleeding), or ‘preference-
sensitive’ health services, where benefit is unclear relative to harm (O’Connor 
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et al., 2003). Where clinicians are discussing ‘effective’ health services with 
patients, consultations surrounding risk may be more direct and concern 
motivations and barriers to change. On the other hand, where clinicians are 
discussing ‘preference-sensitive’ health services, counselling is non-directive, 
including discussions of potential benefits and harms, probabilities and options. 
This was similar to the approach adopted by physicians in this study in order to 
influence patients to accept OAC treatment (i.e. highlighting the benefits of 
warfarin). Health communication aimed at educating AF patients on OAC risks 
should aim to provide a clear and simple explanation of these risks, and also 
needs to be accompanied by an explicit plan concerning how OAC treatment 
works in reducing stroke risk (Sheeran, 2002).  
 
6.3.4 Decision making in OAC for AF 
In line with the meta-synthesis (see Chapter 2), the present study found that 
patients and physicians’ experiences of decision making differed. Only one 
patient, Fiona, commented that she accepted warfarin on the basis of a more 
shared information process, i.e. through discussing the pros and cons of 
warfarin. Other patients, both in the accepted and refused group commented 
on their perception of the paternalistic attitude of the physicians. Patients who 
accepted OAC felt that either they were not given any alternative to warfarin, or 
the physician took the decision himself or the patient accepted OAC out of trust 
in the expert. Similarly, patients refused OAC either because they felt that the 
physician did not give them enough information or because of the belief that the 
physician did not have their best interest in mind,for example during Greg’s 
consultation he perceived his physician as pushing him towards participating in 
a trial where he could keep on his drinking habit rather than telling him to 
minimise his alcohol consumption.Physicians on the other hand commented 
that they tried to maintain a shared decision style; however some did mention 
that they ended up taking decisions themselves because patients put trust in 
them. Classical sociological research has shown that patients and physicians 
can have different perspectives of a clinical encounter (Freidson, 1970; Mishler, 
1984; Silverman, 1987) and that patients make sense of their clinical 
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experience in the context of their own views and beliefs (Blaxter, 1983; Eyles & 
Donovan, 1990; Williams & Calnan, 1996).  
 
Furthermore, similar to findings in the meta-synthesis, this study found that 
reports of a paternalistic decision-making style were accompanied with a high 
level of trust in the medical expertise of the physician (see Chapter 2). 
Relationships with health professionals were an integral part of OAC treatment. 
Patients judged these relationships from an ability to trust, communicate and 
connect with the physician. In addition, some patients, such as Josephine, did 
report their general practitioner’s ability to be inclusive of their values and 
perspectives. Patient participants highlighted that long-term relationships 
demonstrating trust and respect increased their confidence in their physician. 
Research has shown trust to be essential to patients and that it is strengthened 
by regular contact and communication (Pullon, McKinlay, Stubbe, Todd, & 
Badenhorst, 2011). In light of this, general practitioners working in primary care 
had an advantage over hospital physicians (cardiologists, general physicians 
and registrars). General practitioners were in a better position to give more time 
or several consultations to patients to reflect on their discussions through 
follow-ups and also to provide continuity of care. In contrast, hospital 
physicians tended to see patients only once or twice and they only had a 
limited time in which to build trust and rapport with the patient. Trust in the 
physician in the case of secondary care was based on the physician being 
seen as the expert, rather than built through time and rapport like in general 
practitioners. 
 
This was also seen in the physicians’ choice of analogies within the 
consultation. Similar to previous literature, findings in this study show that 
doctors are conscious of using metaphorical analogies with patients, and may 
indeed have one or two well-tried analogies (Olweny, 1997; Skelton, Wearn, & 
Hobbs, 2002). Metaphors are acknowledged as playing a part in the 
construction of theory (Harman, 1994) and in the often pictorial and aesthetic 
imagination at work in, for example, the labelling of things (Banville, 1998). 
Participants’ more literal use might casually be interpreted as a medical attempt 
to repackage the body as the mechanical. For example the doctors’ 
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representation of the patient’s body as a house that needs attention to its 
wirings. Nevertheless, on the whole, a central difference between doctors and 
patients appears to be that doctors use a greater frequency of metaphors to do 
with machines. Similarly, doctors talk of themselves as solvers of problems and 
controllers of illness, or the mechanics that are there to fix the car, metaphors 
which hint at knowledge and power (Olweny, 1997; Skelton et al., 2002). Such 
use of metaphors creates an imbalance of power within the consultation that in 
turn promotes a paternalistic approach.  
 
 
6.3.5 Adherence vs. compliance 
This study also highlights the need to change the language used to signify the 
nature and outcome of patient-physician relationships, i.e. whether patients 
understand their diagnosis, take appropriate medication and have the 
knowledge to self-manage long-term conditions like AF. Physicians in this 
programme of work often used the word ‘compliance’ to describe how patients 
accept and follow treatment instructions set out by them. Compliance is 
commonly defined as the extent to which the patient’s behaviour matches the 
physician’s recommendations (Haynes, Taylor & Sackett, 1979). Although the 
term compliance is commonly used in the medical and pharmaceutical 
literature, it has been criticised because of its negative connotations in terms of 
the power difference between the health professional and patient within the 
consultation (Stimson, 1974). Compliance denotes a relationship in which the 
role of the physician is to decide on the appropriate treatment and issue the 
relevant instructions, whereas the role of the patient is to passively follow ‘the 
physician’s orders’. Although during the first part of the consultation physicians 
do seem to adopt a patient centred approach, aiming for adherence, the aim 
during the decision making process, as explored before, was more in line with 
the definition of compliance. Within this connotation, non-compliance may be 
interpreted as a patient’s incompetence in being unable to follow the 
instructions, or worse, as deviant behaviour. This was also corroborated in the 
some of the patients’ perceptions of the consultation, where patients felt they 
did not have any alternative but follow the physicians’ decisions. The term 
 249 
 
 
adherence, on the other hand, has been adopted by many, particularly within 
the psychological and sociological literatures, as an alternative to compliance, 
in an attempt to emphasise that the patient is free to decide whether to follow 
the prescriber’s recommendations and that failure to do so should not be a 
reason to blame the patient (Barofsky, 1978; Delamater, 2006; Meichenbaum & 
Turk, 1987). Adherence develops the definition of compliance by emphasising 
the need for agreement and may be defined as, the active, voluntary and 
collaborative involvement of the patient in a mutually acceptable course of 
behaviour to produce a therapeutic result (Delamater, 2006; Meichenbaum & 
Turk, 1987)..  
 
In view of the physicians’ experiences, although they used the word, 
compliance, their meaning suggested they aimed for adherence, and indeed 
concordance. Physicians’ accounts show that they worked along a sliding 
continuum between compliance-adherence-concordance, however their aim 
was to use concordance, i.e. give patients adequate information and 
opportunity to empower patients to make their own decision. However, they 
sometimes resorted to a model of compliance by ‘advising’ the patient what 
they thought they should do.  
 
 
 
6.4 Challenges that have an influence on OAC for AF 
6.4.1 Time within the consultation 
This study supports previous literature with regards the perception of the lack of 
time in the consultation as a health-care system barrier for OAC prescription 
(see Chapter 2). Quantitative surveys (Airey, & Erens, 1998; Williams & 
Calnan, 1991) and qualitative research (Pollock & Grime, 2002) indicate that 
many patients would like more time with their physician. Patients often want 
longer consultations but are aware of time constraints and are anxious not to 
waste their physician’s time (Pollock & Grime, 2002). Time constraints may 
lead to patient dissatisfaction and thus to non-adherence. This problem of 
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patient dissatisfaction has been addressed in two ways. Some researchers 
have addressed the actual length of the consultation (Freeman, Horder, Howie, 
Hungin, Hill, Shah, et al., 2002; Howie, Heaney, Maxwell, Walker, Freeman & 
Rai, 1999; Shah, 1999; Wilson & Childs, 2002).  This has led to either a call for 
longer consultations (Freeman et al., 2002; Howie et al., 1999; Shah, 1999; 
Wilson & Childs, 2002) or a proposal to change the allocation of time via the 
introduction of new technologies and more flexible practice management 
(Freeman et al., 2002; Wilson & Childs, 2002). Patients and physicians in this 
study confirmed the former, when they recommended that the consultations 
should be longer to allow more time for discussion. 
 
These solutions have drawn upon the evidence that longer consultations are of 
higher quality and are associated with a range of better patient outcomes 
(Howie et al., 1999; Wilson & Childs, 2002) and recognition that each patient’s 
problem requires a different amount of time for appropriate management, which 
was also pointed out by some physicians in this study.  
 
In contrast, others have focused on how the time is spent. From this 
perspective, it has been argued that rather than simply extending the length of 
the consultation, the time available should be managed more effectively. For 
example, Mechanic (2001, 2002) suggested that a change in the process rather 
than the length of the consultation could reduce such patient dissatisfaction, 
stressing the importance of ‘meaningful time’. He also indicates that patient 
dissatisfaction with time remains high in the United States even though actual 
consultation length is twice that in the United Kingdom. This could also be 
related to the difficulty for health care access in the US, as it is operated by a 
privatised system, (i.e. patients usually need to pay some form of health 
insurance to get “free” health care) while in the UK, the NHS is free at the point 
of need. The fact that US patients have to ‘pay’ for their health care could have 
an influence their satisfaction. Similar to Mechanic (2001, 2002), Cape (2002) 
concluded that patients’ perception of time was a better predictor of satisfaction 
than actual time, suggesting a role for each patient’s perceptions and 
experience.  
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Findings in this study support previous studies that patients are dissatisfied with 
their consultation time (Williams & Calnan, 1991; Airey, & Erens, 1998). They 
also indicate that physicians show flexible time management and allocate more 
time where a problem requires it, such as in cardiologist Melanie’s experiences. 
This could indicate that some patients, such as those undergoing initial 
consultations, require more time so that their emotional needs can be met, 
which in turn would allow for greater concordance. This approach is in line with 
research which has addressed patients’ desire for more time by changing the 
actual time patients receive (Howie et al., 1999; Shah, 1999; Freeman et al., 
2002). 
 
An alternative explanation considers the desire for more time as a reflection on 
the content of the consultation. In line with this approach, the results from the 
present study indicate that if patients have their emotional needs met, feel 
listened to and understood, such as in Fiona’s experience, regardless of the 
actual time spent with the physician, they are satisfied not only with the process 
of the consultation but also with the consultation length. Furthermore, they then 
may feel more likely to adhere to the treatment. Accordingly, the desire for 
more time highlights the sense of dissatisfaction with how the time has been 
spent rather than how much time they received. This explanation provides 
empirical support for the concept of ‘meaningful time’ spent in the consultation 
(Mechanic, 2001, 2002). According to this argument, if physicians wish to leave 
their patients feeling satisfied with the time they have given to them, then 
maybe rather than giving them increasing amounts of time they need to 
consider how that time is spent. They can create the sense of more time 
through the process of listening and understanding rather than the reality of 
more time which remains dissatisfactory because it is filled with medical facts 
and information. 
 
6.4.2 Physicians’ adherence to guidelines 
All physicians in this study were aware of existing NICE guidelines on the 
management of AF. However not all general practitioners were knowledgeable 
of the updated European Society of Cardiology clinical guidelines by Camm et 
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al (2010). Conforming to previous studies, general physicians and general 
practitioners commented on the difficulty in adhering to guidelines as real-world 
patients are different from participants recruited in randomised-controlled trials 
with narrow inclusion criteria (Carlsen et al., 2007; see Chapter 2). 
Furthermore, all general practitioners in this study preferred to refer patients to 
secondary care for OAC initiation, supporting the lack of confidence in OAC 
prescription highlighted in previous studies (Boulanger, et al., 2006; Lane & Lip, 
2008a; Taggar & Lip, 2008; Tay et al., 2009; see Chapter 2). This could be a 
result of the fear of jeopardising the relationship with the patient or the fear of 
causing harm to the patient from the wrong decision to treatment (Carlsen et 
al., 2007). Another reason for the referral to secondary care might be the belief 
that cardiologists are more knowledgeable (Ayanian et al., 1994) or the belief 
that the involvement of more physicians, regardless of specialty, may result in 
higher quality care (Choudhry et al., 2006; Rutten et al., 2003). General 
practitioners and general physicians, conforming to findings in the Carlsen et al. 
(2007) study, argued that guidelines needed to be short and simple and 
focused to the particular specialty level of the physician. 
 
6.4.3 Influence of AF and OAC on patients' QoL 
Patients on this study explored the impact that AF and OAC had about their 
quality of life. Some patients, such as Will, commented that symptoms from the 
fast AF had a major impact on his life, so much so that he could not sleep lying 
down. Although Will’s experience was unique among the patients interviewed in 
this study, there are undoubtedly other patients that had similar experiences. 
Such experiences were also reported by patients in McCabe et al.'s (2011b) 
study, who commented that patients were distressed by the symptoms brought 
about from AF. The overriding desire to obtain normality and thereby sustain 
QoL was dominant for Will. In addition to that Will lived in a mental health 
nursing home under constant supervision, which made him feel depressed. 
Literature shows that emotions have an influence on symptom perceptions 
(Sarafino, 2006). Furthermore, the more attention a patient gives to the 
symptom, the more feelings of anxiety are elicited (Broadbent & Petrie, 2007). 
In turn, anxiety will influence patients by making them more mindful, in which 
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case they will scan themselves and the environment for any potential threat, 
thus becoming trapped in a vicious circle (Bar-Haim et al., 2007). This vicious 
circle may have had an impact on Will refusing OAC. His main aim was to 
overcome the symptoms of AF but since OAC treatment was not going to 
change his ‘cure’ beliefs (Leventhal et al., 2003) regarding his perception of AF, 
he refused treatment. This finding was similar to previous literature explored in 
the meta-synthesis (see Chapter 2). Concurring to Horne (1997), although the 
patients’ beliefs and knowledge of OAC side effects and the need for lifestyle 
change, outweigh the need for the use of the medication in the reduction of 
thromboembolism.  
Warfarin is a complex medication that requires lifestyle changes that can be 
perceived as restrictive by some. Patients and physicians in this study 
confirmed previous findings on the influence of OAC on the patients’ lived 
experiences (Bungard et al., 2000; see Chapter 2). Fiona and Jonas 
commented that OAC did not have an impact on their QoL, whilst others such 
as Lionel or Raj commented how they perceived INR monitoring as an 
inconvenience. Previous studies showed that OAC patient related barriers 
included the influences from diet restrictions and regular INR monitoring (blood 
tests). The present study found that with regards to diet physicians’ 
interpretations of patient concerns did not match the patients’ actual 
experiences. Physicians commented that patients found the limitations to diet 
challenging, which confirms previous research findings (Bungard et al., 2000; 
see Chapter 2), however, although patients in this study mentioned that OAC 
had limited their choice of vegetables, they did not feel it had a significant 
negative influence on their QoL and did not impact their decision as to whether 
they accepted or refused OAC. However, patients’ accounts of their dietary 
concerns showed that their knowledge of the dietary influences of vitamin K on 
warfarin was limited, for example Fiona was still unaware of dietary interactions 
when she mentioned that she cannot eat broccoli and that INR would be 
tailored to each individual.  
 
Similar to previous studies, another drawback that patients and physicians 
commented on was the impact of regular OAC monitoring on their QoL 
(Bungard et al., 2000; see Chapter 2). Patients, like Lionel, commented that for 
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him time was of utmost importance to his QoL and he felt that because of OAC, 
it was taken away from him. Raj also commented on the impact of blood 
monitoring OAC on his and his wife’s QoL. Travel, while still undertaken, was 
regarded as bothersome and unsafe on OAC. Raj commented how his 
experiences, when he and his wife saw a patient bleeding in India during his 
travels, influenced his treatment beliefs about the consequences of OAC 
(Leventhal et al., 1984) and bleeding. Further, the change in his treatment 
beliefs also had an impact on his QoL, thus influencing him to discontinue OAC 
treatment. In addition, patients or their carers who were present at the 
interview, like Raj’s wife, expressed their fear in their accounts, when they 
associated the need for INR monitoring with the lack of safety in warfarin. This 
was not reported in other studies. Similarly previous studies have not explored 
the emotional support and the inevitable impact on patient-health professional 
relationship that some patients experienced from repeated monitoring sessions, 
like for Jonas. Jonas explained how he lived alone with his dog after taking 
care of his mother for 17 years when she had a stroke. In his anecdotes Jonas 
points out his rapport with the nurse at the INR clinic, and how going to the INR 
clinic is more of a social event rather than an inconvenience. In addition, 
another aspect of OAC monitoring that was not explored in previous studies is 
the financial burden. Both physicians and patients reported dissatisfaction with 
costs incurred from travelling and hospital parking associated with OAC 
monitoring, especially for pensioners. 
 
This study also highlighted the lack of support by employers who are not well-
informed about OAC. For example Josephine commented on the lack of 
support she received at work after her TIA and Robert commented that he 
could not take time off from his work. In Josephine’s experience, this could 
have influenced her in refusing OAC on the basis that her employers would not 
understand the need for blood monitoring. No study has yet explored the issue 
of support from employers with patients with OAC and how this has impacted 
on its long-term management. In addition, this study told of the support patients 
received from family, e.g. Lionel and Fiona. Health psychology research has 
shown consistently that social support has powerful effects on both 
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psychological and physical wellbeing (Cohen & McKay, 1983; Cohen & Wills, 
1985).  
 
6.4.4. Impact of family members and interpreters on the consultation 
Doctors and patients in this study commented on the presence of family 
members during the medical consultation. Evidence suggests that patients are 
accompanied by family or companions in between 20% to almost 100% of 
consultations and this raises issues about how the presence of others 
influences the process and treatment decision (Audrey, Abel, Blazeby, Falk, & 
Campbell, 2008; Ellingson, 2002; Street & Gordon, 2008; Wolff & Roter, 2008). 
 
Available research shows that companions are more frequently present in 
consultation with older, less healthy and less well-educated patients, and 
suggests that there are some practical benefits associated with companions 
attending a consultation such as provision of emotional support and information 
recall (Audrey et al., 2008; Ellingson, 2002; Street & Gordon, 2008; Wolff & 
Roter, 2008). Companions may also communicate information between the 
patient and the physician, and ask questions on the patient’s behalf, being 
sometimes described as a patient advocate or watchdog (Adelman, Greene, 
Ory, 2000; Beisecker, 1989; Ellingson, 2002; Street & Gordon, 2008; Wolff & 
Roter, 2008). This may lead to physicians giving more attention to concerns 
and topics raised by patients if consultations include significant others (Shields, 
Epstein, Fiscella, Franks, McCann, McCormick et al. 2005; Schilling, Scatena, 
Steiner, Albertson, Lin, Cyran et al., 2002). 
 
Possible drawbacks associated with the presence of companions are 
uncommon but include examples of companions discussing their own 
problems, excluding patients from the conversation with the physician or 
playing a more direct role than anticipated by patients (Greene, Majerovitz, 
Adelman, & Rizzo, 1994) 
 
Another area where physicians commented that patient-physician 
communication is interrupted, occurs when interpreters or translators are used 
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because of the multi-cultural aspect of care Birmingham. While the provision of 
interpreters potentially addresses the language barrier, studies have revealed 
problems with medical interpretation, including inaccuracy and inconsistency 
(Dysart-Gale, 2007; Flores, 2005), and confusion regarding the interpreter's 
role within the consultation (Kaufert &  Koolage, 1984). Ways in which 
physicians can work more effectively with interpreters to minimise the language 
barrier, have been identified in several studies (Abbe, Simon, Angiolillo, 
Ruccione, & Kodish, 2006; Butow, Lobb, Jefford, Goldstein, Eisenbruch, Girgis 
et al., 2012; Schapira, Vargas, Hidalgo, Brier, Sanchez, Hobrecker et al., 2008) 
and include keeping to the schedule so that interpreters' time is spent in the 
consultation, using a trained professional interpreter who is familiar with the 
terminology or area of discussion, briefing the interpreter on the case 
beforehand and discussing potential challenges, speaking directly to the patient 
rather than to the interpreter, checking patient understanding and paraphrasing, 
providing access to written information in the patient's language, and debriefing 
with the interpreter after the consultation (Abbe et al., 2006; Butow et al., 2012; 
Schapira et al., et al., 2008). 
 
 
6.4.5 Perception of warfarin vs. aspirin 
Patients in this study reflected about their perceptions of aspirin and warfarin. 
They perceived aspirin as a natural old wonder drug, while warfarin was 
considered an old drug that needed monitoring. The media had an important 
role in patients’ perceptions of these two drugs. This finding is unique to this 
study as  previous studies have not explored how media influences patient 
perceptions of OAC treatment. Lay individuals have at least two main sources 
of information regarding risk and, by extension, from which to base their 
judgments of risk: the media and interpersonal networks (Frewer, Miles, & 
Marsh, 2002). Interpersonal networks are, by their nature, idiosyncratic and 
dependent on the lived experience. By contrast, information provided through 
media sources may well lead to systematic over- or underestimates. For 
example research has shown in classical studies that individuals’ estimates of 
causes of mortality were not correlated with actual mortality statistics, but 
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participants' estimates were strongly correlated with the frequency of print 
media reporting (Coombs & Slovic, 1979; Frost, Frank & Maibach, 1997; 
Kristiansen, 1983). 
  
Nevertheless, popular media, including newspapers, television and increasingly 
the Internet, has a role in disseminating information to the public about health 
concerns. However the way popular media frames warfarin and aspirin, 
influences patients’ perceptions of said medication. Durfee (2006) states that 
messages are constructed or 'framed' by translating scientific information for 
popular consumption. According to Entman (1993, pp.52), “to frame is to select 
some aspects of a perceived reality and make them more salient in a 
communicating context in such a way as to promote a particular problem 
definition, causal interpretation, moral evaluation, and/or treatment 
recommendation”. In short, how news is presented may influence what patients 
think about issues, people and events (Durfee, 2006). Therefore framing can 
have an influence on patients’ illness or treatment perceptions (Leventhal et al., 
1984, 2003).  
 
There are a number of ‘framing’ techniques used in media to structure issues 
such as “using certain words or phrases, making certain contextual 
references…giving examples as typical, referring to certain sources, and so on” 
(McQuail, 2005, pp. 378-379). For example similar to the patients in this study, 
a recent online article in Forbes magazine referred to aspirin as a ‘Wonder 
Drug’ (Haiken, 2012). This is consistent in newspapers, where aspirin is 
constantly positively-framed as reducing the risk for a myriad of conditions, 
including ‘cancer’, ‘tumour growth’ and even Alzheimer’s disease (BBC News, 
2002, 2003, 2006; Borland, 2012; Smellie, 2012).  
 
In contrast lay articles and newspapers mostly refer to warfarin as ‘rat poison’ 
(e.g. Hope, 2011; Laurance 2013; Kobodlt, 2010;) and all the patients 
interviewed in this study had some knowledge of warfarin being used as rat 
poison. Some patients, such as Josephine and Lionel argued that it was the 
word ‘poison’ that had a negative influence on their perception of warfarin. 
Likewise, even when the benefits of warfarin are described, these are 
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neutralised by the very act of calling it ‘rat poison’ (Hope, 2011; Laurance 2013; 
Kobodlt, 2010). Thus, as mentioned before, patients may associate the word 
‘poison’ with the identity of warfarin, and from internal cognitive schemas they 
have of the word ‘poison’, they might infer dire consequences of them taking 
warfarin. Scheufele (1999) suggests that people also develop in their minds 
what he calls ‘audience frames’ or ‘cognitive schemas’ about topics and issues. 
The way people understand the news is a function of the schemas they receive 
from the mass media. Thus patients may inherently be influenced by the way 
popular media portrays warfarin, which in turn would influence the outcome of 
their decision to refuse or discontinue warfarin.  
 
6.5 Strengths and limitations of the study 
The main strength of this study is that it is the first study to use IPA to explore 
patients’ and physicians’ experiences of the AF consultation and OAC 
management in the United Kingdom. A phenomenological perspective enabled 
the collection of detailed data that has provided an insight into the ways that 
physicians and patients perceive themselves, their relationship towards each 
other and the condition and its treatment. One-on-one interviews provided 
patients with the opportunity to talk about their feelings, to reflect on their 
experience of the consultation and the influence of OAC on their QoL after they 
accepted the treatment. In addition, the collecting of information through direct, 
face-to-face contact with the participants had several advantages over data 
collected from self-report questionnaires. Specifically, questions were more 
likely to be answered in more depth about their experience rather than 
choosing options from a predetermined list. Furthermore, participant nuances 
could be investigated and clarified through further questioning by the 
researcher. Open-ended questions also allowed for the richness and 
complexity of human experiences to emerge, where participants were given 
time to expand on their responses and the supplementary data of respondents’ 
non-verbal behaviour could also be observed.  For these reasons, the semi-
structured interviews were better in eliciting interaction and offered better 
advantages in terms of both the overall quality and the quantity of responses 
(Kvale, 1996). 
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Another asset of this study lies in its innovative bolder IPA design to analyse 
multiple perspectives. This was the first IPA study on AF and OAC that 
conducted individual interviews with physicians in different specialties 
(cardiology, general physicians and general practitioners) and at different 
specialty levels (cardiology registrars). Furthermore, this was also the first 
study that used an IPA method and conducted individual interviews with 
patients who accepted, refused and discontinued OAC for AF.  Working with 
both data sets alongside each other enabled an in depth reading of both sides 
of the health professional-patient relationship and the unpacking of the 
concepts of compliance and adherence as experienced in the consultation. The 
design was such that small homogeneous groups made up sub samples. This 
meant the commitment to idiography, central to IPA, was maintained while 
facilitating the exploration of accounts from a varied sample. In the 
development of methods, IPA is still relatively young, it is important to entertain 
creative designs (Smith et al., 2009). Indeed, rather than rigid adherence to a 
speciﬁc research design, Popay, Rogers & Williams (1998, pp.346) argue that, 
“the hallmark of good qualitative methodology is its variability, rather than its 
standardisation”. Presenting the experiences of participants from different 
groups side by side served to illustrate the complexity of the sense-making 
process, and how it can be influenced by a multitude of personal, social, or 
historical factors as well as the interactional quality of the consultation itself. 
 
 
This study is also subject to some limitations, which need to be taken into 
account. Interviews were conducted with different participants during the same 
period. The study could have adopted a serial design by first interviewing all 
patient groups and then using those data during the physician interviews to 
elicit discussion, instead of case scenarios. However, case scenarios facilitated 
discussion with physicians about their own past experiences of communicating 
with patients; whereas using patient interviews as data could have lead the 
physicians to take a defensive role in trying to reply to the patients’ perceptions.  
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It is important to consider the role of the researcher's interpretations on the 
analysis. As highlighted at the beginning of the research process, the results 
are a co-construction between the participant and the analyst (Smith & Obsorn, 
2003; Smith et al., 2009), and these findings therefore present just one 
interpretation of the data, and as emphasised above remain tentative, 
emergent, open and uncertain (Finlay, 2008). However, frequent discussions 
with the supervisory team acted as a validity check by reflecting on how the 
themes and experiences were interpreted.  
 
As discussed in the methodology chapter (see section 3.4.1) the aim of 
qualitative research is not generalisability as understood in nomothetic 
research. Nevertheless, theoretical transferability is possible (Smith et al., 
2009). In quantitative work generalizability is based on statistical assumptions, 
i.e. the study sample is matched to the target population at large ensuring 
comparability of demographic characteristics and, if done correctly, then it is 
assumed that the findings from the sample are generalizable. In qualitative 
work, however, participants are selected by means of purposive sampling, i.e. 
for their ability to provide information about the phenomenon under 
investigation. Situational, rather than demographic, representativeness is what 
is sought. It may be said, then, that generalizability in qualitative research 
refers to the extent to which theory developed within one study may be 
exported to provide explanatory theory for the experiences of other individuals 
who are in comparable situations (Smith et al., 2009). This position is 
supported by the comments of Popay et al. (1998, pp.348) on the subject of 
generalizability, who emphasize that, ‘…the aim is to make logical 
generalizations to a theoretical understanding of a similar class of phenomena 
rather than probabilistic generalizations to a population’. 
 
6.6 Reflexivity 
As with the previous reflexive account, this section will also be written in the 
first person. 
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6.6.1 Reflexivity during data collection 
6.6.1.1 Patients’ data collection 
Conducting interviews with patients was something I looked forward to since I 
had started reading about AF and OAC, I wanted to understand their side of the 
story, how they felt, what influenced them, their experiences. The first patients I 
interviewed were those who had accepted warfarin as their OAC medication. 
What I experienced during these interviews was not something I had expected. 
Even though the literature I had read showed that because of warfarin’s side-
effects, patients had some concerns, in my mind I was expecting that these 
patients would have accepted warfarin through a shared decision making 
process with their physician. However most of these patients, and later I found 
that most of the patients in the study, commented that they perceived their 
consultation as paternalistic, with the physician taking the decisions based on 
the trust they the patient had placed in them, and for some because they were 
not given any alternative. In later interviews with patients who refused warfarin, 
I also found it interesting how even in this group they mentioned that their 
perception of a paternalistic approach had an influence on them. Patients who 
refused OAC were also more difficult to invite to participate than patients who 
accepted OAC. I had to assure some of them about the aims of the study 
before the interview. Patients who discontinued OAC were the most difficult to 
recruit.  
Some patients had asked me if they could also bring their partner to the 
interviews. I had reflected about this and thought that during a normal 
consultation, significant others would sometimes be present, so I did not refuse. 
In addition having their partners present during the interviews, I felt that they 
added to the experience. I had explained that the main focus of the interview 
was about the AF patient and the experience of AF and OAC however, if they 
had something to add to the experience of the consultation they were free to do 
so as they would do during the consultation.  
 
Throughout this programme of work, this reflective journal and supervisory 
discussions were critical in helping me keep in mind that the patients’ accounts 
of their experiences during the consultation with physicians were their 
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perceptions, it is how they perceived and remembered their experience. 
Through the interviews I felt I could connect with the patients and I could 
empathise when they disclosed some of their experiences with their significant 
others. I clearly remember almost all the interviews with the patients. I think that 
sometimes their pain transferred on to me and I think it showed at times. I 
remember how Jonas told me about his mother’s experience of stroke and how 
he took care of her for 17 years and I think he could hear that I could not speak 
because of the knot I felt in my throat. Similarly, when Lionel burst into tears 
while talking about his fear that one day his partner might have to take care of a 
“cabbage” if he had a stroke, and when Fiona talked about her children. 
However there were also some positive and fun interviews. I really connected 
with Daniel, even though there was more than a span of 50 years and even 
though during his and other older patients’ interviews they sometimes went off 
on a tangent and talked about their younger days, I felt at ease. On doing past 
interviews with older people I found that this was a very good way to build 
‘rapport’ in that short period of time and that in doing so, participants felt more 
at ease in disclosing their experiences with me. At the end of the interview 
Daniel told me to “feel free to call him for a chat again”. Positive instances like 
these encouraged me during the study.  
 
6.6.1.2 Physicians’ data collection 
The first set of interviews conducted with the physicians were a bit daunting. 
The first interview was conducted with one of the consultant cardiologists and I 
felt somewhat anxious. This was something that I noticed during all the 
interviews with the consultant cardiologists. I think that this was due to the fact 
that I perceived them as the experts on AF and that I felt as if I was a young 
student in health psychology that could not offer anything more than what they 
already knew. However, this feeling subsided when I did Peter’s and Melanie’s 
interviews, probably because of the interest they showed in the study and also 
because they smiled a lot.  
 
Consultant general physicians were also happy to help with the study. 
However, like with some of the consultant cardiologist I felt I was intruding on 
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their time. One of the participants also kept on asking me how long the 
interview was going to take, even just 10 minutes into the interview. 
Interviewing general physicians I had the feeling that they struggled with the 
available time more than the cardiologists. During the interviews of both 
cardiologists and general physicians, I sometimes felt that they thought I was 
testing them on their knowledge which influenced me in explaining to the 
participants before the start of the interviews that I was not looking for right or 
wrong answers, but rather experiences, beliefs and perceptions. Another issue 
I struggled with during the interviews with physicians was to help them focus on 
their experiences rather than just evidence and facts. Case scenarios helped 
during this process. I think providing case scenarios helped the physicians 
remember their own particular cases which they sometimes discussed. 
However, before I started the case scenarios I always pointed out that I was not 
searching for a right answer but rather they were there to help them in focusing 
on their experience. 
  
Amongst all the physician interviewees, I felt most comfortable with registrars 
and general practitioners. This was probably because of the smaller age gap 
that there was between registrars and myself. I think registrars were also the 
most at ease during the interviews than the other physicians. General 
practitioners were very accommodating and made me feel comfortable. I only 
interviewed one general practitioner during his office hours, and even though 
he asked me in the beginning how long the interview was going to take, he did 
not put the same pressure on me as the general physician I mentioned 
previously. In addition, before the interviews with the other general 
practitioners, they showed me around their GP surgery.  
 
During the interviews with the physicians I had already started to notice the 
continuous use of the word compliance. Furthermore I started to notice a trend 
towards paternalism. However, I kept in mind a comment which Paul Flowers 
made during an advanced IPA workshop. He said that we should not start 
analysing participants’ anecdotes during the interviews themselves, so I 
postponed thinking about this paternalistic attitude until later in the analysis. 
However, after the first seven interviews, I was sometimes torn between 
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thinking that a paternalistic attitude was important for the patients’ benefit as 
sometimes patients might not be able to make the best decision for their health. 
Keeping a reflective journal helped me in thinking through these thoughts and 
helped me to better understand who I am by engaging and becoming 
accustomed to reflexive practice. Writing my thoughts and decision making 
down in the journal helped me understand how and why I took certain 
decisions. For example when Lionel started crying, through reflection, I 
understood what counter-transference meant. When Lionel became emotional, 
I was becoming emotional as well from the feelings that I was getting when 
remembering my experience with my grandmother’s stroke. Furthermore, 
although I had come to the conclusion that a paternalistic approach was not the 
answer to better patient adherence, I still remain fascinated by how easy it was 
to fall for the lure of a paternalistic approach (in thinking that patients might not 
be able to take the best decisions for their own health). 
 
6.6.2 Reflexivity during analysis 
I added reflections from my journal such as thoughts, questions, doubts and 
trends. Reflexive note-taking continued throughout the rest of the analytical 
steps. The reflective journal I had kept during the interviews helped to refresh 
my memory regarding my own evolving beliefs and perceptions during the data 
collection process, and helped keep track of my interpretations during analysis. 
Needless to say, the journal, although full of rough notes and sometimes 
incomprehensible phrases, was a critical feature to cope with the multitude of 
data throughout each analytical step, especially when synthesising the single 
groups (patients who accepted, patients who refused, patients who 
discontinued, cardiologists, registrars, general physicians, general 
practitioners) and even more crucial when synthesising the analysis across the 
individual studies (the patients’ study, and the physicians’ study). Using mind-
maps were another critical feature that made analysis easier, clearer and more 
comprehensible especially during supervisory discussions. The reflexive 
activity together with the supervisory discussions provided opportunities to think 
about new emerging connections between themes, or possible alternative 
interpretations. Furthermore, I felt that these meetings were crucial for me as a 
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researcher to help control the level of interpretation, in terms of not being over 
interpretative and make assumptions which were not based on evidence, as 
well as generalising to all participants too early in analysis process.  
 
6.7 Conclusions 
This study examined the experiences of patients and physicians with regards 
AF and OAC treatment. This examination included experiences during the 
consultation, such as patient assurance, patient education, and communicating 
risk, and how physicians’ skills in communication had an influence on these 
experiences. Key challenges faced by AF patients and physicians were also 
highlighted. These comprised the issue of time within the consultation, 
physicians’ adherence to guidelines, the influence of AF and OAC on the 
patients’ lived experience and the perceptions of warfarin and aspirin. This 
qualitative study has highlighted the need for implementation of a shared-
decision making process where the individual patient’s values and past 
experiences are taken in consideration when deciding upon treatment. 
 
6.7.1 Research recommendations 
Future studies need to explore the effects of patient reassurance within an AF 
consultation on OAC acceptance. Research into health literacy is an area that 
requires development especially for people from different cultures, non-English 
speaking people, those with cognitive impairment and low/no literacy levels 
which demand the development of appropriate non-traditional educational 
resources. Research is also needed to explore the influence and role the media 
plays in shaping perceptions of OAC treatment. 
  
Observational studies could further help understand the dichotomy of 
perceptions (patients vs. physicians) on decision making within AF 
consultations. Observational methodologies could explore experiences of 
patients and physicians that were present within the same consultations. In 
addition these studies could also be used to aid understanding of the models of 
decision making being used. Researchers could also explore the how skills 
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learnt from motivational interviewing (MInt) could impact the consultation in 
motivating passive patients to participate in decision making. MInt is a goal-
oriented, client-centred counselling style for helping clients to explore and 
resolve ambivalence about behaviour change which has been incorporated 
across diverse populations, settings and health topics (Rollnick, Miller & Butler, 
2008). The efficacy of MInt was ﬁrst demonstrated in the treatment of 
addictions, such as illegal drugs and alcoholism, however two meta-analyses 
(Hettema, Steele, & Miller, 2005; Rubak, Sandbaek, Lauritzen, & Christensen, 
2005) have consolidated the evidence of this client-centred approach and have 
shown it to be effective in improving well-being, promoting exercise and 
smoking cessation, improving dietary lifestyle, encouraging medication 
adherence and managing chronic conditions such as hypertension, 
hypercholesterolemia, obesity and diabetes (Hettema et al., 2005; Rubak et al., 
2005). Observational studies could also investigate the impact of time within 
the AF consultation, comparing longer consultations with more ‘meaningful’ 
consultations on patient satisfaction. 
 
Having significant others present in some of the patient interviews emphasised 
the need to explore the perceptions of family on OAC and how their 
perceptions have an influence on the AF patient. Researching the family’s 
experiences and perceptions of OAC would provide further context and add to 
this research. In addition, there is the need to study the impact of social support 
from significant others on AF patients' experience and acceptance of warfarin.  
 
The investigation of continuous educational support was also recommended by 
patients in this study. There is the need to study the impact of education on AF 
patients and their ability to recall information on a long term basis. Interviews 
showed that some patients were still confused on certain issues related to 
warfarin, for example the dietary limitations. Studies exploring educational 
interventions are also warranted with physicians, such interventions could 
explore communication skills as well as incorporating skills from behaviour 
change techniques such as motivational interviewing. In addition, educational 
interventions could be devised that focus on increasing knowledge and 
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ameliorating adherence to guidelines in general physicians and general 
practitioners. 
 
6.7.2 Practical recommendations 
This study has assisted in giving a voice to the AF patients’ and physicians’ 
experiences, providing examples of good and bad practice and experience. It 
has also identified areas for improvement in relation to patient-physician 
consultations regarding AF and OAC treatment decisions.  
 
This programme of work has shown that health professionals play a crucial role 
in on-going educational support towards patient education. Patients could be 
referred to such an educational service immediately after their initial 
consultation where health psychologists, or health care assistants trained in 
appropriate behaviour change techniques, could go over educational material 
with patients and where time is given to patients to voice their concerns. Such 
theory-led and evidence-based programmes could target patients' confidence 
in communicating with health care professionals, and their skills in self-
management as well as providing accessible information about OAC and AF.  
 
There is also a need to increase physicians’ communication skills. In particular 
the awareness of the diversity of learning styles, an awareness of cultural 
diversity and the use of differing modalities in educational delivery. Health 
literacy needs consideration together with the development of tools that are 
culturally and intellectually sensitive with alternative learning modalities. In 
addition, physicians need to be aware of individual patient values, beliefs and 
past experience during the consultation. For example, patients with past 
experiences of stroke through family or friends may be more influenced by 
increased knowledge of warfarin’s benefits in reducing strokes. Furthermore, 
clinical guidelines need to be tailored towards specialty level, thus facilitating 
OAC management and providing clear roles for each specialty level. Physicians 
also need to be aware of the risks or negative consequences that may result 
from their behaviour, so that they do not transfer their anxiety on to the 
patients. Physicians need to be educated on the benefits of treatment using 
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psycho-social techniques, persuasion techniques, and motivation-enhancement 
methods. Also, physicians must be educated about their decision biases and 
the inconsistency of these biases with best practice.  
 
This qualitative research has found that educational efforts can be focused on 
physician concerns, prescribing barriers, and system specific challenges.  
Physicians need to know that their concerns are acknowledged and understood 
and that any solutions proposed will be relevant to their situation. Educational 
interventions also need to emphasise skills needed by physicians to help 
enhance patient engagement and adherence concerning diet and regular INR 
testing. Finally, on-going education, monitoring and feedback systems are not 
only warranted in patients, but also in physicians, especially in primary care. 
General practitioners could be encouraged to maintain contact with secondary 
care to increase confidence in the initiation of OAC prescription.  
 
There is also a need to increase awareness in patients with regards to the 
possibility of INR testing in GP surgeries. Furthermore, awareness and 
knowledge of AF and warfarin should be increased in the general population 
through the media, so as to minimise myths and connotations associated with 
warfarin. This increase in awareness could also help to improve AF patient 
support from work colleagues and employers, especially when the patient 
needs to attend appointments for INR testing. In addition, patients who are still 
employed should be made aware of the benefit of the new OACs (i.e. that they 
do not need INR monitoring) however they should also be advised about their 
risks (i.e. the lack of antidote). 
 
6.7.3 Conclusion 
This programme of work has used an innovative bolder IPA design to explore 
the patients’ and physicians’ experiences of AF and OAC. It has shown the 
patients’ and physicians’ different experiential perceptions of the consultation. 
While most patients perceived the consultation as taking a paternalistic 
approach to decision making for OAC, physicians showed that although they 
tried to take a shared approach to decision making, because of certain 
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challenges including time, language and trust from the patient, they ended up 
taking a paternalistic route and taking the decision themselves. Interestingly 
this paternalistic approach was the main influence for most patients to either 
accept or refuse warfarin as their OAC medication. This study also showed that 
patient education is still lacking as can be seen from patients' lived experience 
while on OAC and physicians' lack of guidance on how to provide appropriate 
education. There is also a need to shift the physicians’ perceptions of the 
connotations associated with patient compliance towards an approach which 
highlights concordance. 
 
This study has also showed how the perception of time had an impact on the 
quality of the consultation. Both physicians and patients believed that time 
spent in the consultation could be used to better advantage. Difficulty in 
adhering to guidelines was reported as a challenge to general physicians and 
general practitioners. Finally, this programme of work has uncovered patients’ 
perceptions of warfarin and aspirin, i.e. the perception that ‘old’ in relation to 
aspirin treatment means safe and tested, while in relation to warfarin treatment 
it inferred outdated and unsafe. Likewise, patients were aware that aspirin was 
natural, while they were not aware of warfarin being made from natural 
products. In addition the lack of awareness on warfarin was negatively 
influencing patients before they attend to a consultation.  
 
This programme of work has illustrated the benefit of taking an in depth 
phenomenological approach to understanding the lived experience of the 
physician- patient consultation. Together with the meta-synthesis of qualitative 
evidence, this work has strengthened the evidence base and demonstrated that 
there is a need to target patients' and physicians' ability to communicate with 
each other in a comprehensible way; patients require support to become active 
in the consultation while physicians need to work on ways of communicating 
complex material in an accessible manner.  
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Appendix A: Meta-synthesis search strategy 
 
1. ATRIAL FIBRILLATION 
2. atrial flutter 
3. atrial* 
4. (atrial next fibrillation) 
5. cardiac arrhythmia 
6. (cardiac next arrhythmia) 
7. heart rhythm disturbance 
8. (heart next rhythm next disturbance) 
9. irregular heart rhythm 
10. heart rhythm * 
11. supraventricular arrythmia 
12. arrhythmia* 
13. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12) 
14. ANTICOAGULANT THERAPY 
15. oral anticoagulation 
16. coagu* 
17. anticoagulants* 
18. vitamin K antagonist 
19. ethyl biscoumacetate  
20. blood thinner 
21. warfarin 
22. clopidogrel 
23. plavix 
24. enoxaparin 
25. lovenox 
26. clexane 
27. acenocoumarol 
28. sintrom 
29. sinthrome 
30. jantoven 
31. marevan 
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32. waran 
33. phenprocoumon 
34. marcoumar 
35. marcumar 
36. falithrom 
37. phenindione 
38. clorindione 
39. tioclomaro 
40. bishydroxycoumarinl 
41. dicumarol 
42. dicoumarol 
43. coumadin  
44. aspirin 
45. acetylsalicylic acid 
46. (#14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or 
#24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or 
#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or 
#44 or #45) 
47. (#13 and #46) 
48. Qualitative* 
49. Finding* 
50. Interview* 
51. Thesaurus terms: Interviews 
52. (#48 or #49 or #50 or #51) 
53. (#47 and #52) 
  
 
3
0
2
 
Appendix B: CASP (CASP, 2006) table for quality in papers included in meta-synthesis 
 
 
Howitt & Armstrong, 
1999 
Dantas et al., 2004 Fuller et al., 2004 Lipman et al., 2004 
1. Was there a 
clear 
statement of 
the aims of the 
research? 
Yes Yes Yes Yes  
2. Is a qualitative 
methodology 
appropriate? 
Yes  Yes  Yes Yes 
3. Was the 
research 
design 
appropriate?  
Yes – no justification 
given for the choice 
of research design 
Yes – authors 
mentioned how 
qualitative methods 
could be more valuable 
in this study than 
quantitative methods 
Yes - The idea of using 
pictograms and later 
participants encouraged to 
discuss their decisions 
about treatment in more 
detail is appropriate. 
However, participants were 
not patients who suffered 
from AF, so their decisions 
could have been affected 
by the fact that they did not 
go through the same 
experiences as actual 
patients. Furthermore the 
researcher did not justify 
Yes – authors gave 
justification for the design 
  
 
3
0
3
 
this issue. 
4. Was the 
recruitment 
strategy 
appropriate? 
Yes - authors gave a 
detailed account of 
the recruitment 
strategy 
Yes - authors gave a 
detailed account of the 
recruitment strategy. 
Yes - authors discussed 
briefly inclusion and 
exclusion criteria, however 
they did not describe the 
recruitment process 
Yes – authors gave a 
detailed account of the 
recruitment strategy 
5. Was data 
collection 
appropriate? 
Yes – authors gave 
no information on the 
interviews (whether 
recorded, semi- or 
structured etc) 
Yes – authors gave 
details and justification 
for data collection 
method, setting and 
saturation of data 
Yes - Interviews and a 
questionnaire were used to 
collect data. The authors 
did not mention if they 
used a topic guide. Only 
that the participants were 
encouraged to talk about 
their decision. 
Furthermore, there is no 
description of the actual 
interview. 
Yes - Authors gave detailed 
account of the settings from 
where the participants were 
recruited.  
Audio recorded semi-
structured interviews were 
used to collect data. 
Furthermore the authors gave 
in-depth information on how 
the interviews were 
conducted. In addition the 
authors discussed saturation 
of themes 
 
6. Has the 
relationship 
between 
researcher 
and 
participants 
been 
adequately 
considered? 
No - authors did not 
discuss their role in 
sample recruitment, 
choice of location and 
formulation of 
research question. 
 
Yes – discussed how 
the risk of bias during 
interviews was 
minimised. Moreover, 
interviewers were blind 
to interviewees' INR 
status. 
 
No - Authors did not 
discuss the relationship 
between the researcher 
and participants.  Neither 
did they discuss their role 
in sample recruitment and 
choice of location 
Yes - Authors discussed how 
measures were taken to 
minimise bias during the 
interviews. However, authors 
did not discuss bias during 
research question 
formulation, choice of location 
and participant recruitment.  
  
 
3
0
4
 
7. Have the 
ethical issues 
been taken 
into 
consideration? 
Authors only mention 
the exclusion of 
participants who 
could not give 
consent and that 
study was approved 
by the local research 
ethics committee. 
Letter was sent 
explaining study if 
agreeable to patients. 
 
No ethical issues apart 
from informed consent 
and approval by the 
Research Ethics Board 
of the host institution 
were mentioned 
 
Authors mentioned that 
participants consented to 
participate, however they 
did not say if it was 
informed consent. The 
REC approved this study. 
However the authors did 
not discuss any other 
ethical issue 
Informed consent - GPs 
contacted by E-mail, given an 
outline of the proposed 
research and its background, 
and invited to contact TL if 
they were willing to be 
interviewed. 
 
Confidentiality – was only 
towards (patients’ aide 
memoirs) apart from that 
authors did not mention if the 
study was assessed by an 
ethical body and no other 
ethical issue was discussed 
 
8. Was the data 
analysis 
sufficiently 
rigorous? 
No detail regarding 
data analysis was 
mentioned in the 
study; No mention of 
rigor or validity or 
trustworthiness issue 
in the study 
Authors mentioned that 
content analysis was 
used to analyse data. 
Team analysis was 
conducted + discussion. 
Furthermore, they gave 
a detailed account of the 
coding process. 
A very brief description of 
the analysis method was 
given (just one sentence). 
Authors mention 
triangulation with regards 
rigour, however they did 
not mention the process. 
Researchers described in 
detail the analysis process. 
The authors discussed the 
issue of bias during analysis. 
Shared assumptions between 
interviewer and participant 
may have led to some issues 
not being explored. Not much 
interpretative commentary 
included, furthermore it’s not 
easy to see constructivist 
approach. 
 
  
 
3
0
5
 
9. Is there a clear 
statement of 
findings? 
No – authors have 
not discussed the 
credibility of their 
findings 
Yes - The findings in 
this study are clear. 
Furthermore the 
researchers have 
discussed validity issues 
that would increase their 
credibility, such as 
having more than one 
analyst and their 
limitations 
Yes – Clear findings. 
Furthermore authors 
discussed validity issues 
(though not the process) 
and their limitations. 
Yes - The findings in this 
study are explicit. 
Furthermore the researchers 
have discussed rigour issues 
– use of Potter and 
Wetherell’s criteria for validity 
in qualitative research. 
10. How valuable 
is the 
research? 
A lot of issues 
associated with 
qualitative studies’ 
methodology were 
not covered. However 
authors discussed 
limitations and 
importance of the 
study 
Importance in illustrating 
experience, however 
study was not 
exploratory/experiential 
enough because of the 
use of pre-coded 
themes. Imp in 
illustrating decision 
making style during 
consultation 
The study highlights the 
importance of clear 
explanation of risks 
through pictorial info (more 
easily understood) and 
willingness to trade risks 
(bleeding/stroke). However 
patients in study do not 
have AF, so it is based on 
a “what if” scenario and 
authors do not justify their 
choice of patients.  
The figures that show what 
influences GPs’ choice of 
treatment (figure 2 and 3) 
give an idea of the plethora of 
things that have an effect on 
decision making. However it 
looks too complicated. Other 
studies might simplify this. 
Importance of GPs 
interpretation of evidence and 
the significance of accuracy 
in INR. 
 
  
 
3
0
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 Bajorek et al., 2006 Anderson et al., 2007 Bajorek et a., 2007 Wild et al., 2009 
1. Was there a clear 
statement of the 
aims of the 
research? 
Yes Yes Yes 
 
Yes 
2. Is a qualitative 
methodology 
appropriate? 
Yes Yes Yes 
 
Yes 
3. Was the research 
design appropriate?  
Yes - The authors 
have justified the 
suitability of the 
design 
Yes - The researcher has 
justified the research 
design 
Yes - The authors did 
not justify the suitability 
of the design. However it 
was appropriate. 
Yes - The authors 
have justified the 
suitability of the 
design 
4. Was the recruitment 
strategy appropriate? 
Yes - Researchers 
gave a detailed 
account of the 
recruitment strategy 
 
 
Yes - The researchers did 
not explain how the 
participants were selected. 
Neither did they mention 
the sampling method. 
However, the participants 
included in this study were 
appropriate to provide 
access to the type of 
knowledge sought. 
 
 
 
Yes - Researchers gave 
a detailed account of the 
recruitment strategy 
 
 
 
 
Yes – The 
researchers gave a 
detailed account of 
the recruitment 
strategy 
  
 
3
0
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5. Was data collection 
appropriate? 
Yes – authors justified 
the data collection 
method. In addition 
the authors gave 
detailed information 
how the focus group 
was carried out 
Yes - Audio recorded semi 
structured interviews were 
used for data collection. 
The author has also 
justified this method. The 
authors did not mention 
the use of a common topic 
guide in all interviews. 
Authors also mentioned 
theoretical saturation. 
A series of audio 
recorded group 
interviews (focus group) 
were the method used 
for data collection. In 
addition they gave a 
brief description on how 
the focus group was 
carried out. Individual 
interviews would have 
been better. Consultants 
& registrars in the same 
group which may impact 
on honesty. 
Yes – data collection 
was appropriate. 
With detailed 
information on how 
interviews were 
carried out 
6. Has the relationship 
between researcher 
and participants 
been adequately 
considered? 
 
 
 
Yes - In their 
limitations the authors 
discussed 
researcher’s bias. 
However, They did not 
discuss their role in 
sample recruitment 
and choice of location. 
 
 
 
No - Authors did not 
discuss the relationship 
between the researcher 
and participants. Neither 
did they discuss their role 
in sample recruitment and 
choice of location. 
No - The authors did not 
discuss their role in 
sample recruitment, 
choice of location and 
formulation of research 
question 
 
No – the authors did 
not discuss their role 
in sample 
recruitment, choice 
of location and 
formulation of 
research questions 
  
 
3
0
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7. Have the ethical 
issues been taken 
into consideration? 
Authors mentioned 
that participants gave 
informed consent and 
that the study was 
approved by the 
institutional human 
research and ethics 
committee. No other 
ethical issues apart 
from informed consent 
were mentioned. 
The authors did not 
discuss any ethical issues, 
like informed consent or 
confidentiality. However 
they mentioned that, 
“Ethics committee 
approval was secured” 
Authors mentioned that 
participants gave 
informed consent, that 
participating was 
voluntarily and that the 
study was approved by 
the Northern Sydney 
Health Ethics 
Committee. Anonymity 
not mentioned. 
 
 
Authors mentioned 
that they have 
obtained appropriate 
institutional review 
board approval or 
have followed the 
principles outlined in 
the Declaration of 
Helsinki for all 
human or animal 
experimental 
investigations and 
also informed 
consent was 
obtained from the 
participants involved. 
8. Was the data 
analysis sufficiently 
rigorous? 
 
Researchers 
mentioned that 
thematic analysis with 
a phenomenological 
approach was used to 
analyse the data. 
However not much 
detail is given on the 
process. 
 
 
An in-depth description of 
the analysis process 
(grounded theory), is given 
in the paper. Additionally 
authors gave an account 
of the rigour issues in both 
their methods section and 
at the end of the 
discussion section. 
Phenomenology 
described briefly without 
giving a lot of detail 
(Husserl/ Heidegger). 
Member validation for 
accuracy does not fit 
phenomenology. 
Researchers 
mentioned that 
thematic analysis 
was used. Detail is 
also provided on the 
process of coding of 
interviews into 
ATLAS.ti. 
  
 
3
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9. Is there a clear 
statement of 
findings? 
The findings in this 
study are explicit. 
Furthermore the 
researchers have 
discussed rigour 
issues that would 
increase their 
credibility, such as 
triangulation of data 
with the literature, 
user verification, 
having more than one 
analyst 
The findings in this study 
are explicit. Furthermore 
the researchers have 
discussed rigour issues 
that would increase their 
credibility. Good 
interpretative commentary. 
The findings in this study 
are explicit. Furthermore 
the researchers have 
discussed rigour issues 
that would increase their 
credibility, such as 
triangulation of data with 
the literature, user 
verification, having more 
than one analyst. 
The findings in this 
study are explicit. 
Furthermore the 
researchers have 
discussed rigour 
issues that would 
increase their 
credibility, such as 
recoding by an 
independent 
researcher 
10. How valuable is the 
research? 
Study highlights 
nurses’ lack of 
knowledge and power 
with regards warfarin 
prescription. The 
study shows the 
importance of nurses 
to help patients 
because of their 
special relationship 
and that they are an 
underutilised 
resource. 
 
Significant findings that 
focus on physicians in 
unusual but necessary in 
this area. Authors discuss 
these findings with the 
available literature. The 
researchers also 
mentioned that findings 
are not generalisable. 
Physicians are not 
heuristic in their decision 
making but are uncertain 
in decisions/lack 
knowledge 
 
The study demonstrates 
the importance of 
communication between 
health professionals. 
Guidelines need to be 
publicised and made 
relevant for them to be 
used effectively by 
several health 
professionals. 
 
 
 
The study highlights 
patients experience 
with OAC and 
hypothetical new 
drug without OAC 
drawbacks. 
 
  
 
3
1
0
 
 McCabe et al., 2011b Murray et al., 2011 
1. Was there a clear 
statement of the 
aims of the 
research? 
Yes 
 
Yes 
 
2. Is a qualitative 
methodology 
appropriate? 
Yes Yes 
3. Was the research 
design 
appropriate?  
Yes - The authors 
have justified the 
suitability of the 
design 
Yes – The authors have 
justified the suitability of 
the design 
4. Was the 
recruitment 
strategy 
appropriate? 
Yes - Researchers 
gave a detailed 
account of the 
recruitment strategy 
Yes - Researchers gave a 
detailed account of the 
recruitment strategy 
5. Was data 
collection 
appropriate? 
Yes – authors did not 
justify the method for 
data collections, 
however it was 
appropriate. In 
addition the authors 
gave detailed 
information how the 
interviews were 
carried out 
Yes - authors did not 
justify the use of qualitative 
data collection method, 
and the use of telephone 
interviews instead of face-
to-face. In addition the 
authors gave some detail 
on how the interview guide 
was developed and how 
the interviews were carried 
out. 
  
 
3
1
1
 
6. Has the 
relationship 
between 
researcher and 
participants been 
adequately 
considered? 
Yes – Authors 
mentioned that “prior 
and throughout the 
study, the primary 
investigator sought to 
identify and record her 
opinions and 
perceptions in regard 
to living with AF to 
heighten self-
awareness and 
examine their 
influence on data 
analysis.” However, 
they did not discuss 
their role in sample 
recruitment and 
choice of location. 
No - Authors did not 
discuss the relationship 
between the researcher 
and participants. Neither 
did they discuss their role 
in sample recruitment and 
choice of location. 
7. Have the ethical 
issues been 
taken into 
consideration? 
Authors mentioned 
that participants gave 
informed consent and 
that the study was 
approved by the 
institutional human 
research and ethics 
committee. No other 
ethical issues apart 
from informed consent 
were mentioned. 
 
The authors did not 
discuss any ethical issues, 
like informed consent or 
confidentiality. Authors 
only mentioned that the 
study was approved by an 
independent ethical 
committee. 
  
 
3
1
2
 
8. Was the data 
analysis 
sufficiently 
rigorous? 
Researchers gave a 
detailed description of 
the analysis process. 
Though no formal 
name was given to the 
method of analysis. 
Authors also 
discussed their role in 
potential bias during 
analysis and gave 
sufficient data. 
Researchers gave a 
detailed description of the 
analysis process. Authors 
mentioned that open 
coded based on their own 
developed conceptual 
framework was initially 
used, followed by selective 
coding. However authors 
did not present sufficient 
qualitative data. 
9. Is there a clear 
statement of 
findings? 
 
The findings in this 
study are explicit. 
Furthermore the 
researchers have 
discussed 
trustworthiness issues 
that would increase 
their credibility, such 
as having more than 
one analyst, 
auditability of process, 
and member 
verification with 6 
participants after initial 
analysis. 
 
 
Researchers have 
discussed trustworthiness 
issues that would increase 
their credibility, such as 
having more than one 
analyst, and triangulation 
of data. 
  
 
3
1
3
 
10. How valuable is 
the research? 
Study is valuable. It is 
the first qualitative 
study that describes in 
depth the experiences 
of patients with 
symptomatic AF.  
Study is valuable as it 
highlights physicians’ 
educational gaps and the 
need for professional 
development 
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Appendix C: Patient Participant Information Sheet 
Participant Information Sheet 
Part 1 
Title of Main Project: Patients’ and physicians’ experiences of atrial 
fibrillation and anticoagulant therapy: a qualitative journey 
Study 1: Patients’ experiences of warfarin  
 
Dear Patient 
 
We would like to invite you to take part in a study. Before you decide it is 
important for you to understand why this study is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Part 1 deals with the information about the purpose of 
this study and what will happen to you if you decide to take part. Part 2 gives 
you more detailed information about the conduct of the study. Please Ask us if 
there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The purpose of this study is to explore the experiences which influence a 
patient’s decision to accept or decline warfarin as their blood thinning 
medication. We would like to talk to you to explore your experiences and what 
had an effect on your decision in accepting or declining warfarin as your blood 
thinning treatment. We will also explore the effect that this decision has had on 
your everyday experiences following your diagnosis of atrial fibrillation.  
 
Why have I been invited? 
You have been asked to take part in this research study because you have 
atrial fibrillation (an irregular heart rhythm).  This means that your heart does 
not beat in a regular rhythm, some or all of the time.  As your physician will 
have explained to you, having atrial fibrillation can increase your risk of having 
stroke (a blood clot in your brain).  Other conditions, such as having high blood 
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pressure, diabetes, heart failure, having had a previous stroke or mini stroke 
(transient ischaemic attack) and being 75 years of age or older, can further 
increase your risk of having a stroke. Your physician has offered you treatment 
with a blood-thinning medication called warfarin, to decrease your risk of a 
blood clot forming and reduce your risk of having a stroke. Your experiences 
that had an influence on your decision whether to accept or refuse warfarin as 
your blood thinning medication are important to us. So we would like to know 
what influenced your decision to accept or decline treatment with warfarin. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part in the study.  We will 
describe the study and go through this information sheet, which we will then 
give to you.  We will then ask you to sign a consent form to show that you have 
agreed to take part. If you decide to take part, you are still free to change your 
mind at any time during the interview and up to two weeks following it and stop 
taking part in the study, and you do not have to give a reason. Your decision 
will have no bearing on your medical treatment. 
 
What will happen to me if I take part? 
If you agree to take part in this study you will be asked to attend the ASCOT 
centre on one occasion. The researcher will ask you to sign a consent form to 
state that you agree to take part.  
 
After you have signed the consent form, an interview will take place in a quiet 
room in Ascot Centre. The interview is likely to last around 90 minutes. Before 
the interview, the researcher will explain how the interview will run and at the 
end of the interview there will be an opportunity for you to ask questions. The 
interview will be audio recorded so that the researcher can write down what you 
said word-for-word following the interview and analysed later on. The interview 
will explore your experiences of having atrial fibrillation and what influenced 
your decision to accept or refuse warfarin as your blood thinning medication. 
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Expenses and payments  
We will reimburse your travel expenses (bus fare, taxi, fuel allowance and 
parking) for your visit to the hospital to take part in the interview 
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you in taking part in this study. This 
study is exploring your experiences about living with atrial fibrillation and your 
decision to accept or refuse warfarin. However, since we would like you to talk 
about your AF and blood thinning therapy, we understand that issues may arise 
that may be upsetting. The researcher is experienced in dealing with sensitive 
issues and will let you decide whether or not to carry on with the interview 
should you become upset. The researcher will debrief you at the end of the 
interview and give you contact numbers if you would need to discuss your 
feelings or your treatment further. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will have any benefits. However qualitative 
interviews give the participants an opportunity to have their voices and 
problems heard. Thus the interview in itself may help you think about your 
condition, its treatment and anything else related to your atrial fibrillation.  
 
What happens when the research study stops? 
At the end of the study, what you said in the interview will be written down word 
for word so that we can look at it in more detail later on. If you would like to 
know about the results of the study you are free to ask for a copy of a summary 
of findings. 
 
What if there is a problem? 
If you experience any problems or have any concerns, please contact one of 
the people listed in Part 2.  
 
Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  The details are included in Part 2. 
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If the information in Part 1 has interested you and you are considering taking 
part, please read the additional information in Part 2 before making any 
decision. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any point during the interview and up to two 
weeks following it.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak 
to one of the researchers who will do their best to answer your questions 
(contact Mr. Christian Borg Xuereb (0121-507-5053), Dr. Rachel Shaw (0121-
204-4050), or Dr. Deirdre Lane (0121-507-5080).  If you remain unsatisfied and 
wish to complain formally, you can do this through the NHS Complaints 
Procedure.  Details can be obtained from the hospital Complaints and Litigation 
Department on 0121-507-4346. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence than you may have grounds 
for a legal action for compensation against Sandwell and West Birmingham 
Hospitals NHS Trust but you may have to pay your legal costs.  The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of the data collected for the study may be used 
as direct quotes in the results section of any published material. However, your 
name will not appear anywhere in the research and any material that can lead 
to your identity will not appear anywhere in the results or any publishable 
material. A pseudonym will be used instead of your real name in the study. The 
data may also be looked at by representatives of regulatory authorities and by 
people authorised to check that the study is being carried out correctly. 
However, we all have a duty of confidentiality to you as a research participant 
and no identifiable material will be disclosed.  
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What will happen to the information I give? 
As mentioned above, all information that is collected about you during the 
course of the research will be kept strictly confidential. The content of the 
interviews will be kept in a secure location within the hospital and data stored 
on computers will be anonymised (using your assigned pseudonym) and the 
computers will be password protected.  Only the researchers will have access 
to this data. 
What will happen to the results of the research study? 
At the end of the study, we hope to publish the results.  You will not be 
identified in any report or publication.  If you wish, we will send you a summary 
of our findings. 
Who is organising and funding the research? 
This research is being organised by Aston University and the Centre for 
Cardiovascular Studies, City Hospital.  The study is being funded by Aston 
University to cover the running costs of the study.  No payments will be made 
to members of staff involved in this study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called 
a Research Ethics Committee, to protect your safety, rights, well-being, and 
dignity.  This study has been reviewed by the South Birmingham Research 
Ethics Committee and the Aston University LHS Ethics Board. 
 
Further information and contact details 
If you have any questions about the study, please call the person listed below.  
They will answer your questions or give you advice. 
 
Chief Investigator:  Mr. Christian Borg Xuereb 0121-507-5053 
    Dr. Rachel Shaw  0121-204-4050 
    Dr. Deirdre Lane  0121-507-5080 
 
If you have any concerns about this study, please call Balvinder Baines (R&D 
department on 0121-507-4946). 
 
Thank you for taking the time to read this Patient Information Sheet and 
considering whether to take part in the study. 
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Appendix D: Physician Participant Information Sheet 
Participant Information Sheet 
Part 1 
Main Study title: Patients’ and physicians’ experiences of atrial fibrillation 
and anticoagulant therapy: a qualitative journey 
Study 2: Physicians’ experiences of warfarin prescription 
 
Dear Doctor 
 
We would like to invite you to take part in this qualitative study. Before you 
decide it is important for you to understand why this study is being done and 
what it will involve.  Please take time to read the following information carefully 
and discuss it with others if you wish. Part 1 deals with the information about 
the purpose of this study and what will happen to you if you take part. Part 2 
gives you more detailed information about the conduct of the study. Ask us if 
there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
What is the purpose of the study? 
The purpose of this study is to describe the experiences and perceptions of 
doctors in prescribing warfarin to discover what influences their decisions to 
prescribe warfarin to patients with atrial fibrillation. Case scenarios will also be 
used to encourage discussion. This study will also explore whether your clinical 
experience (years in practice and/or specialist training) influences your warfarin 
prescription.   
 
Why have I been invited? 
You have been asked to take part in this research study because you had 
previous experience in deciding whether or not to prescribe warfarin to patients 
with atrial fibrillation. This study will explore what experiences and perceptions 
influenced your decision in prescribing warfarin or not to AF patients and 
therefore your experiences are invaluable to this study.  
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Do I have to take part? 
It is up to you to decide whether or not to take part in the study.  We will 
describe the study and go through this information sheet, which we will then 
give to you to read.  We will then ask you to sign a consent form to show that 
you have agreed to take part. If you decide to take part, you are still free to 
change your mind at any time during the interview or up to two weeks following 
it and stop taking part in the study, and you do not have to give a reason.  
 
What will happen to me if I take part? 
After you have signed the consent form, an interview will take place in a quiet 
room wherever you feel most comfortable. This can either be in the ASCOT 
centre, City Hospital, or at Aston University or in your own office. The interview 
is likely to last around 90 minutes. The interview will be audio recorded so that 
it can be transcribed verbatim and analysed later on. The interview will explore 
your experiences and what influences you when you decide to prescribe 
someone with warfarin or not. Case scenarios will also be explored during the 
interview to facilitate discussion. 
 
Expenses and payments 
You will have your travel expenses (taxi fare or fuel allowance and parking) 
reimbursed if you have to come to City hospital or Aston University for the 
interview.  
 
What are the possible disadvantages and risks of taking part? 
There are no disadvantages or risks to you in taking part in this study. This 
study is exploring your perception and experiences in prescribing warfarin to 
patients with atrial fibrillation. However, you may be concerned about 
confidentiality or divulgement of details. This issue is tackled in Part 2. The 
researcher will debrief you at the end of the interview and give you contact 
numbers if you need to discuss these feelings further. 
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What are the possible benefits of taking part? 
There are no benefits to you in taking part. However qualitative interviews give 
the participants an opportunity to have their voices and challenges or problems 
heard. Thus the interview in itself may help you to reflect on your experiences 
and professional decision-making with regards to AF and anticoagulation 
therapy.  
 
What happens when the research study stops? 
At the end of the study, the interviews will be transcribed verbatim and 
analysed using qualitative analysis. If you would like to know about the results 
of the study you are free to ask for a copy of the summarised findings. 
 
What if there is a problem? 
Any complaint about the way you have been treated during the study or any 
possible harm you might suffer as a result of taking part will be addressed. The 
detailed information about this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you will 
be handled in confidence.  The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
 
Part 2 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any point during the interview and up to two 
weeks following it without giving a reason.  
 
What if there is a problem? 
If you have any concerns about any aspect of this study, you should ask to 
speak to one of the researchers who will do their best to answer your questions 
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(contact Mr. Christian Borg Xuereb (0121-507-5053) or Dr. Rachel Shaw 
(0121-204-4050) or Dr. Deirdre Lane (0121-507-5080).  If you remain 
unsatisfied and wish to complain formally, you can do this through the NHS 
Complaints Procedure.  Details can be obtained from the hospital Complaints 
and Litigation Department on 0121-507-4346. 
 
In the event that something does go wrong and you are harmed during the 
research and this is due to someone’s negligence than you may have grounds 
for a legal action for compensation against Sandwell and West Birmingham 
Hospitals NHS Trust but you may have to pay your legal costs.  The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of the data collected for the study may be used 
as direct quotes in the results section of any published material. However, your 
name will not appear anywhere in the research and any material that can lead 
to your identity will not appear anywhere in the results or any publishable 
material. A pseudonym will be used instead of your real name in the study. The 
data may also be looked at by representatives of regulatory authorities and by 
people authorised to check that the study is being carried out correctly. 
However, we all have a duty of confidentiality to you as a research participant 
and we will do our best to meet this duty.  
 
What will happen to the information I give? 
As mentioned above, all information that is collected about you during the 
course of the research will be kept strictly confidential. The transcribed 
interviews will be kept in a secure location within the hospital and data stored 
on computers will be anonymised (using your assigned pseudonym) and the 
computers will be password protected.  Only the researchers will have access 
to this data. 
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What will happen to the results of the research study? 
At the end of the study, we hope to publish the results.  You will not be 
identified in any report or publication.  If you wish, we will send you a summary 
of our findings. 
 
Who is organising and funding the research? 
This research is being organised by Aston University and the Centre for 
Cardiovascular Studies, City Hospital.  The study is being funded by Aston 
University to cover the running costs of the study.  No payments will be made 
to members of staff involved in this study. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called 
a Research Ethics Committee, to protect your safety, rights, well-being, and 
dignity. This study has been reviewed by the South Birmingham Research 
Ethics Committee and the Aston University LHS Ethics Board. 
 
 
Further information and contact details 
If you have any questions about the study, please call the person listed below.  
They will answer your questions or give you advice. 
 
Chief  Investigator: Mr. Christian Borg Xuereb 0121-507-5053 
    Dr. Rachel Shaw  0121-204-4050 
    Dr. Deirdre Lane  0121-507-5080 
 
If you have any concerns about this study, please call Balvinder Baines (R&D 
department on 0121-507-4946). 
 
Thank you for taking the time to read this Participant’s Information Sheet 
and considering whether to take part in the study. 
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Appendix E: Patient Consent Form 
CONSENT FORM 
Title of Main Project: Patients’ and physicians’ experiences of atrial 
fibrillation and anticoagulant therapy: a qualitative journey 
Study 1: Patients’ experiences of warfarin  
Name of Researchers: Mr. C Borg Xuereb, Dr. R.L. Shaw, Dr D.A. Lane, 
Dr. H.M. Pattison,  Professor GYH Lip 
     
1. I confirm that I have read and understood the information sheet 
dated 24/08/09 ver. 2 for the above study. I have had the opportunity 
to consider the information, ask questions, and have had these 
answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at  
any time, without giving any reason, without my medical care or 
legal rights being  
affected. 
3. I understand that relevant sections of my medical notes and data 
collected during  
the study may be looked at by individuals from QED, from regulatory 
authorities or 
from the NHS Trust, where it is relevant to my taking part in this 
research. I give  
my permission for these individuals to have access to my records. 
 
4. 
 
I agree to take part in the above study. 
 
 
Name of Patient     Date    Signature 
 
 
Name of Person taking consent   Date    Signature 
 
 
Name of person taking consent (if different  Date    Signature 
from researcher) 
1 copy for patient; 1 copy for researcher; 1 copy to be kept in hospital notes 
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Appendix F: Physician Consent Form 
CONSENT FORM 
Title of Main Project: Patients’ and physicians’ experiences of atrial 
fibrillation and anticoagulant therapy: a qualitative journey 
Study 2: Physicians’ experiences of warfarin prescription 
Name of Researchers: Mr. C Borg Xuereb, Dr. R.L. Shaw, Dr D.A. Lane, 
Dr. H.M. Pattison,  Professor GYH Lip 
     
1. I confirm that I have read and understood the information sheet 
dated 24/08/09 (ver. 2) for the above study. I have had the 
opportunity to consider the information, ask questions, and have had 
these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that relevant sections of data collected during the study 
may be looked at by individuals from QED, from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking 
part in this research.  
 
4. 
 
I agree to take part in the above study. 
 
 
 
Name of Physician     Date    Signature 
 
 
Name of Person taking consent   Date    Signature 
 
 
Name of person taking consent (if different  Date    Signature 
from researcher) 
1 copy for physician; 1 copy for researcher; 1 copy to be kept in hospital notes 
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Appendix G: Patient Debrief Form 
Debrief form 
Title of Main Project: Patients’ and physicians’ psychological 
experiences of atrial fibrillation and anticoagulant therapy: a qualitative 
journey 
Study 1: Patients’ experiences of warfarin acceptance and/or refusal  
 
Researchers: Mr. C. Borg Xuereb, Dr. R.L. Shaw, Dr. D.A. Lane, Dr. H. 
Pattison, Prof G.Y.H. Lip 
 
Thank you for taking part in this interview. The purpose of this interview was to 
explore your perceptions and experiences that had an influence on you when 
you accepted/refused warfarin as your blood thinning medication. The data 
collected from these interviews will be transcribed verbatim for analysis. If you 
wish to withdraw your data from the study please contact Mr. Borg Xuereb, Dr. 
Shaw or Dr. Lane (details below) within two weeks of the interview. If you feel 
that you have experienced any feelings of distress as a result of this study and 
want to discuss these feelings, please do not hesitate to contact us. 
 
 
Thank you very much for your participation 
Mr. Christian Borg Xuereb 
Email: christian.borgxuereb@swbh.nhs.uk 
Tel: +44 (0) 121 507 5053 
 
Dr. Rachel Shaw 
Email: r.l.shaw@aston.ac.uk 
Tel:  +44 (0) 121 204 4050 
 
Dr. Deirdre Lane 
Email: deirdre.lane@swbh.nhs.uk 
Tel:  +44 (0) 121 507 5080 (Department PA) 
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Appendix H: Physician Debrief Form 
Debrief form 
Title of Main Project: Patients’ and physicians’ psychological 
experiences of atrial fibrillation and anticoagulant therapy: a qualitative 
journey 
Study 2: Physicians’ experiences of warfarin prescription 
 
Researchers: Mr. C. Borg Xuereb, Dr. R.L. Shaw, Dr. D.A. Lane, Dr. H. 
Pattison, Prof G.Y.H. Lip 
 
Thank you for taking part in this interview. The purpose of this interview was to 
explore your perceptions and experiences that have an influence on warfarin 
prescription. The data collected from these interviews will be transcribed 
verbatim for analysis. If you wish to withdraw your data from the study please 
contact Mr. Borg Xuereb, Dr. Shaw or Dr. Lane (details below) within two 
weeks of the interview. If you feel that you have experienced any feelings of 
distress as a result of this study and want to discuss these feelings, please do 
not hesitate to contact us. 
 
 
Thank you very much for your participation 
Mr. Christian Borg Xuereb 
Email: christian.borgxuereb@swbh.nhs.uk 
Tel: +44 (0) 121 507 5053 
 
Dr. Rachel Shaw 
Email: r.l.shaw@aston.ac.uk 
Tel:  +44 (0) 121 204 4050 
 
Dr. Deirdre Lane 
Email: deirdre.lane@swbh.nhs.uk 
Tel:  +44 (0) 121 507 5080 (Department PA) 
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Appendix I: Study 1 Full Interview Schedules 
 
Refused OAC 
 
Thank you for accepting to take part in this study.  
1. Can you tell me something about yourself? 
a. How old are you? 
b. Are you currently employed? 
c. Where do you work? 
d. If retired:  
i. What was your work before you retired? 
ii. How long have you been retired? 
2. Can you tell me something about your family? 
a. Married?  
b. Children? 
c. Pets? 
3. What is your everyday life like?  
a. Any hobbies? 
b. Social activities? 
c. Lifestyle? 
4. What is your general health status? 
a. Physical, emotional, social, mental and spiritual 
5. Can you tell me about your heart condition? 
a. What does it do to you? 
b. What does it do to your body? 
6. How does it affect your everyday life? 
a. How do you feel about it?  
b. Do you experience any health challenges because of AF? 
i. If yes: Can you tell me about these experiences? 
c. Do you have any concerns or fears about this condition? 
i. If yes: Can you tell me about your concerns or fears? 
7. Can you tell me how you got to know about your heart condition? 
8. Can you speak about your experience during the consultation with the 
doctor? 
9. What did you feel when you were told you had AF? 
10. What was your family reaction when you told them about AF? 
11. Do you think that AF had an effect on your quality of life? 
a. If yes:  
i. What changes do you think it had on you? 
Physical, emotional, social, mental, everyday 
experiences / health? 
ii. How has the diagnosis affected your everyday life 
experiences? 
iii. Where there any changes you had to make in your 
everyday life from  before you knew you  had AF? 
12. What did you feel when you were told you had to start warfarin? 
a. Do you know what warfarin is for? 
b. Do you know what a stroke is?  
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13. What experiences influenced you in declining warfarin as your blood 
thinning medication?  
a. Have you ever heard any rumours about warfarin? 
i. If yes: What do you feel about this issue? 
14. How do you feel about the fact that you decided to decline to take this 
medicine? 
15. Did you tell your family about warfarin?  
16. What was your family reaction when you told them about warfarin? 
a. What about when you told them you declined warfarin as your 
blood thinning medication? 
17. Do you think that warfarin could have had an effect on your quality of 
life? 
a. If yes: What effects do you think it could have had? 
1. Physical, emotional, social, mental, spiritual 
perspective? 
18. Can you speak about the support you were offered if any? 
a. Have you asked anyone to help you? 
b. Family/Friends? 
c. How did this make you feel? 
19. Did you search for any information about your condition and warfarin on 
the internet or in the library? 
a. What sort of information did you find? 
b. How did this make you feel? 
20. Do you know other people that have AF and refused warfarin as well?
  
a. Have you talked to them? 
b. How does this make you feel? 
21. Do you know other people that have AF and are taking warfarin? 
a. Have you talked to them? 
b. What do they say about warfarin? 
c. How does this make you feel? 
22. How are you doing without warfarin? 
a. Do you think you made the right choice or not? 
23. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
Thank you for your patience 
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Discontinued OAC 
 
Thank you for accepting to take part in this study.  
1. Can you tell me something about yourself? 
a. How old are you? 
b. Are you currently employed? 
c. Where do you work? 
d. If retired: What was your work before you retired? 
1. How long have you been retired? 
2. Can you tell me something about your family? 
a. Married?  
b. Children? 
c. Pets? 
3. What is your everyday life like?  
a. Any hobbies? 
b. Social activities? 
c. Lifestyle? 
4. What is your general health status? 
a. Physical, emotional, social, mental and spiritual 
5. Can you tell me about your heart condition? 
a. What does it do to you? 
b. What does it do to your body? 
6. How does it affect your everyday life? 
a. How do you feel about it?  
b. Do you experience any health challenges because of AF? 
i. If yes: Can you tell me about these experiences? 
c. Do you have any concerns or fears about this condition? 
i. If yes: Can you tell me about your concerns or fears? 
7. Can you tell me how you got to know about your heart condition? 
8. Can you speak about your experience during the consultation with the 
doctor? 
9. What did you feel when you were told you had AF? 
10. What was your family reaction when you told them about AF? 
11. Do you think that AF had an effect on your quality of life? 
a. If yes: What changes do you think it had on you? 
1. Physical, emotional, social, mental, everyday 
experiences / health? 
ii. How has the diagnosis affected your everyday life 
experiences? 
iii. Where there any changes you had to make in your 
everyday life from before you knew you had AF? 
12. What did you feel when you where told you had to start warfarin? 
a. Do you know what warfarin is for? 
b. Do you know what a stroke is?  
13. How did you feel while you were taking warfarin? 
14. Did you tell your family about warfarin? 
15. What was your family reaction when you told them about warfarin? 
16. Do you think that warfarin could have had an effect on your quality of 
life? 
a. If yes: What effects do you think it could have had? 
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1. Physical, emotional, social, mental, spiritual 
perspective? 
17. Can you speak about the support you were offered if any? 
a. Have you asked anyone to help you? 
b. Family/Friends? 
c. How did this make you feel? 
18. What experiences influenced you to discontinue warfarin as your blood 
thinning medication?  
a. Have you ever heard any rumours about warfarin? 
i. If yes: What do you feel about this issue? 
19. How do you feel about the fact that you decided to discontinue this 
medicine? 
20. Did you tell your family about warfarin?  
21. What was your family reaction when you told them that you were going 
to discontinue warfarin as your blood thinning medication? 
22. Can you speak about the support you were offered after you decided to 
discontinue wafarin? if any? 
a. Have you asked anyone to help you? 
b. Family/Friends? 
c. How did this make you feel? 
23. Did you search for any information about your condition and warfarin? 
a. What sort of information did you find? 
b. How did this make you feel? 
24. Do you know other people that have AF and discontinued warfarin as 
well?  
a. Have you talked to them? 
b. How does this make you feel? 
25. Do you know other people that have AF and are taking warfarin? 
a. Have you talked to them? 
b. What do they say about warfarin? 
c. How does this make you feel? 
26. How are you doing now that you discontinued warfarin as your blood 
thinning medication? 
a. Do you think you made the right choice or not? 
27. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
Thank you for your patience 
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Accepted OAC 
 
Thank you for accepting to take part in this study.  
1. Can you tell me something about yourself? 
a. How old are you? 
b. Are you currently employed? 
c. Where do you work? 
d. If retired: What was your work before you retired? 
How long have you been retired? 
2. Can you tell me something about your family? 
a. Married?  
b. Children? 
c. Pets? 
3. What is your everyday life like?  
a. Any hobbies? 
b. Social activities? 
c. Lifestyle? 
4. What is your general health status? 
a. Physical, emotional, social, mental and spiritual 
5. Can you tell me about your heart condition? 
a. What does it do to you? 
b. What does it do to your body? 
6. How does it affect your everyday life? 
a. How do you feel about it?  
b. Do you experience any health challenges because of AF? 
i. If yes: Can you tell me about these experiences? 
c. Do you have any concerns or fears about this condition? 
i. If yes: Can you tell me about your concerns or fears? 
7. Can you tell me how you got to know about your heart condition? 
8. Can you speak about your experience during the consultation with the 
doctor? 
9. What did you feel when you were told you had AF? 
10. What was your family reaction when you told them about AF? 
11. Do you think that AF will have an effect on your quality of life? 
a. If yes:  
i. What changes do you think it will have on you? 
Physical, emotional, social, mental, spiritual 
everyday    experiences / health? 
ii. How has the diagnosis affected your everyday life 
experiences? 
iii. Where there any changes you had to make in your 
everyday life from  before you knew you  had AF? 
12. What did you feel when you where told you needed to start warfarin? 
a. Do you know what warfarin is for? 
b. Do you know what a stroke is?  
 
13. Where you offered the chance to refuse warfarin as your blood thinning 
medication? 
14. What experiences do you think influenced you in accepting warfarin as 
your blood thinning medication?  
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15. How do you feel about the fact that now you are taking this medicine 
every day? 
a. Have you ever heard any rumours about warfarin? 
i. If yes: What do you feel about this issue? 
16. Did you tell your family about warfarin? 
17. What was your family reaction when you told them about warfarin? 
18. Do you think that warfarin had an effect on your quality of life? 
a. If yes:  
i. What effects do you think it will have? 
Physical, emotional, social, mental, spiritual 
perspective? 
ii. How will you adapt to these changes? 
b. Where there any changes in your everyday experiences since 
you started taking warfarin?   
19. Can you speak about the support you were offered if any, following 
diagnosis of this condition? 
a. Have you asked anyone to help you? 
b. Family/Friends? 
c. How did this make you feel? 
20. Do you know other people that have AF and are taking warfarin as well?
  
a. Have you talked to them? 
b. How does this make you feel? 
 
21. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
 
22. Thank you for your patience 
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Appendix J: Study 2 Full Interview Schedule 
 
Thank you for accepting to take part in this study.  
 
1. Can you tell me something about yourself? 
a. How old are you? 
b. How long have you been practising? 
 
2. Can you tell me something about your line of work? 
a. What type of patients do you visit? 
b. Did you have any specialised training in the field of AF? 
c. What do you think about warfarin? 
 
3. Can you speak about your experiences during the first consultation with 
an AF patient? 
a. From your experience, what would be going through the patients’ 
mind at that moment? 
b. How do you think they feel? 
 
4. From your experience, how would you explain atrial fibrillation to a 
patient? 
a. From your experience, what would be going through the patients’ 
mind at that moment? 
b. How do you think they feel? 
 
5. What kind of questions or concerns do you usually get from patients 
when you tell them that they have AF?  
a. Do you have any specific experiences you would like to share? 
 
6. Can you tell me about your experiences when you tell an AF patient that 
they need to start warfarin as their anticoagulant therapy? 
a. From your experience, what would be going through the patients’ 
mind at that moment? 
b. How do you think they feel? 
 
7. From your experience, how would you explain warfarin to a patient in lay 
man terms? 
a. Do you talk about risk? 
 
8. From your experience, what kind of questions or concerns do the 
patients put forward after telling them about warfarin? 
 
9. How do you deal with a situation where you do not agree with the 
patient’s decision? 
 
10. Could you take me through your thought process when deciding to 
prescribe warfarin to patients with AF? 
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a. Could you share some actual case experiences that you had 
during your career? 
 
11. What experiences would influence your decision in prescribing warfarin 
or not to patients with AF?   
a. Are there any experiences related to case scenarios that you 
could talk to me about? 
 
12. I have brought with me some case scenarios of AF patients, could you 
go through them one by one and explain to me your thoughts about their 
situation? 
a. What do you think would be going through the mind of the 
patient? 
b. Would you prescribe warfarin? 
c. Why? 
 
13. What barriers do you think physicians face when prescribing warfarin? 
a. Did you experience any of these barriers? 
 
14. How could warfarin use be improved? 
 
15. Looking back at what we talked about, is there anything you wish to add 
about your experience? 
 
16. Thank you for your patience 
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Appendix K: Case scenarios used in physician interviews 
 
From: Watson, T & Lip, G.Y.H. (2006). Management of Atrial Fibrillation. Herz, 
31(9), 849-856. 
 
Case 1 
 
Case 2 
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Case 3  
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Short Cases 
 
From: Gattellari, M., Worthington, J. M., Zwar, N. A. & Middleton, S. (2008b). 
The management of non-valvular atrial fibrillation (NVAF) in Australian general 
practice: bridging the evidence-practice gap. A national, representative postal 
survey. BMC Family Practice, 9, 62. 
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Appendix L: An example of the data analysis from part of the transcript of an interview with a general practitioner   
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Appendix M: An example of the table grouping verbatim extracts according to sub-themes from the 
general physician’s experience of the consultation 
 
Sub-Theme Explanation Quote Interpretation Quote 
Explaining 
information 
without the 
use of 
medical 
jargon and 
reassuring 
the patient 
 
General Physicians, 
like cardiologists, 
emphasise the 
importance of 
describing 
information in lay 
man terms. 
Furthermore, 
explaining 
information in lay 
man terms helps in 
reassuring the 
patient that the 
illness can be 
controlled. This 
Nilan reassures the patient that AF 
is a common disturbance. This 
alleviates the initial anxiety of the 
patient when receiving medical news 
on his heart. Furthermore, he 
informs his patients about both the 
actual name of the disturbance and 
a more common name that more 
easily describes the condition. 
 
Balu pointed out that information to 
the patient needs to be conveyed in 
a way that can be easily understood 
by the patient. Additionally, like 
Manpal, he commented that 
I mean generally I say, you have an abnormal heart 
rhythm. In a normal person, the heart is beating at 
regular intervals. In you the heart is not beating at 
regular intervals, so that’s why your heart beat has 
become irregular and it’s not an uncommon rhythm 
disturbance. It’s very common as people grow older. 
Erm there is a medical term for this, what we call as 
atrial fibrillation or in simple lay terms, irregular heart 
rhythm. (Nilan) 
 
Well mhm… you have got to explain it to them in their 
own simple, basic language… that due to various 
reasons or a particular reason, your heart beat is 
irregular. Now it is very difficult to predict whether this 
is going to be temporary or permanent, but we are 
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helps in overcoming 
the anxiety built 
when receiving the 
bad news. 
 
 
although this illness has its 
difficulties, he assures the patient 
about the safety of care. 
 
Furthermore this assurance is seen 
in Balu’s next quote, where he 
strives to alleviate the patients’ 
concerns.  
 
 
Tom also focuses his consultation 
on patient reassurance. At every 
stage where he gives information 
which could cause anxiety to the 
patient, he balances it out by 
normalising the issue of the 
irregularity of the heartbeat. 
Furthermore, he assures the patient 
that both the AF and the clotting of 
the blood can be controlled. 
going to find the cause for it (Balu) 
 
 
 
Is my heart failing, that’s one of the common 
questions they ask… erm and you’ve got to explain, 
no your heart is not failing, its just that the 
synchronisation and the beating is not as regular as it 
should be. (Balu) 
 
The heart is beating irregularly, it’s not a regular 
pattern. And that’s fine. It could have been doing that 
for years, but there are problems with that. 
Sometimes it goes too fast in that pattern, so we have 
to slow it down a bit so we may use tablets for that. 
The other problem is, while its being irregular, it can 
slightly increase your chance of getting clots. Not 
necessarily happen… most people don’t but it slightly 
increases your chance and we think you would need 
a blood thinning included. That’s the simple way I 
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On being prompted, he provides a 
rationale for why reassurance is an 
integral part of the consultation. He 
argues that providing only 
information on AF without reassuring 
the patients on the safety of 
treatment, can lead to stress and 
anxiety on the patient.  
 
Similar to Nilan, Tom also assures 
his patients by telling them that AF is 
sometimes part of the normal ageing 
process 
 
Manpal relieves the anxiety of his 
patients by assuring them that AF 
can have treatment. 
 
Manpal also argues that it is 
describe it. (Tom) 
 
R – So kind of… from what you told me before, it’s 
like trying to keep the situation calm, reassuring the 
patient on the treatment? 
T – Yes… I don’t want them to go away thinking that 
they’re certain to have a clot and a stroke. Certainly, 
the warfarin keeps away. You know I say there is a 
risk, but it’s not a definite thing. (Tom) 
 
Some of them we just tell them we just don’t know. It’s 
the wiring of the heart getting older and not staying in 
a regular pattern any more. (Tom) 
 
 
AF is a condition which can be reversible, may not be 
reversible but can have treatment (Manpal) 
 
 
If the family wants to speak to me, I am happy to 
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important to give family members an 
opportunity to discuss issues. This 
provides an opportunity to 
strengthen the patient-physician 
relationship. In addition, as one can 
note, on providing an emphasis on 
the “and I do” phrase, he is showing 
that this is an important aspect in 
medical consultations. 
 
speak to them. I have a junior medical team staff who 
also speaks to family and relatives as well. AND I DO 
encourage them to do so. (Manpal) 
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Appendix N: Scans of Study 1 Mind Map Models 
Mind map model of the patients who accepted OAC 
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Mind map model of the patients who refused OAC 
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Mind map model of the patients who discontinued OAC 
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Final mind map model of the three patient groups in Study 1 
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Appendix O: Scans of Study 2 Physicians Mind Map Model  
Mind map model of first overarching theme in study 2: Communicating Information, A shifting paradigm 
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Mind map model of second overarching theme in study 2: Challenges with OAC prescription for AF 
 
